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1  
Abstract 
 
This study aimed to investigate the molecular mechanisms of glucose stimulated insulin 
secretion (GSIS), specifically the role of microRNAs (miRNAs) in this process. 
TaqMan low density miRNA arrays identified a panel of 10 miRNAs down-regulated in 
glucose non-responsive compared to glucose responsive MIN6 cells. Functional 
investigations involving knockdown of mir-200a, mir-130a and mir-410 in MIN6 cells 
exhibiting GSIS resulted in reduced GSIS. This suggested that these three miRNAs 
functioned in supporting the capability of MIN6 cells to secrete insulin in response to 
stimulatory glucose levels i.e. they are “pro-GSIS” miRNAs, presumably down-
regulating “anti-GSIS” mRNAs/protein. Over-expression studies of mir-410 supported 
the idea that it may enhance levels of GSIS.  
 
However, the MIN6 system was somewhat unpredictable. The advent of iPS technology 
represented a possible route for generation of human pancreatic beta cells for the study 
of regulated insulin secretion. Attempts were made to generate iPS cells from the 
MiaPaCa2 pancreatic adenocarcinoma cell-line, normal human epidermal keratinocytes, 
and normal human limbal epithelial cells. Alterations in cell morphology and marker 
expression were observed, possibly representing partially reprogrammed cells, but fully 
reprogrammed iPS cells were not identified. Directed differentiation of an established 
iPS cell line was performed in 2D and 3D culture, with improved efficiency of 
definitive endoderm formation in 3D cultures (a step on the differentiation route 
towards beta cells). 
 
In parallel, serum from diabetes patients was examined to identify new disease 
biomarkers in a collaborative clinical study with Connolly Hospital, Blanchardstown. 
MiRNAs identified as being potentially involved in GSIS from the MIN6 study were 
measured in serum from type 1 and type 2 diabetes patients. Proteomic and 
metabolomic profiling were performed on type 1 diabetes samples. These studies 
demonstrated the importance of stringent criteria for control sample selection, as 
evidenced by altered caffeine and lipid metabolism in control samples in this study. 
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1.0 Introduction 
 
 
3 
1.1 Diabetes Mellitus 
 
Diabetes Mellitus is a metabolic disorder, in which insulin is either not secreted in 
sufficient amounts or does not efficiently stimulate its target cells. Despite high blood 
glucose levels cells starve due to impaired glucose entry into cells, as it is insulin which 
stimulates movement of the GLUT4 glucose transporters for translocation of glucose 
into cells. 
 
Currently, there are more than 346 million people worldwide affected by diabetes. In 
2004, an estimated 3.4 million people died from consequences of high blood sugar, with 
this figure estimated to double by 2030 (Organization 2011). There are three main types 
of diabetes mellitus, type 1 (also known as insulin-dependent diabetes mellitus), type 2 
(known as non-insulin dependent diabetes mellitus) and gestational diabetes. 
 
1.1.1 Type 1 diabetes 
 
Type I diabetes (T1DM) accounts for approximately 10% of diabetes cases 
(Organization 2011). In T1DM, insulin is absent or nearly so because the pancreas lacks 
or has defective beta cells, which are responsible for the production of insulin and 
regulation of blood glucose levels. This condition results from an autoimmune response 
that selectively destroys the pancreatic beta cells (Atkinson and Maclaren 1994). 
Individuals with T1DM require daily insulin injections to survive. T1DM typically 
brews for several years before being diagnosed, as the immune system slowly destroys 
the beta cells of the pancreas. Only when greater than 80% of beta cells are destroyed 
do the symptoms of diabetes arise (Kloppel, Lohr et al. 1985). T1DM develops in an 
individual due to a combination of genetic predisposition and environmental factors. 
 
The normal endogenous insulin secretory profile consists of a basal component along 
with short-lived prandial surges of insulin secretion, released in response to meals. 
Daily insulin injections are unable to match these release profiles, due to the 
pharmacokinetic properties of pharmaceutical insulin preparations, leading to episodes 
of hyper- and hypo-glycemia.  
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1.1.2 Type 2 diabetes 
 
Type 2 diabetes accounts for approximately 90% of diabetes cases (Organization 2011), 
with 55% of patients also suffering clinical obesity. Type 2 diabetes is characterised by 
impaired beta cell function as well as insulin resistance. Insulin resistance is 
characterised by reduced insulin-mediated glucose uptake in insulin target tissues such 
as muscle, liver and adipose. 
 
In an attempt to maintain euglycemia, the pancreas compensates by secreting increased 
amounts of insulin. When insulin secretion can no longer compensate for insulin 
resistance then hyperglycemia develops. Hyperglycemia can cause impaired insulin 
secretion as consistently high glucose levels desensitize beta cells, leading to beta cell 
dysfunction or failure (Hosokawa, Hosokawa et al. 1996). 
  
1.1.3 Gestational diabetes 
 
Gestational diabetes is a condition in which women without previously diagnosed 
diabetes exhibit high blood glucose levels during pregnancy. Pregnancy related 
hormones can block insulin from effectively signalling its target tissues, thereby 
resulting in symptoms similar to type 2 diabetes. Patients with gestational diabetes tend 
to have larger birth weight babies, which increases the chances of delivery related 
complications. Gestational diabetes is routinely screened for in pregnancy by an oral 
glucose tolerance test, with blood glucose levels returning to normal soon after the birth 
(U.S. Preventative Services Task Force recommendation statement 2008). 
 
1.1.4 Secondary complications of diabetes 
Patients with diabetes can develop a number of potentially serious complications 
including cardiovascular disease, retinopathy, nephropathy and neuropathy (Nathan 
1993). The possibility of developing these complications can be reduced by tight 
glycaemic control (The Diabetes Control and Complications Trial Research Group 
1993), this is difficult to  achieve with current diabetes treatments, and risks episodes of 
hypoglycaemia, which can be dangerous for the patient. Replacement of the damaged 
5 
insulin-producing beta cells is the only treatment likely to achieve a constant 
normoglycemic state. Transplantation of the pancreas or preparations of islet tissue have 
been shown to achieve insulin-independence in type 1 diabetes patients (Ricordi and 
Strom 2004), but due to major problems in obtaining donor tissue and in preventing 
immune rejection of the graft, other cell sources need to be considered. Renewable beta 
cell lines need to be established which secrete insulin in a glucose dependent manner. 
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1.2 The Pancreas  
 
The pancreas plays a central role in nutrient regulation and energy balance through two 
distinct types of tissue, exocrine and endocrine. The exocrine function of the pancreas is 
carried out by centroacinar and basophilic cells. Centroacinar cells secrete bicarbonate 
ions which neutralize stomach acid in the duodenum (Slack 1995), while basophilic 
cells produce the digestive enzymes. Pancreatic juices drain into the pancreatic duct and 
from there travel to the duodenum, their site of action (figure 1.1). When partially 
digested food from the stomach reaches the duodenum, the pancreatic juices are 
released via the pancreatic duct and mix with the food. The enzymes in this juice help 
break down the fats and protein into smaller fragments which can be absorbed into the 
body through the small intestine.  
 
 
 
 
Figure 1.1 Location of pancreas within the body 
(www.ncbi.nlm.nih.gov/pubmedhealth) 
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The cells with endocrine function of the pancreas are clustered in groups called islets of 
Langerhans which are scattered around the pancreas and make up 1-2% of the total cell 
mass. These islets are composed of four major cell types, alpha (α), beta (β), delta (δ) 
and PP cells (figure 1.2). Beta cells produce and secrete insulin and amylin. Insulin 
controls the level of glucose in the blood by regulating glucose uptake in target tissues, 
and amylin, also known as IAPP (islet amyloid polypeptide), is co-secreted with insulin, 
and regulates glucose influx into the bloodstream (Weyer, Maggs et al. 2001).  
 
Alpha cells are responsible for producing and secreting the peptide hormone glucagon. 
Glucagon is a 29 amino acid polypeptide with a molecular weight of 3485 Da. 
Glucagon is released in response to hypoglycaemia (Dunning and Gerich 2007; 
Gromada, Franklin et al. 2007) and elevates blood glucose levels by regulating 
breakdown of glycogen to glucose in the liver. Elevated blood glucagon levels are seen 
in diabetes patients, contributing to diabetic hyperglycaemia (Muller, Faloona et al. 
1973). Additionally, diabetes patients exhibit blunted α-cell suppression in response to 
hyperglycaemia (D'Alessio 2011). 
 
Delta cells secrete somatostatin. There are two active forms of somatostatin, ss-14 and 
ss-28, reflecting their amino acid chain length (Florio and Schettini 2001). The ss-14 
variant is produced in the pancreas and functions as an inhibitor of insulin and glucagon 
release, and can also suppress exocrine pancreas secretions (Alberti, Christensen et al. 
1973; Mortimer, Tunbridge et al. 1974; Gerich, Charles et al. 1976). Somatostatin 
inhibition of insulin secretion is associated with a reduction in cAMP generation and 
hyperpolarization of the plasma membrane, leading to decreased intercellular Ca2+ 
concentration, and hence decreased exocytosis (Pipeleers 1987; Nilsson, Arkhammar et 
al. 1989). In addition to the pancreatic delta cells, somatostatin is also produced in the 
stomach, intestine, brain and central nervous system.  
 
PP cells secrete pancreatic polypeptide, a 36 amino acid polypeptide. Pancreatic 
polypeptide is secreted after ingestion of a meal and functions to inhibit the exocrine 
pancreas, as well as playing a role in appetite (Adrian, Besterman et al. 1977). Altered 
pancreatic polypeptide secretion has been observed in a number of disorders associated 
with abnormal eating behaviour, such as Prader-Willi syndrome (Zipf, O'Dorisio et al. 
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1981), morbid obesity (Lieverse, Masclee et al. 1994) and anorexia nervosa (Alderdice, 
Dinsmore et al. 1985; Fujimoto, Inui et al. 1997). 
 
A fifth endocrine islet cell type, the ε cell, has recently been identified (Wierup, 
Svensson et al. 2002; Prado, Pugh-Bernard et al. 2004), which secretes the 28 amino 
acid peptide hormone ghrelin (Kojima, Hosoda et al. 2001). Ghrelin functions to 
increase secretion of growth hormone from the pituitary gland and also has a role in 
stimulating appetite and promoting food intake (Date, Kojima et al. 2000; Ariyasu, 
Takaya et al. 2001; Kojima, Hosoda et al. 2001). 
 
 
 
 
 
 
Figure 1.2 Schematic representation of islet of Langerhans cell composition. 
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1.2.1 Insulin  
 
Beta cells were first identified as the source of insulin in 1938 (Richardson and Young 
1938). Insulin is synthesized by beta cells as a single chain precursor molecule called 
preproinsulin, preproinsulin is discharged into the cisternal space of the rough 
endoplasmic reticulum, where the signal peptide is cleaved, leaving proinsulin (figure 
1.3). Proinsulin is then transported to the Golgi apparatus by microvesicles (Orci 1984), 
where it is packaged into secretory granules. Proinsulin consists of three domains, an 
amino-terminal B chain, a carboxy-terminal A chain, and a connecting C-peptide chain. 
Conversion of proinsulin to insulin begins in the golgi and continues within the 
maturing secretory granule, where it is exposed to several specific endopeptidases 
(prohormone convertases 2 and 3, and carboxy peptidase H) (Hutton 1994). These 
enzymes remove the C-peptide chain, liberating two cleavage dipeptides, connected by 
two disulphide bridges, finally yielding insulin (figure 1.3). These secretory granules 
containing mature insulin remain within the cytoplasm until the cell is stimulated to 
release. 
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Figure 1.3 Processing of preproinsulin to insulin. Signal sequence of preproinsulin in 
cleaved, generating proinsulin. Disulphide bonds are formed between A and B chain, C 
chain is cleaved generating mature insulin (www.betacell.org). 
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1.2.2 Glucose Stimulated Insulin Secretion 
 
Mature insulin granules are transported to the cell surface via cytoskeleton filaments. 
On reaching the plasma membrane, the insulin granules become docked in the 
membrane (Bratanova-Tochkova, Cheng et al. 2002; Olofsson, Gopel et al. 2002; 
Straub and Sharp 2002), and are considered to be in different states of readiness for 
secretion. They may be primed and capable of being released, termed the ‘immediately 
releasable’ (IR) pool, or they may be un-primed and incapable of being released, termed 
the ‘readily releasable’ (RR) pool (Barg, Ma et al. 2001; Barg, Eliasson et al. 2002; 
Bratanova-Tochkova, Cheng et al. 2002; Straub and Sharp 2002).   
 
When beta cells are exposed to an increase in glucose concentration, insulin is released 
in a biphasic response. The first phase consists of a rapid burst of release which reaches 
its maximum four minutes after stimulation followed by a low secretion rate, the second 
phase shows an increasing rate of secretion to a plateau at thirty minutes (Cerasi and 
Luft 1963). The first phase is due to the release of granules from the IR pool, while the 
second phase is due to the release of granules that have to be prepared for immediate 
release, i.e. converted from the RR pool to the IR pool.   
 
Glucose is the major stimulator of insulin secretion in mammalian beta cells. Beta cells 
have an active glucose transporter – GLUT2, which maintains the intracellular glucose 
concentration at the same level as the plasma (Thorens, Sarkar et al. 1988). The rate of 
insulin secretion is dependent on the rate of glucose metabolism; the rate-limiting step 
being its phosphorylation to glucose-6-phosphate, which is catalyzed by glucokinase. 
Glucokinase acts a glucose sensor in insulin secreting cells (Matschinsky 1990). 
 
Following phosphorylation, glucose-6-phosphate is metabolised within the cell 
generating ATP via glycolysis. The change in ATP/ADP ratio stimulates the ATP 
sensitive K-channel (KATP) to close, preventing potassium ions from leaving the cell. 
Due to the action of the K+ ions trapped within the cell, the plasma membrane becomes 
depolarized, which in turn opens voltage-gated calcium channels allowing an influx of 
Ca2+ (figure 1.4). This increase in Ca2+ results in a spike in exocytosis of insulin 
granules (the first phase) in a concentration dependent manner (Grodsky 1972; Grodsky 
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1972; Nesher and Cerasi 2002).  At the low secretion stage between the first and second 
phases, the IR pool is depleted (Olofsson, Gopel et al. 2002) and must be resupplied. 
Granules from the RR pool are primed for conversion to the IR pool before they can be 
released by exocytosis, leading to the second phase of the response. The rate of 
exocytosis during the second phase increases over time until it plateaus out at a higher 
level. 
 
The overall rate of insulin secretion is controlled by the concentration of glucose to 
which the beta cell is exposed, the interaction of glucose with glucokinase and the 
physiological state of the beta cell (Matschinsky 1996). 
 
The capillaries which serve the insulin producing beta cells are permeable to peptides; 
therefore, after exocytosis from beta cells, insulin molecules can readily enter the 
bloodstream for transport to target cells elsewhere, mainly in liver, muscle, and adipose 
tissue. 
 
Insulin signals these tissues that blood glucose is higher than necessary, as a result, cells 
take up excess glucose from the blood and convert it to the storage compounds 
glycogen and triacylglycerol.  
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Figure 1.4 Regulated insulin secretion. Rising blood glucose levels trigger insulin 
secretion from beta cells. Starting with the uptake of glucose by the GLUT2 transporter, 
the glycolytic phosphorylation of glucose causes a rise in the ATP:ADP ratio. This rise 
inactivates the potassium channels that depolarise the membrane, causing the calcium 
channel to open up allowing calcium ions to flow inward. The ensuing rise in levels of 
intracellular calcium leads to the exocytotic release of insulin from their storage 
granules (Rani 2008). 
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1.2.3 Cell models for studying GSIS 
 
Due to the limited availability and restricted culture potential of primary pancreatic 
tissue for the study of the molecular mechanisms of GSIS, much work has been put into 
the development of pancreatic beta cell lines. Various transformation approaches have 
been employed to overcome the replicative senescence associated with primary 
pancreatic beta cells in attempts to generate immortalised pancreatic beta cell lines 
(Gazdar, Chick et al. 1980; Santerre, Cook et al. 1981; Newgard 1994). These 
experiments have proven difficult as the differentiated phenotype and the proliferative 
phenotype are mutually exclusive cell processes. Many of the cell lines generated 
exhibit some degree of de-differentiation and loss or reduction of mature beta cell 
function.  
 
A number of pancreatic beta cell lines have been generated, such as MIN6, β which 
produce significant amounts of insulin, up to one third of that found in normal beta 
cells, and also maintain a normal glucose response within the physiological range 
(Asfari, Janjic et al. 1992; Ishihara, Asano et al. 1993; Radvanyi, Christgau et al. 1993; 
de la Tour, Halvorsen et al. 2001). MIN6 cells are the most widely used of these cell 
lines, as the mature differentiated phenotype of these cells is thought to be most stable 
compared to other cell lines available. However, with increasing time in culture 
hormone secretion, and the glucose responsiveness in all these cell lines is reduced 
(Skelin, Rupnik et al. 2010). Previous studies in our lab on the MIN6 cell line indicate 
that loss of GSIS associated with increasing time in culture is not due to a decrease in 
insulin production (O'Driscoll, Gammell et al. 2004), but is more likely caused by de-
differentiation coupled to an altered capacity of these cells to successfully fold, modify 
and secrete proteins and to respond to problems associated with oxidative stress 
(Dowling, O'Driscoll et al. 2006; O'Driscoll, Gammell et al. 2006). 
 
MIN6 cells which have been maintained in culture for an extended period, and exhibit a 
reduced GSIS phenotype may represent a potential model for the study of beta cell 
dysfunction associated with type 2 diabetes, as beta cell dysfunction in these patients 
has also been suggested to occur through a de-differentiation mechanism (Prentki and 
Nolan 2006). 
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1.3 Pancreas Development 
 
Much of what we already know about pancreatic development is based on experiments 
with nonhuman organisms (McKnight, Wang et al. 2010), as limited biological material 
exists for experiments with human development. Knowledge of human pancreas 
development can be utilised for generation of replacement cells for type 1 diabetes. In 
vitro methods attempt to recapitulate the sequence of endogenous signalling pathways 
that first create progeny cells resembling definitive endoderm, then primitive gut tube 
epithelium, foregut pancreatic progenitors, islet progenitors and in the final step 
hormone positive progeny producing insulin positive cells. 
 
1.3.1 Specification of Pancreatic Fate 
 
Gastrulation occurs at embryonic day 6.5 (E6.5) in the mouse. During gastrulation, 
embryonic reorganisation occurs to form three germ layers, endoderm, mesoderm and 
ectoderm, with endoderm and mesoderm arising from a common cluster of 
mesendoderm. Wnt signalling is required for primitive streak formation and 
differentiation of mesendoderm cells (Liu, Wakamiya et al. 1999). Subsequent nodal 
signalling determines mesoderm or endoderm fate of mesendoderm cells, with high 
nodal levels leading to endoderm and low levels leading to mesoderm (Conlon, Lyons 
et al. 1994; Brennan, Lu et al. 2001; Vincent, Dunn et al. 2003). 
 
At E7.5, gastrulation is complete, definitive endoderm cells roll up to form the gut tube. 
The dorsal endoderm is adjacent to the notochord and the ventral pancreatic endoderm 
is adjacent to the hepatic diverticulum and the cardiogenic mesoderm (figure 1.5).  
 
By E9.5 the first sign of pancreatic buds appear, on the dorsal and ventral side of the 
primitive gut tube (Edlund 2002). The dorsal mesenchyme condenses and through 
signalling from the adjacent mesoderm, the endoderm region evaginates to form the 
dorsal bud (figure 1.6) (Munger 1958; Kallman and Grobstein 1964; Pictet, Clark et al. 
1972). As the stomach and duodenum rotate, the ventral bud comes into contact with 
the dorsal bud and they fuse at approximately E12.0-13.0. The ventral bud goes on to 
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form the posterior part of the head of the pancreas, while the dorsal bud forms the 
remainder of the organ. 
 
 
 
 
 
Figure 1.5 Endodermal junction of an E8.5 mouse embryo (Bonal and Herrera 2008). 
Dorsal endoderm develops towards the pancreatic fate in response to mesodermal 
factors (secreted from the notochord and aortae, in purple). Dorsal endoderm is 
characterised by co-expression of Pdx1 (yellow) and Ptf1a (blue). Ventrally the 
cardiomesoderm defines the presumptive liver (red) in the ventral endoderm. Adjacent 
to it, at the leading edge of the embryonic endoderm, the ventral pancreatic primordium, 
which only expresses Pdx-1, is specified by unknown mechanisms. n-notochord, a-
aortae. 
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Figure 1.6 Development of dorsal pancreas in rodents. (A) Close proximity of dorsal 
aspect of gut endoderm and notochord at E8. (B) The two dorsal aortae fuse, separating 
the gut endoderm from the notochord, E8.75-9.0. (C) The mesenchyme proliferates 
separating the dorsal endoderm from the dorsal aortae E9.0-9.5 (Slack 1995).  
 
 
1.3.1.1 Hedgehog signalling 
Sonic Hedgehog (Shh) is expressed in regions of the gut endoderm except where the 
dorsal and ventral buds form and almost defines the boundary where the pancreas 
develops. Shh inhibition using cyclopamine can lead to ectopic pancreatic development 
in the stomach and intestine (Kim and Melton 1998). Inhibition of Shh expression in the 
dorsal bud is mediated by notochord signalling via FGF2 and Activin (Hebrok, Kim et 
al. 1998). Inhibition in the ventral bud is mediated by release of factors from the cardiac 
mesoderm, the factors released from the cardiac mesoderm are less well known (Kim, 
Hebrok et al. 1997). Inhibition of Shh allows expression of the transcription factor 
pancreatic and duodenal homeobox 1 (Pdx1), which is a marker of pancreatic and 
duodenal progenitor cells. This initial induction of pdx1 expression is triggered by 
hepatocyte nuclear factor 6 (Hnf6) transcription factor. Hb9 and Isl1 are also required in 
the dorsal bud for pdx1 expression, while Hex1 is required in the ventral bud. 
 
1.3.1.2 Influence of notochord, aorta and mesenchyme 
The notochord is in contact with the dorsal prepancreatic endoderm up until E8, 
removal of notochord from early chick embryos prevented correct dorsal pancreas 
formation (Kim, Hebrok et al. 1997), possibly through lack of activin and FGF2 
signalling. At E8.75-9.0 the two dorsal aortae fuse, separating the notochord from the 
pancreatic endoderm. The aortic endothelium is involved in the induction of pancreatic 
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differentiation from the early endoderm. Removal of the aorta in Xenopus endoderm 
prevents pancreas development, however co-culture with other endothelial cells allowed 
correct pancreas development (Lammert, Cleaver et al. 2001). It is unknown what 
signalling molecules contribute to aortic endothelium promotion of pancreas 
development.  
 
At E9.0-9.5 the mesenchyme proliferates separating the dorsal endoderm from the 
dorsal aortae (figure 1.3). Dorsal mesenchyme, in response to signals from the aorta, 
secretes FGF10, which promotes dorsal pancreas development. FGF10 promotes 
accumulation of Pdx1+ pancreatic progenitor cells, but at the expense of cellular 
differentiation (Elghazi, Cras-Meneur et al. 2002). Disruption of FGF signalling can 
lead to under-development of the pancreas, while over-expression of FGF10 leads to 
excessive accumulation of pancreatic progenitor cells and formation of over-sized 
pancreas (Jacquemin, Yoshitomi et al. 2006). Further differentiation of these expanded 
progenitor cells into endocrine or exocrine cells may be also modulated by FGF 
signalling.  
 
Mesenchyme is critical for acinar development. Contact of pancreatic epithelial cells to 
mesenchyme leads exclusively to acinar differentiation, while absence of direct contact 
of mesenchyme with pancreatic epithelium leads exclusively to endocrine 
differentiation (mainly beta cell differentiation) (Li, Manna et al. 2004). FGF signalling 
from pancreatic mesenchyme apparently favours exocrine differentiation. Exogenous 
FGF enhances the presence of amylase positive cells, while a pdx1-FGF4 transgenic 
mouse, with FGF4 expressed in all early pancreatic epithelial cells, had ductal 
degeneration of the pancreas with persistent acini and severe destruction of the 
endocrine tissue (Dichmann, Yassin et al. 2006). In addition, FGF10 and FGF7 lead to 
enhanced proliferation of pancreatic epithelium with reduced endocrine differentiation 
(Elghazi, Cras-Meneur et al. 2002; Hart, Papadopoulou et al. 2003; Norgaard, Jensen et 
al. 2003). Mesenchyme suppression of endocrine differentiation due to contact of 
mesenchyme with pancreatic epithelium may be mediated by enhanced notch 
signalling-induced hairy enhancer of split 1 (hes1) expression and inhibition of 
neurogenin 3 (ngn3) expression (Duvillie, Attali et al. 2006). 
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1.3.1.3 Activin 
Activins are members of the TGFβ family of signalling molecules. They signal through 
a large family of receptors to activate smads and other intracellular pathways to initiate 
specific cell responses.  
 
Activin A and B are present in endocrine cells of the developing pancreas (Furukawa, 
Eto et al. 1995; Maldonado, Kadison et al. 2000) and enhance differentiation of 
endocrine cells while suppressing differentiation of exocrine/acinar cells. Addition of 
activin to embryonic pancreas explant cultures inhibits branching morphogenesis 
associated with ductal and acinar differentiation (Ritvos, Tuuri et al. 1995). Inhibition of 
activin activity using follistatin (which is present in early pancreatic mesenchyme), was 
sufficient to replace the pro-exocrine/anti-endocrine effect of mesenchyme (Miralles, 
Czernichow et al. 1998). Exogenous activin has also been shown to increase the number 
of insulin-positive cells as well as insulin content in cultured human fetal pancreas 
(Demeterco, Beattie et al. 2000). Activin may mediate its effects on insulin positive 
differentiation by reducing expression of pre-proglucagon and Arx (transcription factor 
vital for α-cell differentiation) (Mamin and Philippe 2007), and by inducing expression 
of neurogenin3 (ngn3: a key determinant of pancreatic endocrine lineage selection) 
(Zhang, Mashima et al. 2001). 
 
1.3.1.4 Hepatocyte nuclear factor 6 (Hnf6) 
Hnf6 is a transcription factor, expressed at E8 in early pre-pancreatic endoderm, it is 
subsequently expressed in early pancreatic epithelium at E9.0-10.0 (Rausa, Samadani et 
al. 1997; Jacquemin, Lemaigre et al. 2003; Maestro, Boj et al. 2003). Hnf6 is a key 
determinant of pancreatic specification, and is an inducer of pdx1 expression. Hnf6 null 
mice exhibit reduced size of pancreas-specified endoderm and are born with hypoplastic 
pancreas (Jacquemin, Durviaux et al. 2000; Jacquemin, Lemaigre et al. 2003). The 
effects observed in Hnf6 null mice may be mediated through a lack of induction of pdx1 
expression. Hnf6 is also an inducer of ngn3 expression. Hnf6 null mice also show a 
reduction in ngn3 positive cells (Jacquemin, Durviaux et al. 2000). Following Hnf6 
induced pdx1 expression in pancreatic progenitors; Hnf6 expression becomes limited to 
ductal and acinar cells from E18. 
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1.3.1.5 Pancreatic and duodenal growth factor 1 (Pdx1) 
Pdx1 is first expressed at E8.5 in all epithelial cells of the developing pancreas 
following induction by Hnf6, and represents the earliest marker of endocrine and 
exocrine progenitors. Pdx1 expression is suppressed in cells as they commit to 
endocrine (Jensen, Heller et al. 2000) or ductal lineages (Jonsson, Ahlgren et al. 1995; 
Gu, Dubauskaite et al. 2002). As endocrine cells begin to differentiate towards the 
insulin positive β-cell lineage, pdx1 expression reappears. Low pdx1 expression also 
persists in 20% δ-cells, acinar and ductal cells (Guz, Montminy et al. 1995; Wu, 
Gannon et al. 1997).  
 
Pdx1 null mice exhibit limited dorsal bud formation with no ventral bud formation 
(Ahlgren, Jonsson et al. 1996). The dorsal bud contained a few insulin and glucagon 
expressing cells, but without expansion of these cells (Ahlgren, Jonsson et al. 1996), 
indicating that pdx1 expression is not required for early budding of dorsal pancreas, or 
for formation of early endocrine cells, but is required in later steps of pancreas 
development. Pdx1 null mutations in humans were also associated with pancreas 
agenesis (Stoffers, Zinkin et al. 1997). 
 
The number of pdx1 positive progenitors formed between E8.5-12.5 is thought to 
determine the size of the adult pancreas. The pool of pdx1 positive progenitors depends 
on the proper commitment and proliferation of early endodermal cells into pdx1 
positive cells. Disruption of Notch, FGF or Wnt/β-catenin signalling leads to a reduced 
pool of pdx1 positive progenitors, and hence pancreatic hypoplasia (Stanger, Tanaka et 
al. 2007).  
 
Pdx1 expression is required for growth and maturation of acinar cells (Holland, Hale et 
al. 2002; Hale, Kagami et al. 2005), with inhibition of pdx1 from E13.5-14.0 leading to 
reduction of acinar cells, and the cells that were present were immature (Hale, Kagami 
et al. 2005). Pdx1 expression is necessary for correct glucose regulated insulin synthesis 
in β-cells (MacFarlane, Read et al. 1994; Marshak, Totary et al. 1996). Pdx1 inhibition 
in β-cells leads to β-cell depletion and increased numbers of α-cells, due to the loss of 
normal β-cell inhibition of α-cell development (Ahlgren, Jonsson et al. 1998; Lottmann, 
Vanselow et al. 2001; Thomas, Devon et al. 2001; Holland, Hale et al. 2002; Gannon, 
Ables et al. 2008). 
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1.3.1.6 Pancreas specific transcription factor 1a (PTF1a) 
PTF1a is first expressed at E9.5 in the cells of the foregut endoderm which give rise to 
ventral and dorsal pancreas, its induction in dorsal pancreas is mediated by pdx1, while 
factors mediating its induction in ventral pancreas are unknown (Krapp, Knofler et al. 
1998; Burlison, Long et al. 2008). PTF1a and pdx1 are co-expressed in pancreatic 
progenitor cells from E9.5 to E12.5. Expanding the field of pdx1/PTF1a co-expressing 
cells in Xenopus foregut leads to oversized pancreas, suggesting that pdx1/PTF1a co-
expression induced formation of increased numbers of pancreatic progenitor cells 
(Afelik, Chen et al. 2006). 100% acinar cells, 95% ductal cells, 75% alpha cells, and 
100% of non-alpha endocrine cells are derived from PTF1a positive progenitor cells. By 
E16 PTF1a expression becomes restricted to acinar cells, with low expression 
remaining in some early endocrine progenitor cells (Kawaguchi, Cooper et al. 2002; 
Chiang and Melton 2003; Lin, Biankin et al. 2004; Zecchin, Mavropoulos et al. 2004; 
Zhou, Law et al. 2007). In PTF1a null mutant mice, exocrine pancreas is absent, while 
endocrine cells locate within the spleen (Krapp, Knofler et al. 1998; Lin, Biankin et al. 
2004) and PTF1a mutations in human led to pancreas agenesis (Sellick, Barker et al. 
2004), indicating a role for PTF1a in both endocrine and exocrine lineage development. 
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1.3.2 Maintenance of uncommitted pancreatic progenitors 
Notch signalling and sox9 activity prevent commitment of pancreatic progenitors into 
endocrine or exocrine cells by promoting progenitor self-renewal. TGFβ and Prox1 
mediate commitment to endocrine and exocrine fates following sufficient expansion of 
progenitor cell pools. 
 
1.3.2.1 Notch signalling 
Notch is a cell membrane bound receptor. When bound by notch ligands such as jagged, 
serrate, or delta-like molecules, progenitor cells are maintained in an undifferentiated 
state, allowing expansion of pdx1 positive progenitors up to E12.5. Notch signalling 
stimulates up-regulation of hes1 (a member of notch signalling pathway), which in turn 
leads to ngn3 suppression, maintaining the undifferentiated state. Hes1 null mice exhibit 
severe pancreas hypoplasia due to inappropriate commitment of early precursor cells to 
endocrine lineages (Jensen, Pedersen et al. 2000). Notch may also be involved further 
downstream in specification of endocrine cell types; as mutations in notch ligands such 
as deltaA lead to increased number of β-cells, and jagged 1B mutants have increased α-
cell population (Zecchin, Filippi et al. 2007). 
 
1.3.2.2 Sox9 
Sox9 is a transcription factor involved in the maintenance of undifferentiated progenitor 
cells, and is thought to mediate the transition from pancreatic progenitor to endocrine 
committed cells through ngn3. Sox9 is expressed from E9.5 in pdx1 positive 
progenitors; following progenitor cell specification sox9 expression is restricted to 
acinar cells and a small number of ductal cells (Seymour, Freude et al. 2007). Sox9 
displays a similar expression pattern to hnf6 and possibly functions in conjunction with 
hnf6, as conditional deletion of sox9 displayed similar phenotype to hnf6 null mutants, 
with formation of ductal structures and lack of endocrine cells (Seymour, Freude et al. 
2007). Sox9 can interact with the regulatory elements of hnf6 and ngn3 genes (hnf6 is 
an inducer of ngn3 expression) (Lynn, Smith et al. 2007; Seymour, Freude et al. 2007). 
Hes1 positive cells are likely precursors of ngn3 positive cells, sox9 co-localises with 
hes1 indicating a possible role for sox9 in mediating transition of hes1 positive/ngn3 
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negative endocrine progenitors to hes1 negative/ngn3 positive endocrine committed 
cells (Seymour, Freude et al. 2007). 
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1.3.3 Specification of endocrine progenitors 
Pancreatic hormone expression is first detected in the first wave of endocrine cell 
generation (E9.5 – E10.5); however, these early hormone-expressing cells do not 
contribute to the mature endocrine cell population. Mature pancreatic endocrine cells 
arise from neurogenin 3 expressing progenitor cells (Bonal and Herrera 2008). 
 
1.3.3.1 Neurogenin 3 (ngn3) 
The transcription factor Ngn3 is first expressed in early pancreatic endoderm at E9.0, 
peaking at E15.5, and decreases substantially by E17.5 (Apelqvist, Li et al. 1999). Ngn3 
positive cells represent endocrine progenitor cells which can give rise to cells 
expressing the islet transcription factors neuroD, nkx6.1 and pax6 (Jensen, Heller et al. 
2000). All pancreatic endocrine cells derive from ngn3 positive cells (Gu, Dubauskaite 
et al. 2002). Ngn3 expression is repressed by notch signalling. Inactivation of notch 
signalling leads to premature expression of ngn3 and endocrine development 
(Apelqvist, Li et al. 1999). Ngn3 expression is also modulated by Hnf6 (Jacquemin, 
Durviaux et al. 2000). 
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1.3.3.2 Nkx transcription factors 
Nkx are a family of homeodomain transcription factors. Three family members – 
nkx2.2, nkx6.1 and nkx6.2 are involved in regulation of endocrine pancreas 
development. 
 
Nkx2.2 
Nkx2.2 is first expressed at E9.5 in pdx1 co-expressing cells (Sussel, Kalamaras et al. 
1998; Chiang and Melton 2003); by E12.5 nkx2.2 expression is restricted to ngn3 
positive cells. Nkx2.2 null mice develop with no β-cells, 80% reduction in α-cells and 
slight reduction in PP-cells, indicating that nkx2.2 is required for commitment and 
differentiation of endocrine precursors to α-cells, β-cells and PP-cells, with expression 
remaining in these mature cell types (Sussel, Kalamaras et al. 1998). Nkx2.2 can bind 
and activate mafA and insulin gene expression (Cissell, Zhao et al. 2003; Raum, Gerrish 
et al. 2006), its effect on endocrine commitment and differentiation may be mediated 
though these factors. 
 
Nkx6.1 and nkx6.2 
Nkx6.1 and nkx6.2 expression become detectable in the pancreatic epithelium by E10.5. 
Pdx1 null mice have reduced nkx6.1 positive cells, while nkx6.2 positive cells are 
unaffected, indicating that pdx1 acts upstream of nkx6.1, but not nkx6.2 (Pedersen, 
Nelson et al. 2005). Nkx6.1 expression becomes restricted to β-cells by E15, and 
expression continues in mature β-cells (Sander, Sussel et al. 2000). Nkx6.2 becomes 
restricted to α- and acinar cells by E15, but is turned off by E15.5 (Sander, Sussel et al. 
2000). Nkx6.1 plays an important role in β-cell generation. Nkx6.1 null mice have 85% 
reduction in β-cells due to inability of insulin-positive cells to self-renew beyond E13 
(Sander, Sussel et al. 2000; Henseleit, Nelson et al. 2005). There is some evidence that 
nkx6.1 and nkx6.2 may exhibit functional compensation when expression of one is 
knocked down. Transgenic expression of nkx6.2 is capable of rescuing the nkx6.1 null 
phenotype when expressed in pdx1 positive cells, but not ngn3 positive cells, indicating 
that nkx’s function upstream of ngn3 (Nelson, Schaffer et al. 2007). Nkx6.2 null mice 
develop normal pancreas, while nkx6.1 and nkx6.2 double null mice have 65% 
reduction in α-cells, suggesting that nkx6.1 compensates lack of nkx6.2 expression in 
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the nkx6.2 null mutant to allow correct α-cell development (Henseleit, Nelson et al. 
2005). 
 
1.3.3.3 Pax4 and Arx 
Pax4 is first expressed in the pancreatic epithelium from E9.5 (Sosa-Pineda, 
Chowdhury et al. 1997; Brink, Chowdhury et al. 2001), with expression peaking from 
E13-E15 (Wang, Elghazi et al. 2004). Pax4 is a marker of endocrine progenitor cells 
which give rise to α-, β-, δ- and PP-cells (Greenwood, Li et al. 2007). As endocrine cells 
mature pax4 expression diminishes (Smith, Ee et al. 1999). Pax4 null mice lack β- and 
δ- cells. Some early embryonic insulin-positive cells were detected in these null 
mutants, but fully mature β-cells did not develop, indicating that pax4 is not required for 
the initial formation of β-cells, but for the proliferation and maturation of these cells 
(Sosa-Pineda, Chowdhury et al. 1997; Wang, Elghazi et al. 2004). In these null mutants, 
the number of α-cells was greatly increased (Heller, Jenny et al. 2005). 
 
Arx is an enhancer of α-cell differentiation, and is directly target for inhibition by pax4. 
Arx null mice develop no α-cells, the α-cell precursors become directed towards β- and 
δ-cell lineages due to pax4 expression (Collombat, Mansouri et al. 2003; Collombat, 
Hecksher-Sorensen et al. 2005). Over-expression of arx is also capable of redirecting β- 
and δ-cell precursors to α- and PP-cell lineages (Collombat, Hecksher-Sorensen et al. 
2007).  
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1.3.4 Maintenance of islet cell identity 
 
Pax6 expression is required for the proliferation and maturation of all endocrine cells, 
while MafA, pdx1 and beta2/neuroD are required for insulin gene expression in β-cells, 
and Brn4 required for glucagon expression in α-cells. 
 
1.3.4.1 Pax6 
Pax6 is expressed in early embryonic pancreas from E9.0 (Turque, Plaza et al. 1994). 
Pax6 expression is induced in endocrine committed cells which also express neuroD 
and isl1 (Jensen, Heller et al. 2000). NeuroD in conjunction with E47 can induce pax6 
expression (Marsich, Vetere et al. 2003). These pax6 positive cells then initiate 
hormone expression possibly through pax6 binding sites in the promoter regions of the 
preproglucagon, insulin and somatostatin genes (Sander, Neubuser et al. 1997). 
Pax6/glucagon double positive cells are detected by E9.5, and pax6/insulin double 
positive cells are detected at E12.5 (Sander, Neubuser et al. 1997; St-Onge, Sosa-Pineda 
et al. 1997; Heller, Stoffers et al. 2004). Pax6 is involved in the expansion of endocrine 
cell types; pax6 null mutants have 75-100% reduction in α-cells and 65% reduction in 
β-cells (Sander, Neubuser et al. 1997; St-Onge, Sosa-Pineda et al. 1997). 
 
1.3.4.2 MafA 
MafA is expressed in mature β-cells; it binds to enhancer elements of the insulin gene, 
in response to glucose and stimulates insulin gene expression. MafB is expressed in α-
cells and stimulates glucagon expression. MafA acts downstream to pax4 and pax6 to 
maintain mature β-cell identity. MafA inactivation does not effect the early stages of 
pancreas development, but leads to reduced expression of β-cell markers such as 
insulin1, insulin2, pdx1, beta2/neuroD and glut2 (Zhang, Moriguchi et al. 2005). 
 
1.3.4.3 NeuroD 
NeuroD expression is first detected in pancreatic epithelium from E9.5, and from E14.5 
in ngn3 expressing cells, following birth neuroD expression is limited to β-cells. Ngn3 
stimulates neuroD expression by binding enhancer regions of the neuroD promoter 
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(Huang, Liu et al. 2000). Expression of neuroD represents a transition from proliferative 
ngn3 positive progenitor cells, to post-mitotic committed cells (Jensen, Heller et al. 
2000; Gu, Dubauskaite et al. 2002). NeuroD is involved in formation and maturation of 
β-cells; it is an activator of insulin gene expression. NeuroD null mice still form 
endocrine cells, but at reduced numbers, due to increased apoptosis from E17 (Naya, 
Huang et al. 1997). 
 
1.3.4.4 Other factors required for β-cell identity 
As mentioned above, pdx1 is also an activator of insulin gene expression (MacFarlane, 
Read et al. 1994; Marshak, Totary et al. 1996). Pdx1 is required for expression of a 
number of β-cell markers, including glut2 and glucokinase (Serup, Petersen et al. 1995). 
Pdx1 expression is limited to β-cells and 20% α-cells from E19.  
 
Conversely to its function in pancreatic endoderm specification, hedgehog signalling is 
required for maintenance of mature β-cell identity (Thomas, Rastalsky et al. 2000). 
Hedgehog signalling activates pdx1 expression, which in turn activates insulin gene 
expression (Thomas, Lee et al. 2001). 
 
1.3.4.5 Specification of exocrine lineages 
Acinar cells develop from the tips of ductal branches from E14.5; by E16.5 zymogen 
granules are present for storage of digestive enzyme. Pdx1 expression is required from 
E13.5 for commitment and maturation of exocrine cells. Pdx1 is necessary for induction 
of PTF1a, which in turn stimulates expression of acinar specific genes such as 
elastase1, chymotrypsinogen B and α-amylase2 (Cockell, Stevenson et al. 1989). Mist1 
transcription factor is not required for early exocrine development, but is necessary at 
later stages for correct organisation and maturation of acini, indicated by mist1 null 
mice (Pin, Rukstalis et al. 2001). Expression of srf transcription factor is also critical of 
maintenance of exocrine identity postnatal (Miralles, Lamotte et al. 2006). Notch 
signalling is required for exocrine commitment, while wnt/β-catenin and TGFβ 
signalling are required for differentiation and expansion of exocrine committed cells.  
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1.4 In vitro differentiation of pancreatic cells 
 
In vitro models for differentiation of human ES cells to pancreatic phenotypes are 
mainly based on knowledge of mouse pancreas development. However, differences 
exist between mouse and human pancreas development, such as duration of 
embryogenesis, organ morphology and islet organisation. 
 
Mouse embryonic stem cell lines (mES cells) were developed a number of years before 
the establishment of the first human embryonic stem cell lines (Evans and Kaufman 
1981; Martin 1981; Thomson, Itskovitz-Eldor et al. 1998), therefore initial in vitro 
pancreatic differentiation protocols were designed for use with mES cells. Initial 
attempts at differentiation of mES cells were based on spontaneous differentiation of 
embryoid bodies (Shiroi, Yoshikawa et al. 2002) or over-expression of pancreas-
specific genes (Levinson-Dushnik and Benvenisty 1997; Blyszczuk, Czyz et al. 2003; 
Vincent, Treff et al. 2006). While some insulin positive cells were detected in these 
initial studies, this limited success prompted the use of more developmental-biology 
based approaches, to mimic the natural development of the pancreas in vivo for 
differentiation of both human and mouse ES cells in vitro (D'Amour, Bang et al. 2006; 
Jiang, Au et al. 2007; Jiang, Shi et al. 2007; Phillips, Hentze et al. 2007; Shim, Kim et 
al. 2007; Zhang, Jiang et al. 2009).  
 
Differentiation of pancreatic beta cells from ES cells can be broken into four specific 
developmental stages- endoderm formation, pancreas specification, endocrine 
specification and beta-cell maturation (Murtaugh 2007; Spence and Wells 2007; Gittes 
2009). Definitive endoderm is the first step ES cells must achieve for differentiation 
towards pancreatic cells types, in vivo this step is achieved during gastrulation, during 
which ES cells are specified for ectoderm, endoderm or mesoderm formation. In vivo 
experiments have shown that nodal signalling is required for endoderm specification 
(Conlon, Lyons et al. 1994; Brennan, Lu et al. 2001; Vincent, Dunn et al. 2003). To 
mimic this signalling process in vitro another member of the TGFβ family- Activin A is 
used as it binds and activates the same receptors as nodal (de Caestecker 2004). The use 
of Activin A and low serum conditions can achieve cultures of up to 80% definitive 
endoderm cells, as measured by percentage of sox17 expressing cells (D'Amour, 
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Agulnick et al. 2005). These efficiencies can be increased further still with the use of 
Wnt3a (D'Amour, Bang et al. 2006), stimulating Wnt signalling which is an important 
regulator of mesendoderm and primitive streak formation (Liu, Wakamiya et al. 1999). 
 
Following formation of definitive endoderm cells, removal of Activin A allows 
formation of cells resembling gut-endoderm (D'Amour, Bang et al. 2006). Pancreas 
specification of posterior foregut-like cells is initiated by inhibition of hedgehog 
signalling (Hebrok, Kim et al. 1998; Lau, Kawahira et al. 2006), which can be 
mimicked in vitro using FGF2 (bFGF) (Jiang, Au et al. 2007). Expansion of PDX-1 
positive pancreatic progenitor cells can be induced by FGF10 signalling (Bhushan, Itoh 
et al. 2001; Ye, Duvillie et al. 2005).  Noggin has also been shown to enhance 
differentiation of definitive endoderm into pancreatic endoderm (Jiang, Au et al. 2007; 
Kroon, Martinson et al. 2008; Zhang, Jiang et al. 2009). 
 
The next stage of pancreas formation involves endocrine versus exocrine specification; 
endocrine cells are marked by ngn3 expression. EGF signalling plays a role in 
expansion of endocrine specified cells in vivo  (Miettinen, Huotari et al. 2000), this 
effect of EGF can also be mimicked in in vitro differentiation protocols (Jiang, Au et al. 
2007; Zhang, Jiang et al. 2009).  
 
The final stages of beta-cell directed differentiation protocols employ factors such as 
extendin-4 (D'Amour, Bang et al. 2006), NGF (Navarro-Tableros, Fiordelisio et al. 
2007), nicotinamide (Jiang, Au et al. 2007) and IGF11 (Jiang, Au et al. 2007) to induce 
the maturation and terminal differentiation of pancreatic beta cells. The final steps of 
pancreatic maturation remain the least well understood. Using protocols and signalling 
molecules similar to those discussed above, many groups have achieved insulin 
producing cells, however many of these cells are polyhormonal and do not represent 
fully mature pancreatic beta cells (D'Amour, Bang et al. 2006; Jiang, Au et al. 2007). 
Pancreatic progenitor cells transplanted into mice undergo a maturation process in vivo 
and exhibit functions of mature pancreas which cannot yet be replicated in vitro (Jiang, 
Shi et al. 2007; Kroon, Martinson et al. 2008). Much work remains to be performed to 
understand the in vivo molecular and signalling processes responsible for the maturation 
of transplanted progenitor cells.  
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1.5 Induced pluripotent stem cells 
 
The generation of induced pluripotent stem cells (iPS cells) represents a significant 
advancement in stem cell research. iPS cells can be generated from somatic cell types 
by forced expression of stem cell related genes- oct4, sox2, c-myc and klf4 (Takahashi 
and Yamanaka 2006; Takahashi, Tanabe et al. 2007), this technology overcomes the 
ethical and political concerns associated with human embryonic stem cell research, and 
also represents a potential avenue for the generation of autologous transplantation 
material.  
 
At the time of undertaking this study, lentiviral based reprogramming techniques were 
the gold standard of reprogramming technologies, due to increased transduction 
efficiency compared to the original retroviral methods (Blelloch, Venere et al. 2007; 
Yu, Vodyanik et al. 2007). However, concerns remained about genomic modifications 
of iPS cells containing viral genes insertions at random integration sites. Since this work 
was completed a number of newer techniques using non-integrating plasmids, 
recombinant proteins and mRNAs have been developed to overcome these problems 
associated with viral based methods (Okita, Nakagawa et al. 2008; Kim, Kim et al. 
2009; Zhou, Wu et al. 2009; Warren, Manos et al. 2010). 
 
Initially, fibroblasts were typically the cell type selected for iPS reprogramming, as they 
had been previously shown to be capable of reprogramming via nuclear transfer and cell 
fusion techniques (Wakayama, Perry et al. 1998; Tada, Takahama et al. 2001; Cowan, 
Atienza et al. 2005). However, keratinocytes showed faster reprogramming rates and  
improved efficiency compared to fibroblasts (Aasen, Raya et al. 2008; Maherali, 
Ahfeldt et al. 2008). Cells with a progenitor or adult stem cell phenotype generally 
reprogram with increased efficiency compared to mature cell types, as these cell types 
already endogenously express at least one of the reprogramming factors (Kim, Zaehres 
et al. 2008). Factors which are endogenously expressed in the starting population cell 
type can be removed from the reprogramming cocktail, however this leads to a 
reduction in reprogramming efficiency compared to reprogramming with all four factors 
(Kim, Zaehres et al. 2008). 
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Molecular characterisation of colonies formed following treatment with reprogramming 
cocktail is vital to identify truly reprogrammed iPS cells, as semi-reprogrammed cells 
may exhibit morphology similar to ES cells (Takahashi, Tanabe et al. 2007). Nanog is 
the marker of choice for such applications, as is routinely used to differentiate truly 
reprogrammed from semi-reprogrammed cells, as this marker is exclusively expressed 
in true pluripotent cells (Maherali and Hochedlinger 2008). Oct4, sox2, c-myc and klf4 
expression is also monitored during iPS cell generation, as viral expression of these 
genes should be detectable for the duration of the reprogramming protocol, however, 
once reprogrammed has occurred, viral transgene expression should be silenced and 
endogenous expression of these markers should begin. 
 
iPS cells have been shown to possess similar if not equal differentiation potential as 
hES cells (Takahashi and Yamanaka 2006; Takahashi, Tanabe et al. 2007). A number of 
studies have demonstrated differentiation of iPS cells into pancreatic phenotypes, with 
similar efficiencies as that achieved with ES cells (Tateishi, He et al. 2008; Maehr, 
Chen et al. 2009; Zhang, Jiang et al. 2009), these differentiated iPS cells also exhibit 
insulin secretion properties, however, this insulin secretion profile more closely 
resembles that of fetal islets rather than mature pancreatic beta cells (Tateishi, He et al. 
2008).   
 
Progress in the understanding of normal pancreatic development, specifically the late 
stages of beta cell maturation will allow the design of more efficient directed 
differentiation protocols, which will bring the potential use of iPS derived pancreatic 
beta cells closer to the clinic. 
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1.6 MicroRNAs 
 
MicroRNAs (miRNAs) are endogenous small non-coding RNAs of 19-28 nucleotides in 
length that regulate gene expression at the post-transcriptional level by binding to 
complementary sites in the 3’ untranslated region (3’UTR) of target mRNAs. Based on 
the level of complementarity, miRNAs can direct mRNAs for degradation or 
translational repression (Bartel 2004). MiRNA biogenesis, function, and mechanisms of 
action is reviewed in full in appendix E (Hennessy and O'Driscoll 2008). 
 
Of particular interest to the area of diabetes, miRNAs have been implicated to play a 
role in regulation of insulin secretion (Poy, Eliasson et al. 2004; Plaisance, 
Abderrahmani et al. 2006; Baroukh, Ravier et al. 2007; Lovis, Gattesco et al. 2008), 
pancreatic islet development and β-cell differentiation  (Joglekar, Parekh et al. 2007; 
Joglekar, Parekh et al. 2007; Kloosterman, Lagendijk et al. 2007; Lynn, Skewes-Cox et 
al. 2007; Correa-Medina, Bravo-Egana et al. 2009; Joglekar, Joglekar et al. 2009; Poy, 
Hausser et al. 2009), insulin resistance (Teleman, Maitra et al. 2006; He, Zhu et al. 
2007; Huang, Qin et al. 2009; Ling, Ou et al. 2009), and have been associated with 
secondary complications of diabetes, such as diabetic nephropathy (Kato, Zhang et al. 
2007; Wang, Wang et al. 2008) and cardiovascular disease (Xiao, Luo et al. 2007; 
Wang, Qian et al. 2009). A number of miRNAs have been shown to be directly 
involved in glucose stimulated insulin secretion (GSIS); indicating potential therapeutic 
targets for enhancement of GSIS and β-cell function in type 2 diabetes patients. 
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1.6.1 miRNAs associated with β-cell insulin secretion 
 
MiRNAs are critical for pancreatic beta cell function. MiRNA inactivation in adult 
murine beta cells resulted in establishment of a diabetic phenotype, as a result of 
dysfunctional insulin synthesis (Melkman-Zehavi, Oren et al. 2011). Mir-375 is, 
apparently, an important miRNA which negatively regulates GSIS in the murine 
insulinoma cell line, MIN6, and is thought to act at the late stages of exocytosis through 
its target myotrophin (Poy, Eliasson et al. 2004). Glucose is a negative modulator of 
mir-375 expression. Mir-375 also negatively regulates insulin gene expression in INS-
1E cells by directly targeting PDK1, thereby glucose induced reduction of mir-375 
ultimately leads to increased insulin gene expression (El Ouaamari, Baroukh et al. 
2008). Mir-30d expression is also glucose modulated in MIN6 cells and mouse 
pancreatic islets; with up-regulation of mir-30d levels induced by high glucose 
concentrations. Over-expression of mir-30d in MIN6 cells leads to increased insulin 
gene expression, while knockdown leads to reduced expression (Tang, Muniappan et al. 
2009), although it is unknown whether the effect of glucose-induced mir-30d, on insulin 
expression, is also mediated through PDK1. Mir-19b was also shown by luciferase 
reporter assay to directly target neuroD1 and hence regulate insulin 1 expression in 
MIN6 cells (Zhang, Zhang et al. 2011). 
 
Another miRNA mir-124a, targets transcription factor foxa2, which in turn regulates 
PDX-1 (which regulates insulin transcription) and potassium channel subunits Kir6.2 
and sur1. Overexpression of mir-124a leads to increased Ca2+ levels within MIN6 cells, 
possibly due to dysregulation of Kir6.2 and sur1 subunits (Baroukh, Ravier et al. 2007). 
Overexpression of mir-124a in MIN6 B1 cells led to increased insulin secretion in 
response to basal glucose concentrations and reduced secretion in response to 
stimulatory glucose concentrations (Lovis, Gattesco et al. 2008). Mir-124a affects the 
expression of a number of other exocytosis related proteins in MIN6 B1 cells including 
SNAP25, Rab3A, synapsin-1A, Rab27A and Noc2; although only Rab27A is a direct 
target of mir-124a (Lovis, Gattesco et al. 2008). These exocytosis-related proteins also 
have predicted binding sites for regulation by other miRNAs, but these still remain to be 
experimentally validated (Abderrahmani, Plaisance et al. 2006). 
 
35 
Mir-9 negatively regulates GSIS in INS-1E cells by directly targeting transcription 
factor onecut2, which in turn regulates granuphilin, a negative modulator of exocytosis 
(Plaisance, Abderrahmani et al. 2006). Mir-96 mediated reduction of GSIS in MIN6 B1 
cells is also associated with reduced expression of granuphilin and Noc2 exocytosis 
related proteins.  
 
High levels of mir-34a are observed in islets from diabetic db/db mice. Over-expression 
of mir-34a in MIN6 B1 cells leads to reduced GSIS, possibly through its target protein 
VAMP2 which plays a role in β-cell exocytosis (Lovis, Roggli et al. 2008). As each 
miRNA can target multiple mRNAs, regulation of insulin secretion may be controlled 
by a small network of miRNAs co-ordinately targeting the extensive range of proteins 
involved in regulation of exocytosis. 
 
A more comprehensive understanding of the function of miRNAs in regulated insulin 
secretion could potentially identify miRNA targets which could be manipulated in order 
to maintain or enhance GSIS of replacement beta cells for treatment of type 1 diabetes, 
or for treatment of beta cell dysfunction associated with type 2 diabetes. 
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1.6.2 MiRNAs as therapeutic targets 
 
Until recently, miRNAs had not been considered as classical therapeutic targets, as they 
do not code for proteins. Initial studies aimed at exploiting miRNAs as a form of 
therapy have shown promising results. Following intravenous injection of modified 
antisense oligonucleotides (termed antagomirs) into mice, in vivo inhibition of four 
miRNAs – mir-16, mir-122, mir-192 and mir-194 – has been successfully demonstrated 
(Krutzfeldt, Rajewsky et al. 2005). This approach resulted, not only in blockage of 
target miRNAs, but also in their degradation in most organs analysed, including liver, 
kidney, heart, lung, intestine, bone marrow, muscle, skin, fat, ovaries and adrenals. Lack 
of effect observed in brain is possibly due to restricted diffusion of charged nucleic 
acids across the blood–brain barrier. Alternative approaches to targeting miRNAs 
therapeutically by inhibiting Drosha, Dicer or other miRNA pathway components are 
being investigated as alternative approaches to targeting miRNAs directly. Conversely, 
where reduced miRNA expressed is associated with a disease phenotype and increased 
expression of relevant miRNA could be of potential therapeutic relevance to rescue 
disease phenotype, introduction of miRNA mimics is being investigated. However, 
suitable expression vectors have yet to be identified for the safe delivery and 
maintenance of such effects long-term (Esau and Monia 2007).  
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1.7 Biomarkers in diabetes 
 
Type 1 diabetes typically brews for a number of years before symptoms become evident 
and the condition is diagnosed, by this stage approximately 80% of pancreatic cells are 
destroyed (Kloppel, Lohr et al. 1985). Once diagnosed, patients are on insulin treatment 
for the remainder for their life. Therefore, there is a great need to identify predictive 
biomarkers for type 1 diabetes, so that autoimmune attack of the pancreatic beta cells 
can be treated before the damage becomes irreparable. 
 
1.7.1 MiRNAs as serum biomarkers 
Serum microRNAs are highly stable, being resistant to RNaseA digestion and other 
harsh conditions (low/high pH, boiling, extended storage and freeze/thaw cycles) 
making them ideal for use in the clinical setting as biomarkers (Chen, Ba et al. 2008). 
 
Serum miRNA expression profiling has demonstrated the presence of different miRNA 
expression patterns in pathological conditions such as NSCLC (Chen, Ba et al. 2008), 
colorectal cancer (Chen, Ba et al. 2008), diffuse large B-cell lymphoma (Lawrie, Gal et 
al. 2008), prostate cancer (Mitchell, Parkin et al. 2008), ovarian cancer (Resnick, Alder 
et al. 2008) and type 2 diabetes (Chen, Ba et al. 2008), as well as physiological 
conditions such as pregnancy (Chim, Shing et al. 2008; Gilad, Meiri et al. 2008). 
 
A recent study of serum from pregnant females identified three miRNAs- mir-132, mir-
29a and mir-222 associated with development of gestational diabetes and represent 
potential biomarkers for prediction of this pregnancy complication (Zhao, Dong et al. 
2011). Distinct miRNA profiles have also been identified in patients with type 2 
diabetes (Chen, Ba et al. 2008; Zampetaki, Kiechl et al. 2010), pre-diabetes, and 
patients with normal glucose tolerance but at risk of developing type 2 diabetes (Kong, 
Zhu et al. 2011). Table 1.1 details patient populations and main findings from these 
biomarker discovery studies. These miRNA profiles may represent potential biomarkers 
for prediction of type 2 diabetes and allow patients to make the relevant lifestyles 
changes required before establishment of the disease.  
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The scope for miRNA serum biomarkers spans a wide range of diseases and 
physiological conditions. Together with their stability, resistance to RNase degradation, 
and non-invasive procurement techniques would make them an ideal tool for disease 
diagnosis.  
1.7.2 Protein biomarkers in diabetes serum 
Proteins also represent a potentially useful class of serum biomarkers, as specific 
protein levels can be easily and sensitively measured in the clinical setting using ELISA 
technology. A range of proteomic profiling experiments on diabetes serum have been 
published in the literature, these studies identify specific protein profiles associated with 
type 1 diabetes (Metz, Qian et al. 2008), type 2 diabetes (Zhang, Sun et al. 2010), 
metabolic disease (Matsumura, Suzuki et al. 2006), as well as secondary complications 
of diabetes (Otu, Can et al. 2007; Gianazza, Mainini et al. 2010; Madan, Gupt et al. 
2010), these studies are detailed in table 1.1. The promising results from these studies 
indicate the potential for protein biomarkers for prediction, diagnosis and management 
of diabetes. 
 
1.7.3 Metabolite biomarkers in diabetes serum 
Recent advances in mass spectrometry technologies in combination with data 
processing software for large scale metabolite profiling (Ryals, Lawton et al. 2007; 
Evans, DeHaven et al. 2009) has prompted a surge in metabolomic profiling 
experiments and biomarker studies which were previously unachievable. Metabolomic 
profiling of diabetes serum gives an insight into the extent of metabolomic 
dysregulation characteristic of diabetes. Distinct metabolite profiles have been identified 
for type 1 diabetes (Oresic, Simell et al. 2008; Lanza, Zhang et al. 2010), type 2 
diabetes (Li, Xu et al. 2009; Suhre, Meisinger et al. 2010), pre-diabetes (Zhang, Wang 
et al. 2009; Gall, Beebe et al. 2010; Lucio, Fekete et al. 2010; Tsutsui, Maeda et al. 
2010; Zhao, Fritsche et al. 2010), as well as secondary complications of diabetes (Xia, 
Liang et al. 2009; Zhang, Yan et al. 2009). The main findings of these studies are 
detailed in table 1.1. Metabolite biomarkers have been used extensively over the years 
for monitoring disease, e.g. glucose for diabetes, cholesterol for heart disease, the use of 
straight forward, rapid biochemical assays for metabolite quantification also makes 
metabolites an ideal candidate for biomarker identification. 
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Condition Biomarker 
Type 
 
Study Population Findings Reference 
Gestational 
Diabetes 
miRNA 68 gestational diabetes patients 
and 68 controls 
Decreased levels of mir-29a and mir-222 associated 
with gestational diabetes. 
(Zhao, Dong et 
al. 2011) 
Type 2 diabetes miRNA Study population not detailed in 
publication 
Identified a miRNA fingerprint for type 2 diabetes, 
including 3 diabetes specific miRNAs (not named in 
the publication). 
(Chen, Ba et 
al. 2008) 
Type 2 diabetes miRNA 18 newly diagnosed type 2 
diabetes patients (n-T2D), 19 pre-
diabetes patients, 19 type 2 
diabetes susceptible patients with 
normal glucose tolerance (s-
NGT) 
Increased levels of mir-9, mir-29a, mir-30d, mir-34a, 
mir-124a, mir-146a and mir-375 during disease 
progression. 
(Kong, Zhu et 
al. 2011) 
Type 2 diabetes miRNA 80 type 2 diabetes patients and 80 
controls 
Decreased levels of mir-20b, mir-21, mir-24, mir-15a, 
mir-126, mir-191, mir-223, mir-320 and mir-486, while 
increased levels of mir-28-3p in type 2 diabetes serum. 
(Zampetaki, 
Kiechl et al. 
2010) 
Type 1 diabetes Protein 10 type 1 diabetes patients, 4 type 
1 diabetes patients with diabetic 
nephropathy and 9 controls 
Increased levels of fibrinopeptide A in type 1 diabetes 
serum, while decreased levels of fibrinopeptide A 
fragments in patients with type 1 diabetes alone and 
type 1 diabetes with nephropathy. 
(Gianazza, 
Mainini et al. 
2010) 
Diabetic 
nephropathy 
Protein 31 type 2 diabetes patients with 
diabetic nephropathy and 31 type 
2 diabetes patients without 
nephropathy 
Identified a 12-peak proteomic signature which predicts 
type 2 diabetes patients who will subsequently develop 
diabetic nephropathy. 
(Otu, Can et al. 
2007) 
Diabetic 
microvascular 
complications 
Protein Type 2 diabetes patients with 
(n=40) and without (n=20) 
diabetic microvascular 
complications, and 30 control 
healthy samples 
PAI-1, fibrinogen, vWF increased in T2D compared to 
healthy controls. Diabetic retinopathy associated with 
decreased protein S and vWF levels. Diabetic 
nephropathy associated with increased PAI-1 and vWF 
levels.  
(Madan, Gupt 
et al. 2010) 
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Type 2 diabetes Protein Serum from rat model of type 2 
diabetes, and control heathy rat 
(n=1) 
Differential expression of apolipoproteins and α2-HS-
glycoprotein in serum from type 2 diabetes rat 
compared to non diabetic control. 
(Matsumura, 
Suzuki et al. 
2006) 
Type 2 diabetes Protein 10 type 2 diabetes rats, and 10 
healthy control rats 
Decreased levels of apolipoprotein E, apolipoprotein A-
1, Ig gamma-2A chain C region, and increased levels of 
transthyretin, haptoglobin, serum amyloid P-componen, 
prothrombin were identified in type 2 diabetes 
compared to control healthy rats. 
(Zhang, Sun et 
al. 2010) 
Type 1 diabetes Protein 10 newly diagnosed type 1 
diabetes patients, and 10 healthy 
controls 
Increased levels of α-2-glycoprotein 1, corticosteroid-
binding globulin, lumican, and decreased levels of 
clusterin and serotransferrin in type 1 diabetes 
compared to control samples. 
(Metz, Qian et 
al. 2008) 
Type 1 diabetes Metabolite 56 patients who subsequently 
progressed to type 1 diabetes, and 
73 non-diabetic controls 
Increased levels of succinic acid and 
phosphatidylcholine at birth in patients who would later 
develop type 1 diabetes. 
Reduced levels of triglycerides and antioxidant ether 
phospholipids, and increased levels of proinflammatory 
lysoPCs before seroconversion to autoantibody 
positivity. 
(Oresic, Simell 
et al. 2008) 
Type 1 diabetes Metabolite Type 1 diabetes patients during 
insulin treatment and acute 
insulin deprivation (n=9), and 
non-diabetic controls (n=9) 
Increased levels of lactate, acetate, allantoin and 
ketones identified during insulin deprivation.  
Protein synthesis and breakdown, gluconeogenesis, 
ketogenesis, amino acid oxidation, mitochondrial 
bioenergetics and oxidative stress pathways altered 
during insulin deprivation. 
(Lanza, Zhang 
et al. 2010) 
Type 2 diabetes Metabolite 48 type 2 diabetes patients and 31 
healthy controls 
2-hydroxyisotubyric acid, linoleic acid, palmitic acid 
and phosphate levels correctly distinguished type 2 
diabetes and control specimens. 
(Li, Xu et al. 
2009) 
Type 2 diabetes Metabolite 40 type 2 diabetes patients and 60 
healthy controls 
Alterations in pathways related to kidney dysfunction 
(3-indoxyl sulphate), lipid metabolism 
(Suhre, 
Meisinger et 
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(glyceropholipids, free fatty acids), and interaction with 
the gut microflora (bile acids) were identified in type 1 
diabetes patients. 
al. 2010) 
Pre-type 2 
diabetes 
Metabolite 399 non diabetes subjects with a 
range of insulin sensitivities and 
glucose tolerance 
Identified α-hydroxybutyrate as an early marker of both 
insulin resistance and impaired glucose regulation. 
(Gall, Beebe et 
al. 2010) 
Pre-type 2 
diabetes 
Metabolite 48 non-diabetic subjects 
exhibiting high to low insulin 
sensitivities 
Identified alterations in lipid-related pathways 
(arachidonic acid metabolism, essential fatty acid 
metabolism, and biosynthesis of unsaturated fatty 
acids), steroid hormone biosynthesis and bile acid 
metabolism associated with changes in insulin 
sensitivity. 
(Lucio, Fekete 
et al. 2010) 
Pre-type 2 
diabetes 
Metabolite Diabetic mice and normal control 
mice (number of mice in each 
group not specified in the 
publication) 
Alterations in metabolites related to lysine biosynthesis 
and degradation were identified in diabetic compared to 
control mice, before onset of type 2 diabetes. 
(Tsutsui, 
Maeda et al. 
2010) 
Pre-type 2 
diabetes 
Metabolite 39 subjects with normal glucose 
tolerance, and 12 subjects with 
impaired glucose tolerance 
Alterations in fatty acid, tryptophan, uric acid, bile acid 
and lysophosphatidylcholine metabolism, and TCA 
cycle associated with pre-diabetes state.  
Decreased levels of gut flora-associated metabolites 
(hippuric acid, methylxanthine, methyluric acid and 3-
hydroxyhippuric acid) identified in subjects with 
impaired glucose tolerance.  
(Zhao, Fritsche 
et al. 2010) 
Pre-type 2 
diabetes 
Metabolite Subjects with normal glucose 
tolerance (n=80), impaired 
glucose tolerance (n=77) and type 
2 diabetes (n=74) 
Alterations in choline, glucose and amino acid 
metabolism, and TCA cycle identified in type 2 
diabetes and impaired glucose tolerance subjects 
compared to normal glucose tolerance subjects. 
Alterations in glucose, fatty acid, protein/amino acid 
metabolism identified in impaired glucose tolerance 
subject compared to type 2 diabetes subjects. 
(Zhang, Wang 
et al. 2009) 
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Type 2 diabetes 
and diabetic 
nephropathy 
Metabolite 8 diabetic nephropathy patients, 
33 type 2 diabetes patients and 25 
healthy controls 
Alterations in leucine, dihydrosphingosine and 
phytoshpingosine were identified in type 2 diabetes 
patients with and without diabetic nephropathy 
compared to healthy control specimens. 
(Zhang, Yan et 
al. 2009) 
Diabetic 
nephropathy 
Metabolite 88 subjects with diabetic 
nephropathy and 50 healthy 
control subjects 
Altered levels of adenosine, inosine, uric acid, xanthine 
and creatinine in diabetic nephropathy subjects 
compared to healthy controls. 
(Xia, Liang et 
al. 2009) 
 
Table 1.1 MiRNA, proteomic and metabolomic profiling studies for the identification of biomarkers for type 1 diabetes, type 2 diabetes, pre-
diabetes and secondary complications of diabetes. 
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Aims 
 
MicroRNAs involved in glucose stimulated insulin secretion in MIN6 cells: 
• To investigate the mechanisms of regulated insulin secretion, in particular, the 
role of miRNAs in this process. 
• To profile miRNA expression in glucose responsive and glucose non-responsive 
MIN6 cells, to identify miRNAs differentially expressed in these cell 
populations. 
• To determine if these differentially expressed miRNAs have a direct effect on 
regulated insulin secretion by over-expression and knockdown of miRNA 
targets, while monitoring GSIS response.  
 
Attempt to generate iPS cells and differentiation of an established iPS cell line 
towards pancreatic phenotypes: 
• To generate iPS cells using retroviral and conditioned media reprogramming 
techniques, followed by subsequent testing of reprogramming status by analysis 
of pluripotency marker expression. 
• To compare directed differentiation of iPS cells in 3D and 2D culture systems. 
To evaluate differentiation efficiency by PCR analysis of differentiation and 
pluripotency marker expression. 
• To determine transdifferentiation potential of human limbal stromal cells 
towards pancreatic phenotypes, measured by PCR analysis of pancreatic marker 
expression. 
 
Biomarker discovery in diabetes serum specimens: 
• To determine if GSIS related miRNAs are differentially expressed in serum 
specimens from type 1 and type 2 diabetes patients. 
• To perform proteomic, metabolomic and miRNA profiling on serum from 
diabetes patients to identify potential disease biomarkers. 
• To validate potential protein, metabolite and miRNA markers in a larger cohort 
of patients to evaluate if expression trends were maintained in larger sample size 
study. 
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2.0 Materials and Methods 
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2.1 Culture of cell lines 
2.1.1 Cell lines 
The cell lines used during the course of this study are listed in table 2.1. Cell lines were 
maintained under standard culture conditions, 5% CO2, at 37ºC and fed every 2-3 days, 
except iPS cells which were fed every day.  
Cell Line Cell Type Source 
MIN6 Murine pancreatic beta cells  Dr. Per Bendix 
Jeppesen* 
iPS (hFib2-iPS4) Human induced pluripotent stem cells  Dr. George Daley** 
MEF Mouse embryonic fibroblasts ATCC 
293 Human embryonic kidney cells Stratagene 
MiaPaCa2 Human pancreatic carcinoma cells ATCC 
NHEK Normal human epidermal keratinocytes ATCC 
L-epi Limbal epithelial cells Mr. Kishore Reddy*** 
Stromal Limbal stromal cells Mr. Kishore Reddy*** 
ESD3 Mouse embryonic pluripotent stem cells ATCC 
Table 2.1. Cell lines used in this study 
*Dr. Per Bendix Jeppesen, Aarhus University, Denmark. 
**Dr. George Daley, Howard Hughes Medical Institute and Children’s Hospital Boston. 
***Limbal epithelial and stromal cells were isolated from donor cornea-sclera ring by Mr. 
Kishore Reddy, NICB. Donor cornea retrieved by Dr. William Murphy at The Royal 
Victoria Eye and Ear Hospital, Dublin. 
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2.1.2 Preparation of cell culture media 
DMEM for culture of MIN6 cells was purchased pre-made at 1X concentration (Gibco 
21885). DMEM/F12 (D8437), DMEM (D5671), MEM (M5650) and RPMI (R8758) for 
culture of additional cell-lines used in this thesis were also purchased at 1X 
concentration from Sigma Aldrich. Basal media was stored at 4oC up to their expiry 
date as specified on each individual container. Working stocks of culture media were 
prepared as 100mL aliquots and supplemented as required (table 2.2).  These were 
stored for up to 3 weeks at 4oC, after this time, fresh culture medium was prepared. 
 
Cell Line Basal Media FCS (%) Additives 
MIN6 DMEM 10 880µL of 45% glucose solution 
(Sigma G8769) / 100mL media 
iPS (hFib2-iPS4) DMEM/F12  20% Knockout serum,                
1mL L-Glutamine,                                   
1mL Non-essential amino acids,                              
3.5µL β-mercaptoethanol,       
10ng/mL bFGF 
MEF DMEM 10 4mM L-Glutamine 
293 DMEM 5 4mM L-Glutamine 
MiaPaCa2 DMEM 5 4mM L-Glutamine 
NHEK KBM (Lonza 
CC-3103) 
 KGM SingleQuots (Lonza CC-
4152) 
L-epi DMEM+HAM 
F12 (3:1) 
10 5ug/mL insulin, 10ng/mL rhEGF, 
100ng/mL cholera toxin A subunit, 
0.4µg/mL hydrocortisone, 2nM 
triiodothryonine 
Stromal DMEM 10 N/A 
ESD3 DMEM 10 0.1mM 2-mercaptoethanol, 2000U 
LIF / 100mL media  
Table 2.2 Media requirements for cell lines used in this study (N/A- non applicable). 
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2.1.3 Subculture of cell lines 
Prior to subculture, cells were monitored for contamination and were subcultured when 
cells reached 70-80% confluency. The cell culture medium was removed from the tissue 
culture flask and discarded into a sterile waste bottle. The flask was then rinsed with 
10mL pre-warmed 1X Ca2+/Mg2+- free PBS (Gibco, 14200-067). 1.5mL trypsin/EDTA 
solution (0.25% trypsin, 0.01% EDTA in PBS) was then added; the flask was given a 
gentle swirl to coat the surface (for MIN6 cell-line, trypsin-EDTA solution was then 
removed). The flask was then incubated at 37oC for 5 minutes. 10mL culture media was 
added to inactivate the trypsin and the cell suspension was removed and placed in a 
sterile universal container. Cells were centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded from the universal and the pellet re-suspended in pre-warmed 
culture medium, media was aspirated up and down a number of times to ensure a single-
cell suspension. A cell count was performed and cells re-seeded to flasks or assay plates 
at the required density.  
 
2.1.3.1 Subculture of iPS cells 
IPS cells were subcultured as per protocol from Harvard Stem Cell Institute. Cells were 
washed with PBS before addition of 1mL collagenase (200 units/mL) per well of a 6-
well plate and incubated at 37ºC for 10 minutes. When visible curling and thickening of 
colonies around the edges was seen, collagenase was removed and 1mL of iPS media 
was added. iPS cell clusters were scraped from the plate using a Pasteur pipette. The 
solution containing loosened cell clusters was placed into a universal tube, the well was 
rinsed with an additional 1mL iPS media, and this was also transferred into the 
universal tube. The cell suspension was centrifuged at 1000 rpm for 2 minutes, 
supernatant was removed and cell clusters were resuspended in fresh media, avoiding 
excess pipetting to maintain cell clusters. iPS clusters were then plated in 6-well plate 
pre-coated with gelatin and irradiated MEF feeder layer, at the ratio of 1:6. 
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2.1.4 Cell counting 
Cell counting and viability determinations were carried out using a trypan blue (Gibco, 
15250-012) dye exclusion technique. 
Cells were trypsinised, pelleted and resuspended in media. An aliquot of the single-cell 
suspension was then added to trypan blue at a ratio of 5:1. After 3 minutes incubation at 
room temperature, a sample of this mixture was applied to the chamber of a 
haemocytometer over which a glass cover slip had been placed. Cells in the 16 squares 
of the four outer corner grids of the chamber were counted microscopically. The 
average cell numbers per 16 square corner grid was calculated taking into account the 
dilution factor, and multiplied by a factor of 104 to determine the number of cells per 
mL in the original cell suspension. Non-viable cells stained blue, while viable cells 
excluded the trypan blue dye as their membranes remained intact, and remained 
unstained. On this basis percentage viability could be calculated. 
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2.1.5 Cryopreservation of cells 
Freezing media was prepared as described in table 2.3 and then placed on ice until 
required. Appropriate number of cryogenic vials (Greiner, 122 278) were labelled with 
the cell line name, passage number, date and placed on ice at this point. Cells were 
trypsinised and counted as outlined in section 2.1.3 and 2.1.4. The supernatant from the 
centrifuged cells was removed and the cell pellet resuspended in freezing media to a cell 
density of 5x106 cells/mL. 1mL of cell suspension in freezing media was then added to 
each pre-cooled cryovial. Cryovials were placed on ice for 10 minutes, and then 
transferred to a -80oC freezer overnight in a Boehringer Mannheim enzyme box, and 
then placed in liquid nitrogen for storage.  
 
Cell Line Freezing Media 1X 
MIN6 Complete media + 10% DMSO 
iPS (hFib2-iPS4) 50% complete media + 40% FCS + 10% DMSO 
MEF FCS + 10% DMSO 
293 FCS + 5% DMSO 
MiaPaCa2 FCS + 5% DMSO 
Stromal 80% DMEM + 10% FCS + 10% DMSO 
ESD3 FCS + 20% DMSO 
Table 2.3 Freezing media composition 
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2.1.6 Thawing of cryopreserved cells  
Prior to thawing 8mL of culture media was added to a tissue culture flask and allowed 
to equilibrate in a 37°C, 5% CO2 humidified incubator overnight. A sterile universal 
tube containing 5 mL growth medium was pre-warmed before thawing cells. This 
allowed for the rapid transfer and dilution of thawed cells to reduce their exposure time 
to the DMSO freezing solution (DMSO is toxic at room temperature). For thawing iPS 
cells, media was supplemented with 10mM ROCK inhibitor Y27632 (Calbiochem, 
688000). The cryovial taken from the liquid nitrogen storage and immediately diluted 
with media using a Pasteur pipette, and its contents were transferred to the universal. 
The suspension was centrifuged at 1000 rpm for 5 minutes (2 minute for iPS cells), the 
DMSO-containing supernatant was removed and the pellet was then resuspended in 
fresh growth medium, ensuring a single-cell suspension was achieved (minimal 
pipetting was used for iPS cells to maintain cell clusters). Viability counts were carried 
out (section 2.1.4) to determine the efficacy of the freezing/thawing procedures. Thawed 
cells were placed in tissue culture flasks with the appropriate volume of medium and 
allowed to attach overnight. The following day cells were fed with fresh warmed 
medium to remove any residual traces of DMSO. 
2.1.7 Irradiation of cells 
Mouse embryonic fibroblasts (MEF) were routinely maintained in DMEM, 5% FCS. To 
harvest for irradiation, cells were trypsinised at 60-70% confluency, washed and 
transported in HBSS (Ca2+ and Mg 2+ free) to the cell irradiator, which was a MDS 
Nordion Gammacell 3000. Inactivation of MEFs was achieved by treatment with a 30 
gray radiation dose. Irradiated MEF were stored in liquid nitrogen in freezing media 
containing 10% DMSO, at a cell density of 500,000 cells per vial, sufficient for seeding 
3 wells of 6-well plate. 
2.1.8 Sterility checks 
Sterility checks were routinely carried out on all media and supplements used for cell 
culture. Samples of basal media were inoculated into columbia blood agar plates 
(Oxoid, CM331), sabauraud dextrose (Oxoid, CM217) and thioglycollate broths (Oxoid, 
CM173) which enable detection of most contaminants including bacteria, fungus and 
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yeast. All cell lines used in this study were mycoplasma-free, testing was carried out in-
house every four months. 
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2.2 Specialised techniques in cell culture 
 
2.2.1 Glucose stimulated insulin secretion (GSIS) assay of cultured cells 
The GSIS profile of MIN6 cells was examined at glucose concentrations of 3.3 and 16.7 
mmol/L. MIN6 cells were seeded at 2 x 105 cells/well in a 24-well plate and allowed to 
grow for 72 hours prior to the GSIS assay. Following this, 1X KRB (Krebs–Ringer 
Bicarbonate) was prepared from an aliquot of frozen 10X stock (36.525g NaCl, 2.2g 
KCl, 0.941g CaCl2.2H2O and 1.22g MgCl2.6H2O dissolved in 500mL H2O), BSA and 
HEPES were added to a final concentration of 0.1% and 25mM respectively. The KRB–
BSA was adjusted to pH 7.4 with 1M NaOH. This solution was incubated for 30 
minutes at 37°C and 5% CO2. Glucose concentrations of 3.3 and 16.7mmol/L were 
prepared with conditioned 1X KRB and placed at 37°C and 5% CO2 for 30 minutes. 
MIN6 cells to be analysed were rinsed twice in 1X KRB and were equilibrated with 1X 
KRB for 15 minutes at 37°C. After equilibration, the glucose-containing media was 
added (1mL/well), incubated at 37°C and 5% CO2 for 60 minutes. The GSIS assay was 
then terminated by placing the plate on ice. Conditioned medium (300µL) was removed 
from each well, placed in an ice-cold eppendorf tube, centrifuged at 1000 rpm for 2 
minutes and 200µL supernatant was removed for analysis by (pro)insulin ELISA 
(Mercodia, AB, Sylveniusgatan, Uppsala, Sweden 10-1124-10) (see section 2.2.2). A 
volume of 200µL of 0.1M NaOH was added to each well to lyse cells for protein assay 
normalisation (section 2.2.3). Plates were then stored at -20ºC until required. 
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2.2.2 ELISA Analysis for Insulin and Proinsulin 
Analysis of conditioned media was carried out using an insulin ELISA kit (Mercodia, 
10-1124-10). The kit was supplied with reagents, standards and pre-coated ELISA 
plates. Standard protocol was followed as per manufacturer’s instructions. In brief, 
standards and samples (25µL) were added directly to the coated plate (mouse 
monoclonal anti-insulin) in triplicate. 50µL conjugate solution (enzyme conjugate 11X 
in enzyme conjugate buffer) was then added to the samples and standards. The plate 
was wrapped in foil (to prevent debris falling into the wells) and incubated at room 
temperature for 2 hours on a belly dancer set to maximum speed. Following this, the 
conjugate/sample mixes were tapped off into the sink and the wells were washed 6 
times with washing solution (wash buffer 21X diluted with UHP). After washing, the 
plate was tapped firmly on absorbent tissue to remove the excess wash solution. At this 
point 200µL peroxidase substrate was added to each well. As it is light sensitive, this 
reaction was allowed to develop in the dark (the plate was wrapped in tinfoil) for 15 
minutes and stopped by adding 50µL stop solution per well. The plates were mixed 
gently and read at 405nm on a plate reader (BIO-TEK®, Synergy HT). 
2.2.3 Protein quantification 
Lysed samples were removed from the freezer and placed on ice.  A BSA stock solution 
of 1mg/mL was prepared in UHP.  Diluted BSA standards of 0, 0.2, 0.4, 0.6 and 
0.8mg/mL were prepared and 5µL of standards or sample were placed in triplicate wells 
on a 96-well plate (Costar, 3596). The Biorad Dc Protein Assay was used for protein 
quantification. 25µL of Reagent A (Bio-Rad, 500-0113) followed by 200µL of Reagent 
B (Bio-Rad, 500-0114) were added to each test well.  The plate was kept in the dark at 
room temperature for 15 minutes prior to reading absorbance at 750nm on a plate 
reader. 
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2.2.4 MiRNA transfection for monitoring GSIS 
MIN6 cells were transfected with Ambion® Pre-miR™ miRNA precursors and 
Ambion® Anti-miR™ miRNA inhibitors). Ambion® Pre-miR™ miRNA precursors are 
chemically modified dsRNA molecules designed to mimic mature miRNA molecules. 
They enable functional analysis of individual microRNAs via “gain-of-function” 
experiments. Ambion® Anti-miR™ miRNA inhibitors are chemically modified, single 
stranded nucleic acids designed to specifically bind to and inhibit mature miRNA 
molecules. They enable detailed study of miRNA biological effects via “reduction-of-
function” experiments. Pre-mir negative was used as a negative control for pre-mir 
experiments. Anti-mir negative was used as a negative control for anti-mir experiments.  
Cell suspensions were prepared at a cell density of 4x105 cells/mL. Solutions of 
pre/anti-mirs and negative controls were prepared in optiMEM (final concentration 
50nM). 2µL lipofectamine was diluted in 50µL optiMEM per well to be transfected, 
mixtures were incubated at room temperature for 5 minutes. After incubation diluted 
lipofectamine was added to each pre/anti-mir and negative control mix and incubated 
for a further 20 minutes. 100µL of pre/anti-mir/lipofectamine mix was added per well of 
24-well plate. 500µL cell suspension was then added to each well to achieve a final 
concentration of 2x105 cells/well, with 50nM pre/anti-mir and 2µL lipofectamine per 
well. Plates were gently mixed and incubated at 37ºC for 24 hours. At 24 hours the 
transfection media was removed and replace with complete growth media. Cells were 
allowed to grow for a further 48 hours until GSIS assay was performed (section 2.2.4) 
to determine effect of transfection on GSIS capacity of MIN6 cells. 
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2.2.5 Differentiation towards pancreatic cell types 
Cells were differentiated in either 2D or 3D culture. For 2D cultures 6-well plates were 
pre-coated with 1:20 dilution of matrigel (BD Biosciences, 354230) in DMEM for 30 
minutes prior to seeding cells. Cells to be differentiated were then added directly to the 
pre-coated plates and allowed to attach for 24 hours before addition of differentiation 
media. For 3D cultures, 24-well plates were percolated with 1.5mg/mL collagen type 1 
for 30 minutes. Cells to be differentiated were suspended in 600µL of media containing 
1.5mg/mL collagen type 1 and 200µL of matrigel. 800µL was then added to each well 
of a 24-well plate. 3D cultures were allowed to gel for 2 hours, then 350µL of media 
was added per well. Cells were allowed to proliferate for up to 3 days in 3D culture 
before initiation of differentiation.  
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2.2.5.1 Directed differentiation protocol 
Cells in 2D and 3D culture were treated with either differentiation media or control 
media. For iPS differentiation experiments control media consisted of iMEF 
conditioned iPS media. For stromal cell differentiation experiments control media 
consisted of standard stomal media - DMEM 10% FCS. Directed differentiation 
consisted of four stages, summarised in figure 2.1. 
Stage 1: Definitive endoderm induction 
Cells were treated with RPMI media supplement with 1X B27 (Invitrogen, 0080085-
SA), 4nM Activin A (R&D Systems, 338-AC), and 1mM Sodium Butyrate (Sigma, 
B5887) for 24 hours. Media was changed to RPMI, B27, 4nM Activin A and 0.5mM 
sodium butyrate, cells were cultured in this for 6 days. On day 8 cells were harvested 
for RNA to check expression of definitive endoderm markers. 
Stage 2: Pancreatic endoderm induction 
Cells in 2D culture were treated with 200units/mL collagenase IV and each well of a 6-
well plate was transferred to a well of an ultra-low attachment 6-well plate, while cells 
in 3D culture were maintained in the original 24 well plate. Media was changed to 
RPMI/B27 supplemented with 20ng/mL EGF (R&D systems, 236-EG), 2ng/mL bFGF 
(Invitrogen, 13256-029) and 100ng/mL noggin (R&D systems, 1967-NG). Cells were 
maintained in this media for 2 weeks. On day 22 cells were harvested for RNA to check 
expression of pancreatic endoderm markers. 
Stage 3: Endocrine induction 
Cells were cultured in RPMI/B27 media supplemented with 20ng/mL EGF and 
100ng/mL noggin for 1 week. On day 29 cells were harvested for RNA to check 
expression of endocrine markers. 
Stage 4: Islet maturation 
Cells were cultured in RPMI media supplemented with 0.5% BSA (Sigma, A7888), 
10mM nicotinamide (Sigma, N0636) and 50ng/mL insulin-like growth factor (R&D 
systems, 292-G2) for 5 days. Media was then changed to RPMI, 0.5% BSA and 10mM 
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nicotinamide for a further 2 days. On day 36 cells were harvested for RNA to check 
expression of mature islet markers. 
 
 
 
Figure 2.1 Summary of directed differentiation protocol used in this study for 
generation of pancreatic cells from iPS cells (Jiang, Au et al. 2007). 
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2.2.6 Generation of hanging drop cultures 
Stromal cells were trypsinised and a cell count performed. Cells were centrifuged at 
1,000 rpm for 5 minutes. Cell pellet was resuspended at a cell density of 1x106 
cells/mL. 20µL drops of cell suspension were placed of the inside lid of a petri dish, the 
lid was covered with drops and then placed on the petri dish base, 10mL water was 
added to the petri dish base to prevent evaporation of media. Hanging drops were 
incubated for 48 hours, and then transferred to suspension culture in petri dish coated 
with 2% agar. Cell clusters were maintained in suspension culture for 48 hours before 
seeding 2D, 3D or monolayer differentiation studies (section 2.2.5). 
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2.3 Lentivirus Techniques 
 
2.3.1 Generation of Lentiviral Particles 
Lentiviral particles were generated by co-transfecting the lentiviral ORF expression 
clone containing oct4 [EX-T2820-Lv07], sox2 [EX-T2547-Lv07], c-myc [EX-Z2845-
Lv07] or klf4 [EX-Z2836-Lv07] gene together with the lentiviral packaging plasmids 
(GeneCopoeia PLv-PK-01). The lentiviral ORF plasmid contains the elements required 
for packaging, transduction and stable integration of the viral construct into the host 
genomic DNA. While the lentiviral packaging plasmids contain the elements required 
for transcription and packaging of an RNA copy of the ORF construct into active viral 
particles.  
 
2.3.1.1 Transformation of ORF expression clones 
ORF expression clones were supplied by Genecopoeia on filter paper discs. To 
reconstitute the plasmids the filter paper discs were placed in 1.5mL centrifuge tubes 
containing 50µL TE buffer. Tubes were then incubated for 60 minutes at room 
temperature to allow resolubilisation of plasmids.  
 
To perform the transformation OneShot Max Efficiency DH5α T1 competent cells 
(Invitrogen 12297-016) were allowed to thaw on ice. 50µL of competent cells were 
added to 3µL of the reconstituted plasmids, or 3µL of pUC19 plasmid as a control 
transformation. Tubes were flicked to ensure even mixing of plasmid with cells and 
placed on ice for 5 minutes. Cell/plasmid mixtures were then heat-shocked for 30 
seconds at 42ºC, and then placed back on ice for 2 minutes. 500µL of pre-warmed SOC 
media (supplied with competent cells) was added to the cells/plasmid mix and incubated 
in a shaking incubator at approximately 250rpm at 37ºC for 45 minutes to allow cells to 
recover from the heat-shock. 100µL of transformation mixture was spread onto LB agar 
plates and incubated at 37ºC overnight.  
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2.3.1.2 Generation of ORF expression clone plasmid stocks 
Transformation colonies were picked and a single colony was seeded into 5mL LB 
broth cultures and incubated in a shaking incubator overnight. 1.5mL of culture media 
was then used to seed a 250mL large scale culture. After overnight incubation in a 
shaking incubator at 37ºC, plasmid DNA was harvested using Endofree Plasmid Maxi 
Kit (Qiagen 12362) as per manufacturer’s instructions. DNA concentration was 
assessed using the Nanodrop (section 2.4.4) and then stored at -80ºC until required. 
 
2.3.1.3 Plasmid transfection to generate viral particles 
293 cells were seeded in 90mm tissue culture dishes at a density of 4x106 cells/plate 
approximately 6 hours before performing transfection. DNA mix was prepared by 
adding 1µg of each of the packaging plasmids with 2µg of the ORF expression clone 
plasmid, made up to 15µL with TE buffer. Fugene was prepared by adding 18µL 
Fugene 6 (Roche, 11814443001) to 200µL opti-MEM reduced-serum media 
(Invitrogen, 11058-021) and allowed to stand for 5 minutes. DNA mix was added to 
diluted fugene mix and incubated at room temperature for 15 minutes. Media was 
removed from pre-plated 293 cells and replaced with 8mL fresh DMEM, the 
fugene/DNA mix was then added dropwise to the culture, swirled and incubated at 
37ºC. At 24 hours post transfection media containing Fugene was removed and fresh 
low serum media (DMEM 2% FCS) was added. Conditioned media was harvested at 48 
and 72 hours post-transfection and filtered with 0.45µM low protein binding filter. 
Conditioned media containing active viral particles was then aliquoted and stored at -
80ºC until required. 
 
61 
2.3.2 Lentivirus transduction for generation of iPS cells 
Cells to be transduced were seeded at a density of 5x104 cells/well in a 6-well plate one 
day before transduction. Media was removed and replaced with 1mL of fresh media per 
well. 250µL of each of the 4 viruses (oct4, sox2, c-myc and klf4) were mixed with 1µL 
of 8mg/mL polybrene, added dropwise to the well and incubated at 37ºC. After 24 
hours, media was removed and 1mL of fresh media added per well. 250µL of each of 
the viruses were mixed with 1µL polybrene, added drop wise to the well and incubated 
at 37ºC. After 24 hours, virus containing media was removed and replaced with fresh 
media. Five days after virus treatment, cells were trypsinised and cells from a single 
well of a 6-well plate were seeded into a 90mm tissue culture dish pre-coated with 
irradiated MEF cells. 24 hours after trypsinisation media was changed to iPS media. 
Colonies should appear approximately 10 days after trypsinisation.  
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2.3.3 Conditioned media generation of iPS cells 
Conditioned media induction of reprogramming was performed using limbal epithelial 
cells, using a protocol adapted from Balasubramanian et al., (Balasubramanian, Babai et 
al. 2009). Limbal epithelial cells were isolated from donor corneal-sclera ring using the 
explant technique. This involved growing of cells from explants on a transwell 
membrane with 3T3 feeder layers in the lower chamber. Once limbal epithelial cells 
began to emerge from the explants, cells were treated with enriched media (1X B27, 
20ng/mL EGF, 10ng/mL bFGF and 100ng/mL noggin) for 7 days, followed by 
treatment with ESD3 conditioned media (50% ESD3 conditioned media, 48% ES media 
and 2% FCS) for 10 days. In this study B27 supplement was used in the enriched media 
instead of N2 supplement used by Balasubramanian et al., 2009. 
 
2.3.3.1 Collection of ESD3 conditioned media 
ESD3 cells were grown on 0.1% gelatin coated flasks. Conditioned media was collected 
once cells reached 60% confluency. Conditioned media was centrifuged at 1,800rpm for 
5 minutes, filtered using 0.45µm filter and stored at -20ºC until required. 
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2.4 RNA Analysis 
 
2.4.1 RNA isolation cells using MirVana kit 
To analyse levels of RNA in cells, cell pellets of 1x105 cells were prepared. Cell pellets 
were washed twice with PBS and then stored at -80ºC until required. MirVana miRNA 
isolation kit (AM1560, Applied Biosystems) was used for all RNA analysis studies in 
section 3.1. MirVana miRNA isolation kit contains all wash buffers, lysis buffer and 
reagents required for the procedure, standard protocol was performed as per 
manufacturer’s instructions. In brief, 600µL lysis buffer was added to cell pellets, 
pipetting up and down to ensure complete lysis of cells. 1/10 volume of miRNA 
homogenate additive was added; mixed by vortexing and allowed to stand on ice for 10 
minutes. A volume of acid-phenol:chloroform (equal to the volume of lysis buffer 
added i.e. 600µL) was added, vortexed for 60 seconds and centrifuged for 5 minutes at 
maximum speed. The aqueous (upper) phase was carefully removed without disturbing 
the lower phase, and transferred to a fresh tube, taking note of the volume removed. 
1.25 times the noted volume of 100% ethanol was added to the aqueous phase and 
transferred to the filter cartridge in a collection tube. Up to 700µL was applied at a time, 
for larger samples larger the mixture was applied in successive applications to the same 
filter. Mixture was centrifuged for 15 seconds at 10,000 rpm, the eluent was discarded, 
and this was repeated until all of the lysate/ethanol mixture was through the filter. 
700µL miRNA wash solution 1 was applied to filter and centrifuged for 10 seconds. 
Flow-through was discarded. 500µL wash solution 2/3 was applied and centrifuged for 
10 seconds. Flow-through was discarded and wash step repeated with wash solution 2/3. 
Flow-through was discarded and filter cartridge was centrifuged for 1 minute to remove 
residual fluid from the filter. Filter cartridge was transferred to fresh collection tube; 
25µL RNase free water (pre-heated to 95ºC) was applied to the filter cartridge, taking 
care to cover the entire surface of the filter. This was centrifuged for 30 seconds at 
maximum speed to recover RNA, and repeated with 25µL RNase free water and 
centrifuged for a further 30 seconds at maximum speed, the eluent was collected and 
store at -80ºC until required.  
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2.4.2 RNA isolation from cells using TriReagent 
RNA isolation using TriReagent was used for RNA analysis in section 3.2. 1mL 
TriReagent was added per well of 24-well plate for RNA isolation. These samples were 
allowed to stand for 5 minutes at room temperature to allow complete dissociation of 
nucleoprotein complexes. 0.2mL of chloroform was added per mL of TriReagent. 
Samples were shaken vigorously for 15 seconds and allowed to stand for 15 minutes at 
room temperature. The resulting mixtures were centrifuged at 13,000 rpm in a 
microcentrifuge for 15 minutes at 4ºC. The colourless upper aqueous phase (containing 
RNA) was removed into a fresh tube. To this 0.5mL of ice-cold isopropanol (Sigma, 
I9516) was added. The samples were mixed and incubated at room temperature for 10 
minutes, and then centrifuge at 12,000 rpm for 30 minutes at 4ºC to pellet the 
precipitated RNA. Taking care not to disturb RNA pellet, the supernatant was removed 
and the pellet was subsequently washed by the addition of 750µL of 75% of ethanol and 
vortexed. The samples were centrifuged at 7,500 rpm for 5 minutes at 4ºC. The 
supernatant was removed and the wash step was repeated. The RNA pellet was allowed 
to air-dry for 10 minutes and then re-suspended in 50µL of RNase free water. To 
facilitate dissolution the sample was repeatedly pipetted.   
 
2.4.3 RNA isolation from serum using TriReagent 
Frozen serum samples were allowed to thaw on ice, and 250µL was aliquoted into 
labelled eppendorf tubes. To each 250µL serum aliquot 750µL TriReagent was added. 
TriReagent/serum samples were allowed to sit for 5 minutes to ensure complete 
dissociation of nucleoprotein complexes. 0.2mL of chloroform was added to each tube 
and shaken vigorously for 15 seconds, then allowed to stand for 15 minutes at room 
temperature. The resulting mixture was then centrifuged at 13,000 rpm in a 
microcentrifuge for 15 minutes at 4oC. The colourless upper aqueous phase (containing 
RNA) was removed into a fresh RNase-free eppendorf tube. Glycogen (Sigma, G1767) 
1.25 µL (final concentration 120 µg/mL) and 0.5 mL of ice-cold isopropanol (Sigma, 
I9516) were added. The samples were mixed by inverting, incubated at room 
temperature for 10 minutes and stored at -20oC overnight, to ensure maximum RNA 
precipitation.  
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Tubes were then centrifuge at 12,000 rpm for 30 minutes at 4oC to pellet the 
precipitated RNA. Taking care not to disturb RNA pellet, the supernatant was removed 
and the pellet was subsequently washed by the addition of 750µL of 75% of ethanol and 
vortexed. Centrifugation was followed at 7,500 rpm for 5 minutes at 4oC. The 
supernatant was removed and the wash step was repeated. Each RNA pellet was 
allowed to air-dry for 10 minutes and subsequently re-suspended in 5µL of RNase free 
water. To facilitate dissolution repeated pipetting was done (figure 2.2) 
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Figure 2.2 RNA isolation using TriReagent from serum 
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2.4.4 RNA Quantification using NanoDrop 
RNA was quantified spectrophotometrically at 260nm and 280nm using the 
NanoDrop® (ND-1000 spectrophotometer). A 1µL aliquot of RNA was placed on the 
nanodrop pedestal. The ND-1000 software automatically calculated the quantity of 
RNA in the sample based on an OD260 of 1 being equivalent to 40mg/mL RNA. The 
software simultaneously measured the OD280 of the samples allowing the purity of the 
sample to be estimated from the ratio of OD260/OD280. This was typically in the range of 
1.8-2.0. A ratio of <1.6 indicated that the RNA may not be fully in solution.  
2.4.5 Total RNA Analysis using the Bioanalyser 
The Agilent 2100 Bioanalyser is a microfluidics-based platform for the analysis of 
proteins, DNA and RNA. The miniature chips are made from glass and contain a 
network of interconnected channels and reservoirs. The RNA 6000 Nano LabChip kit 
was used for this study. 
RNA 6000 Nano Labchip kit contains all components required for the procedure, 
standard protocol was performed as per manufacturer’s instructions. In brief, RNA Gel 
Matrix was vortexed and 550µL added into top receptacle of spin filter and centrifuged 
at 4,000 rpm for 10 minutes. RNA dye concentrate was vortexed for 10 seconds and 
1µL added to 65µL of RNA gel matrix, and then vortexed to mix, gel-dye mix was then 
centrifuged for 10 minutes at 14,000 rpm. RNA samples to be analysed and RNA ladder 
were heat denatured at 70°C for 2 minutes. 
9µL gel-dye mix was added to the appropriate wells; the plunger was then pressed to 
allow gel-dye mix to enter channels. 5µL of fluorescent dye marker was added to each 
well, followed by 1µL of denatured RNA sample per well. 1µL RNA ladder was added 
into the well marker ladder to allow for size comparison of RNA samples. The chip was 
then vortexed at 2,400 rpm for 1 minute. 
The Agilent Bioanalyser instrument is fully automated and electrophoretically separates 
the RNA samples. The resulting data is represented as an electropherogram (figure 2.3).  
The fluorescence was measured on the Y-axis and the time in seconds is measured on 
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the X-axis. The first peak on the graph at 22.5 seconds represents the RNA marker, 
which acts as a control for each well. The second peak at approximately 25 to 28 
seconds represents the small RNA fraction; including miRNAs. The third and fourth 
peak at approximately 41 and 47.5 seconds represent the 18S and 28S ribosomal RNA. 
The height of peaks represents the quantity of RNA in each fraction. Figure 2.2 shows 
an example of good quality cell RNA, the 18S and 28S ribosomal RNA peaks are quite 
sharp. As RNA degrades, the 28S RNA peak decreases and smaller fragments are 
visible.  
 
 
 
 
 
 
Figure 2.3 Electropherogram generated using the Agilent Bioanalyser.  
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2.4.6 End-Point RT-PCR analysis 
2.4.6.1 DNase treatment of RNA 
 
Total RNA was pre-treated with RNase-free DNase to remove any contaminating 
genomic DNA. 1µg of RNA was treated with 1U of RNase-free DNase enzyme 
(Promega, M6101) according to table 2.4. RNA was incubated at 37ºC for 30 minutes. 
 
 
 
Reagent Volume 
RNA in water 1-8µL 
RQ1 RNase-free DNase 10X reaction buffer 1µL 
RQ1 RNase-free DNase 1U/µg RNA 
Nuclease-free water to a final volume of 10µL 
Table 2.4 Preparation of master mix for DNA digestion reaction 
 
To this mixture 1µL of RQ1 DNase Stop Solution was added to terminate the reaction, 
and mixture was incubated at 65ºC for 10 minutes to inactivate the DNase. 
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2.4.6.2 Reverse transcription of DNase-treated RNA 
Messenger RNA was copied to cDNA by reverse transcriptase (Sigma, M1302) using 
an oligo dT primer. Reverse transcription reaction was performed in two steps. Step one 
involved incubating 1µg RNA with the oligo dT primer and dNTPs for 10 minutes at 
70ºC according to table 2.5. The reaction mixture was then placed on ice and the 
remaining components for step two of the reverse transcription reaction were added 
according to table 2.6. 
Reagent Volume 
DNase-treated RNA 1µg RNA in 11µL 
10mM dNTPs (Sigma, DNTP100) 1µL 
50µM oligo dT (MWG) 1µL 
Table 2.5 Preparation of reaction mix for step 1 of reverse transcription 
 
Reagent Volume 
10X MMLV Reverse Transcriptase Buffer 2µL 
MMLV 1µL 
RNase Inhibitor (40U/µL) (Sigma, R2520) 0.5µL 
Nuclease-free water 3.5µL 
Table 2.6 Preparation of reaction mix for step 2 of reverse transcription 
 
Reaction mixtures were allowed to stand at room temperature for 10 minutes, and were 
then incubated at 37ºC for 50 minutes to allow first stand synthesis, followed by 10 
minutes at 80ºC to denature the MMLV reverse transcriptase. The resultant cDNA was 
stored at -20ºC until required. Minus RT negative controls were also prepared for each 
set of reactions, water was added instead of MMLV enzyme for the reverse transcription 
reaction. The resultant mix was then used as template for the PCR reaction. No 
amplification should be detected from the –RT controls. If a band is amplified this 
indicates that there is genomic DNA contamination in the isolated RNA. 
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2.4.6.3 PCR 
The cDNA was analysed for the expression of genes of interest by PCR. Table 2.7 lists 
the standardised PCR mix which did not change significantly throughout this thesis. 
2.5µL cDNA was added to the following reaction mixture (table 2.7). The samples were 
mixed and centrifuged before being placed on the thermocycler (Biometra). 
Reagent Volume 
10X PCR buffer 2µL 
25mM MgCl2 2.8µL 
10mM dNTPs (Sigma, DNTP100) 1.6µL 
10mM Forward primer (MWG) 1µL 
10mM Reverse primer (MWG) 1µL 
Taq DNA polymerase (Sigma, D4545) 0.2µL 
Nuclease-free water 8.9µL 
Table 2.7 PCR reaction mixture 
 
A typical PCR protocol is outlined below. However annealing temperatures can vary 
from primer set to primer set therefore a full list of the primers used in this thesis and 
the annealing temperatures are listed in table 2.8. 
95oC for 3 min    (Denaturation step) 
Followed by   
30 cycles of: 
 95oC for 30 seconds  (Denaturation) 
52-60oC for 30 seconds (Annealing) 
72oC for 1 minute  (Extension) 
And 
   72oC for 7 min   (Extension) 
Resultant PCR products were stored at -20ºC until they were analysed by gel 
electrophoresis.
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Target Forward & Reverse Primer 5’-3’ Annealing 
Temperature 
Product 
Size 
(bp) 
Oct-4 GTAAGCTGCGGCCCTTGCTG  
GGCACTGCAGGAACAAATTCT 
54ºC 165 
c-myc GGCGGGCACTTTGCACTGGA  
CGCGGGAGGCTGCTGGTTTT 
60ºC 190 
Klf4 GCAGCCACCTGGCGAGTCTG  
CCGCCAGCGGTTATTCGGGG 
62ºC 130 
Sox2 TAAATACCGGCCCCGGCGGA  
GGCGCCGGGGAGATACATGC 
59ºC 520 
Nanog TGAACCTCAGCTACAAACAG   
TGGTGGTAGGAAGAGTAAAG 
52ºC 154 
Amylase GATGGCGCCAAATAAGGAAC   
GACATCACAGTATGTGCCAG 
53ºC 197 
Sox17 CTCGACGGCTACCCGTTGCC    
TCCTTAGCTCCTCCAGGAAGTGTG 
62ºC 674 
Cxcr4 AGTTGATGCCGTGGCAAACTGGTA   
CAGGATAAGGCCAACCATGATGT 
58ºC 346 
Foxa2 GAGGACAAGTGAGAGAGCAAGTGG  
AGGAGTCTACACAGTAGTGGAAAC 
59ºC 235 
Hnf4α AGATTGCCAGCATCGCAGATGTG 
TGCCGAGGGACAATGTAGTCATT 
58ºC 224 
Pdx1 CGGACATCTCCCCGTACGAGGT 
TCATCCATGGGAAAGGCAGCTGG 
57ºC 180 
Hlxb9 ACTGCTCCTCGGAGGACGACTC 
CCAGCAGTTTGAACGCTCGTGAC 
57ºC 587 
Ngn3 CACTCGCACACGGGGGAACT 
TGGTGAGCTTCGCGTCGTCT 
56ºC 245 
Nkx6.1 TGGCCTGTACCCCTCATCAAGGA 
ACTTGGTCCGGCGGTTCTGGA 
57ºC 216 
Ptf1a TCCATCAACGACGCCTTCGAGG 
GGGAGGGAGGCCATAATCAGGGT 
56ºC 294 
Nkx2.2 GTCCAGGCCCAGCAGTGGACTT 
AACGCTGGGACGGTTTGGTCC 
58ºC 348 
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Pax4 TTGCCTGGCCCTGCCTCGAT 
TTTTTGGGGATGCATGCTGGAAGATTT 
56ºC 446 
Insulin AGCCGCAGCCTTTGTGAACCAACA 
TTCCATCTCTCTCGGTGCAGGAGGCG 
57ºC 326 
Ghrelin GAATCAAGCTGTCAGGGGTTC 
CTAAACTTAGAGAGAGGTGAGTAAG 
52ºC 145 
Somatostatin TTTGACCAGCCACTCTCCAGCTC 
TGCAGCCAGCTTTGCGTTCTCG 
57ºC 357 
Glut2 CTCACTATAGACATGTTTTGGGTGT 
AGTCCTGATATGCTTCTTCCAGC 
52ºC 370 
Glucagon AGGCAGCTGGCAACGTTCCCTTCA 
GCCAAGTTCTTCAACAATGGCGACC 
57ºC 382 
N-cadherin GTGCCATTAGCCAAGGGAATTCAGC   
GCGTTCCTGTTCCACTCATAGGAGG 
62ºC 370 
CK-12 GAAGAAGAACCACGAGGATG  
TCTGCTCAGCGATGGTTTCA 
54ºC 146 
CK-3 CGTACAGCTGCTGAGAATGA    
CTGAGCGATATCCTCATACT 
53ºC 261 
ABCG2 GGTTTCCAAGCGTTCATTCAAA  
TAGCCCAAAGTAAATGGCACCTA 
54ºC 112 
∆Np63 CTGGAAAACAATGCCCAGAC   
GGGTGATGGAGAGAGAGCAT 
55ºC 198 
β-actin CGGGAAATCGTGCGTGACAT   
GGAGTTGAAGGTAGTTTCGTG 
55ºC 228 
Table 2.8 List of primers used in this study. 
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2.4.6.4 Gel Electrophoresis of PCR products 
1% agarose (Sigma, A9539) gels were used for PCR gel electrophoresis, which were 
prepared and run in 1X TAE prepared with 10X TAE stock (121g Tris base, 9.3g 
EDTA, 28.5mL glacial acetic acid and made up to 500mL with UHP). The gel was then 
poured into an electrophoresis unit and supplemented with 5µL ethidium bromide 
(10mg/mL) per 50mL gel. Ethidium bromide is a dye that binds to double stranded 
DNA by interpolation (intercalation) between the base pairs. Here it fluoresces when 
irradiated in the UV part of the spectrum. Sample wells were formed by placing a comb 
into the top of the gel prior to hardening. 
To prepare the PCR product samples for electrophoresis, 2µL of 10X loading buffer 
(30% Glycerol, 0.1M EDTA, 0.25% bromophenol blue made up to 10mL with water) 
was added to 20µL PCR product and the mixture was loaded to the gel with an 
appropriate size marker (Sigma, P1473). The gels were electrophoresed at 100V for 45 
minutes. The gel was viewed with a gel analyzer (an EpiChemi II Darkroom, UVP 
Laboratory Products) and photographed using Labworks software (UVP). 
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2.4.7 Quantitative real time miRNA RT-PCR (qRT-PCR) 
2.4.7.1 Reverse Transcription of miRNA (cDNA Synthesis)  
For reverse transcription of miRNAs, cDNA was reverse transcribed from total RNA 
samples using specific miRNA primers from the TaqMan MicroRNA Assays and 
reagents from the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems) 
(figure 2.4). 
 
 
Figure 2.4 Two-step reverse transcription PCR of miRNAs (image from 
www.appliedbiosystems.com). 
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For each miRNA to be reverse transcribed a specific looped RT primer was used to 
reverse transcribe that specific miRNA (figure 2.4). For multiple miRNAs to be reverse 
transcribed from the same RNA sample, multiple reactions needed to be performed, as 
only a single miRNA species was reverse transcribed per reaction. 
Based on the nanodrop concentration reading, total RNA was diluted to 2ng/µL in 
RNase free water. 5µL of diluted RNA was added to an eppendorf tube. The RT-primer 
for the specific miRNA to be reverse transcribed, and the components of the TaqMan 
microRNA reverse transcription kit were allowed to thaw on ice. Once thawed, reverse 
transcription master mix was prepared as per table 2.9. Volumes from table 2.9 were 
scaled up when multiple reverse transcription reactions were performed, plus an extra 
10% excess was made up to allow for pipetting losses. 
 
Reagents Master Mix Volume / 15µL reaction 
100mM dNTPs 0.15µL 
MultiScribe Reverse Transcriptase, 50U/µL 1.00µL 
10x Reverse Transcription Buffer 1.50µL 
RNase Inhibitor, 20U/µL 0.19µL 
Nuclease-free water 4.16µL 
Total 7.00µL 
Table 2.9 miRNA reverse transcription master mix 
 
For each 15µL reverse transcription reaction, 5µL RNA (diluted to 2ng/µL), 7µL master 
mix and 3µL TaqMan RT-primer were added to a tube, mixed by vortexing, and 
centrifuged to bring mixture to the bottom of the tube. Reaction tubes were incubated on 
ice for 5 minutes before loading onto BioMetra T3 thermocycler, thermocycler 
parameters are outlined in table 2.10. 
 
Step Type Time (minutes) Temperature (ºC) 
Hold 30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
Table 2.10 Thermocycler parameters for microRNA reverse transcription reaction 
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2.4.7.2 TaqMan real-time miRNA PCR 
TaqMan probes are oligonucleotides that have fluorescent reporter dyes attached to the 
5' end and a non-fluorescent quencher coupled to the 3' end. These probes are designed 
to hybridize to an internal region of a PCR product. In the unhybridized state, the 
proximity of the fluorophore and the quencher molecules prevents the detection of 
fluorescent signal from the probe. During PCR, when the polymerase replicates a 
template on which a TaqMan probe is bound, the 5'- nuclease activity of the polymerase 
cleaves the probe. This decouples the fluorescent dye, thus, increasing the fluorescence 
in each cycle proportional to the amount of probe cleavage. 
TaqMan microRNA assays and TaqMan universal PCR master mix (Applied 
Biosystems) were used for miRNA PCR analysis in this study. cDNA synthesised as per 
section 2.4.7.1. was used as the template for PCR reactions. Each PCR reaction was 
performed in triplicates.  In order to exclude any amplification product derived from 
genomic DNA or any other contaminant that could contaminate the RNA preparation, 
total RNA without reverse transcription was used as a negative control.  As an 
additional control, water on its own was amplified as a negative control to rule out 
presence of any contaminating RNA or DNA. 
PCR master mix was prepared as described in table 2.11, and were scaled up when 
multiple PCR reactions were performed, plus an extra 10% excess was prepared to 
allow for pipetting losses. 
Reagents Master Mix Volume / 20µL reaction 
TaqMan Universal PCR master mix 10.00µL 
RNase-free water 7.67µL 
Total Volume 17.67µL 
Table 2.11 miRNA PCR master mix 
For each 20µL PCR reaction, 1.33µL cDNA (prepared from section 2.4.7.1), 17.67µL 
master mix and 1µL TaqMan miRNA assay mix (containing PCR primers and TaqMan 
probe) were added per well of a MicroAmp fast optical 96-well reaction plate (Applied 
Biosystems). Plates were then sealed with optical adhesive film (Applied Biosystems) 
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and run on the 7500 Fast Real-time PCR system according to the cycling parameters in 
table 2.12, on the 9600 emulation mode. 
 
AmpliTaq Gold® 
Enzyme Activation 
PCR 
Cycle (40 cycles) 
Step 
Hold 
Denature Anneal/Extend 
Time 10 min 15 sec 60 sec 
Temp (ºC) 95 95 60 
Table 2.12 Thermocycling parameters for miRNA PCR 
MiRNA real-time PCR analysis in this study was preformed using the TaqMan miRNA 
assays outlined in table 2.13. 
Real-time PCR data was analysed using the comparative cycle threshold (Ct) method, 
which involves comparison of the Ct values of the samples of interest with a control or 
calibrator sample (such as an untreated sample). The Ct values of both the calibrator and 
the samples of interest are normalised to an appropriate endogenous control, generating 
a ∆Ct for both the sample of interest and the control/calibrator samples.  
∆Ct = Ct [target] – Ct [endogenous control] 
∆∆Ct is then calculated as the difference between ∆Ct for the sample and calibrator. 
∆∆Ct = ∆Ct [sample] - ∆Ct [calibrator] 
Relative quantification (RQ) of target expression is calculated from the equation below 
as a difference of one Ct is equal to 2 fold change in expression level. 
RQ = 2-∆∆Ct 
RQ values greater than one indicate an increase in expression, while RQ values between 
zero and one indicate a reduction in expression levels. 
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Target miRNA Supplier Assay ID 
hsa-mir-376a# Applied Biosystems 4378104 
mmu-mir-369-5p Applied Biosystems 4378118 
hsa-mir-130a Applied Biosystems 4373145 
hsa-mir-27a Applied Biosystems 4373287 
hsa-mir-410 Applied Biosystems 4378093 
mmu-mir-124a Applied Biosystems 4373295 
hsa-mir-200a Applied Biosystems 4378069 
mmu-mir-337 Applied Biosystems 4373338 
hsa-mir-532 Applied Biosystems 4380928 
hsa-mir-320 Applied Biosystems 4373055 
mmu-mir-192 Applied Biosystems 4373308 
mmu-mir-379 Applied Biosystems 4373349 
hsa-mir-375 Applied Biosystems 4373027 
hsa-mir-9 Applied Biosystems 4373285 
hsa-let-7b Applied Biosystems 4373168 
hsa-mir-140 Applied Biosystems 4373138 
hsa-mir-21 Applied Biosystems 4373090 
hsa-mir-24 Applied Biosystems 4373072 
hsa-mir-29a Applied Biosystems 4373065 
hsa-mir-29c Applied Biosystems 4373289 
hsa-mir-30d Applied Biosystems 4373059 
hsa-mir-345 Applied Biosystems 4373039 
hsa-mir-28 Applied Biosystems 4373067 
hsa-mir-16 Applied Biosystems 4373121 
Table 2.13 TaqMan miRNA assays used for analysis of miRNA expression in MIN6 
cells and diabetes serum study. 
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2.4.8 TaqMan Low Density miRNA arrays (TLDAs) 
TaqMan low density miRNA arrays (TLDAs) consist of a 384-well microfludic card 
used for performance of 384 simultaneous real-time PCR reactions (figure 2.5). Each 
well contains a different set of TaqMan primers and probes, for detection of a single 
miRNA target. One RNA sample is used per card, to allow for profiling of 384 targets. 
 
Figure 2.5 TaqMan Low Density miRNA array format (image from 
www.appliedbiosystems.com). 
Reverse transcription of miRNAs for use on TLDA cards were performed using 
TaqMan Multiplex RT-primer pools. These Multiplex pools consisted of 8 separate 
primer pools, and each pool containing 48 different RT-primers allowing for reverse 
transcription of 48 different miRNAs per pool. Each primer pool corresponds to a port 
on the TLDA card, therefore 8 different primer pools allowed for reverse transcription 
of the 384 targets to be detected by the TLDA. 
RNA was isolated (as per section 2.4.1 for MIN6 TLDAs, and section 2.4.3 for diabetes 
serum TLDAs) and quantified (as per section 2.4.4), according to quantification reading 
RNA was diluted to 50ng/µL with RNase-free water. 2µL RNA was required per RT-
reaction, as 8 RT-reactions were required to run each TLDA card, therefore 16µL of 
diluted RNA was required. 
 81 
Each RT-reaction master mix was prepared as per table 2.14. For each samples 8 RT-
reactions were prepared, plus and extra 10% excess to allow for pipetting losses. 
Reagent Volume for one 
RT-reaction 
Volume for one sample 
(8 RT-reactions) 
100mM dNTPs 0.20µL 1.6µL 
MultiScribe reverse transcriptase, 
50U/µL 
2.00µL 16.0µL 
10X reverse transcription buffer 1.00µL 8.0µL 
RNase Inhibitor, 20U/µL 0.125µL 1.0µL 
RNase-free water 3.675µL 29.4µL 
Total 7.00µL 56.0µL 
Table 2.14 MultiPlex miRNA reverse transcription master mix 
Eight tubes were prepared per sample, for 8 multiplex reverse transcription reactions, to 
each tube 7µL master mix, 2µL diluted RNA, and 1µL of the appropriate MultiPlex RT-
primer pool were added. Tubes were mixed gently and centrifuged to bring solution to 
the bottom of tube and stored on ice for 5 minutes before loading thermocycler. 
Thermocyler parameters are outlined in table 2.15. 
 
Step Type Time (minutes) Temperature (ºC) 
Hold 30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
Table 2.15 Thermocycler parameters for MultiPlex miRNA reverse transcription. 
The generated cDNA was then diluted 62.5 fold by adding 615µL of RNase-free water 
to each of the 8 RT-reactions. 8 PCR master mixes per sample were prepared, as 
outlined in table 2.16, for each RT-reaction. 
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Reagent Volume per fill reservoir 
Diluted RT-reaction 50µL 
TaqMan universal PCR master mix 50µL 
Total 100µL 
Table 2.16 PCR master mix for miRNA TLDA 
 
Tubes were mixed and centrifuged to bring solution to the bottom of tube. 100µL of 
master mix from table 2.16 was loaded into the corresponding port on the TLDA card, 
i.e. RT-reaction mix generated from MultiPlex primer pool 1 was loaded into port 1 
(figure. 2.5). Once all the ports were loaded the TLDA card was centrifuged at 1,200 
rpm for 2 consecutive 1 minute spins. TLDA cards were then sealed and the ports 
removed, cards were then loaded onto the 7900HT Fast Real-Time PCR instrument on 
standard mode, with thermocycling parameters outlined in table 2.17. 
 
AmpErase UNG 
Activation 
AmpliTaq Gold® 
Enzyme Activation 
PCR 
Cycle (40cycles) 
Step 
Hold Hold 
Denature Anneal/Extend 
Time 2 min 10 min 30 sec 60 sec 
Temp (ºC) 50 94.5 97 59.7 
Table 2.17 Thermocycler parameters for miRNA TLDA analysis 
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2.5 Collecting Serum from blood 
 
Diabetes and control serum specimens were collected by Dr. Ana Rakovac Tisdall, 
Connolly Hospital Blanchardstown. Two blood specimens of approximately 10mL were 
taken with consent from each patient recruited for the diabetes and control serum study. 
From the collected blood samples, the red blood cells were allowed to clot naturally. 
These specimens were processed within 3-4 hours of blood draw. Serum specimens 
from control volunteers (no history or symptoms of diabetes) were also collected and 
processed the same way. 
 
Blood specimens were processed by removing the serum from the clotted blood and 
placing into a 10mL centrifuge tube. The tubes were then centrifuged at room 
temperature for 15 minutes at 400 rcf (relative centrifugal force). After centrifugation 
the cleared serum was carefully removed and passed through a 0.45µm filter to further 
ensure no particles / platelets were retained. The serum was then aliquoted into 1mL 
aliquots and stored at -80°C until required. Serum specimens were coded according to 
the order they arrived in DCU at e.g. DCU serum 1 (DS-1), DCU serum 2 (DS-2) etc. 
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2.6 Label-free LC-MS serum proteomics 
 
Proteomic analysis was performed on serum samples from newly diagnosed type 1 
diabetes (T1DM new), established diabetes (T1DM old), matched controls (control new 
and control old) and autoimmune samples. Serum samples were prepared using the 
ProteoMinerTM Protein Enrichment Kit (BioRad, 163-3007). ProteoMinerTM is a 
column-based technique, with the column containing a highly diverse bead-based 
library of peptide ligands. High abundance proteins saturate their high affinity ligands 
and excess protein is washed away, while low abundance proteins are concentrated on 
their specific ligands. ProteoMinerTM columns were prepared according to 
manufacturers instructions, 1mL of serum was then applied to column and rotated end-
on-end for 2 hours to allow binding of protein to ligand. Column was then washed and 
proteins eluted in 300µL of elution buffer. 
 
50µL of elute was then processed using the ReadyPrep 2D Cleanup Kit (BioRad, 163-
2130) according to manufacturers instructions. This kit allows for precipitation of 
protein leaving behind salts, detergents and nucleic acid contaminants. Precipitated 
protein was resuspended in 100µL of MS grade water. Protein concentration was 
assessed using Quick-Start Bradford Dye Reagent 1X (BioRad, 500-0205). Protein 
samples were diluted 1:4 with water, then 5µL diluted sample was added per well of a 
96 well plate. Each sample was analysed in triplicate. 200µL of Bradford reagent was 
added to each sample and incubated for 15 minutes. The absorbance was then read at 
595nm. Using the concentration calculated from the Bradford assay, 20µg of each 
sample was used for the digestion steps. 
 
To prepare protein samples for digestion, samples were first incubated with 1µL 5mM 
dithiothreitol reducing agent for 30 minutes at 37ºC. 1µL of 25mM iodoacetamide was 
then added to each sample and incubated in the dark for 20 minutes at room 
temperature. Digestion of protein samples was performed with Endoproteinase Lys-C 
(Promega, V1071) at a ratio of 100/1, protein/enzyme w/w, i.e. 20µg of protein was 
digested with 0.2ug of Endoproteinase Lys-C. Samples were incubated at 37ºC for 3 
hours to allow the digestion to occur. Samples were subsequently digested with trypsin 
(sequence grade, Promega). 7.5µL of trypsin and 80µL of 50mM ammonium 
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bicarbonate was added to each sample and incubated overnight at 37ºC. Following 
overnight incubation 2% trifluoroacetic acid (TFA) and 20% acetonitrile were added to 
each sample to stop the trypsin digestion. 
 
To prepare the samples for MS analysis, digested peptides were processed using 
PepClean C-18 Spin Columns (Pierce, 89870) according to manufacturer’s instructions 
to remove interfering contaminants and chemicals. Peptide samples were eluted in 80µL 
of 80% ACN/water v/v, dried down using a speed-vac (MAXI dry plus) and stored at -
20ºC until required. Samples were resolubilised in 80µL of LC-MS grade water with 
0.1% TFA and 2% ACN. 40µL was then transferred to glass vials. Mass spectrometry 
was performed by Dr. Paul Dowling. Peptides were first submitted to the nano-LC-
MS/MS using an Ultimate 3000 system (Dionex) coupled to an LTQ-Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific) operating in positive mode with a spray voltage 
of 1.6kV. 6.5µL of each sample was injected onto a C18 precolumn (300µm inner 
diameter x 5mm; Dionex) at 25µL/min in 5% ACN, 0.05% TFA. After a 3 minute 
desalting step, the precolumn was switched on line with the analytical column (75µm 
inner diameter x 25cm PepMap C18; Dionex) equilibrated in 98% solvent A (2% ACN, 
0.05% TFA) and 2% solvent B (98% ACN. 0.04% FA). Peptides were eluted using a 
10-35% gradient of solvent B during 150 minutes at a 300nL/min flow rate. Data were 
acquired with Xcalibur software version 2.0.7 (Thermo Fisher Scientific). The mass 
spectrometer was operated in the data-dependent mode and was externally calibrated. 
Survey MS scans were acquired in the Orbitrap in the 300-2000m/z range with the 
resolution set to a value of 60,000 at m/z 400. Up to seven of the most intense multiply 
charged ions (1+, 2+ and 3+) per scan were CID fragmented in the linear ion trap. A 
dynamic exclusion window was applied within 40s. All tandem mass spectra were 
collected using a normalized collision energy of 35%, an isolation window of 3m/z, and 
one microscan.  
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2.6.1 Validation of proteomics targets 
ELISAs were used for validation of targets identified from proteomic profiling study 
(section 2.5). Validation was performed on the same 8 newly diagnosed type 1 diabetes 
(T1DM new), established diabetes (T1DM old), and matched controls (control new and 
control old) serum specimens used for the profiling experiment, as well as an additional 
22 T1DM old and control old specimens 
2.6.1.1 Vitronectin 
A vitronectin ELISA kit was sourced from American Diagnostica GmbH (803). Serum 
specimens to be analysed were diluted by a factor of 4,000 using dilution buffer. 
Standards were reconstituted as per manufacturer’s instructions using dilution buffer. 
100µL of diluted samples or standards were added to each well, and incubated for 1 
hour at room temperature on a shaker at 250rpm. The plate was then washed 4 times 
using wash buffer and excess liquid was removed from the plate by tapping on 
absorbent paper 4-5 times between each wash step. 100µL of detection antibody was 
added to each well and incubated for 1 hour at room temperature on a shaker at 250rpm. 
The plate was then washed 4 times using wash buffer, and excess liquid was removed 
after each wash step by tapping plate on absorbent paper. 100µL of substrate was added 
and incubated for 5 minutes at room temperature. 50µL stop solution was added and 
plate was read at 450nm. A polynomial standard curve was plotted using the absorbance 
of the standards, using the equation of the line the vitronection concentration was 
calculated for each sample. 
 
2.6.1.2 Clusterin 
A clusterin ELISA was sourced from Phoenix Pharmaceuticals (EK-018-35). Serum 
specimens to be analysed were diluted by a factor of 6,000 using assay buffer. 
Standards were reconstituted as per manufacturer’s instructions using assay buffer. 
300µL assay buffer was added to each well of the ELISA plate and allowed to stand for 
5 minutes, buffer was then removed and plate tapped on absorbent paper to remove 
excess liquid. 100µL of diluted samples or standards were added to each well and 
incubated for 2 hours at room temperature on a shaker at 350rpm. Plate was washed 
four times using assay buffer, plate was tapped on absorbent paper to remove excess 
liquid between each wash step. 100µL of detection antibody was added to each well and 
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incubated for 2 hours at room temperature on a plate shaker at 350rpm. Plate was 
washed four times, tapping on absorbent paper between each wash. 100µL substrate 
solution was added and incubated for 30 minutes at room temperature on a shaker at 
350rpm. 100µL stop solution was added and absorbance was read at 450nm on a plate 
reader. Standard curve was plotted as log concentration versus log absorbance. Equation 
of the line was used for calculation of clusterin concentration in serum specimens. 
 
2.6.1.3 Vitamin K-dependent protein S 
A vitamin K-dependent protein S ELISA was sourced from USCN Life Science Inc. 
(E1971h). Serum specimens to be analysed were diluted by a factor of 10 using sample 
diluent. Standards were reconstituted as per manufacturer’s instructions using sample 
diluent. 50µL of diluted samples or standards were added to each well, followed by 
50µL of detection reagent A, and incubated for 1 hour at 37ºC. The plate was washed 
three times using wash buffer, and tapped on absorbent paper after the last wash to 
remove excess liquid. 100µL detection reagent B was added and incubated for 45 
minutes at 37ºC. The plate was washed five times with wash buffer, and tapped on 
absorbent paper after last wash. 90µL of substrate solution was added to each well and 
incubated at 37ºC for 30 minutes. 50µL of stop solution was added and absorbance read 
at 450nm on a plate reader. A 4-parament logistic standard curve was plotted and using 
the equation of the line vitamin K-dependent protein S concentration in serum 
specimens was calculated. 
 
2.6.1.4 Apolipoprotein L1 
An apolipoprotein L1 ELISA kit was sourced from USCN Life Science Inc. (E9374Hu). 
Serum specimens to be analysed were diluted by a factor of 5 using PBS. Standards 
were reconstituted as per manufacturer’s instructions using standard diluent. 100µL of 
diluted samples or standards were added to each well and incubated for 2 hours at 37ºC. 
Liquid was removed from wells, and without washing, 100µL of detection reagent A 
was added and incubated for 1 hour at 37ºC. The plate was washed three times using 
wash solution and tapped on absorbent paper after each wash to remove excess liquid. 
100µL of detection reagent B was added to each well and incubated for 30 minutes at 
37ºC. The plate was washed five times using wash solution, and tapped on absorbent 
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paper after each wash. 90µL of substrate solution was added to each well and incubated 
for 15 minutes at 37ºC. 50µL stop solution was added to each well and absorbance read 
at 450nm on a plate reader.  
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2.7 Serum metabolite profiling 
 
Overnight fasting whole blood specimens were collected from newly diagnosed type 1 
diabetes patients (n=8) and age/BMI/gender matched healthy controls (n=8). Samples 
were processed as outlined in section 2.5 and resulting serum specimens were stored at -
80ºC until required. Serum specimens (500µL) were shipped on dry-ice to Metabolon 
Inc., North Carolina, USA, where the metabolomic profiling was performed. 
 
Metabolon incorporates three independent complimentary analysis platforms to 
maximise the number of small molecules and metabolites that the combined systems 
can identify and measure. Two independent ultra-high performance liquid 
chromatography / tandem mass spectrometry (UHPLC/MS/MS2) injections (one 
optimised for basic compounds, and the other for acidic compounds) and one GC/MS 
injection per sample are performed. 
 
Firstly, small molecules were extracted from serum specimens using methanol to allow 
precipitation of proteins. The extract supernatant was then split into four equal aliquots; 
two for UHPLC/MS, one for GC/MS and one reserve aliquot. Aliquots were then dried 
overnight to remove solvent.  
 
For the UHPLC methods, one aliquot was reconstituted in 50µL 0.1% formic acid and 
the other in 50µL 6.5mM ammonium bicarbonate pH 8.0. For GC/MS analysis, aliquots 
were derivatized using equal parts N,O-bistrimethylsilyltrifluoroacetamide and a solvent 
mixture of acetonitrile:dichloromethane:cyclohexane (5:4:1) with 5% triethylamine at 
60ºC for 1 hour. All reconstitution solvents contained instrument internal standards used 
to monitor instrument performance.  
 
UHPLC/MS was carried out using a Waters Acquity UHPLC coupled to an LTQ mass 
spectrometer equipped with an electrospray ionization source. Two independent 
UHPLC/MS injections were performed on each sample. The acidic injections were 
monitored for positive ions and the basic injections were monitored for negative ions. 
The derivatized samples for GC/MS were analyzed on a Thermo-Finnigan Trace DSQ 
fast-scanning single-quadrupole MS. 
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The resulting MS/MS2 data was then searched against Metabolon’s reference standard 
library. This library was generated from 1500 standards and contains the retention 
time/index, mass to charge (m/z), and MS/MS spectral data for all molecules in the 
library, including their associated adducts, in-source fragments, and multimers. The 
library allows identification of experimentally detected metabolites based on a multi-
parameter match basis. All identifications and quantifications were subjected to QC to 
verify the quality of the identification and peak integration. 
 
2.7.1 Validation of metabolomics target – Fibrinopeptide A 
Validation of metabolite target was performed on the same 8 T1DM new and control 
samples as well as 30 T1DM old and control old samples. Fibrinopeptide A ELISA was 
sourced from Hyphen BioMed (catalogue number RK016A). Serum specimens to be 
analysed were diluted by a factor of 1,500 using sample diluent. Standards were 
reconstituted as per manufacturer’s instructions using sample diluent. 100µL of anti-
FPA antibodies were added to 1mL diluted samples or standards in an eppendorf tube, 
and incubated at 37ºC for 1 hour. 200µL of sample/antibody or standard/antibody mix 
was added to each well of ELISA plate, and incubated for 1 hour at room temperature. 
The plate was washed five times using wash solution. 200µL antibody conjugate 
solution was added to each well and incubated for 1 hour at room temperature. The plate 
was washed five times using wash solution. 200µL substrate solution was added to each 
well and incubated for 5 minutes at room temperature. 50µL stop solution was added 
and incubated for 10 minutes, and then absorbance was read at 450nm. Standard curve 
was plotted as log concentration versus log absorbance, and FPA concentration of 
samples was calculated using the equation of the line.  
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3.0 Results 
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3.1 MicroRNAs involved in glucose stimulated insulin secretion in MIN6 cells 
 
This study set out to investigate the mechanisms of regulated insulin secretion; in 
particular the role miRNAs might play in this process. As no human pancreatic beta-cell 
lines are currently available, a murine insulinoma cell line which exhibits regulated 
insulin secretion was used. However, with increasing time in culture MIN6 cells lose 
their glucose responsiveness. To investigate any possible role that miRNAs might play 
in regulated insulin secretion, miRNA analysis was performed on low passage glucose 
responsive and high passage glucose non-responsive cells. 
 
3.1.1 Identification of glucose responsive and non-responsive MIN6 cells 
The responsiveness of pancreatic β cells to glucose is measured as a fold change in 
insulin secretion (protocol outlined in section 2.2.1, 2.2.2 and 2.2.3). This fold change 
indicates the increase in insulin secreted in response to stimulatory concentrations of 
glucose (16.7mM glucose) compared to basal insulin secretion (3.3mM glucose). With 
increasing time in culture, this GSIS fold change decreases (figure 3.1.1).  
 
MIN6 cells were continuously cultured while monitoring GSIS at each passage to 
determine at which passage GSIS reached a minimum level. Insulin secretion was 
measured by ELISA, and data was normalised using protein assay to determine insulin 
secretion per mg of protein. 
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Figure 3.1.1 Increasing time in culture led to reduction of glucose stimulated insulin 
secretion (numbers above bars indicate fold change of insulin secretion in response to 
16.7mM glucose compared to 3.3mM glucose) (n=3). Error bars represent standard 
error (except passage 39, error bars represent range, n=2).  
 
 
 
Biological triplicate flasks were prepared and GSIS monitored at each passage, cell 
pellets for RNA extraction were also prepared at each passage. With increasing passage 
number average fold change decreases. Fold change variations between biological 
triplicates are seen due to the sensitive nature of the MIN6 cells. Passage 37 represents 
the most reproducibly glucose responsive cells, with an average GSIS fold change of 
3.3 (figure 3.1.1). Passage 40 represents the most non-glucose responsive cells, with an 
average GSIS fold change of 1.3 (figure 3.1.1). Therefore, passage 37 cell pellets were 
chosen as the glucose responsive sample and passage 40 cell pellets were chosen as the 
non-glucose responsive sample for miRNA profiling analysis. These passages are also 
sufficiently close to limit other changes in the cells, which could contribute to 
differential miRNA expression.  
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3.1.2 RNA quality control 
 
RNA was isolated from biological triplicate cell pellets of MIN6 glucose responsive and 
glucose non-responsive pellets (using technique outlined in section 2.4.1). Total RNA 
quality was assessed on the Agilent Bioanalyser, to ensure sufficient quality for miRNA 
profiling analysis (section 2.4.5). 
 
All traces show good quality RNA, with no signs of degradation (figure 3.1.2). Height 
of 18S and 28S peaks indicate high yield of isolated RNA. RNA appears to be of 
sufficient quantity and quality to proceed with miRNA profiling analysis. 
 
 
 
 
 
Figure 3.1.2 RNA traces of isolated RNA from Agilent Bioanalyser 
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3.1.3 TaqMan Low Density MicroRNA Arrays 
 
TaqMan Low Density microRNA arrays (TLDAs), available from Applied Biosystems, 
are 384-well micro fluidic cards used for performance of 384 microRNA real time PCR 
reactions simultaneously (protocol outlined in section 2.4.8). Each well contains a 
different TaqMan primer and probe set, detecting a different microRNA.  
 
At the time of experimentation TLDAs were only available in human format. Therefore, 
the human specific TLDAs were assessed for their suitability to be used with murine 
RNA. TLDAs are 384 well cards, 19 wells of which are controls containing either 
endogenous control assays or blank wells. The 365 remaining wells represent 365 
different human miRNAs. The sequence of each was retrieved from the miRNA 
database - miRBase (www.mirbase.org/) (Griffiths-Jones 2004; Griffiths-Jones, 
Grocock et al. 2006; Griffiths-Jones, Saini et al. 2008) and the human sequence was 
compared against the murine equivalent sequence to assess homology (figure 3.1.3). 
242 of 365 sequences were found to be conserved between human and mouse. For a 
further 121 sequences there was no murine equivalent registered in miRBase. The 
remaining 2 miRNA sequences represent what are now described as “dead” miRNAs 
i.e. sequences which were initially thought to be miRNAs but have more recently been 
described as potential tRNA fragments. 
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MiRNAs common to human and
mouse (unchanged in glucose
responsive vs. non-responsive MIN6
cells)
MiRNAs common to human and
mouse (differentially expressed in
glucose responsive vs. non-responsive
MIN6 cells)
MiRNAs not present in mouse
(according to miRBase, and not
detected in MIN6 TLDAs)
MiRNAs not present in mouse
(according to miRBase, but detected in
MIN6 cells by TLDAs)
Dead miRNAs
Controls
 
Figure 3.1.3 Pie chart representation of 384 well human TLDA card. 242 miRNAs 
were found to be common to human and mouse, 12 of which were identified as 
differentially expressed in glucose responsive MIN6 cells compared to glucose non-
responsive cells. A further 121 of the 384 miRNAs are not known to be present in 
mouse according to the miRBase (release 18, November 2011), 21 of which were 
detected by TLDA in MIN6 cells (table 3.1.1). 2 miRNAs (i.e. mir-594 and mir-565) 
are now known to be dead miRNAs, and 19 wells constitute control wells. 
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3.1.3.1 Novel murine miRNAs 
 
121 of 365 human miRNAs have no murine equivalent registered in miRBase. 
However, 21 of these 121 miRNAs were reproducibly detected in all 6 TLDA cards run 
with the murine MIN6 RNA samples, indicating that these human miRNA sequences 
may have a conserved murine homolog (table 3.1.1).  
 
MiRNA Average CT  
mir-515-3p 32.33 
mir-517a 33.64 
mir-517b 32.68 
mir-517c 33.46 
mir-518c 32.61 
mir-518d 32.22 
mir-518e 32.88 
mir-520f 34.88 
mir-521 33.96 
mir-518f 31.59 
mir-519c 32.53 
mir-519e 32.09 
mir-564 33.43 
mir-596 29.97 
mir-597 33.86 
mir-617 31.94 
mir-646 31.68 
mir-650 31.56 
mir-572 31.84 
mir-512-3p 34.05 
mir-659 31.96 
 
Table 3.1.1 Human miRNAs not previously known to have an equivalent homolog in 
mouse but detected by TLDA in MIN6 murine pancreatic β cells during the course of 
this study (n=6).  
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3.1.3.2 MiRNA profiling of glucose responsive compared to glucose non-responsive 
MIN6 cells 
 
In order to identify miRNAs which may be responsible for the loss of GSIS in MIN6 
cells, miRNA profiling was performed on glucose responsive MIN6 cells and glucose 
non-responsive MIN6 cells using TaqMan Low Density miRNA arrays (protocol 
outlined in section 2.4.8). Endogenous controls RNU44, RNU48 and RNU6B were 
incorporated onto each plate; however, none of these transcripts were detected in the 
samples used. Therefore, miRNA let-7b was chosen as endogenous control for 
normalisation, as levels of this miRNA were unchanged in all samples. Fold changes 
were calculated using the comparative Ct method detailed in section 2.4.7.2. Following 
application of Student’s t-test, differentially expressed targets were identified as 
miRNAs with p-value < 0.05. Using this criterion 10 differentially expressed miRNAs 
were identified (table 3.1.2). Mir-376a and mir-124a, although just beyond the level of 
statistical significance, were also added to this list for further investigation as (section 
1.5.1) these miRNAs are known to be highly expressed in pancreatic islets. All 
differentially expressed miRNAs were down-regulated in glucose non-responsive 
compared to glucose responsive MIN6 cells. 
 
Of the 246 miRNAs on the human TLDA panel which were present in mouse (including 
miRNAs not thought to have a murine homolog, but detected in this study in MIN6 
cells), 4.9% were differentially expressed in glucose responsive compared to non-
glucose responsive cells (table 3.1.2). Fold changes shown in table 3.1.2 are changes in 
glucose non-responsive cells compared to glucose responsive cells. All 12 differentially 
expressed miRNAs were down-regulated in non-GSIS cells compared to GSIS cells 
(table 3.1.2). This data was presented at RNAi 2008 (see poster appendix E). 
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Target miRNA 
Fold Change 
Glucose non-responsive Vs.  
glucose responsive MIN6 cells 
P-value 
mir-376a -2.6 0.055 
mir-369-5p -2.56 0.014 
mir-130a -2.53 0.037 
mir-27a -2.21 0.021 
mir-410 -2.19 0.018 
mir-124a -1.87 0.056 
mir-200a -1.79 0.037 
mir-337 -1.79 0.013 
mir-532 -1.43 0.017 
mir-320 -1.41 0.033 
mir-192 -1.35 0.015 
mir-379 -1.23 0.015 
Table 3.1.2 MiRNAs differentially expressed in glucose responsive and glucose non-
responsive MIN6 cells. Fold change indicates expression levels in glucose non-
responsive MIN6 cells compared to glucose responsive MIN6 cells. 
 
 
 100 
3.1.3.3 Validation of TLDA targets 
 
All 12 TLDA targets from table 3.1.2 were validated using single-plex RT-PCR 
(protocol outlined in section 2.4.7). Each miRNA target is reverse transcribed in a 
singleplex reaction. Table 3.1.3 shows results of single-plex experiments. For the TLDA 
experiment, let-7b was used as endogenous control in validation experiments, and 
glucose responsive, P37 cells were designated as calibrator. Fold changes indicated are 
for glucose non-responsive compared to glucose responsive cells. 
 
 
TLDA results Single-plex Results 
Target 
Fold change 
Glucose non-
responsive Vs. 
glucose responsive 
P-value 
Fold change 
Glucose non-
responsive Vs. 
glucose responsive 
P-value 
mir-376a -2.6 0.055 -1.86 0.0029 
mir-369-5p -2.56 0.013 -1.5 0.001 
mir-130a -2.53 0.037 1.15 0.45* 
mir-27a -2.21 0.02 1.3 0.15* 
mir-410 -2.189 0.018 -1.1 0.7* 
mir-124a -1.87 0.056 3.03 0.058* 
mir-200a -1.79 0.037 -2.69 0.0005 
mir-337 -1.79 0.01 -2.49 0.0018 
mir-532 -1.43 0.017 -1.88 0.0044 
mir-320 -1.41 0.03 -1.38 0.127* 
mir-192 -1.35 0.015 -1.63 0.069* 
mir-379 -1.23 0.0149 -1.56 0.038 
Table 3.1.3 Comparison of TLDA and single-plex validation results. Fold changes were 
calculated using the comparative Ct method. Fold changes indicate changes in non-
glucose responsive cells compared to glucose responsive cells. (*indicates non-
statistically significant result). 
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According to the single-plex validation experiment mir-130a, mir-27a, mir-410, mir-
124a, mir-320 and mir-192 were not statistically significantly differentially expressed in 
glucose responsive compared to glucose non-responsive cells, as p-values are greater 
than 0.05 (table 3.1.3). These results are conflicting with TLDA results, where all 
targets chosen were significantly differentially expressed between the two populations. 
 
Mir-124a was 1.56 fold down-regulated according to TLDA results, conversely, single-
plex validation experiments showed mir-124a up-regulated 3.03 fold (table 3.1.3). The 
p-value of mir-124a result from TLDA experiment is on the border of being statistically 
significant; this miRNA was chosen as a target regardless, as it had previously been 
shown to be involved in regulation of exocytosis related proteins (Plaisance, 
Abderrahmani et al. 2006). P-value for mir-124a from validation experiment remained 
on the border of statistical significance for single-plex validation experiments. 
 
Single-plex validation experiments showed reduced fold changes for mir-376a and mir-
369-5p, and improved fold changes for mir-200a, mir-337 and mir-532 compared to 
TLDA results (table 3.1.3). 
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3.1.3.4 Putative miRNA targets 
 
Microarray and proteomic studies performed in house identified mRNAs (Gammell 
2002; O'Driscoll, Gammell et al. 2006; Rani 2008) and proteins (Dowling, O'Driscoll et 
al. 2006) differentially expressed in glucose responsive compared to glucose non-
responsive MIN6 and MIN6 B1 cells. Here, bioinformatic analysis was performed on 
these mRNA and protein targets using the miRanda algorithm 
(http://www.microrna.org/microrna/home.do) to determine if they could potentially be 
regulated by the miRNAs identified as of interest in this study. A large number of these 
mRNAs were found to contain putative binding sites for the target miRNAs, including 
several mRNAs of which could potentially be targeted by more than one of the 
identified miRNAs. Table 3.1.4 shows mRNAs and proteins which were up-regulated in 
glucose non-reponsive cells, representing potential targets for the miRNAs down-
regulated in this cell population.  
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MicroRNA mRNA (Gammell 2002; O'Driscoll, Gammell et 
al. 2006; Rani 2008) 
Protein 
(Dowling, 
O'Driscoll 
et al. 2006) 
mir-376a Faf1 N/A 
mir-130a Egr1, neuroD1, gap 43, txnip, Rgs4, Mxi1, 
IVNS1abp, meox2 (x2), ccna2, smn (x2), BMP6 
N/A 
mir-27a Isl1, Bhlhb9, ube2g1, Pnrc1, meox2, FGF12, btg2 DUT 
mir-410 Pld1, Rgs4, Serf1, eya2 Hmgb1 (x2) 
mir-124a Egr1, Trib1, eif4b, meox2, ccna2, btg2, eya2 N/A 
mir-200a Ceacam1, txnip, Jun, Rgs4, IVNS1abp (x2), smn, 
Faf1 
Hmgb1 
mir-320 Mxi1 (x2), bri3, FGF12 (x2), gnas, btg2 (x2), BMP6 Ppp1cb 
mir-192 N/A Hmgb1 (x2) 
mir-379 Dusp1 N/A 
Table 3.1.4 mRNAs and proteins previously identified in our laboratory as up-regulated 
in glucose non-responsive compared to glucose responsive MIN6 and MIN6 B1 cells 
(Gammell 2002; Dowling, O'Driscoll et al. 2006; O'Driscoll, Gammell et al. 2006; Rani 
2008) with putative binding sites for miRNAs identified here by TLDAs (x – multiple 
putative binding sites in target mRNA, N/A – non-applicable, no putative binding sites 
found in these mRNA sequences).  
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3.1.4 Functional Validation of microRNA targets 
 
Functional validation of miRNA targets was performed in order to evaluate miRNA 
effect on GSIS, using the protocol outlined in section 2.2.4.  Pre-mir and anti-mirs were 
used for over-expression and knockdown of miRNAs respectively. All target miRNAs 
were down-regulated in non-glucose responsive cells, following from this knockdown 
of miRNA targets in glucose responsive cells would be expected to lead to a reduction 
in GSIS. While over-expression of miRNA targets in glucose non-responsive cells 
would be expected to lead to an increase in the GSIS response. However, as is often 
observed in science, functional validation studies may not always follow the trend 
observed in the profiling study. To allow for this possibility, functional validation over-
expression studies were performed in cells with a GSIS response to ensure that 
‘unexpected’ reductions in GSIS may also be observed. 
 
A time course assay was performed to determine how long the effect of anti-mir was 
present in the cell. As an example, cells were transfected with anti-mir-532 to 
knockdown expression of mir-532; anti-mir-negative was transfected into cells as a 
control. RNA was collected at several time points from anti-mir-532 and control 
transfected cells and assessed for mir-532 levels (table 3.1.5) (section 2.4.7). 96% 
knockdown of miRNA levels was achieved after only 24 hours, with knockdown only 
decreasing slightly to 80% by 144 hours (figure 3.1.4). 
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Time Treatment Ct Mir-532 Ct let-7b ∆Ct ∆∆Ct RQ 
% mir-532 
knockdown 
24hrs am-neg  30.463 26.186 4.277  0 1 0 
  am-532 34.588 25.549 9.039 4.762 0.037 96.3 
48hrs am-neg  30.029 25.649 4.38  0 1 0 
  am-532 33.484 25.722 7.761 3.381 0.096 90.4 
72hrs am-neg  29.798 25.214 4.584  0 1 0 
  am-532 32.319 24.669 7.65 3.066 0.119 88.1 
96hrs am-neg  28.92 24.373 4.548  0 1 0 
  am-532 32.603 24.844 7.759 3.211 0.108 89.2 
120hrs am-neg  28.53 24.111 4.419  0 1 0 
  am-532 31.716 24.206 7.51 3.091 0.117 88.3 
144hrs am-neg  28.391 24.169 4.222  0 1 0 
  am-532 30.418 23.788 6.629 2.407 0.189 81.1 
Table 3.1.5 Time course assay for knockdown of mir-532. Cells were transfected with 
anti-mir-532 (am-532) or anti-mir-negative (am-neg), and levels of mir-532 measured at 
set time-points. Let-7b was used as endogenous control for normalisation of PCR data. 
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Figure 3.1.4 Percentage knockdown of mir-532 levels in MIN6 cells treated with anti-
mir-532 (am-532) and control anti-mir-negative (am-neg). Data normalised to 
endogenous control let-7b. 
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A time point of 72 hours post-transfection was chosen for determination of GSIS 
response following manipulation of miRNA expression as anti-mir still exhibiting 
approximately 90% knockdown of miRNA expression at this stage (figure 3.1.4). Also, 
72 hours post transfection potentially allows time for manipulated miRNA to effect the 
target mRNA and allow any downstream effect on GSIS to be detected. 
 
Knockdown and over-expression experiments were performed for each target miRNA. 
For miRNAs which exhibited an effect on GSIS, experiments were carried out a large 
number of times to establish if these effects were reproducible or just a random 
variation in GSIS of MIN6 cells. Results of individual assays can be seen in appendix 
A. Biological triplicate experiments were then chosen from the large number of 
individual assays as representatives of manipulation of each specific miRNA, the 
Student’s t-test was then applied to determine if such changes were of statistical 
significance. 
 
For miRNAs which did not exhibit effects on GSIS, experiments were performed at 
least in biological duplicate. Anti-mir negative, pre-mir negative and untreated controls 
were performed with each experiment to prove that effect on GSIS was due to 
manipulation of specific miRNA, rather than a more general or non-specific event. 
According to our TLDA analysis, each of the 12 miRNAs had reduced expression in 
glucose non-responsive MIN6 cells (table 3.1.2); therefore, pre-mir over-expression of 
miRNA would be expected to improve GSIS function, while anti-mir reduction of 
miRNA would be expected to reduce GSIS function. Functional validation experiments 
were designed to perform pre-mir over-expression experiments in low or non-GSIS 
cells, as pre-mir transfection was expected to improve GSIS, and anti-mir knockdown 
experiments in GSIS-competent cells, as anti-mir transfection was expected to reduce 
GSIS based on the TLDA results. However, due to the variable nature of the GSIS 
response in MIN6 cells sometimes cells which were expected to exhibit low or non-
GSIS response showed a good GSIS, while cells expected to exhibit good GSIS 
response were low or non-GSIS response. 
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3.1.4.1 Mir-410 
 
Mir-410 expression was reduced in non-GSIS MIN6 cells (table 3.1.2), therefore 
knockdown of this target with mir-410 inhibitors was expected to reduce GSIS function 
of MIN6 cells, while mir-410 mimics were expected to improve GSIS function. 
 
(a) Knockdown of mir-410 
Anti-mir-410 (am-410) was transfected into MIN6 cells (section 2.2.4). GSIS response 
of cells was then measured following 72 hours post transfection to test the effects of 
miRNA manipulation on GSIS (section 2.2.1). 
 
Transfection controls can be inconsistent with large differences in the GSIS fold change 
of control cells, therefore triplicate experiments (appendix A, figure 3, 10 and 11) where 
the GSIS of controls was consistent were taken as representatives of the effect of 
knockdown of mir-410 levels in MIN6 cells. Knockdown of mir-410 in GSIS-
competent cells using am-410 led to a reduction in GSIS, from 2.3 fold GSIS in am-neg 
treated cells to 1.6 fold GSIS in am-410 treated cells. The Student’s t-test showed that 
the decrease in GSIS of these triplicate experiments was statistically significant (figure 
3.1.5). 
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Figure 3.1.5 Knockdown of mir-410 levels in GSIS-competent MIN6 cells (error bars 
indicate standard error of biological triplicates). 
 
*P ≤ 0.05 
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(b) Over-expression of mir-410 
 
Pre-mir-410 (pm-410) was used for over-expression of mir-410 levels in MIN6 cells 
(section 2.2.4). GSIS response of cells was then measured 72 hours post transfection to 
test effects of miRNA manipulation on GSIS (section 2.2.1). 
 
A large number of repeats were performed for this assay to determine if over-expression 
of mir-410 had an effect on GSIS. Some assays showed large differences in GSIS fold 
change of controls. When the fold change of pm-410 transfected cells is within this 
range it is difficult to determine the effect of pm-410 transfection or if an effect is being 
disguised by the large range in GSIS of controls. Therefore, three replicate experiments 
where the effect of pm-410 was obvious and did not lie within the large range in GSIS 
of controls, were taken as representative experiments (appendix A, figures 17, 19 and 
21). Over-expression of mir-410 in GSIS-competent MIN6 cells led to an increase in 
GSIS response in these cells, from 1.6 fold GSIS in pm-neg treated cells to 3.8 fold 
GSIS in pm-410 treated cells. The t-test of these replicates indicated that the increase in 
GSIS in pm-410 transfected cells relative to pm-neg transfected cells is statistically 
significant (figure 3.1.6).  
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Figure 3.1.6 Over-expression of mir-410 in GSIS-competent MIN6 cells (error bars 
indicate standard error of biological triplicates) (* indicates statistical significance p-
value ≤ 0.05). 
*P ≤ 0.05 
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3.1.4.2 Mir-200a 
 
Mir-200a expression was reduced in non-GSIS MIN6 cells (table 3.1.2), therefore, 
knockdown of this target with anti-mir-200a (am-200a) was expected to reduce GSIS 
function of MIN6 cells, while mir-200a over-expression (pm-200a) was expected to 
improve GSIS function. 
 
(a) Knockdown of mir-200a 
Three assays (appendix A, figures 25, 26 and 27) were picked as representatives of the 
effect of mir-200a over-expression. Knockdown of mir-200a in GSIS-competent MIN6 
cells led to a reduction in GSIS response in these cells, from 1.6 fold GSIS in am-neg 
treated cells to 0.9 fold GSIS in am-200a treated cells. The Student’s t-test of these 
replicates (figure 3.1.7) indicated a statistically significant decrease in GSIS of am-200a 
transfected cells relative to am-neg transfected cells. 
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Figure 3.1.7 Knockdown of mir-200a levels in GSIS-competent MIN6 cells (error bars 
indicate standard error of biological triplicates) (* indicates statistical significance p-
value ≤ 0.05). 
 
(b) Over-expression of mir-200a 
Three replicates for mir-200a over-expression were tested; however, no clear trend for 
mir-200a functional effect on GSIS was seen. 
 
*P ≤ 0.05 
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3.1.4.3 Mir-130a 
 
Mir-130a expression was reduced in non-GSIS MIN6 cells (table 3.1.2), therefore 
knockdown of this target with mir-130a inhibitors was expected to reduce GSIS 
function of MIN6 cells, while mir-130a mimics were expected to improve GSIS 
function. 
 
(a) Knockdown of mir-130a 
Appendix A, figure 34, 36 and 37, were chosen as representative assays for the effect of 
mir-130a knockdown. Knockdown of mir-130a in GSIS-competent cells led to a 
decrease in GSIS in these cells, from 1.8 fold GSIS in am-neg treated cells to 1.1 fold 
GSIS in am-130a treated cells. The Student’s t-test determined that the decrease in 
GSIS of am-130a cells relative to am-neg transfected cells was statistically significant 
(figure 3.1.8).  
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Figure 3.1.8 Knockdown of mir-130a levels in GSIS-competent MIN6 cells (error bars 
indicate standard error of biological triplicates) (* indicates statistical significance p-
value ≤ 0.05). 
 
 
 
 
*P ≤ 0.05 
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(b) Over expression of mir-130a 
Over-expression of mir-130a showed reduced GSIS relative to control cells in three of 
five replicates performed (appendix A, figures 41, 42 and 44). These replicates were 
taken as representatives of the effect of over-expression of mir-130a. Over-expression 
of mir-130a in GSIS-competent cells led to a slight, but not statistically significant 
reduction in GSIS response in these cells from 2.2 fold GSIS in pm-neg treated cells to 
1.3 fold GSIS in pm-130a treated cells (figure 3.1.9). 
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Figure 3.1.9 Over-expression of mir-130a in MIN6 cells (error bars indicate standard 
error of biological replicates). 
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3.1.4.4 Mir-376a 
 
Mir-376a expression was reduced in non-GSIS MIN6 cells (table 3.1.2), therefore 
knockdown of this target with mir-376a inhibitors was expected to reduce GSIS 
function of MIN6 cells, while mir-376a mimics were expected to improve GSIS 
function.  
 
(a) Knockdown of mir-376a 
 
Knockdown of mir-376a levels was performed in five replicates, with two replicates 
showing no effect on GSIS, two replicates showing slightly reduced GSIS relative to 
control cells, while the last replicate had unreliable controls. Therefore there were no 
clear trends of an effect on GSIS following knockdown of mir-376a levels.  
 
(b) Over-expression of mir-376a 
 
Over-expression of mir-376a was assessed in five replicates, two replicates showing 
increased GSIS relative to control cells, two replicates showed decreased GSIS, while 
one replicate showed unreliable controls, therefore no clear trends of an effect were 
observed in GSIS for over-expression of mir-376a.  
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3.1.4.5 Mir-369-5p 
 
(a) Large-scale assays for over-expression and knockdown of mir-369-5p 
expression 
 
Performing transfection GSIS assays in bulk (appendix A, figures 55 and 56) led to 
diminished GSIS response compared to cells at the previous passage when a single 
GSIS assay was performed. Therefore, the numbers of transfection controls were 
reduced. Also, knockdown transfections were performed separate to over-expression 
transfections, to try to maintain a good GSIS response of cells. 
 
(b) Knockdown of mir-369-5p 
 
Knockdown of mir-369-5p transfections were performed a number of times, three 
replicates showed no change in GSIS of am-369-5p transfected cells, two replicates 
showed unreliable controls, while five replicates showed a decrease in GSIS following 
knockdown of mir-369-5p levels relative to controls cells. Three of these replicates 
were taken as representatives of the effect of am-369-5p (appendix A, figure 60, 61 and 
64). An average of 1.3 fold GSIS was seen for am-neg treated cells compared to 0.8 fold 
GSIS for am-369-5p treated cells. The Student’s t-test was applied to these replicates; 
however, the decrease in GSIS was not statistically significant (figure 3.1.10). 
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Figure 3.1.10 Knockdown of mir-369-5p levels in MIN6 cells (error bars indicate 
standard error of biological triplicates). 
 
 
 
(c) Over-expression of mir-369-5p 
 
Seven replicates of mir-369-5p over-expression were performed; four replicates showed 
no effect of mir-369-5p over-expression on GSIS, one replicate showed improved GSIS, 
while two replicate showed unreliable controls. Therefore, the trend showed that over-
expression of mir-369-5p did not affect GSIS. 
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3.1.4.6 Mir-27a 
 
(a) Large-scale assays for over-expression and knockdown of mir-369-5p 
expression 
 
Performing transfection GSIS assays in bulk (appendix A, figure 70 and 71) led to 
diminished GSIS response compared to cells at the previous passage when a single 
GSIS assay was performed. Therefore the numbers of transfection controls were 
reduced; also knockdown transfections were performed separate to over-expression 
transfections, to try to maintain a good GSIS response of cells. 
 
(b) Knockdown of mir-27a 
 
Five replicates of mir-27a knockdown were performed, three of which indicated that 
knockdown of mir-27a did not effect GSIS relative to control cells (appendix A, figure 
71, 72 and 74). 
 
(c) Over-expression of mir-27a 
 
Six replicates of mir-27a over-expression were performed, three indicated that over-
expression of mir-27a did not have any effect on GSIS relative to control cells 
(appendix A, figures 71, 75 and 76), two replicates showed decreased GSIS (appendix 
A, figures 77 and 78) and one replicate had inconsistent controls (appendix A, figure 
70). Therefore, the general trend of mir-27a over-expression is no effect on GSIS. 
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3.1.4.7 Mir-124a 
 
Mir-124a expression was reduced in non-GSIS MIN6 cells (table 3.1.2), therefore, 
increasing and decreasing mir-124a expression should increase and decrease GSIS 
response of these cells, respectively. 
 
(a) Knockdown of mir-124a  
Mir-124a knockdown assay was performed a number of times to determine the effect on 
GSIS, the general trend to the assays indicates that knockdown of mir-124a does not 
affect GSIS relative to control cells. 
 
(b) Over-expression of mir-124a 
Seven replicates of mir-124a over-expression were performed, two of which showed no 
effect on GSIS (appendix A, figures 91 and 92), two showed in increase in GSIS 
(appendix A, figure 87 and 88), and a further two showed a decrease in GSIS (appendix 
A, figures 86 and 89), therefore no clear trend was observed for effect of mir-124a over-
expression on GSIS. 
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3.1.4.8 Mir-337 
 
Mir-337 expression was manipulated in MIN6 cells to determine if changes in the 
expression levels of this miRNA could affect GSIS phenotype of the cells. 
 
(a) Knockdown of mir-337  
The general trend for mir-337 knockdown, showed that knockdown of mir-337 levels 
did not affect GSIS compared to control cells. 
 
(b) Over-expression of mir-337 
No clear trends are observed for the effect of over-expression of mir-337 on GSIS 
response of MIN6 cells. 
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3.1.4.9 Mir-532 
 
Mir-532 expression was reduced in non-GSIS MIN6 cells according to TLDA analysis 
(table 3.1.2), therefore manipulation of miRNA expression to increase and decrease mir-
532 levels would be expected to increase and decrease GSIS responsiveness of the cells 
respectively. 
 
(a) Knockdown of mir-532 
Duplicate assays for knockdown of mir-532 showed no effect on GSIS relative to 
control cells; therefore no triplicates were performed as the trend was clear from 
duplicate assays. 
 
(b) Over-expression of mir-532 
Of three replicate performed, two experiments show no effect on GSIS for pm-532 
transfected cells, therefore, the general trend indicates that over-expression of mir-532 
does not affect the GSIS capability of MIN6 cells. 
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3.1.4.10 Mir-320 
 
Mir-320 levels were manipulated in MIN6 to determine if this miRNA played a 
functional role in GSIS of these cells. 
 
(a) Knockdown of mir-320 
Six replicates were performed for knockdown of mir-320; five replicates were in 
agreement that no effect on GSIS was observed for am-320 treated cells. Therefore, the 
trend indicates that knockdown of mir-320 does not effect the GSIS capability of MIN6 
cells.  
 
(b) Over-expression of mir-320 
Appendix A, figure 111 indicates that over-expression of mir-320 may lead to a 
decrease in GSIS; however, this transfection would have to be repeated to determine if 
this is a true effect of mir-320 over-expression. 
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3.1.4.11 Mir-192 
 
Mir-192 levels were reduced in non-GSIS MIN6 cells, therefore, manipulation to 
increase and decrease levels of this miRNA would be expected to increase and decrease 
GSIS responsiveness, respectively. 
 
(a) Knockdown of mir-192  
Three of four replicates for knockdown of mir-192 showed no effect on GSIS, therefore, 
the trend indicates that knockdown of mir-192 did not affect the GSIS capability of 
MIN6 cells. 
 
(b) Over-expression of mir-192 
Two of three replicates for over-expression of mir-192 showed a decrease in GSIS; 
therefore, the general trend indicates that over-expression led to a decrease in GSIS 
capability of MIN6 cells. 
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3.1.4.12 Mir-379 
 
Mir-379 levels were manipulated in MIN6 cells to determine if this miRNA played a 
role in the GSIS phenotype of these cells. 
 
(a) Knockdown of mir-379 
Duplicate assays for knockdown of mir-379 showed no effect on GSIS relative to 
control cells; therefore, no triplicates were performed as the trend was clear from 
duplicate assays. 
 
(b) Over-expression of mir-379 
Two of three replicates showed a decrease in GSIS of pm-379 transfected cells, 
therefore, the general trend indicates that over-expression of mir-379 led to a decrease 
in the GSIS capability of MIN6 cells. 
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3.1.4.13 Summary of Functional Validation Studies 
 
Table 3.1.6 summarises results of functional validation of miRNA targets. Mir-410, 
mir-200a and mir-130a exhibited significant effects on GSIS following manipulation 
with miRNA inhibitors and mimics. 
 
 
 
MicroRNA 
Anti-Mir knockdown of 
miRNA 
Pre-Mir over-expression of 
miRNA 
mir-376a No effect No effect 
mir-369-5p Reduced GSIS minimally No effect 
mir-130a Reduced GSIS *  Reduced GSIS minimally 
mir-27a No effect No effect 
mir-410 Reduced GSIS *  Improved GSIS *  
mir-124a No effect No effect 
mir-200a Reduced GSIS *  No effect 
mir-337 No effect No effect 
mir-532 No effect No effect 
mir-320 No effect Reduced GSIS minimally 
mir-192 No effect Reduced GSIS minimally 
mir-379 No effect Reduced GSIS minimally 
Table 3.1.6 Functional validation of miRNA targets in MIN6 cells. (* denotes statistical 
significance). 
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3.1.5 Summary of miRNAs involved in GSIS in MIN6 cells 
 
Using TLDA technology, this study identified 12 miRNAs differentially expressed 
between glucose responsive and glucose non-responsive MIN6 cells (table 3.1.2), as 
well as 12 novel murine miRNAs (table 3.1.1). Over-expression and knockdown studies 
were performed on these miRNA targets in MIN6 cells to determine if these miRNAs 
played a functional role in the regulation of GSIS. Knockdown of mir-410, mir-200a 
and mir-130a in GSIS competent MIN6 cells led to a significant decrease in GSIS 
response compared to anti-mir negative transfected control cells. These three miRNAs 
may function in supporting the capability of MIN6 cells to secrete insulin in response to 
stimulatory levels of glucose. Experiments with over-expression of mir-410 supported 
the rational that it may enhance levels of glucose stimulated insulin secretion.  
 
The MIN6 cell line as a model for study GSIS can be undependable due to considerable 
day-to-day variations in GSIS response between control cells. This varying GSIS 
response of control cells makes it difficult to decipher the effect of treatment on GSIS. 
Therefore, as iPS technology became available it represented a potential technique for 
generation of a human pancreatic beta cell model for studying the regulation of GSIS, 
without the ethical and moral concerns associated with embryonic stem cell research. 
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3.2 Attempts to generate iPS cells and differentiation of an established iPS cell line 
towards pancreatic phenotypes 
 
Induced pluripotent stem cells (iPS cells) can be generated from fully differentiated 
adult somatic cells by forced expression of a defined set of transcription factors 
(Takahashi, Tanabe et al. 2007). iPS cells represent a potential route for the generation 
of human pancreatic beta cell models. However the technology is currently technically 
challenging with very low efficiency rates for the reprogramming of somatic cells back 
to a pluripotent, embryonic stem cell-like phenotype. These low efficiency rates differ 
among different cell types and this issue was considered in the selection of starting cell 
populations chosen for reprogramming. 
 
Three different cell types were selected for generation of iPS cells in this study, 
MiaPaCa2 pancreatic adenocarcinoma cell line, normal primary epidermal keratinocytes 
and limbal epithelial cells. MiaPaCa2 cells were selected due to their pancreatic origin 
as MiaPaCa2 generated iPS cells may maintain some pancreatic epigenetic memory and 
be more easily pushed towards pancreatic lineages in subsequent directed differentiation 
experiments. Keratinocytes were used as the reported reprogramming efficiencies were 
100 fold higher than fibroblasts (Aasen, Raya et al. 2008), which were the standard cell 
type used for reprogramming at the time this work was undertaken. Limbal epithelial 
cells are the stem cell population for the cornea epithelia. These cells were used for 
reprogramming as reports suggest that reprogramming occurs with increased efficiency 
in such cultures of stem cell populations.(Kim, Zaehres et al. 2008) 
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3.2.1 Generation of Virus Particles 
iPS cell generation by forced expression of transcription factors- oct4, sox2, c-myc and 
klf4 was attempted using a lenti-viral expression system.  
 
Lentiviral particles were generated by co-transfecting the lentiviral ORF expression 
clone (containing oct4, sox2, c-myc or klf4 gene) together with the lentiviral packaging 
plasmids (protocol outlined in section 2.3.1). The lentiviral ORF plasmid contains the 
elements required for packaging, transduction and stable integration on the viral 
construct into the host genomic DNA, however, it lacks the elements required for 
transcription and packaging of an RNA copy of the ORF construct into active viral 
particles. These elements are provided by the lentiviral packaging plasmids. The 
packaging plasmids are two plasmids which contain all the structural, regulatory and 
replication genes required to produce lentivirus. 
3.2.2 Validation of correct insert in lenti-viral ORF expression clones 
 
The lentiviral ORF expression clones containing oct4, sox2, c-myc and klf4 were used 
to transform competent E.coli cells (protocol outlined in section 2.3.1.1). The lentiviral 
ORF plasmids also contain the ampicillin resistance gene (figure 3.2.1), thereby 
allowing selection of the E.coli cells which have taken up the plasmid. Transformed 
cells were seeded into small scale 5mL cultures. After overnight incubation, plasmid 
DNA was isolated. Plasmid DNA was then analysed to verify that the correct insert was 
contained in the lentiviral plasmid backbone. To verify this, the lentiviral plasmids was 
digested with Nhe1 and Xba1 restriction enzymes to release the ORF insert, the 
resultant mixes were then run on an agarose gel, and based on the size of the excised 
ORF it was deduced that a sequence of the correct size has been inserted into the 
plasmids.  
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Figure 3.2.1 Lentiviral ORF expression clone plasmid map. Oct4, sox2, c-myc or 
klf4 genes were inserted into the region labelled ORF. Plasmid also contains ampicillin 
resistance gene to allow for selection of cells which have taken up the plasmid.  
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The klf4 insert was expected to be 1413 base pairs, c-myc was 1365 base pairs, sox2 
was 954 base pairs and oct4 was 495 base pairs (figure 3.2.2). Bands at the expected 
sizes were seen on the agarose gel, indicating that sequences of the correct size were 
inserted in the expression plasmids. 
 
Once confirmed that correct size insert was present in the expression plasmids, large 
250mL cultures were initiated in order to generate large stocks of each of the expression 
plasmids and also to create glycerol stocks of transformed cells for storage. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2 Agarose gel of digested plasmid DNA 
Lane 1- DNA marker 
Lane 2&3 – Klf4 (1413 bp) 
Lane 4&5 – c-myc (1365 bp) 
Lane 6&7 – sox2 (954 bp) 
Lane 8&9 – oct4 (495 bp) 
1    2    3   4   5    6   7    8    9 
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3.2.3 Optimisation of plasmid transfection conditions 
 
A lentiviral ORF expression plasmid containing the GFP (green fluorescent protein) 
reporter gene was used for optimisation of transfection conditions. This plasmid was co-
transfected with the lentiviral packaging plasmids into 293 cells and transfection 
efficiency was determined based on transient expression of the GFP reporter gene 
(section 2.3.1). Different transfection reagents, volume of transfection reagent and 
plasmid concentration were analysed for transfection efficiency (figure 3.2.3). 
 
The lowest volume of fugene transfection reagent showed the greatest transfection 
efficiency (figure 3.2.3). Lipofectamine transfection reagent also showed good 
transfection efficiency. Supernatant containing active viral particles was harvested from 
the fugene 18µL 4:2:2 plasmid concentration, and lipofectamine 10µL 4:2:2 plasmid 
concentration wells for optimisation of viral infection. 
 
 
 129 
                  
  
    
A: Fugene 18µL, 2:1:1 µg/plasmid  B: Fugene 18µL, 4:2:2 µg/plasmid   C: Fugene 18µL, 8:4:4 µg/plasmid 
 
 
   
D: Fugene 36µL, 2:1:1 µg/plasmid   E: Fugene 36µL, 4:2:2 µg/plasmid  F: Fugene 36µL, 8:4:4 µg/plasmid 
A B C 
D E F 
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G: Lipofect 10µL, 2:1:1 µg/plasmid  H: Lipofect 10µL, 4:2:2 µg/plasmid 
 
Transfection 
Reagent 
Transfection 
Efficiency 
2:1:1 plasmid conc 
Transfection 
Efficiency 
4:2:2 plasmid conc 
Transfection 
Efficiency 
8:4:4 plasmid conc 
Fugene 18µl 60% 90% <5% 
Fugene 36µl 30% 70% <5% 
Lipofectamine 10µl 70% 80%  
I: Summary table of percentage of cells expressing GFP for each transfection condition 
 
Figure 3.2.3 GFP reporter gene expression in transfected cells. Images A-H are fluorescent microscope images of GFP expression in 
transfected cells. Cells were transfected with either Fugene or Lipofectamine transfection reagents, and with differing volumes of 
transfection reagents. Differing concentration of plasmids were also transfected. Ratios of plasmid concentrations represent concentration 
of expression clone to each of the packaging plasmids, with the expression clone being transfected at double the concentration of each 
packaging plasmid for each treatment. Table I shows a summary of percentage GFP positive cells achieved for each transfection condition. 
G H 
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3.2.4 Optimisation of viral transduction 
 
MiaPaCa2 pancreatic adenocarcinoma cells were used for optimisation of viral 
transduction, as these cells would subsequently be used for transduction with the four 
factor viruses for iPS cell generation. Cells were treated with either lipofectamine (10µL 
4:2:2) or fugene (18µL 4:2:2) generated virus, for either a single dose, or double dose 
(with the second dose being administered 24hrs after first virus treatment). Virus treated 
cells were then analysed for transduction efficiency by monitoring GFP expression 
using a fluorescent microscope (figure 3.2.4). 
 
 
 
  
 
 
 
  
 
 
 
Figure 3.2.4 GFP reporter gene expression in cells treated with GFP virus. Images 
A-D are fluorescent microscope images of GFP expression in infected MiaPaCa2 cells. 
Cells were infected with either Fugene or Lipofectamine generated virus, with either a 
single dose, or two doses of virus. Images were taken 7 days post first virus treatment. 
A: MiaPaca, 1 dose of Fugene 
(18µL, 4:2:2 µg/plasmid) virus 
B: MiaPaca, 2 doses of Fugene 
(18µL, 4:2:2 µg/plasmid) virus 
C: MiaPaca, 1 dose of lipofectamine 
(10µL, 4:2:2 µg/plasmid) virus 
D: MiaPaca, 2 doses of lipofectamine 
(10µL, 4:2:2 µg/plasmid) virus 
A B 
C D 
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Treating MiaPaCa2 cells with a second dose of virus greatly improved the percentage of 
GFP positive cells compared to single dosed cells, for both fugene and lipofectamine 
generated virus (figure 3.2.4). Cells treated with a second dose of fugene or 
lipofectamine generated virus showed approximately 90% GFP positive cells, as 
assessed by eye using a fluorescent microscope, indicating the high efficiency of viral 
infection. As the infection efficiencies were very similar for virus generation with 
fugene and lipofectamine, fugene was used for all subsequent viral experiments. 
 
3.2.4.1 Calculation of multiplicity of infection (MOI) 
 
The viral titre was quantified to allow calculation of multiplicity of infection (MOI). 
Guava flow cytometer was used to determine the percentage of cells expressing GFP 
after viral infection, as a more accurate calculation was required than estimating 
infection efficiency from fluorescent microscope images. MiaPaCa2 cells were infected 
using the optimised transduction conditions, for either one or two doses of virus. Cells 
were analysed by the Guava flow cytometer for GFP expression at 3 time-points, 24, 48 
and 72 hours after the second dose of virus was administered (table 3.2.1).  
 
Cell counts were performed on wells to be analysed by the guava flow cytometer (table 
3.2.1). A multiplicity of infection (MOI) of 5 is recommended for generation of iPS 
cells (Park and Daley 2009), i.e. 5 viral particles per cell. As described in section 2.3.2, 
5x104 cells were seeded per well of a 6-well plate for iPS cell generation, therefore, to 
allow for an MOI of 5, 2.5x105 viral particles would be required to achieve this MOI. 
Table 3.2.1 shows that per 1mL of viral suspension 3.3x105 were infected, indicating 
there were at least 3.3x105 active viral particles per mL of viral suspension. As this is 
above the threshold of 2.5x105 viral particles required for an MOI of 5, this indicates 
that the viral suspension is sufficiently concentrated and does not require any additional 
concentrating procedures. This technique represents a relatively crude method for 
determining MOI, as the infected cells may have been infected by more than one active 
viral particle. Therefore, this technique was utilised to ensure that cells were being 
treated with the minimum number of active viral particles required. 
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Treatment 24 hours 48 hours 72 hours 
Single Dose 41% 66% 60% 
Twice Dosed 75% 83% 80% 
Total Cell Count 8x105 1.6x106 2.5x106 
Number of infected cells for single 
virus treatment 3.3x10
5 1.1x106 1.5x106 
 
Table 3.2.1 Percentage of GFP positive cells as measured by Guava cytometer, at three 
different time points following treatment with virus. Cell counts were performed on cell 
suspensions before guava flow cytometer analysis. 
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3.2.5 Development of protocol to generate iPS cells 
 
MiaPaCa2 pancreatic adenocarcinoma cell line, epidermal keratinocytes and limbal 
epithelial cells were subjected to the iPS protocol (section 2.3.2), using the conditions 
optimised in section 3.2.4.  
 
3.2.5.1 Attempt to generate iPS cells from MiaPaCa2 cell line 
 
Cells were either treated with the four factor cocktail- oct4, sox2, c-myc and klf4, or the 
three factor cocktail- oct4, sox2 and klf4. c-myc was excluded from the 3 factor cocktail 
as c-myc is thought to lead to the generation of an increased number of false positive 
colonies (Eggan 2009). Cells were treated with 2 doses of virus. After four days cells 
were trypsinised onto a mitomycin C treated MEF feeder layer, and cultured in 
embryonic stem cell (ES) media. By day 8 following the second viral treatment, cells 
with distinctly different cell morphology to untreated parent MiaPaCa2 had emerged 
(figure 3.2.5). 
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Figure 3.2.5 iPS virus treatment of MiaPaCa2 cells. A- mitomycin C treated MEF cells. B- untreated MiaPaCa2 parental cells growing on 
a mitomycin C treated MEF feeder layer. C- MiaPaCa2 cells at 8 days post second viral treatment, grown on MEF feeder layer with ES 
media. 
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Cultures treated with either 3-factors or 4-factors showed the same mixture of cell 
morphologies at 8 days post second viral treatment. Cultures were a mixture of colonies 
of typical MiaPaCa2 morphology and colonies of more rounded, less-stretched out cells 
(figure 3.2.5, image C).  
 
By day 24 the colonies of rounded, less-stretched cells grew to form large clusters with 
a tightly packed core of cells with rounded morphology, while cells at the periphery of 
these clusters displayed ‘typical’ MiaPaCa2 morphology (figure 3.2.6). Cultures treated 
with either 3 factors (oct4, sox2 and klf4) or 4 factors (oct4, sox2, klf4 and c-myc) 
showed similar cell morphology trends. 
 
Colonies were grown until they were visible by eye (figure 3.2.7). Single colonies with 
the best ‘ES-like’ morphology i.e. tightly packed core and clear defined colony edges, 
were then picked and trypsinised into single cell suspensions. Cell suspensions were 
then seeded into wells with mitomycin C treated MEF feeder layer. 4 wells were seeded 
for each colony trypsinised, 2 wells for RNA isolation, and 2 wells to continue the 
culture. 
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Figure 3.2.6 Virus treated MiaPaCa2 cells 24 days post infection. A- MiaPaCa2 cells 
treated with 3-factor cocktail. B- MiaPaCa2 cells treated with 4-factor cocktail. Both 
treatments resulted in colonies of similar morphologies. 
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Colonies displayed some morphological properties somewhat similar to ES cells, such 
as the tightly packed core; however, all colonies formed had uneven edges, with cells of 
typical MiaPaCa2 morphology, unlike the defined edges of ES colonies. 
 
 
 
  
Figure 3.2.7 MiaPaCa2 cells 31 days post virus treatment. A- 10X magnification of 
colonies formed. B- 4X magnification of colonies formed. 
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3.2.5.2 Validation of MiaPaCa2 reprogramming 
 
Two wells of each clone were harvested for RNA (section 2.4.1), while the remaining 
two wells were maintained in culture to freeze stocks of each clone. Five clones of 3-
factor treated cells and five clones of 4-factor treated cells were analysed for expression 
of oct4, sox2, c-myc and klf4 (figure 3.2.8). After treatment with virus, cells which are 
reprogrammed should reactivate endogenous expression of these factors, to maintain 
cells in a pluripotent state. Clones were analysed to determine expression levels of these 
factors (protocol outlined in section 2.4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.8 Agarose gel electrophoresis of PCR products generated from MiaPaCa2 
virus treated colony clones. 5 three-factor clones, and 5 four-factor clones were 
analysed for expression of oct4, sox2, c-myc, klf4 and endogenous control β-actin. 
Untreated MiaPaCa2 cells, MEF murine feeder cells and NTC (no template control) 
control were also analysed. 
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C-myc and klf4 expression was detected in all clones; untreated MiaPaCa2 cells also 
expressed these factors (figure 3.2.7). Very low level sox2 expression was seen in some 
clones. Levels of Oct4 expression are seen to increase in the virus treated cells 
compared to untreated parental MiaPaCa2 cells, except for MiaPaCa2 3-factor treated 
clone 3 cells, which has lost expression of the oct4 gene. β-actin expression was also 
analysed in these cells as an endogenous control to demonstrate equal concentrations of 
RNA used in reverse transcription reactions. 
 
MiaPaCa2 virus treated cells were growing on a MEF feeder layer when the cells were 
trypsinised to harvest cells for RNA, there may have been some contaminating MEF 
cells. Hence, MEF cells were included in analysis to determine if PCR primers also 
amplified murine cDNA and if so, was expression of factors in MEF cells leading to 
false positive results in virus treated MiaPaCa2 clones.  
 
Amylase expression which is characteristic of pancreatic MiaPaCa2 cells was analysed 
to determine if virus treated cells still expressed this pancreatic marker (figure 3.2.9). 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.9 Agarose gel electrophoresis of amylase PCR products. Amylase 
expression was analysed in MiaPaCa2 3-factor treated cells, clones 1 to 5 and 
MiaPaCa2 4-factor treated cells, clones 1 to 5. Parent untreated MiaPaCa2 cells, MEF 
murine feeder cells and NTC (no template control) were also analysed. 
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Three-factor clone 3 MiaPaCa2 cells differ from untreated parental MiaPaCa2 cells by 
lack of amylase expression (figure 3.2.9). However, these cells have not become 
reprogrammed into iPS cells, as they lack expression of the pluripotency marker Oct4 
(figure 3.2.8). 
 
Although virus-treated cells display altered morphology (figure 3.2.5, 3.2.6 and 3.2.7) 
these cells have not been reprogrammed to iPS cells as they have maintained expression 
of the mature differentiation marker amylase (figure 3.2.9).  
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3.2.5.3 Attempt to generate iPS cells from keratinocytes 
 
Normal human epidermal keratinocytes were initially treated with GFP virus using the 
conditions optimised using MiaPaCa2 cells (outlined in section 2.3.2), to ensure that 
this treatment led to efficient transduction efficiency in these cells. High levels of GFP 
expression was seen after treatment with GFP virus using the conditions optimised. 
 
Keratinocytes were treated with the four factor cocktail- oct4, sox2, c-myc and klf4, or 
the three factor cocktail- oct4, sox2 and klf4. Cells were treated with 2 doses of virus, 
after four days cells were trypsinised onto a mitomycin C treated MEF feeder layer, and 
cultured in embryonic stem cell (ES) media (figure 3.2.10).  
 
The morphology of keratinocytes changed considerably once plated onto MEF feeder 
layer cells, this change in morphology was also observed for control keratinocytes not 
treated with virus. Keratinocytes on MEF feeder layer formed dense colonies of cells, 
while cells not on MEF feeder layer formed a monolayer of cells. Control cells not 
treated with virus, cells treated with 4-factor virus cocktails and cells treated with 3-
factor virus cocktail all showed the same morphology. However, once attached to the 
MEF feeder layer, these cells did not proliferate and subsequently died off. 
 
Reprogrammed iPS cells were not generated from keratinocyte cultures, as iPS cells 
maintain unlimited proliferative potential in the undifferentiated state unlike the cells 
generated by virus-treatment in this study which failed to proliferate and eventually died 
(figure 3.2.10). 
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Figure 3.2.10 Viral reprogramming of keratinocytes. A- Mitomycin C treated MEF feeder layer. B- Untreated keratinocytes growing on 
MEF feeder layer. C- Virus treated keratinocytes growing on MEF feeder layer, 14 days after virus treatment. 
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3.2.5.4 Attempt to generate iPS cells from limbal epithelial cells using 4-factor 
virus cocktail 
 
The limbal epithelial ring was dissected from donor cornea and then cut into small 
pieces and cultured using the explant technique to allow proliferation of the limbal 
epithelial cells. Once sufficient outgrowth from explant was achieved, these cells were 
then trypsinised and prepared for virus treatment. Cells were initially treated with GFP 
virus using the optimised conditions (outlined in section 2.3.2), to ensure that these 
conditions led to efficient transduction efficiency in these cells. High levels of GFP 
expression was seen after treatment with GFP virus using the optimised conditions 
(figure 3.2.11).  
 
 
 
 
Figure 3.2.11 Fluorescent microscope images of GFP expression in limbal epithelial 
cells 48 hours post transduction with GFP virus. 
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To generate iPS cells, limbal epithelial cells were treated with the 4-factor virus cocktail 
(as per section 2.3.2). Following 72 hours the second virus treatment some morphology 
changes were seen in virus treated cells compared to controls (figure 3.2.12). 
 
Untreated limbal epithelial cells show the typical cuboidal epithelial morphology, figure 
3.2.12 A. While cells treated with virus begin to show cell processes and cell clusters 
(figure 3.2.12 B & C), however, some cells in virus treated cultures did maintain the 
typical cuboidal morphology. These cells (shown in figure 3.2.12 B & C) were then 
trypsinised and seeded into plates with mitomycin C treated MEFs and cultured in ES 
media. However, following trypsinisation and seeding onto MEFs, these virus-treated 
cells failed to proliferate any further. These cells did not represent fully reprogrammed 
cells, as genuine iPS cells exhibit unlimited proliferative potential in the 
undifferentiated state. 
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A. Untreated cells    B. Cells treated with virus   C. Cells treated with virus 
Figure 3.2.12 Limbal epithelial cells 72 hours post virus treatment. A: Limbal epithelial control cells, not treated with virus. B & C: 
Limbal epithelial cells treated with 4-factor cocktail of viruses.  
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3.2.5.5 Attempt to generate of iPS cells from limbal epithelial cells using 
conditioned media 
 
In this study retroviral based induction of iPS cells did not generate fully reprogrammed 
iPS cells (section 3.2.5.1 to 3.2.2.4). Therefore an alternative method was utilised for 
generating iPS cells from limbal epithelial cells using a conditioned media based 
reprogramming technique identified by Balasubramanian et al., (Balasubramanian, 
Babai et al. 2009). Generation of iPS cells using the ESD3 conditioned media technique 
involved a 2-stage protocol (figure 3.2.13) (outlined in section 2.3.3).  
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Figure 3.2.13 Flowchart of limbal epithelial cell treatment. Stage 1 involves treatment 
of cells with enriched media, followed by stage 2 treatment with ESD3 conditioned 
media. Control cells are maintained in enriched media for the duration of the 
experiment. 
 
 
7 Days 
 
Treatment with enriched media 
(B27, EGF, bFGF, noggin) 
 Stage 1 
Control 
Cells maintained in 
enriched media 
Treated cells 
Cultured in ESD3 
conditioned media 
Stage 2 
Trypsinise to gelatin or iMEF coated wells 
Limbal explant culture 
Outgrowth of limbal epithelial cells 
10 days 
 149 
Stage one of the treatment with enriched media led to a distinct change in cell 
morphology. In contrast to the typical epithelial cuboidal morphology of the control 
cells maintained in normal culture media (figure 3.2.14 A), cells treated with enriched 
media exhibited a stretched spindle type morphology with cell processes (figure 3.2.14 
B and C). No neurospheres were observed, in contrast to the observations reported by 
Balasubramanian et al (Balasubramanian, Babai et al. 2009).  
 
Stage two involved trypsinisation of enriched media treated cells onto gelatin coated or 
irradiated MEF (iMEF) coated wells. Cells were treated with ESD3 conditioned media 
(ESD3 CM) (section 2.3.3.1) for 10 days, and control cells were maintained in stage 1 
enriched media for the entire duration of the protocol. 
 
At the halfway point of stage 2, control cells maintained in enriched media resumed the 
standard limbal epithelial cell morphology (figure 3.2.15 A and D). Cells treated with 
ESD3 CM displayed altered morphology (figure 3.2.15 B, C, E and F).  Cell clusters 
were observed in ESD3 CM treated cultures on iMEF feeder layer (figure 3.2.15 E and 
F). Similar clusters were observed at a slightly later time point in ESD3 CM treated 
cultures grown on gelatin. 
 
At day 14, the end of stage 2 treatment, the cell clusters observed in ESD3 CM treated 
cells on iMEF at day 7 of stage 2, did not show any obvious increase in size (figure 
3.2.16 E), nor was there any obvious outgrowth from the cluster. A single cluster of a 
different morphology was also seen in ESD3 CM treated cells grown on iMEFs 
(indicated with red arrow, figure 3.2.16 E), this cluster contained tightly packed cells 
which appeared to be more adherent to the culture dish, rather than the smaller clusters 
observed in both treatment conditions. 
 
At the end of stage 2, control cells maintained in the stage 1 enriched media maintained 
the typical cuboidal epithelial morphology (figure 3.2.16 A and D).  
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A: untreated cells grown eye media  B: cells grown in enriched media  C: cells grown in enriched media 
Figure 3.2.14 Limbal epithelial cells after stage 1 treatment with enriched media for 7 days. Limbal epithelial cells grown in 6-well plate 
inserts, with 3T3 feeder cells in bottom layer of well. Control cells (A) were maintained in the standard eye media and exhibit typical 
epithelial cuboidal morphology. Cells treated with enriched media (B & C) show a different morphology with long stretched cells with 
protrusions. 
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A: control cells on gelatin   B: treated cells on gelatin   C: treated cells on gelatin 
   
D: control cells on iMEFs   E: treated cells on iMEFs   F: treated cells on iMEFs 
 
Figure 3.2.15 Limbal epithelial cells during stage 2 at 7 days of ESD3 CM treatment. Cells were grown on plates coated with gelatin alone 
(A, B & C) or gelatin and iMEFs (D, E & F). Control cells (A & D) were maintained in enriched media and did not receive ESD3 CM. 
Cells in B, C, E & F were treated with enriched media for 7 days followed by ESD3 CM for 7 days. 
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A: Control cells on gelatine (10X)  B: Treated cells on gelatine (10X)  C: Treated cells on gelatine (20X) 
 
   
D: Control on iMEF (10X)   E: Treated cells on iMEF (10X)  F: Treated cells on iMEF (20X) 
 
Figure 3.2.16 Limbal epithelial cells at the end of stage 2, after 14 days of ESD3 CM treatment. Cells were grown on plates coated with 
gelatin and iMEFs (D, E & F) or gelatin alone (A, B & C). Control cells (A & D) were maintained in enriched media and did not receive 
ESD3 CM. Cells treated with enriched media for 7 days followed by ESD3 CM for 14 days were plated on gelatin or gelatin and iMEF 
coated plates (B, C, E & F). (10X and 20X indicate the magnification at which these images were taken). 
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3.2.5.6 Validation of limbal epithelial cell reprogramming 
 
Cells from these wells were harvested for RNA analysis (section 2.4.1) to check if 
different marker expression was seen between the control cells exhibiting cuboidal 
morphology and treated cells on gelatin and iMEFs with fibroblast morphology (figure 
3.2.17 and 3.2.18). Limbal epithelial cells from the same donor, maintained in standard 
limbal epithelial cell culture were also analysed for marker expression, as a control, to 
determine if conditioned media treatment induced changes in marker expression. 
Limbal stromal cells were also analysed for marker expression to determine if 
fibroblast-like cell types emerging at the end of stage 2 treatment were a result of 
stromal cell contamination. RNA from an established iPS cell line was also analysed to 
determine if ESD3 CM treatment induced full reprogramming of limbal epithelial cells, 
and hence marker expression similar to established iPS cells. 
 
C-myc, oct4 and klf4 expression was detected in all cell types and for all conditions 
analysed (figure 3.2.17), however, iPS cells had much higher expression levels of oct4 
compared to other cell types. Sox2 pluripotency marker was only detected in iPS cells, 
untreated limbal epithelial cells maintained in eye media, and ESD3 CM treated cells. 
Limbal epithelial cells maintained in the enriched media, or ESD3 CM treated cells on 
gelatin had lost expression of this marker (figure 3.2.17). Control limbal epithelial cells 
maintained in enriched media express terminal differentiation markers CK-3 and CK-12 
(figure 3.2.18). N-cadherin is associated with adult stem cells. Levels of this marker are 
reduced in control cells maintained in enriched media, while high levels are maintained 
in ESD3 CM treated cells. Control cells maintained in enriched media showed similar 
expression of ∆Np63 as untreated limbal epithelial cells. ABCG2 levels were only 
detected at very low levels in limbal epithelial, stromal and iPS cells. Pluripotency 
marker, nanog, was only detected in iPS cells. 
 
It is clear that ESD3 CM treatment has induced specific cell morphology (figure 3.2.16) 
and marker expression changes (figure 3.2.17 and 3.2.18) compared to untreated limbal 
epithelial cells, and control cells maintained in enriched media for the entire duration of 
the experiment. However, as these cells do not express the pluripotency marker nanog 
(figure 3.2.18), therefore, they do not represent fully reprogrammed cells. 
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Figure 3.2.17 Expression levels of oct4, sox2, c-myc and klf4 in limbal epithelial cells 
treated with ESD3 CM for 14 days, as well as control cells which were maintained in 
enriched media. Stromal cells, limbal epithelial cells (untreated, in eye media), iPS cells 
and iMEFs were also included for comparison. 
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Figure 3.2.18 Expression levels of CK-3, CK-12, N-cadherin, ∆Np63, ABCG2, nanog 
and endogenous control β-actin, in limbal epithelial cells treated with ESD3 CM for 14 
days, as well as control cells which were maintained in enriched media. Stromal cells, 
limbal epithelial cells (untreated), iPS cells and iMEFs were also included to allow 
comparison. 
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3.2.5.7 Summary of attempts to generate iPS cells 
 
Attempts at using retro-viral and conditioned media based reprogramming technology 
were unsuccessful in generating fully reprogrammed iPS cells. Cells displaying altered 
morphology and marker expression may represent cells stuck in a semi-reprogrammed 
state. At this time, commercially available iPS cell lines were beginning to come on 
stream. In order to continue the aim of establishing a human pancreatic beta cell model, 
one such iPS line- hFib2-iPS4 was purchased from George Daley’s lab, Children’s 
Hospital Boston. Additionally, a transdifferentiation approach was also undertaken 
using human limbal stromal cells available in our lab. Recent studies have suggested 
that these cells resemble bone marrow derived mesenchymal stem cells and possess 
similar differentiation potential towards ectoderm, mesoderm and endoderm lineages 
(Dravida, Pal et al. 2005; Polisetty, Fatima et al. 2008). Directed differentiation 
protocols were applied to both iPS and stromal cells to establish the potential of these 
cells to differentiate towards pancreatic lineages. 
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3.2.6 Differentiation of an established iPS cell line towards pancreatic phenotypes 
 
A directed differentiation protocol established by Jiang J. et al., was used to 
differentiate iPS cell line- hFib2-iPS4 towards pancreatic lineages (protocol described 
in section 2.2.5.1) (Jiang, Au et al. 2007). Treated cells were then analysed for 
expression of pancreatic markers. Differentiation protocols were performed on iPS cells 
in 2D culture- grown on a thin matrigel layer, and cells in 3D culture- suspended within 
a thick matrigel/collagen gel (described in section 2.2.5). Marker expression was then 
compared to assess which culture method led to the highest efficiency of pancreatic 
differentiation. 
 
iPS cells grown in 2D culture spread out from the tightly packed core of the iPS cluster 
(figure 3.2.19 A). iPS cells grown in 3D culture were suspended within the 
matrigel/collagen gel. These cells maintained tight, densely packed colonies with even 
edges and minimal outgrowth (figure 3.2.19 B). Cells in 2D and 3D cultures were 
maintained in iMEF conditioned iPS media for 2 days following seeding of cultures. 
 
 
 
  
A: iPS cells in 2D culture  B: iPS cells in 3D culture 
 
Figure 3.2.19 iPS cells grown in 2D and 3D culture. A-iPS cells grown on matrigel 
coated dishes. B-iPS cells embedded in a thick matrigel/collagen gel. 4X magnification 
for both images. 
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After allowing cells to settle and grow in the 2D and 3D culture conditions for 2 days, 
differentiation media was then added to initiate differentiation of iPS cells towards 
pancreatic phenotypes. While control cells were maintained in iMEF conditioned ES 
media. Following 8 days of treatment, cells were monitored for changes in cell 
morphology (figure 3.2.20) and mRNA expression (figure 3.2.21). 2D control cells 
exhibited small compact cell morphology, while 2D cultures treated with differentiation 
media exhibited larger cell morphology, with more distinguished cell-cell boundaries 
(figure 3.2.20 A & B). In 3D control cultures, cells maintained tight, densely packed 
colonies, while cultures treated with differentiation media displayed slightly different 
morphology, with less densely packed colonies and outgrowth of cells from colonies 
(figure 3.2.20 C & D). 
 
Cxcr4 definitive endoderm marker expression was detected in untreated iPS cells, with 
increased expression in 2D and 3D differentiation media treated cells. Similar trends in 
marker expression were seen for Foxa2 and Hnf4α, low expression in untreated iPS and 
higher expression in 2D and 3D differentiation media treated cells (figure 3.2.21). No 
change in nanog pluripotency marker expression level was seen in control or treated 
cells. 
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A: 2D control cells  B: 2D differentiated cells 
 
 
C: 3D control cells  D: 3D differentiated cells 
 
Figure 3.2.20 Day 8 iPS cells in 2D and 3D culture. A and C represent iPS control cells 
maintained in iMEF conditioned iPS media, while B and D cultures were treated with 
differentiation media. 
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Figure 3.2.21 PCR of day 8 differentiation and control cultures. Expression levels of 
definitive endoderm markers- cxcr4, foxa2 and hnf4a were examined, as well as 
pluripotency marker- nanog, and endogenous control B-actin. 
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At day 8, once cells had reached the definitive endoderm stage of the protocol, 2D cell 
cultures were treated with 200units/mL of collagenase IV and transferred to low-
attachment 6-well plates to allow spheroid formation. 2D cultures did not respond well 
to collagenase treatment and culture on low-attachment plates, a large proportion of 
cells died. The remaining cells failed to proliferate, some small irregular shaped clumps 
were observed (see red arrow, figure 3.2.22 A and B) in control and differentiated 
cultures, with the majority of cells remaining in a single cell suspension.  
 
The 3D cultures were maintained in the same matrigel/collagen gel. The 3D 
differentiated clusters exhibited a large degree of dense outgrowth from the original 
cluster by day 21. The outgrowth in 3D control conditions was minimal in comparison 
to differentiated wells (figure 3.2.22 C and D). Cells from both 2D and 3D cultures 
were harvested for RNA on day 21 to check expression of pancreatic endoderm markers 
(figure 3.2.23). However, insufficient cell number remained in the 2D conditions to 
perform mRNA expression analysis. 
 
PDX-1 is used as a marker of pancreatic endoderm. Very low expression of this marker 
was detected in the 3D control condition, while it was absent from 3D differentiated 
cells (figure 3.2.23). Nanog, a marker of pluripotency, showed very slightly reduced 
expression in 3D differentiated cells relative to 3D control and iPS cells. β-actin 
expression was also analysed as an endogenous control (figure 3.2.23). Hlxb9, ngn3, 
nkx6.1 and ptf1a pancreatic endoderm marker expression was also examined in 3D 
control and differentiated cultures, but expression was undetected. 
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A: 2D control cells    B: 2D differentiated cells 
 
 
C: 3D control cells    D: 3D differentiated cells 
 
Figure 3.2.22 Morphology of cells in 2D and 3D cultures on day 21, treated with iMEF 
conditioned iPS media or differentiation media. 
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Figure 3.2.23 mRNA expression of 3D differentiated and control cultures after 21 days 
of treatment. B-actin is used as an endogenous control to show equal cDNA levels 
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At day 29, pancreatic endocrine/exocrine stage of differentiation protocol, cells had 
similar morphology to day 21. The 2D control and differentiated cultures still remained 
sparse (figure 3.2.24 A and B). The 3D control cells showed some outgrowth from 
clusters, while 3D differentiated cultures showed very dense outgrowth of very small 
cells (figure 3.2.24 C and D, respectively). 3D control and differentiated cultures were 
harvested for RNA. Nkx6.1, nkx2.2, ngn3 and pax4 expression levels were analysed to 
determine if cells had differentiated to the pancreatic endocrine/exocrine stage. 
Expression levels for these markers were undetected in both control and differentiated 
3D cultures. 
 
At day 36, mature islet stage of the differentiation protocol, cell morphology was 
observed (figure 3.2.25). The 2D control and differentiation cultures maintained the 
same morphology from day 21 and 29, very few live cells remained and a lot of cell 
debris could be seen in the media. The 3D control and differentiated cells displayed 
outgrowth of cells from the original cluster, with a larger area of outgrowth for the 
differentiated cultures (figure 3.2.25).  
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A: 2D control culture    B: 2D differentiated culture 
 
 
C: 3D control culture    D: 3D differentiated culture 
 
Figure 3.2.24 Morphology of 2D and 3D cultures on day 29, treated with iMEF 
conditioned iPS media as control or differentiation media. 
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A: 2D control culture    B: 2D differentiated culture 
 
  
C: 3D control culture    D: 3D differentiated culture 
 
Figure 3.2.25 Morphology of 2D and 3D cultures on day 36, treated with iMEF 
conditioned iPS media as control or differentiation media. 
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RNA was isolated from day 36 3D differentiation and 3D control cultures. The 
expression of mature islet markers was examined in day 36 cultures in addition to the 
intermediate time points of the experiment (figure 3.2.26). Insulin, a marker of 
pancreatic beta cells, was detected in day 36 control cultures, and absent in all other 
time points and conditions examined. Somatostatin and amylase, which are markers of 
pancreatic delta cells and acinar cells respectively, was detected in untreated iPS cells 
and in the early stages of the experiment on day 8 and 21 in both control and 
differentiated cultures. Somatostatin and amylase levels became undetectable in day 29 
cultures and day 36 differentiation culture, with increased levels observed in day 36 
control cultures. Ghrelin, a marker of pancreatic epsilon cells, detected only in day 36 
control cultures. Glut2, another marker of mature pancreatic beta cells was detected at 
low levels in day 8 and 21 control and differentiation cultures, and day 36 control 
cultures. Glut2 expression was undetectable in day 29 control and differentiation 
cultures and day 36 differentiation culture.  
 
Nanog expression was used as a marker of pluripotency. Nanog levels were high in 
untreated iPS cells and day 8 control and differentiation cultures. Nanog levels were 
lower in day 21 differentiation and control cultures, lower again in day 29 control and 
differentiation cultures, and undetectable in day 36 differentiation cultures. Nanog 
expression appeared to rise again in day 36 control cultures. B-actin expression was 
used as an endogenous control; however, levels of this were lower in day 29 control and 
differentiation cultures and day 36 differentiation cultures (figure 3.2.26). 
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Figure 3.2.26 mRNA expression of 3D differentiated and control cultures after each 
stage of the pancreatic differentiation protocol. B-actin is used as an endogenous control 
for normalisation of mRNA expression levels. 
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A second biological replicate of the 3D iPS cell differentiation to pancreatic phenotype 
was performed. At day 8, cultures were harvested for RNA to check for expression of 
definitive endoderm markers. Cxcr4, hnf4a and foxa2 expression was detected at higher 
levels in 3D differentiated cells compared to 3D control cells (figure 3.2.27). Sox17 
expression was undetected in all samples analysed. Expression of nanog pluripotency 
marker remains the same in untreated iPS cells and day 8 control and differentiated cells 
(figure 3.2.27).  
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Figure 3.2.27 PCR of day 8 differentiation and control cultures. Expression levels of 
definitive endoderm markers- cxcr4, foxa2 and hnf4a were examined, as well as 
pluripotency marker- nanog, and endogenous control B-actin. 
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At day 21 control and differentiated cells were harvested for RNA to monitor 
expression of pancreatic endoderm markers. Pancreatic endoderm markers ngn2, 
nkx6.1, hlxb9 and ptf1a were undetected in all samples. PDX1 expression was detected 
in both 3D differentiated and control cells, with higher levels seen in 3D control cells 
(figure 3.2.28). Nanog pluripotency marker was also detected in all samples analysed.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.28 PCR of day 21 3D differentiation and control cultures. Expression levels 
of pancreatic endoderm marker PDX-1 is shown, as well as pluripotency marker nanog, 
and b-actin endogenous control.  
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Cultures were also harvested at day 29 and day 36. RNA from day 8, 21, 29 and 36 was 
analysed for expression of mature islet markers (figure 3.2.29). Somatostatin, amylase 
and ghrelin showed a similar expression pattern. Expression of these three markers was 
detected in untreated iPS cells, day 8 control and differentiated cells, and day 29 control 
cells. Low amylase expression is also seen in day 36 control cells. Mature islet markers 
insulin and glut2 were undetected in all samples analysed. Pluripotency marker nanog 
shows higher expression in untreated iPS cells, day 8 control and differentiated cells 
and day 29 cells, compared to low expression in day 21 control and differentiated cells, 
day 29 differentiated cells and day 36 control and differentiated cells. B-actin 
endogenous control expression shows varying expression levels between samples. 
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Figure 3.2.29 PCR of 3D differentiated and control cultures after each stage of the 
pancreatic differentiation protocol.  
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3.2.6.1 Summary of directed differentiation of iPS cell line hFib2-iPS4 
iPS cells differentiated in 3D culture showed improved efficiency for definitive 
endoderm formation compared to 2D culture, based on expression of definitive 
endoderm markers cxcr4, foxa2 and hnf4α (figure 3.3.21). Further differentiation 
towards more mature pancreatic lineages showed less conclusive results, as untreated 
iPS cells expressed a number of mature pancreatic markers (figure 3.2.26 and 3.2.29), 
indicating that these cells may have already undergone some spontaneous differentiation 
prior to beginning the directed differentiation protocol. 
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3.2.7 Trans-differentiation of limbal stromal cells towards pancreatic phenotypes 
 
Stromal cells isolated from donor cornea-sclera ring were differentiated towards 
definitive endoderm (protocol outlined in section 2.2.5.1 stage 1). These cells grow in 
monolayer culture, therefore monolayer cells were treated with differentiation media 
while control cells were maintained in standard stomal media (DMEM, 10% FCS). 
Following 8 days treatment with differentiation or control media cells were harvested to 
monitor expression of definitive endoderm associated genes such as cxcr4, foxa2, hnf4α 
and sox17. However, under these conditions, stromal cells in control or differentiation 
media did not express detectable levels of definitive endoderm associated genes.  
 
Cell clusters of stromal cells were generated using the hanging drop technique (figure 
3.2.30 B) (section 2.2.6). Clusters were then either cultured in 3D in a thick 
matrigel/collagen gel, 2D on a thin matrigel layer, or clusters were trypsinised to a 
single cell suspension and grown in monolayer. Cells were allowed to settle and 
proliferate in their 3D, 2D or monolayer conditions for 2 days before initiation of 
differentiation (figure 3.2.30) (section 2.2.5).  
 
Differentiation media was added to cells for 8 days to allow definitive endoderm 
formation (as outlined in section 2.2.5.1 stage 1). Control cells were also prepared in 
3D, 2D and monolayer cultures, and maintained in the standard stromal cell media 
(DMEM, 10% FCS). No obvious cell morphology changes were observed by day 8 in 
control or differentiation media treated cells (figure 3.2.31). At day 8, control and 
differentiation media treated cells were harvested to monitor expression of definitive 
endoderm associated genes (figure 3.2.32).  
 
 
 
 
 
 
 
 
 
 
 
 176 
 
 
A: untreated stromal cells (10X)  B: stromal aggregates in suspension (4X) 
 
 
C:stromal aggregates in 3D culture (10X)  D: stromal aggregates in 2D culture (10X) 
 
 
E: stromal aggregates trypsinised (10X) 
 
Figure 3.2.30 Stromal cell culture treatments. Stromal cell aggregates were prepared 
using hanging drop technique (B), these aggregates were then cultured in 3D in a thick 
matrigel/collagen gel (C), in 2D on a thin matrigel layer (D), or were subject to 
trysinisation and subsequent single cells suspension cells formed a monolayer (E). 
Untreated cells before aggregate formation (A). 10X and 4X indicate magnification at 
which images were taken. 
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A: 3D control stromal cells   B: 3D differentiated stromal cells 
 
 
C: 2D control stromal cells   D: 2D differentiated stromal cells 
 
 
E: Control trypsinised aggregates  F: Differentiated trypsinised aggregates 
 
Figure 3.2.31 Day 8 of stromal cell differentiation protocol. Stromal cell aggregates 
were cultured in 3D (A & B), 2D (C & D) or aggregates were trypsinised and grown in 
monolayer format (E & F). Cells were treated with differentiation media to induce 
definitive endoderm formation (A, C & E), or standard stromal media (B, D & F) as a 
control. 
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Figure 3.2.32 Gene expression in differentiated stromal cells. Definitive endoderm 
markers cxcr4, foxa2 and Hnf4α and mesenchymal marker αSMA in differentiated and 
control stromal cells. β-actin is used as an endogenous control. 
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Definitive endoderm marker expression was examined in stromal cells in 3D, 2D and 
monolayer cultures treated with differentiation media and standard stromal media 
(figure 3.2.32). Cxcr4, Foxa2 and Hnf4α are markers of definitive endoderm. Foxa2 and 
Hnf4α expression was not detected in differentiated or control cells. 2D cultured stromal 
cells showed the highest expression of cxcr4 compared to 3D or monolayer cultured 
cells (figure 3.2.32). Higher cxcr4 expression was seen in control cells maintained in 
standard stromal cell media (DMEM 10% FCS) compared to cells cultured in 
differentiation media (RPMI with 1X B27, 4nM activin A, 1mM sodium butyrate) 
(section 2.2.5.1). This trend was seen in both 3D and 2D cultures. Very low levels of 
cxcr4 expression were seen in monolayer cultures. Expression of cxcr4 was absent from 
untreated stromal cells without hanging drop treatment. αSMA is a mesenchymal 
marker which is expressed in stromal cells, expression levels of this marker remained 
similar in control cells and cells treated with differentiation media.  
 
As 2D stromal cultures showed the highest cxcr4 expression (figure 3.2.32), 2D cultures 
were extended to the next step of the differentiation protocol- the pancreatic endoderm 
stage. 2D stromal cells were treated with pancreatic endoderm differentiation media 
from day 8 to day 21, while control cells were maintained in standard stromal cell 
media. At day 21 no obvious cell morphology changes were observed in control and 
differentiation media treated cells (figure 3.2.33), RNA was harvested from cells at this 
time point to monitor pancreatic endoderm marker expression (figure 3.2.34). 
 
Pancreatic endoderm markers pdx-1, hlxb9, ptf1a and nkx6.1 were undetected in all 
samples analysed. Ngn3 expression was detected at low levels in untreated stromal 
cells, but was undetected in control and differentiated cells in 2D culture (figure 3.2.34). 
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A: 2D control stromal cells  B: 2D differentiated stromal cells 
 
Figure 3.2.33 Day 21 of stromal cell differentiation protocol. Stromal cell aggregates 
were seeded into matrigel coated plates, control cells were maintained in stromal media 
(A), and differentiated cells were treated with differentiation media to induce pancreatic 
endoderm formation (B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.34 Day 21 PCR of stromal differentiation and control cells in 2D culture.  
 
 
B-actin 
Ngn3 
2D
 
D
iff
 
 2D
 
Co
n
tr
o
l 
  U
n
tr
ea
te
d 
 -
R
T 
 N
TC
 
 181 
3.2.7.1 Summary of directed differentiation of stromal cells 
 
Directed differentiation of stromal cells in standard monolayer culture showed no 
potential for pancreatic differentiation. However, when hanging drops were generated 
with these cells, subsequent directed differentiation induced expression of definitive 
endoderm marker cxcr4 (figure 3.2.32). Cell-cell interactions and signalling which 
occur while cells are in hanging drop and cluster formation may influence the 
propensity of stromal cells to differentiation towards pancreatic lineages. Further 
directed differentiation towards more mature pancreatic lineages did not yield any 
positive marker expression. 
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3.2.8 Stromal cell treatment with iMEF conditioned media 
 
Irradiated MEF conditioned media seemed to induce expression of some mature 
pancreatic markers in iPS cells (figure 3.2.26 and 3.2.29). Therefore stromal cells were 
treated with iMEF CM to determine if this treatment could induce pancreatic 
differentiation in these cells. 
 
Stromal cell aggregates were prepared using the hanging drop technique (section 2.2.6), 
aggregates were then embedded in a 3D thick matrigel/collagen gel (as described in 
section 2.2.5), and fed with either standard stromal media – DMEM with 10% FCS, or 
irradiated MEF conditioned ES media (iMEF CM). Cells were maintained under these 
conditions for 36 days before harvesting cells for RNA (as described in section 2.4.2) 
for analysis of mature pancreatic islet marker expression. Cells morphology differences 
were seen between stromal cells treated with standard media and iMEF CM. In the 
control condition cell aggregate outline is unclear with outgrowth of cells from the 
aggregate (figure 3.2.35 A), while iMEF CM treated aggregates still have a very clear 
aggregate border (figure 3.2.35 C). iMEF CM treated cells which have grown out from 
the aggregate also have a more stretched morphology, with more defined cell junctions 
compared to control cells in DMEM with 10% FCS (figure 3.2.35 B and D). 
 
Mature pancreatic islet marker expression was also analysed in control and iMEF CM 
treated 3D stromal cultures, untreated stromal cells in standard monolayer culture were 
also analysed as a comparison. Amylase expression was detected in 3D control and 3D 
iMEF CM treated cells, with higher expression in iMEF CM treated cells (figure 
3.2.36). Amylase expression was undetected in untreated stromal cells in standard 
monolayer culture. Insulin, somatostatin, glut2 and ghrelin expression were undetected 
in all samples analysed. 
 
This experiment was repeated to confirm the observed results. While similar cell 
morphology changes were seen as figure 3.2.36, the amylase expression in these cells 
was different. Equal amylase expression was seen in untreated 2D stromal cells, 3D 
stromal cells in standard stromal media, and 3D stromal cells in iMEF CM. Increased 
amylase expression was seen in stromal cell hanging drops (figure 3.2.37). 
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A: Stomal cells in DMEM 10% FCS  B: Stromal cells in DMEM 10% FCS 
 
 
C: Stomal cells in iMEF CM   D: Stromal cells in iMEF CM 
 
Figure 3.2.35 Day 36 stromal cells. Stromal cell aggregates were cultured in 3D format 
in a thick matrigel/collagen gel. Cells were then treated with the standard stromal media 
DMEM and 10% FCS (A & B), or iMEF conditioned media with 8ng/mL bFGF (C & 
D).  
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Figure 3.2.36 Day 36 PCR of stomal cells in 3D treated with iMEF CM or standard 
stromal media, DMEM 10% FCS. Untreated stromal cells in standard monolayer culture 
were also analysed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.37 Day 36 PCR of stomal cells in 3D treated with iMEF CM or standard 
stromal media, DMEM 10% FCS. Untreated stromal cells in standard monolayer 
culture, and hanging drop culture were also analysed. 
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3.2.8.1 Summary of iMEF CM treatment of stromal cells 
 
Stromal cell hanging drops in 3D culture were treated with iMEF CM for 36 days to 
induce pancreatic differentiation. Mature pancreatic exocrine marker- amylase, was 
detected in untreated and iMEF CM treated stromal cells (figure 3.2.37). Higher 
amylase levels were detected in stromal cells in hanging drop suspension culture. This 
highlights the influence of the poorly understood cell-cell signalling interactions which 
take place when cells are altered from monolayer cultures to cell clusters. 
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3.3 Biomarker discovery in diabetes serum specimens 
A clinical study of diabetes serum was performed in parallel to the cell culture based 
studies in section 3.1 and 3.2. A number of techniques were used in this study to 
identify serum biomarkers of potential use for the diagnosis, treatment and management 
of diabetes patients. MicroRNAs (miRNAs) identified in section 3.1 as being potentially 
involved in glucose stimulated insulin secretion in MIN-6 cells, were analysed in 
diabetes serum to determine if these miRNAs were dysregulated in type 1 and type 2 
diabetes patients. MiRNA profiling was also performed to identify additional miRNAs 
which may play a role in the pathogenesis of diabetes.  
 
New proteomic profiling technologies in the form of label-free LC-MS became 
available through the core facilities in the NICB during the course of this study. 
Therefore, the opportunity was taken to perform proteomic profiling of diabetes serum 
specimens using this new technology. Proteomic profiling was performed on serum 
specimens from newly diagnosed and established type 1 diabetes patients, to identify 
proteins which may be involved in the establishment and progression of disease state.  
 
Metabolomic profiling, which is now available as a commercial service provided by 
Metabolon Inc., was also performed on newly diagnosed type 1 diabetes serum samples, 
in addition to potentially identifying disease biomarkers, metabolomic profiling also 
allows insight into the metabolic dysregulation characteristic of diabetes patients.  
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3.3.1 Analysis of serum for miRNA biomarkers 
In the study of miRNAs involved in glucose stimulated insulin secretion in MIN-6 
cells (section 3.1) a set of 12 miRNAs were identified as potentially involved in this 
process. Advancing on these findings, we hypothesised that these miRNAs may also 
be differentially expressed in the serum of people with and without diabetes. 
 
 
3.3.1.1 Evaluation of target miRNA levels in serum from type 1 diabetes patients 
and control serum  
Initial experiments were performed on serum from three type one diabetes mellitus 
(T1DM) patients with established disease, compared to three non-diabetic control 
serum specimens. Levels of 14 different miRNAs were tested in these specimens 
(figure 3.3.1). Two of which had been identified from the literature (mir-9 and mir-
375) (Poy, Eliasson et al. 2004; Plaisance, Abderrahmani et al. 2006), and 12 of which 
were identified from miRNA arrays of the pancreatic beta cell line MIN6 (table 3.1.2). 
MiRNA levels were tested using TaqMan real-time PCR chemistries, ct values are 
shown in appendix B, table 2.1. Mir-337, mir-200a and mir-410 expression was 
undetected in these samples. 
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Figure 3.3.1. Fold change of miRNA levels in T1DM sera (n=3) compared to non-diabetic sera controls (n=3). T1DM and control 
samples were not matched for this initial analysis. Fold changes were calculated from group average ct values by 2-(ct(T1DM)-ct(Control) , as no 
suitable endogenous control identified for this work. As fold changes were calculated from averaged ct values, therefore no standard 
deviations are shown. 
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Mir-124a, mir-130a, mir-9, mir-532, mir-192 and mir-379 were identified from this 
initial study as being present at differing levels in T1DM serum compared to control 
sera (> 1.4 fold differential expression). Analysis of these six miRNAs was expanded 
to an additional 5 T1DM serum specimens compared to 5 non-diabetic control sera, 
which were age, gender and BMI matched (figure 3.3.2 – 3.3.6). Ct values are plotted 
rather than fold change, as no suitable endogenous control was identified for these 
serum specimens. 
 
Mir-124a : 
 
Mir-124a levels were significantly higher in T1DM sera compared to non-diabetic sera 
by 5.33 fold, in all five matched pairs (reflecting an average increase in Ct value of 
2.17) (figure 3.3.2). Lower Ct value indicates increased target expression. Individual ct 
values for each matched pair shown in appendix B, table 2.2. 
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Figure 3.3.2 Ct values of mir-124a in T1DM sera (n=5) compared to non-diabetic sera 
(n=5). Significance indicated by * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.005. Fold changes 
calculated from 2-(ct(T1DM)-ct(Control), as no suitable endogenous control identified for this 
serum specimens. Error bars indicate standard deviation. 
 
** 
5.33 fold 
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Mir-130a : 
 
In the initial analysis of 3 T1DM samples and 3 controls, mir-130a was down-
regulated in T1DM samples (figure 3.3.1). In this expanded study mir-130a is present 
at higher levels in T1DM sera relative to matched non-diabetic control sera in three 
sets of matched pairs. While in the remaining two pairs higher levels of mir-192 are 
detected in the control non-diabetic sera. There is no consistent trend seen in this 
miRNA in these samples (figure 3.3.3). Individual ct values for each matched pair is 
shown in appendix B, table 2.3. 
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Figure 3.3.3 Ct value of mir-130a in T1DM sera (n=5) compared to non-diabetic sera 
(n=5). Error bars indicate standard deviation. 
 
 
Mir-9 : 
Mir-9 levels were present at higher levels in T1DM serum compared to non-diabetic 
serum in one set of matched pairs. In a further two sets of matched pairs mir-9 levels 
went from present in T1DM sera to undetected in non-diabetic sera, and in the 
remaining two sets of matched patients, mir-9 was undetected in both non-diabetic and 
T1DM sera (appendix B, table 2.4).  
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Mir-532 : 
 
Mir-532 is present at higher levels in T1DM sera relative to matched non-diabetic 
control sera in three sets of matched pairs. In the remaining two pairs higher levels of 
mir-532 are detected in the control sera. There is no consistent trend seen in mir-532 
levels in these serum specimens (figure 3.3.4). Individual ct values for each matched 
pair are shown in appendix B, table 2.5. 
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Figure 3.3.4 Ct value of mir-9 in T1DM sera (n=5) compared to non-diabetic sera 
(n=5). Error bars indicate standard deviation. 
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Mir-192: 
 
Mir-192 is present at higher levels in T1DM sera compared to matched non-diabetic 
sera controls, in four of the five matched pairs (figure 3.3.5), although not significantly 
so. In the additional matched pair, mir-192 expression is detected in T1DM sample- 
DS-35, while it is undetected in its matched control- DS-33. Ct values for each 
matched pair are shown in appendix B, table 2.6. 
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Table 3.3.5 Ct values of mir-9 levels in T1DM sera (n=4) compared to non-diabetic 
sera (n=4). The additional matched pair is not included on this graph as mir-192 levels 
were undetected in the matched control specimen. Error bars indicate standard 
deviation. 
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Mir-379 : 
 
Mir-379 levels were on average higher in T1DM sera compared to non-diabetic sera 
(figure 3.3.6). Four of the five matched pairs showed higher mir-379 levels in T1DM 
sera, however, one matched pair T1DM sample- DS-13 and control sample- DS-18 
showed the opposite trend, therefore this change in mir-379 level was not significant. 
Individual ct values for each sample are shown in appendix B, table 2.7. 
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Table 3.3.6 Ct values of mir-379 in T1DM sera (n=5) compared to non-diabetic 
control sera (n=5). Error bars indicate standard deviation. 
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Mir-124a expanded study : 
 
Figure 3.3.2 showed a promising trend in the levels of mir-124a present in T1DM sera 
relative to non-diabetic control sera. On average, in T1DM sera, mir-124a levels were 
significantly increased by 5.33 fold. An additional 10 T1DM samples and matched 
controls were analysed to assess if the mir-124a trend remained in a larger cohort of 
patients (figure 3.3.7)  
 
Of the additional 10 sets of T1DM matched pairs analysed, 6 pairs showed the same 
trend of increased levels of mir-124a in T1DM as observed previously (figure 3.9). 
While 4 matched pairs showed reduced levels of mir-124a in T1DM sera. Ct values of 
individual samples are shown in appendix B, table 2.8. 
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Figure 3.3.7 Ct values of mir-124a in T1DM sera (n=10) compared to non-diabetic 
sera (n=10). Error bars indicate standard deviation. 
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3.3.1.2 TaqMan Low Density miRNA array profiling of T1DM serum 
 
TaqMan low density miRNA arrays were performed on three T1DM sera and three 
matched non-diabetic control sera. These miRNA arrays profile 365 target miRNAs 
plus three endogenous controls – RNU44, RNU48 and RNU6B. These endogenous 
controls were undetected in all sera samples analysed, therefore, all target miRNA 
results were analysed to identify a suitable miRNA to act as endogenous control.  
 
Mir-28 and mir-326 were identified as potential endogenous controls for this diabetic 
sera study, due to their low ct (cycle threshold), standard deviation and insignificant p-
values (i.e. these miRNAs not present at significantly different levels in T1DM sera 
compared to control sera) (table 3.3.1). 
 
TLDA results were normalised against mir-28 and separately against mir-326 as 
endogenous controls. MiRNAs with significant p-values and fold changes according to 
both endogenous controls were identified for follow-up analysis (table 3.3.2). 
 
Following normalisation against both endogenous controls seven miRNAs were 
identified as present at significantly higher levels in T1DM sera compared to non-
diabetic control sera (table 3.3.2). 
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Endogenous 
Control Average Ct P-value 
Standard 
Deviation 
mir-28 25.81 0.147 0.484 
mir-326 31.59 0.47 0.831 
Table 3.3.1 Potential sera miRNA endogenous controls 
 
 
  Mir-28 control Mir-326 control 
MicroRNA Fold Change P-value Fold Change P-value 
miR-140 6.851 0.038 6.506 0.012 
miR-21 6.931 0.048 6.583 0.011 
miR-24 5.723 0.042 5.436 0.008 
miR-29a 6.326 0.022 6.008 0.002 
miR-29c 8.388 0.025 7.967 0.016 
miR-30d 5.64 0.044 5.357 0.018 
miR-345 7.624 0.036 7.242 0.001 
Table 3.3.2 MiRNA targets from TLDA analysis. Fold changes indicated miRNA 
levels in T1DM sera (n=3) relative to non-diabetic control sera (n=3). 
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3.3.1.3 Validation of TLDA miRNA targets in T1DM serum 
 
Levels of endogenous control mir-28 were analysed in 5 T1DM samples and their 
matched controls using single-plex PCR, however mir-28 was undetected in one 
T1DM sample and one control sample. In the remaining samples mir-28 was present at 
significantly different levels in T1DM sera relative to control sera indicating that this 
miRNA is not a suitable endogenous control for normalisation of PCR data, therefore 
for further validation of TLDA targets no endogenous control was used.  
 
Seven miRNAs- mir-140, mir-21, mir-24, mir-29a, mir-29c, mir-30d and mir-345 were 
identified from TLDA analysis as present at significantly higher levels in T1DM sera 
relative to control sera (table 3.3.2). However in the expansion of this study to a further 
10 sets of matched pairs, none of the miRNAs tested showed a consistent trend in all 
matched pairs (table 3.3.3). Though the trends were not consistent throughout all 
specimens, it was noted that subgroups of matched pairs showed the same trends of 
miRNA expression. T1DM pairs DS-68, DS-74, DS-82, DS-84 and DS-95 pairs all 
showed reduced levels of miRNA targets relative to their matched controls, while DS-
88, DS-93 and DS-98 pairs were in agreement with the samples used for TLDA 
analysis, and showed increased levels of target miRNAs relative to their matched 
controls. 
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Matched Pairs MiRNA fold change  
T1DMs Controls Mir-140 Mir-21 Mir-24 Mir-29a Mir-29c Mir-30d Mir-345 
DS-68 DS-56 -7.91 -7.17 -7.08 -5.41 -4.47 -3.8 -3.72 
DS-74 DS-36 -4.51 -5.3 -3.67 -3.67 -2.63 -3.34 -2.4 
DS-82 DS-7 -4.55 -3.81 -3.37 -2.97 -5.23 -4.78 -4.6 
DS-84 DS-27 -2.81 -1.65 -2.78 -1.93 -1.35 -2.13 -1.4 
DS-95 DS-51 -1.34 -2.57 -2.04 -1.08 -1.52 -2.15 -1.28 
DS-88 DS-39 40.79 26.8 19.93 10.46 19.83 4.85 4.54 
DS-90 DS-53 1.27 -1.26 -1.06 1.09 -1.05 -1.74 1.17 
DS-93 DS-33 120.34 103.54 44.38 26.23 61.65 19.6 9.03 
DS-98 DS-50 4.45 2.18 3.17 4.64 3.58 1.87 4.75 
DS-99 DS-53 1.02 -1.19 1.03 1.02 1.15 -1.29 1.09 
 
Table 3.3.3 Single-plex validation of miRNA array targets in T1DM (n=10) and matched control (n=10) sera. Fold change indicates 
change in expression level in T1DM serum compared to control serum for each matched pair. Fold changes calculated from 2-(ct(T1DM)-
ct(Control)
, as no suitable endogenous control identified for this work. Red indicates reduced level of miRNA target in T1DM serum relative 
to control. Yellow indicates increased level of miRNA target in T1DM serum relative to control serum. 
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3.3.1.4 Evaluation of GSIS related miRNAs in serum from type 2 diabetes patients 
relative to control serum 
 
Expression levels of the 12 miRNAs which were identified from miRNA arrays of the 
pancreatic beta cell line MIN6 (table 3.1.2) were tested in six type 2 diabetes mellitus 
(T2DM) sera and matched non-diabetic controls.   
 
Mir-369-5p : 
Mir-369-5p expression was down-regulated in glucose non-responsive cells compared 
to glucose responsive cells (table 3.1.2). In accordance with this result, mir-369-5p 
levels are decreased in T2DM sera compared to control non-diabetic sera for four of 
the matched pairs analysed. For the additional two pairs mir-369-5p is detected in the 
control samples, but is beyond the level of detection in the T2DM samples (figure 
3.3.8) (appendix B, table 2.9).  
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Figure 3.3.8 Average Ct value of mir-369-5p levels in T2DM sera (n=4) compared to 
non-diabetic sera (n=4). The two additional matched pairs were not included in this 
graph as mir-369-5p levels were undetected in the T2DM specimens. Error bars 
indicate standard deviation. 
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Mir-130a : 
 
Mir-130a expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-130a levels are decreased 
in T2DM sera compared to control non-diabetic sera, for three sets of matched pairs. 
For the remaining three sets of matched pairs, mir-130a levels are increased in T2DM 
sera relative to control sera. Therefore no consistent change was seen in mir-130a 
expression in these samples (figure 3.3.9) (appendix B, table 2.10). 
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Figure 3.3.9 Average Ct value of mir-130a in T2DM sera (n=6) compared to non-
diabetic sera (n=6). Error bars indicate standard deviation. 
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Mir-27a : 
 
Mir-27a expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-27a levels are decreased in 
T2DM serum for 5 of the 6 matched pairs, but increased in the remaining T2DM 
sample, this change is not significant (figure 3.3.10) (appendix B, table 2.11). 
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Figure 3.3.10 Average Ct value of mir-27a levels in T2DM sera (n=6) compared to 
control sera (n=6). Error bars indicate standard deviation. 
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Mir-124a  
 
Mir-124a expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-124a levels were 
decreased in T2DM sera compared to control non-diabetic sera, for three sets of 
matched pairs. For the remaining three sets of matched pairs, mir-124a levels were 
increased in T2DM sera relative to control sera in 2 sets of matched pairs, but levels 
remained unchanged in the last set (figure 3.3.11) (appendix B, table 2.12). 
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Figure 3.3.11 Ct value for mir-124a in T2DM sera (n=6) compared to non-diabetic 
sera (n=6). Error bars indicate standard deviation. 
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Mir-410 : 
 
Mir-410 expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-410 levels were decreased 
in T2DM sera compared to control non-diabetic sera, for three sets of matched pairs. 
For the remaining three sets of matched pairs, mir-410 levels are unchanged in T2DM 
sera relative to control sera (figure 3.3.12) (appendix B, table 2.13). 
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Figure 3.3.12 Ct value for mir-410 levels in T2DM sera (n=6) compared to non-
diabetic sera (n=6). Error bars indicate standard deviation. 
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Mir-200a : 
 
Mir-200a expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-200a levels are decreased 
in T2DM sera compared to control non-diabetic sera, for two sets of matched pairs. 
For the remaining three sets of matched pairs, mir-200a levels are increased in T2DM 
sera relative to control sera, and the remaining matched pair mir-200a is undetected in 
both specimens and control sera (figure 3.3.13) (appendix B, table 2.14). 
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Figure 3.3.13 Ct value for mir-200a levels in T2DM sera (n=4) compared to non-
diabetic sera (n=4). The two additional matched pairs were not plotted on this graph as 
mir-200a levels were undetected in the control specimens and one of the T2DM, while 
low level mir-200a were detected in the additional T2DM sample. Error bars indicate 
standard deviation. 
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Mir-532 : 
 
Mir-532 expression was down-regulated in glucose non-responsive cells compared to 
glucose responsive cells. In accordance with this result, mir-532 levels are decreased in 
T2DM sera compared to control non-diabetic sera, for two sets of matched pairs. Mir-
532 levels are increased in T2DM sera relative to control sera for two sets of matched 
pairs, and the remaining two sets of matched pairs mir-200a levels are unchanged in 
sample and control sera (figure 3.3.14) (appendix B, table 2.15). 
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Figure 3.3.14 Ct value for mir-532 levels in T2DM sera (n=6) compared to non-
diabetic sera (n=6). Error bars indicate standard deviation. 
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Mir-376a, mir-337, mir-320, mir-192 and mir-379 : 
 
Mir-376a, mir-337, mir-320, mir-192 and mir-379 expression levels were reduced in 
non-glucose responsive cells relative to glucose responsive MIN6 cells, however, in 
this study of T2DM and control sera, levels of these miRNAs were undetected. 
 
 
A summary of target miRNA expression in T2DM sera is shown in figure 3.3.15. 
Some slight changes were seen in expression of these miRNAs, however these changes 
were not statistically significant. 
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miRNA expression in T2DM and control serum
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Figure 3.3.15 MiRNA expression levels in T2DM (n=6) and control (n=6) serum specimens. Expression levels are represented by Ct 
values. Error bars indicate standard deviation. 
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3.3.1.5 Summary of miRNA biomarker study 
 
• Levels of GSIS related miRNAs were examined in T1DM old and control old 
samples 
o Mir-124a, mir-130a, mir-9, mir-532, mir-192 and mir-379 were 
differentially expressed (n=3) 
o Study was expanded to n=5 (n=15 for mir-124a), however miRNA 
expression trends were not consistent  
• TLDA miRNA profiling of T1DM old and control old (n=3) identified 7 
differentially expressed miRNAs 
o mir-140, mir-21, mir-24, mir-29a, mir-29c, mir-30d and mir-345 
o TLDA miRNA targets validated in 6 T1DM and control samples 
o miRNA expression trends were not consistent  
• Levels of GSIS related miRNAs were examined in T2DM and control samples  
o No statistically significant changes were seen in these miRNA levels in 
T2DM and control samples (n=6) 
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3.3.2 Proteomic profiling of type 1 diabetes serum 
3.3.2.1 Patient characteristics 
Serum from newly diagnosed type 1 diabetes (3.14 ± 2.66 months mean duration since 
diagnosis) and type 1 diabetics with established disease (minimum 18 months), as well 
as age/BMI/gender matched healthy controls for each group (n=8) were used for the 
analysis. Table 3.3.4 shows the general characteristics of newly diagnosed type 1 
diabetes (T1DM new) patients and healthy controls (control new) used in the study. 
Table 3.3.5 shows the general characteristics of type 1 diabetes patients with established 
disease (T1DM old) and their matched controls (control old) which were used in this 
study. 
 
An additional group of serum samples from patients with a range of autoimmune and 
inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, asthma, eczema, 
systemic lupus erythematosus, hashimoto’s thyroiditis, psoriatic arthritis and pernicious 
anemia were also analysed in this experiment. The mean age of these patients was 31.4 
± 4.9 years. The autoimmune group was included in this experiment to allow 
identification of markers directly related to type 1 diabetes rather than markers of 
general autoimmune/inflammatory conditions. 
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 T1DM new  
(n=8) 
Control new  
(n=8) 
P-value 
Age (years) 26 ± 5 27 ± 2 0.50 
BMI (Kg/m2) 24.64 ± 4.2 24.94 ± 2.6 0.87 
Fasting glucose (mmol/L) 6.49 ± 3.06 4.49 ± 0.37 0.11 
HbA1c (%) 7.69 ± 1.96 5.15 ± 0.30 0.008 
Cholesterol (mmol/L) 4.29 ± 0.55 5.05 ± 0.44 0.013 
HDL-cholesterol (mmol/L) 1.25 ± 0.42 1.35 ± 0.39 0.63 
LDL-cholesterol (mmol/L) 2.53 ± 0.41 3.19 ± 0.55 0.02 
Triglyceride (mmol/L) 1.09 ± 0.38 1.37 ± 1.07 0.50 
Table 3.3.4 General characteristics of the newly diagnosed type 1 diabetes patients and 
their matched controls. Mean values shown for 8 patients per group. 
 
 
 
 
 
 T1DM old  
(n=8) 
Control old  
(n=8) 
P-value 
Age (years) 44.75 ± 12.84 42.25 ± 4.80 0.62 
BMI (Kg/m2) 28.46 ± 4.36 28.37 ± 4.88 0.97 
Fasting glucose (mmol/L) 11.06 ± 5.69 4.79 ± 0.38 0.017 
HbA1c (%) 7.99 ± 1.29 5.37 ± 0.24 0.00016 
Cholesterol (mmol/L) 3.95 ± 0.66 5.19 ± 0.54 0.0011 
HDL-cholesterol (mmol/L) 1.56 ± 0.39 1.45 ± 0.17 0.49 
LDL-cholesterol (mmol/L) 1.91 ± 0.29 2.74 ± 1.09 0.071 
Triglyceride (mmol/L) 1.02 ± 0.87 1.35 ± 0.89 0.47 
Table 3.3.5 General characteristics of the type 1 diabetes patients with established 
disease and their matched controls. Mean values shown for 8 patients per group. 
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3.3.2.2 Serum pre-treatment with ProteoMinerTM 
 
Identification of protein biomarkers in serum can be difficult due to the large dynamic 
range of proteins present in this biological fluid. Serum proteins span a concentration 
range of 11 orders of magnitude, with the 20 most abundant proteins representing 97-
99% of the total protein mass (Anderson and Anderson 2002). The presence of high 
abundance proteins interferes with detection of low abundance proteins, which may be 
of importance to the biological dysfunction being studied. Therefore a new sample 
preparation tool- ProteoMinerTM, was used for the preparation of serum samples in this 
study. 
 
ProteoMinerTM facilitates compression of the dynamic range of protein concentrations 
by decreasing the concentration of a number of well know high abundance proteins such 
as albumin and IgG, hence enriching for medium and low abundance proteins. 
ProteoMinerTM is a column based procedure, whereby serum samples are passed 
through a column containing a highly diverse bead-based library of combinatorial 
peptide ligands, with each unique peptide ligand binding a unique protein. High 
abundance proteins saturate their ligands and excess protein is washed through, while 
low abundance proteins are concentrated on their specific ligands (figure 4.3.1). 
ProteoMinerTM has many advantages over standard immunodepletion techniques for 
removal of the high abundance serum proteins. ProteoMinerTM facilitates protein elution 
in small volumes, combining low abundance protein concentration and compressing of 
the dynamic range in one step. While standard immunodepletion techniques remove a 
number of high abundance proteins but may still leave low abundance proteins 
relatively dilute, requiring a separate concentrating step. Immunodepletion may also 
lead to co-depletion of low abundance proteins of interest (Shen, Kim et al. 2005), 
whereas ProteoMinerTM prevents co-depletion of proteins bound to high abundance 
proteins.  
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Figure 4.3.1 Representation of ProteoMinerTM protocol. Image taken from 
ProteominerTM Protein Enrichment Technology sample preparation guide 
(http://wolfson.huji.ac.il/purification/PDF/AlbuminRemoval/BIORAD_ProteoMiner.pd
f) 
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3.3.2.3 Label-free LC-MS data analysis 
 
Following the preparation of serum samples by ProteoMinerTM, label-free liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) was performed for 
analysis of peptide composition in these samples. LC-MS/MS measures the peptide 
constituents rather than intact proteins as peptides are more suitable for LC analysis and 
have better ionization properties. Trypsin was used for protein digestion as it cleaves at 
well-defined sequence locations, resulting in non-overlapping peptide mixtures 
(Christin, Bischoff et al. 2011). 
 
Label-free LC-MS/MS does not utilise isotopic labelling of proteins, instead, signal 
intensities are directly compared between LC-MS/MS runs. Label-free LC-MS/MS is 
now being used more frequently where previously 2D DIGE gels were used as standard 
for biomarker discovery. 2D DIGE gels have several limitations including insufficient 
resolving power to fully separate peptides in the gel, difficulty in analysing hydrophobic 
proteins, restricted sample throughput, complex sample preparation, incomplete 
labelling, as well as high costs (Ong and Pandey 2001; Tuli and Ressom 2009; Sandin, 
Krogh et al. 2011). Label-free LC-MS overcomes these issues while allowing increased 
proteome coverage compared to gel based techniques. 
 
LC is the most commonly used method for separating peptides before downstream mass 
spectrometry analysis (Tuli and Ressom 2009). A nano LC system was used for this 
proteomic profiling application, where the stationary phase consisted of silica based 
C18 reverse phase column. The mobile phase used consisted of a 10-35% gradient of 
solvent B (98% acetonitrile, 0.04% FA) with solvent A (2% acetonitrile, 0.05% 
trifluroroacetic acid) over a 150 minute period. Reverse phase LC columns are most 
suited for analysis of complex peptide mixtures (Tuli and Ressom 2009) with the most 
polar or hydrophilic peptides eluting first and most non-polar hydrophobic peptides 
eluting towards the end of the 150 minute period.  
 
The mass spectrometer consists of three main components: the ionisation source which 
converts the eluting peptides into the gas phase, the mass analyser which separates the 
ions based on the mass to charge ratio (m/z), and the detector which registers relative 
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abundance of ions (Tuli and Ressom 2009). In this study, tandem mass spectrometry 
was employed. This incorporates several mass analysers in series, which enables ions 
from the first analyser (parent ions) to undergo collision induced dissociation (CID) to 
generate product ions which are then separated based on m/z in the subsequent mass 
analysers. Detection of parent and daughter ions allows extra confidence in peptide 
identification. MS/MS spectral files from the mass spectrometer containing m/z 
information of parent and product ions of each peptide can be compared to identify 
differentially abundant ions or peptides which can be directly searched against a 
database of proteins which have been digested in silico. 
 
Data analysis was performed using Progenesis LC-MS software available from Non-
Linear Dynamics. Raw MS data files were imported to Progenesis LC-MS software 
package. A reference run is selected as the sample which is most representative of the 
data, all additional sample runs are then aligned to the reference sample run. Alignment 
of sample runs allows correction of variable peptide retention times during 
chromatographic separation and hence allows comparison of different sample runs. 
Once sample runs have been aligned, the software is then able to detect features in each 
run. Detected features are then filtered based on an anova p-value of less than 0.2; this 
cut-off value was chosen so as not to exclude too many peptides from the analysis, as 
subsequent identified proteins would be filtered with more stringent criteria at a later 
stage. From this list of filtered features a principal component analysis (PCA) plot is 
generated. The MS/MS data from this list of filtered features is then exported into the 
external search engine MASCOT to match these identified features to known peptides, 
using the following search criteria: database-Swissprot/UniProt, enzyme-trypsin, allow 
up to 2 missed cleavages, taxonomy-homo sapiens, fixed modifications-
carbamidomethyl (C), variable modifications-oxidation (M), peptide tolerance-10ppm, 
MS/MS tolerance-0.8Da, and peptide charge-2+, 3+ and 4+. Once identifications have 
been assigned, this information is then imported to progenesis. Various statistical 
criteria can then be applied to identified peptides to generate a list of proteins. For this 
experiment a statistical criteria of anova p-value less than 0.05, and peptide number 
greater than 1 was applied to generate lists of differentially expressed proteins.  
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3.3.2.4 All groups analysis 
 
8 serum samples per group were included in this experiment. One control sample (DS-
171) was incompatible for alignment with any reference sample selected, this may be 
due to sub-optimal sample handling or a problem associated with the LC-MS run, 
therefore this sample could not be used in the data analysis. All other sample runs 
aligned with reference run without any problems. LC-MS data for all samples from each 
group were imported to the progenesis software (excluding control sample DS-171), 
following successful alignment and filtering of detected features (anova p-value ≤ 0.2), 
a PCA plot is generated. Figure 3.3.16 shows the PCA plot for all sample groups. The 
pink spots represent the T1DM new samples while the purple spots represent the control 
new samples, which are the matched controls for the T1DM new samples. While they 
didn’t form distinctly separate clusters, the control new sample spots were clustered 
quite closely on the bottom right part of the PCA plot. The T1DM new sample spots, 
while not as closely clustered, were mainly located in the top left corner of the plot. The 
autoimmune/inflammatory disease serum specimens were represented by the cyan 
spots, these showed a very similar clustering pattern to the T1DM new samples. The 
T1DM old samples were represented by the blue spots while the control old samples, 
which are the matched controls for the T1DM old samples were represented by the 
orange spots. The T1DM old spots were mainly located in the right portion of the plot 
while the control old spots were located in the left of the plot. While each sample group 
did not result in the formation of distinctly separate clusters, each sample group 
clustered in a separate area of the plot. The loose filter criteria for peptide identification 
(anova p-value 0.2) would also contribute to the samples not clustering as tight as we 
would like, however, we did not want to apply too stringent criteria at this stage to 
exclude peptides from the analysis, as identified proteins would be filtered using more 
stringent criteria at a later stage. 
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Figure 3.3.16 PCA plot for all sample groups. Pink spots represent T1DM new samples, blue spots represent T1DM old samples, purple 
spots represent control new samples, orange spots represent control old sample and the cyan spots represent the autoimmune samples.  
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3.3.2.5 Type 1 newly diagnosed (T1DM new) versus matched controls (control 
new) 
 
Progenesis analysis was performed in triplicate for all comparisons analysed, using a 
different reference sample for each replicate. Samples with the highest number of 
detected features were chosen as reference samples. Therefore, 3 lists of differentially 
expressed proteins were generated for each comparison analysed (these lists are shown 
in appendix C). Proteins common to all three lists were then identified, and reported in 
the results section. 
 
For the T1DM new versus control new comparison, the first replicate was performed 
with a T1DM new sample (DS-169) as reference sample, the second replicate with a 
control new sample (DS- 175) and the third replicate with another control new sample 
(DS-178). A PCA plot was generated for each analysis performed. The PCA plot is used 
to determine if the data clusters according to the experimental conditions. Figures 3.3.17 
shows a very clear distinction between the T1DM new and control new sample clusters, 
T1DM new samples are shown in pink, while the control new samples are shown in 
blue. DS sample codes used in this study are identifier codes given to serum specimens 
as the volunteers are recruited, to avoid using patient names to identify individual 
specimens. 
 
A list of differentially expressed proteins was also generated for each replicate analysis 
performed (see appendix C, table 1, 2 and 3). Proteins that were common to all three 
lists are identified in table 3.3.6, these included the proteins complement C5, clusterin, 
inter-alpha-trypsin inhibitor heavy chain H3, c-reactive protein, POTE ankyrin domain 
family member E and beta-actin-like protein 3. 
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Figure 3.3.17 PCA plot for T1DM new and control new samples. DS-175 control new sample was used as reference run. Pink spots 
indicate the T1DM new samples while the blue spots indicate the control new samples. 
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      Average Normalised 
Abundances 
Accession Description Reference 
run used 
Fold Anova (p) peptides T1DM new Control New 
DS-169  +1.65 0.03 20 1.88E+006 1.14E+006 
DS-175  +1.74 0.004 20 2.24E+006 1.28E+006 
P01031 
 
Complement C5  
DS-178 +1.63 0.04 9 4.70E+005 2.88E+005 
 
DS-169  +1.72 0.04 13 1.78E+007 1.03E+007 
DS-175  +1.68 0.01 12 2.68E+007 1.59E+007 
P10909 
 
Clusterin  
DS-178 +1.57 0.02 4 8.49E+005 5.41E+005 
 
DS-169  +2.43 0.01 3 9.40E+004 3.88E+004 
DS-175  +2.7 0.007 5 1.53E+005 5.66E+004 
Q06033 
 
Inter-alpha-trypsin inhibitor heavy chain 
H3  
DS-178 +2.5 0.02 2 8.37E+004 3.34E+004 
 
DS-169  +6.09 0.02 6 1.22E+006 2.00E+005 
DS-175  +6.22 0.01 4 1.24E+006 1.99E+005 
P02741 
 
C-reactive protein  
DS-178 +8.05 0.02 4 4.21E+005 5.23E+004 
 
DS-169  -1.97 0.02 3 5.39E+004 1.06E+005 
DS-175  -1.92 0.03 2 6.34E+004 1.22E+005 
Q6S8J3 
 
POTE ankyrin domain family member E  
DS-178 -2.02 0.03 3 6.91E+004 1.40E+005 
 
DS-169  -1.98 0.02 2 4.86E+004 9.63E+004 
DS-175  -1.92 0.03 2 6.34E+004 1.22E+005 
Q9BYX7 
 
Beta-actin-like protein 3  
DS-178 -2.03 0.03 2 6.31E+004 1.28E+005 
Table 3.3.6 Proteins differentially expressed in T1DM new compared to control new samples. 
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3.3.2.6 Type 1 diabetes with established disease (T1DM old) versus matched 
controls (control old) 
 
The analysis of these groups was performed in triplicate using a different reference 
sample for each replicate. The first replicate was performed with a T1DM old sample 
(DS-84) as reference sample, the second replicate with a control old sample (DS- 162) 
and the third replicate with another control old sample (DS-39) as reference sample. A 
PCA plot was generated (figure 3.3.18), showing two distinct clusters, however one of 
the T1DM old samples (pink) clustered with the control old samples (blue), rather than 
with the other T1DM old samples. 
 
A list of differentially expressed proteins was also generated for each replicate analysis 
performed (see appendix C, table 4, 5 and 6). Proteins that were common to all three 
lists were identified in table 3.3.7, these included the proteins antithrombin III, 
apolipoprotein E, apolipoprotein C-II, vitronectin, ficolin-2, ceruloplasmin, vitamin K-
dependent protein S, apolipoprotein A-1, transthyretin, C4b binding protein alpha chain, 
serum amyloid A-4 protein, mannan-binding lectin serine protease 1, apolipoprotein L1, 
platelet factor 4, apolipoprotein C-IV, von willebrand factor, complement component 
C8 beta chain, actin- cytoplasmic 2, complement factor H related protein 1, POTE 
ankyrin domain family member E and beta-actin-like protein 3. 
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Figure 3.3.18 PCA plot for T1DM old and control old samples. DS-84 T1DM old sample was used as reference run. Pink spots indicate 
the T1DM old samples while the blue spots indicate the control old samples.
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      Average Normalised 
Abundances 
Accession Description Reference 
run used 
Fold Anova (p) peptides T1DM old Control old 
DS-84 -2.55 0.05 18 6.43E+007 1.64E+008 
DS-162 -2.31 0.03 17 3.15E+007 7.27E+007 
P01008 
 
Antithrombin-III  
DS-39 -2.37 0.03 16 2.79E+007 6.63E+007 
 
DS-84 -2.19 0.02 12 1.46E+007 3.20E+007 
DS-162 -2.05 0.02 15 1.07E+007 2.19E+007 
P02649 
 
Apolipoprotein E  
DS-39 -2.05 0.02 15 1.05E+007 2.16E+007 
 
DS-84 -2.41 0.01 4 4.06E+006 9.79E+006 
DS-162 -2.25 0.01 5 3.13E+006 7.05E+006 
P02655 
 
Apolipoprotein C-II  
DS-39 -2.5 0.007 5 2.76E+006 6.88E+006 
 
DS-84 -1.72 0.03 5 2.55E+007 4.39E+007 
DS-162 -1.62 0.03 5 1.71E+007 2.77E+007 
P04004 
 
Vitronectin  
DS-39 -1.57 0.03 6 1.76E+007 2.77E+007 
 
DS-84 -3 0.02 5 5.81E+005 1.75E+006 
DS-162 -2.81 0.02 7 4.37E+005 1.23E+006 
Q15485 
 
Ficolin-2  
DS-39 -2.88 0.02 6 4.10E+005 1.18E+006 
 
DS-84 +1.7 0.03 6 5.53E+005 3.25E+005 P00450 
 
Ceruloplasmin  
DS-162 +1.44 0.04 8 4.51E+005 3.13E+005 
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DS-39 +1.6 0.03 7 5.17E+005 3.23E+005 
 
DS-84 -2.47 0.05 7 1.52E+006 3.75E+006 
DS-162 -2.13 0.006 4 4.03E+005 8.59E+005 
P07225 
 
Vitamin K-dependent protein S  
DS-39 -2.24 0.005 6 4.03E+005 9.04E+005 
 
DS-84 -1.9 0.05 5 2.66E+007 5.06E+007 
DS-162 -1.76 0.04 4 1.99E+007 3.50E+007 
P02647 
 
Apolipoprotein A-I  
DS-39 -1.75 0.05 5 1.96E+007 3.44E+007 
 
DS-84 -2.69 0.04 4 2.14E+006 5.74E+006 
DS-162 -2.39 0.03 3 1.63E+006 3.91E+006 
P02766 
 
Transthyretin  
DS-39 -2.46 0.04 3 1.51E+006 3.71E+006 
 
DS-84 -2.62 0.04 3 5.67E+006 1.49E+007 
DS-162 -2.39 0.03 3 4.23E+006 1.01E+007 
P04003 
 
C4b-binding protein alpha chain 
DS-39 -2.4 0.03 4 4.16E+006 9.97E+006 
 
DS-84 -2.34 0.02 2 8.40E+005 1.97E+006 
DS-162 -2.25 0.02 2 5.16E+005 1.16E+006 
P35542 
 
Serum amyloid A-4 protein  
DS-39 -2.37 0.01 3 5.00E+005 1.19E+006 
 
DS-84 -1.97 0.005 4 4.04E+005 7.95E+005 
DS-162 -1.95 0.002 4 2.82E+005 5.49E+005 
P48740 
 
Mannan-binding lectin serine protease 1  
DS-39 -1.91 0.002 4 2.79E+005 5.35E+005 
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DS-84 -4.07 0.003 2 7.27E+004 2.96E+005 
DS-162 -2.44 0.03 3 7.75E+004 1.89E+005 
O14791 
 
Apolipoprotein L1  
DS-39 -2 0.02 3 1.25E+005 2.49E+005 
 
DS-84 -2.1 0.05 2 7.12E+005 1.49E+006 
DS-162 -1.98 0.05 2 5.30E+005 1.05E+006 
P02776 
 
Platelet factor 4  
DS-39 -1.97 0.05 2 5.22E+005 1.03E+006 
 
DS-84 -3.42 0.03 4 1.28E+005 4.38E+005 
DS-162 -3.14 0.02 4 1.45E+005 4.56E+005 
P63261 
 
Actin, cytoplasmic 2  
DS-39 -3.09 0.03 4 1.52E+005 4.71E+005 
 
DS-84 -3.99 0.01 3 6.77E+004 2.70E+005 
DS-162 -3.72 0.009 3 4.79E+004 1.78E+005 
Q9BYX7 
 
Beta-actin-like protein 3  
DS-39 -3.63 0.02 3 5.17E+004 1.88E+005 
 
DS-84 -3.99 0.01 3 6.77E+004 2.70E+005 
DS-162 -3.72 0.009 3 4.79E+004 1.78E+005 
Q6S8J3 
 
POTE ankyrin domain family member E  
DS-39 -3.63 0.02 3 5.17E+004 1.88E+005 
 
DS-84 -2.9 0.02 2 5.04E+004 1.46E+005 
DS-162 -3.53 0.003 2 2.86E+004 1.01E+005 
P55056 
 
Apolipoprotein C-IV  
DS-39 -3.03 0.004 2 3.58E+004 1.08E+005 
 
DS-84 -4.42 0.02 2 1.76E+004 7.80E+004 
DS-162 -3.51 0.01 2 1.67E+004 5.87E+004 
P04275 
 
von Willebrand factor  
DS-39 -3.9 0.01 2 1.41E+004 5.50E+004 
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DS-84 -1.88 0.006 3 2.30E+006 4.34E+006 
DS-162 -1.74 0.02 3 1.42E+006 2.47E+006 
Q03591 
 
Complement factor H-related protein 1  
DS-39 -1.74 0.03 2 1.34E+006 2.33E+006 
 
DS-84 +1.46 0.01 3 8.24E+004 5.64E+004 
DS-162 +1.86 0.001 2 6.35E+004 3.41E+004 
P07358 
 
Complement component C8 beta chain  
DS-39 +1.91 0.00005 2 6.34E+004 3.31E+004 
 
Table 3.3.7 Proteins differentially expressed in T1DM old compared to control old samples. 
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3.3.2.7 Type 1 newly diagnosed (T1DM new) versus type 1 diabetes with 
established disease (T1DM old)  
 
The analysis of this comparison was performed in triplicate using a different reference 
sample for each replicate. The first replicate was performed with a T1DM new sample 
(DS-169) as reference sample, the second replicate with a T1DM old sample (DS-74) 
and the third replicate with another T1DM old sample (DS-90). A PCA plot was 
generated for this comparison (figure 3.3.19), showing two distinct clusters, however 
one of the T1DM old sample- DS-29 (blue) clustered slightly closer to the T1DM new 
(pink), rather than with the other T1DM old samples. 
 
A list of differentially expressed proteins was also generated for each replicate analysis 
performed (see appendix C, table 7, 8 and 9). Proteins that were common to all three 
lists were identified in table 3.3.8, these included the proteins complement C4-B, 
prothrombin, clusterin, Ig mu chain C region, antithrombin III, Ig kappa chain C region, 
vitronectin, vitamin K-dependent protein and apolipoprotein C-1. 
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Figure 3.3.19 PCA plot for T1DM new and T1DM old. DS-169 control sample was used as reference run. Pink spots indicate the T1DM 
new samples while the blue spots indicate the T1DM old samples.
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      Average Normalised 
Abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptides T1DM new T1DM old 
DS-169 +1.35 0.02 47 1.11E+08 8.23E+07 
DS-74 +1.45 0.01 46 1.56E+08 1.08E+08 
P0C0L5 
 
Complement C4-B  
DS-90 +1.48 0.01 44 1.62E+08 1.09E+08 
 
DS-169 +1.39 0.05 19 3.08E+07 2.22E+07 
DS-74 +1.4 0.05 15 4.57E+07 3.27E+07 
P00734 
 
Prothrombin  
DS-90 +1.42 0.03 17 4.69E+07 3.31E+07 
 
DS-169 +1.43 0.005 7 2.10E+07 1.47E+07 
DS-74 +1.42 0.003 9 3.31E+07 2.34E+07 
P10909 
 
Clusterin  
DS-90 +1.45 0.003 10 3.35E+07 2.31E+07 
 
DS-169 +1.57 0.04 4 6.61E+06 4.21E+06 
DS-74 +1.57 0.04 5 1.26E+07 8.04E+06 
P01871 
 
Ig mu chain C region  
DS-90 +1.55 0.03 6 1.43E+07 9.25E+06 
 
DS-169 +1.44 0.006 10 2.35E+07 1.63E+07 
DS-74 +1.43 0.01 13 3.12E+07 2.18E+07 
P01008 
 
Antithrombin-III  
DS-90 +1.46 0.007 13 4.18E+07 2.87E+07 
 
DS-169 +1.54 0.03 4 6.15E+06 4.00E+06 
DS-74 +1.55 0.02 5 9.42E+06 6.07E+06 
P01834 
 
Ig kappa chain C region  
DS-90 +1.58 0.02 4 9.56E+06 6.06E+06 
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DS-169 +1.45 0.03 4 1.72E+07 1.18E+07 
DS-74 +1.46 0.03 5 2.57E+07 1.76E+07 
P04004 
 
Vitronectin  
DS-90 +1.42 0.03 4 3.39E+07 2.38E+07 
 
DS-169 +1.71 0.007 4 6.27E+05 3.67E+05 
DS-74 +1.49 0.0009 5 6.24E+05 4.18E+05 
P07225 
 
Vitamin K-dependent protein S  
DS-90 +2.2 0.003 2 6.16E+05 2.80E+05 
 
DS-169 +1.55 0.004 4 2.59E+06 1.67E+06 
DS-74 +1.56 0.002 2 3.78E+06 2.42E+06 
P02654 
 
Apolipoprotein C-I  
DS-90 +1.59 0.002 3 3.88E+06 2.45E+06 
Table 3.3.8 Proteins differentially expressed in T1DM new compared to T1DM old. 
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3.3.2.8 Target protein selection for follow up 
 
Proteins for follow up were selected based on their potential interest in both the T1DM 
new and T1DM old studies. Clusterin was identified as being up-regulated in T1DM 
new samples relative to T1DM old (table 3.3.8) and control new samples (table 3.3.6). 
Vitronectin was down-regulated in T1DM old samples relative to T1DM new (table 
3.3.8) and control old (table 3.3.7). Vitronectin was also up-regulated in two of the three 
replicates for T1DM new versus control new comparison (appendix C, table 1 and 2). 
Vitamin K-dependent protein S levels showed the same pattern as vitronectin. This 
protein was down regulated in T1DM old samples relative to T1DM new (table 3.3.8) 
and control old samples (table 3.3.7), it was also up-regulated in two of the three 
replicate comparisons of T1DM new versus control new samples (appendix C, table 1 
and 2). Apolipoprotein L1 was down-regulated in T1DM old relative to control old 
samples (table 3.3.6), while it was also down-regulated in one of the replicates for 
T1DM old versus T1DM new comparisons (appendix C, table 9).  
 
These proteins were also selected on the basis that they had no conflicting identified 
peptides. Conflicting peptides are peptides that are not unique to the named protein, and 
may be present in a number of other different proteins. Performing each comparison in 
triplicate with different reference samples, as well as assigning filter criteria of anova p-
value less than 0.05 and proteins with no conflicting peptides allowed identification of 
the most robustly changed proteins in the samples analysed. Using these criteria, 
clusterin, vitronectin, apolipoprotein L1 and vitamin K-dependent protein S were 
selected for follow up validation in a larger cohort of patient samples. 
 
Control new and control old samples were compared to determine if protein changes 
seen in disease versus control samples were related to disease phenotype or were related 
to control samples used. A PCA plot of control new and control old samples was 
generated (appendix C, figure 1), this indicated that DS-7 was a slight outlier for the 
control old group. Differentially expressed protein lists were generated with and without 
the DS-7 outlier sample (appendix C, table 10, 11 and 12). Apolipoprotein L1 and 
vitronectin were unchanged in the control old versus the control new comparison, with 
and without outlier DS-7 sample included in analysis. This indicates that changing 
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levels of these proteins are due to the disease phenotype. Clusterin and vitamin K-
dependent protein S were seen to be up-regulated in the control old samples relative to 
the control new samples in comparisons with and without outlier sample DS-7 
(appendix C, table 10, 11 and 12). However, as these proteins were also identified as 
being differentially expressed in the T1DM new versus T1DM old comparison (table 
3.3.8), therefore their differential expression is not alone due to the control samples 
being used. 
 
Protein changes between autoimmune (n=8) and control samples (n=16) were also 
analysed, to determine if protein targets identified in the T1DM study were specifically 
type 1 diabetes related, or if they were general autoimmune or inflammation related 
proteins. Three lists of differentially expressed proteins were generated for autoimmune 
versus control sample comparison, using control samples DS-175, DS-178 and DS-39 
as reference run, complete lists shown in appendix C, table 13, 14 and 15. No changes 
in vitronectin, clusterin or vitamin K-dependent protein S were seen in any of the 
autoimmune versus control comparisons, indicating that changes in these protein levels 
in the T1DM study were specifically diabetes related. One of the three comparisons 
(appendix C, table 14) showed decreased levels of apolipoprotein L1 in autoimmune 
samples. Therefore, it is possible that decreased levels of apolipoprotein L1 in T1DM 
old samples could be related to a general autoimmune or inflammatory response. 
However, as apolipoprotein L1 were increased in T1DM new samples, this protein for 
selected for validation studies. 
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3.3.2.9 ELISA validation of target proteins 
 
Protein targets identified in label-free LC-MS study were validated using ELISA 
technology. Validation was performed on the same 8 T1DM new, T1DM old and 
control samples which were used in the label-free study, as well as an additional 22 
T1DM old and control old samples. 
 
3.3.2.9.1 Vitronectin 
 
Vitronectin: T1DM new vs. control new 
Label free proteomics analysis showed vitronectin levels to be significantly increased in 
T1DM new samples compared to controls by approximately 1.44 fold. An ELISA kit 
was sourced from American Diagnostica GmbH (catalogue number 803) for validation 
of this target protein (protocol outlined in section 2.6.1.1). ELISA detection of 
vitronectin in these same T1DM new and matched controls showed no change in 
vitronectin levels, with a fold change of 1.02 (figure 3.3.20). Looking at each individual 
matched pair separately (figure 3.3.21), vitronectin levels were higher in the T1DM new 
specimens in four of the eight matched pairs. 
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Figure 3.3.20 Average vitronectin serum concentration in T1DM new and control new 
specimens. Error bars indicate standard deviation. 
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Figure 3.3.21 Vitronectin serum concentrations in 8 T1DM new and control new serum 
specimens. 
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Vitronectin: T1DM old vs. control old 
In T1DM old compared to control old serum specimens, vitronectin was shown to be 
significantly reduced in the label free proteomic experiment by approximately 1.64 fold. 
Validation of this target was performed in a larger cohort of 30 T1DM old samples, 
including the samples used for the label free proteomics experiment. ELISA validation 
also showed reduced vitronectin levels (1.14 fold) in T1DM old samples compared to 
matched controls (figure 3.3.22). The student’s t-test indicated that this reduction in 
vitronectin was significant with a p-value less than 0.05.  
 
Looking at each individual matched pair, reduced vitronectin levels in T1DM old serum 
is seen in 23 of the 30 matched pairs (figure 3.3.23). 
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Figure 3.3.22 Average vitronectin serum concentrations in 30 T1DM old and 30 control 
old serum specimens. Error bars indicate standard deviation. 
 
 
 
 
* P  ≤ 0.05 
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Figure 3.3.23 Vitronectin serum concentrations in 30 T1DM old and 30 matched control old serum specimens. 
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Vitronectin: T1DM new vs. T1DM old 
In the label free proteomics experiment vitronectin levels were significantly decreased 
in T1DM old serum specimens compared to T1DM new specimens by approximately 
1.44 fold. On expansion of the T1DM old sample cohort to 30 specimens vitronectin 
levels were unchanged (1.02 fold) in T1DM new and T1DM old serum specimens, 
according to ELISA quantification (figure 3.3.24).  
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Figure 3.3.24 Average vitronectin serum concentration of T1DM new (n=8) and T1DM 
old (n=30) serum specimens. Error bars indicate standard deviation. 
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3.3.2.9.2 Clusterin 
 
Clusterin: T1DM new vs. control new 
Clusterin protein levels were found to be significantly up-regulated (1.66 fold) in T1DM 
new (n=8) versus control new samples (n=8) from the label free proteomics experiment. 
This target was validated using a clusterin ELISA sourced from phoenix 
pharmaceuticals (catalogue number EK-018-35) in the same T1DM new and control 
new serum specimens (protocol outlined in section 2.6.1.2); however, the same trend 
was not seen (figure 3.3.25). Looking at the ELISA results of each matched pair 
individually (figure 3.3.26), 6 of the 8 sets of matched pairs show reduced clusterin 
levels in T1DM new sample compared to control. The increased clusterin expression 
detected in the label-free experiment may have been skewed by the outlier T1DM new 
sample in pair 1 (figure 3.3.26), which shows almost double the level of clusterin 
compared to the other T1DM new samples analysed. 
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Figure 3.3.25 Average clusterin serum concentration of T1DM new (n=8) and control 
(n=8) serum specimens. Error bars indicate standard deviation. 
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Figure 3.3.26 Clusterin serum concentrations of 8 T1DM new and matched control new 
serum specimens. 
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Clusterin: T1DM old vs control old 
Clusterin levels were unchanged in T1DM old and control old samples from the label-
free proteomics results. No change in expression level of this protein was seen when 30 
T1DM old and 30 control samples were analysed (figure 3.3.27). Looking at the 
matched pairs individually (figure 3.3.28), large fluctuations in clusterin expression was 
seen in both control and T1DM old serum specimens. 16 of 30 matched pairs showed 
lower clusterin levels in T1DM old samples relative to control; with the remaining 14 
pairs showing higher clusterin levels in the T1DM old samples (figure 3.3.28). 
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Figure 3.3.27 Average clusterin serum concentration of T1DM old (n=30) and control 
old (n=30) serum specimens. Error bars indicate standard deviation. 
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Figure 3.3.28 Clusterin serum concentrations in 30 T1DM old and 30 matched control old serum specimens. 
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Clusterin: T1DM old vs. T1DM new 
Clusterin expression was significantly up-regulated by 1.43 fold in T1DM new samples 
relative to T1DM old samples according to the label-free proteomics analysis. However, 
validation of clusterin expression by ELISA in 30 T1DM old samples and the same 8 
T1DM new samples used in the initial analysis showed no significant change in 
clusterin expression (figure 3.3.29). 
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Figure 3.3.29 Average clusterin serum concentration of T1DM old (n=30) and T1DM 
new (n=8) serum specimens. Error bars indicate standard deviation. 
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3.3.2.9.3 Vitamin K-dependent protein S 
 
Vitamin K-dependent protein S: T1DM new vs. control new 
Vitamin K-dependent protein S was found to be significantly up-regulated in T1DM 
new serum compared to control new serum, by approximately 1.42 fold, from the label 
free proteomics experiment. An ELISA kit was sourced from USCN Life Science Inc. 
(catalogue number E1971h) for validation of this target protein (protocol outlined in 
section 2.6.1.3). On validation of this target protein using ELISA with the same T1DM 
new and control new samples, vitamin K-dependent protein S was seen to be 
significantly down-regulated in T1DM new samples by 1.24 fold (figure 3.3.30). Figure 
3.3.31 shows the individual levels of vitamin K-dependent protein S in each of the 
matched pairs. Lower levels of vitamin K-dependent protein S are seen in T1DM new 
samples for 6 of the 8 matched pairs. One matched pair shows no change, while one 
pair shows higher vitamin K-dependent protein S levels in the T1DM new specimen.  
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Figure 3.3.30 Average vitamin K-dependent protein S serum concentration in T1DM 
new (n=8) and control new (n=8) serum specimens. Error bars indicate standard 
deviation. 
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Figure 3.3.31 Vitamin K-dependent protein S serum concentration in T1DM new and 
matched control serum pairs. 
 
 
* P ≤ 0.05 
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Vitamin K-dependent protein S: T1DM old vs. control old 
In T1DM old compared to control old label free proteomic analysis, vitamin K-
dependent protein S was significantly down-regulated in T1DM old serum specimens 
by approximately 2.28 fold. ELISA validation of this target was performed using an 
expanded cohort of 30 T1DM old and 30 control old samples; however no significant 
change in vitamin K-dependent protein S levels were seen in these samples (figure 
3.3.32). Looking at each matched pair individually (figure 3.3.33) no consistent change 
was seen in vitamin K-dependent protein S expression, this target was present at lower 
levels in T1DM old serum in 15 of the 30 matched pairs, higher levels in 14 of 30 
matched pairs, and no change in one pair. 
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Figure 3.3.32 Average vitamin K-dependent protein S serum concentration of T1DM 
old (n=30) and control old (n=30) serum specimens. Error bars indicate standard 
deviation. 
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Figure 3.3.33 Vitamin K-dependent protein S serum concentration in individual matched pairs of T1DM old (n=30) and control old (n=30) 
serum specimens. 
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Vitamin K-dependent protein S: T1DM old vs. T1DM new 
Label free proteomics analysis identified vitamin K-dependent protein S as being 
significantly up-regulated in T1DM new serum specimens compared to T1DM old. 
However, on expansion of the T1DM old cohort, ELISA quantification of vitamin K-
dependent protein S found no significant change in levels of this target in T1DM new 
and old serum (figure 3.3.34). 
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Figure 3.3.34 Average vitamin K-dependent protein S serum concentration in T1DM 
old (n=30) and T1DM new (n=8) serum specimens. Error bars indicate standard 
deviation. 
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3.3.2.9.4 Apolipoprotein L1 
 
Label free proteomics analysis showed a significant 2.84 fold decrease in apolipoprotein 
L1 in T1DM old serum relative to control old serum, in addition to a 1.88 fold decrease 
when T1DM old specimens were compared to T1DM new specimens. 
 
The human apolipoprotein L1 ELISA used for this validation study was sourced from 
USCN Life Science Inc. (catalogue number E9374Hu), however no suggested serum 
dilutions were included in this kit. Therefore, an apolipoprotein L1 concentration 
estimation was performed using two serum samples (T1DM old sample DS-100 and 
T1DM new sample DS-170), and three dilutions of each sample, at 1:10, 1:500 and 
1:5,000, as well as the lowest and highest points of the standard curve. The 
apolipoprotein L1 ELISA used for this experiment is based on a sandwich ELISA 
technique (protocol outlined in section 2.6.1.4), therefore higher concentrations of 
apolipoprotein L1 should lead to high absorbance readings at 450nm. For each sample 
analysed, the 1:10 dilution showed the highest absorbance, with a lower absorbance 
reading for the 1:500 dilutions, as expected. However, absorbance readings for 1:5,000 
dilutions showed higher absorbance reading than the 1:500 dilutions for both samples 
tested (table 3.3.9). As the lowest dilution (1:10) absorbance readings were only 
marginally above the lowest standard curve reading, therefore a 1:5 dilution was chosen 
to perform ELISA on all remaining samples. 
 
Sample Absorbance 
1.25ng/mL standard 0.21 
80ng/mL standard Too high 
DS-100 1:10 dilution 0.349 
DS-100 1:500 dilution 0.120 
DS-100 1:5000 dilution 0.262 
DS-170 1:10 dilution 0.297 
DS-170 1:500 dilution 0.138 
DS-170 1:5000 dilution 0.251 
Table 3.3.9 Apolipoprotein L1 serum concentration estimation. Absorbance values 
measured at 450nm for two serum samples (DS-100 and DS-170), serially diluted to 
1:10, 1:500 and 1:5000.  
 248 
8 T1DM new and controls, as well as 30 T1DM old and matched control samples were 
diluted 1:5 before performing the apolipoprotein L1 ELISA. All sample absorbances 
were below the lowest point on the standard curve, therefore apolipoprotein L1 
concentrations could not be deduced. DS-100 and DS-170 samples which were used for 
the concentration estimation were also diluted 1:5 and assayed again with all other 
samples. However, the absorbance reading was lower than the lowest point on the 
standard curve for DS-170, and the DS-100 absorbance reading was lower than the 
blank absorbance reading of the standard diluent solution. 
 
The low absorbance readings of serum samples may indicate that apolipoprotein L1 
levels were beyond the level of detection, however, as more dilute samples showed 
higher absorbance readings during the concentration estimate, this may indicate that 
these pre-coated ELISA plates may not have been uniformly coated with the anti-
apolipoprotein L1 capture antibody.  
 
 
 249 
3.3.2.10 Summary of proteomic biomarker study 
 
Label-free proteomics and ELISA validation results for each target analysed are shown 
in table 3.3.10. Only two comparisons reached statistical significance when validated 
using ELISA technology, 1) vitamin K-dependent protein S, in the T1DM new versus 
control comparison, and 2) vitronectin, in the T1DM old versus control comparison. 
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 T1DM new vs control new T1DM old vs control old T1DM new vs T1DM old 
 Proteomics 
(n=8) 
ELISA 
(n=8) 
Proteomics 
(n=8) 
ELISA 
(n=30) 
Proteomics 
(n=8) 
ELISA 
(T1DM 
new=8, T1DM 
old=30) 
Vitronectin 1.45 fold up in 
T1DM new 
(2/3) 
No change  1.64 fold down in 
T1DM old 
1.14 fold down in 
T1DM old 
(significant) 
1.44 fold up in 
T1DM new 
No change  
Clusterin  1.66 fold up in 
T1DM new 
No change  No change No change  1.43 fold up in 
T1DM new 
No change  
Vitamin K-
dependent 
protein S 
1.42 fold up in 
T1DM new 
(2/3) 
1.24 fold down 
in T1DM new 
(significant) 
2.28 fold down in 
T1DM old 
No change  1.80 fold up in 
T1DM new 
No change  
Apolipoprotein 
L1 
No change Un-measurable 2.84 fold down in 
T1DM old 
Un-measurable 1.88 fold up in 
T1DM new (1/3) 
Un-measurable 
 
Table 3.3.10 Changes in target protein levels according to label-free proteomic analysis and ELISA validation 
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3.3.3 Metabolomic profiling of type 1 diabetes serum 
 
Metabolomics is the study of all metabolites in an organism and how they change in 
relation to a biological perturbation. In comparison to other ‘omics’ technologies 
metabolomics provides the added advantage of not only taking into account genetics, 
but also the effects of lifestyle, diet and environment of the individual being analysed. 
The Human Metabolome Database (HMDB) is an electronic database containing 
information on all known small molecule metabolites in the human body (Wishart, 
Knox et al. 2009). Currently, HMDB contains information on over 7,900 metabolites. 
 
Metabolites can vary greatly in their physical properties, as of yet no single technique is 
capable of detecting and quantifying such a diverse range of compounds. The diagnostic 
company Metabolon incorporate three independent analysis platforms in their procedure 
for metabolite profiling, in order to get maximum separation of the different types of 
biochemicals present in the samples. Two separate ultra-high performance liquid 
chromatography / tandem mass spectrometry (UHPLC/MS/MS) injections and one 
GC/MS injection are performed per sample. One UHPLC/MS/MS injection was 
optimised for detection of positive ions while the second injection was optimised for 
negative ion detection. While the GC/MS platform allows for better separation of 
carbohydrates which are difficult to detect with LC methods. 
 
Two types of metabolomic analysis exist, targeted and non-targeted. Targeted 
approaches allow for highly sensitive metabolite detection, over a wide dynamic range. 
However, only metabolites which are targeted for detection will be profiled; hence, 
unknown biochemicals of potential biological relevance may be missed. The non-
targeted approach employed by Metabolon allows detection of all small molecules 
present in the sample being analysed, compound characteristics are then compared 
against Metabolon’s proprietary library of chemical standards. This platform also allows 
for detection of new metabolites not yet documented in the reference library. Therefore, 
non-targeted metabolomic profiling allows the greatest biochemical coverage for 
analysis of the human metabolome (Evans, DeHaven et al. 2009).   
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This study aimed to identify small molecule biomarkers in newly diagnosed type 1 
diabetes serum specimens, to potentially aid in early diagnosis of type 1 diabetes. It is 
generally believed that by the time of diagnosis of type 1 diabetes, up to 90% of 
pancreatic beta cells exhibit either impaired beta cell function or have undergone 
apoptosis as a result of autoimmune mediated attack (Matveyenko and Butler 2008). 
Once such a significant portion of beta cell mass is lost, patients will require insulin 
therapy for the remainder of their life. For this reason, it is of great interest to identify 
biomarkers for early detection of type 1 diabetes to allow treatment of autoimmune 
disease before substantial pancreatic damage has been done. 
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3.3.3.1 Patient characteristics 
Metabolomic profiling of diabetes serum samples was performed by Metabolon Inc. 
USA.  Serum from newly diagnosed type 1 diabetes patients (3.14 ± 2.66 months mean 
duration since diagnosis) and age/BMI/gender matched healthy controls (n=8) were 
used for the analysis. Table 3.3.11 shows the general characteristics of patients 
involved in the study. 
 
 
 
 Type 1 Diabetes Patients 
(n=8) 
Healthy Controls 
(n=8) 
P-value 
Age (years) 26 ± 5 27 ± 2 0.50 
BMI (Kg/m2) 24.64 ± 4.2 24.94 ± 2.6 0.87 
Fasting glucose 
(mmol/L) 
6.49 ± 3.06 4.49 ± 0.37 0.11 
HbA1c (%) 7.69 ± 1.96 5.15 ± 0.30 0.008 
Cholesterol (mmol/L) 4.29 ± 0.55 5.05 ± 0.44 0.013 
HDL-cholesterol 
(mmol/L) 
1.25 ± 0.42 1.35 ± 0.39 0.63 
LDL-cholesterol 
(mmol/L) 
2.53 ± 0.41 3.19 ± 0.55 0.02 
Triglyceride (mmol/L) 1.09 ± 0.38 1.37 ± 1.07 0.50 
Table 3.3.11 General characteristics of the study population. Mean values shown for 8 
patients per group. 
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3.3.3.2 Identification of metabolite targets 
An internal standard was added to each sample before injection onto the mass 
spectrometers. Instrument variability was determined by calculating the median 
relative standard deviation (RSD) for the internal standard (table 3.3.12). A small 
amount of each study sample was also used to create a homogenous pool called the – 
client matrix. Technical replicates of this client matrix were used to determine overall 
process variability by calculating the median relative standard deviation of all 
endogenous metabolites (table 3.3.12). Process variability as measured by median 
RSD passed Metabolon’s quality control criteria (table 3.3.12). Metabolon recommend 
an RSD cut off value of 13%  to ensure minimum process variability. 
 
Overall, 302 biochemicals were detected in the serum samples. Biochemical data was 
analysed using two different methods- Welch’s two-sample t-test was used to compare 
disease group versus control group as a whole, while matched pairs t-test was used to 
analyse the individual matched pairs. A p-value of less than or equal to 0.05 was used 
as a cut-off for identification of significantly different biochemicals. 
 
Comparing disease group to control group- 19 biochemicals reached statistical 
significance, with 5 biochemicals at higher levels and 14 biochemicals at lower levels 
in disease group relative to control. A further 13 biochemicals were just beyond the 
level of significance and were termed ‘approaching significance’, with p-value greater 
than 0.05 but less than 0.1. Of the 13 biochemicals approaching significance 4 were 
present at higher levels and 9 at lower levels in disease versus control specimens (table 
3.3.13). 
 
The matched pairs analysis showed very similar results to the group analysis. 21 
biochemicals were significantly different, 5 of which were at higher levels and 16 at 
lower levels in disease versus control. 11 biochemicals were in the approaching 
significance group, 6 of which were at higher levels and 5 at lower levels in disease 
group (table 3.3.13).  
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QC sample Measurement Median RSD 
Internal standards Instrument variability 4% 
Endogenous Metabolites Overall process variability 11% 
Table 3.3.12 QC measurements of instrument and process variability 
 
 
 Welch’s Two-Sample 
t-Test 
Matched Pairs 
t-Test 
Biochemical with p ≤ 0.05 19 21 
Biochemicals ()   
Biochemicals approaching significance 
0.05<p>0.10 
13 11 
Biochemicals ()   
Table 3.3.13 Biochemicals detected at significantly altered levels in type 1 newly 
diagnosed diabetes versus control serum specimens. 
 
 
Table 3.3.14 lists all biochemicals which were identified as significantly different 
either by Welch’s two-sample analysis or by matched pair analysis. The fold change 
for the matched pair analysis is reported as the average fold changes for each of the 
individual matched pairs. Direction of fold change for all biochemicals in table 3.3.14 
is consistent whether analysed with Welch’s two sample analysis or matched pair 
analysis, although in a limited number of cases the biochemical only reaches statistical 
significance with one of analysis methods. Box and whisker plots of all significantly 
different biochemicals are shown in appendix D, figure 1.  
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Group Analysis Matched Pairs Analysis 
Metabolite Fold Change P-value  Average Fold Change P-value 
1,5-anhydroglucitol  2.85 0.0036 2.7 0.0063 
fibrinogen cleavage peptide  2.67 0.0085 5.01 0.012 
caffeine 2.5 0.0439 1.96 0.0156 
isovalerylcarnitine 1.92 0.0081 1.69 0.0138 
Theophylline 1.89 0.059 1.61 0.0316 
1-pentadecanoylglycerophosphocholine 1.82 0.0038 1.67 0.0053 
Paraxanthine 1.78 0.0962 1.51 0.0358 
malate  1.72 0.0036 1.61 0.0022 
3-carboxy-4-methyl-5-propyl-2-furanpropanoate 1.72 0.0847 1.67 0.0176 
1,7-dimethylurate 1.67 0.0424 1.43 0.0474 
2-methylbutyroylcarnitine 1.64 0.0214 1.41 0.0469 
glucose  1.58 0.0162 1.59 0.0175 
arginine  1.56 < 0.001 1.59 < 0.001 
N-acetyl threonine 1.54 0.0337 1.35 0.0659 
hexanoylcarnitine 1.49 0.0256 1.33 0.0746 
catechol sulfate 1.49 0.0099 1.59 0.0027 
sebacate 1.47 0.0081 1.41 0.0239 
 257 
propionylcarnitine 1.39 0.0335 1.33 0.0209 
succinylcarnitine 1.37 0.0445 1.33 0.0441 
1,3-dimethylurate 1.37 0.0345 1.28 0.0223 
urate 1.23 0.0758 1.22 0.0281 
5-oxyproline 1.16 0.0225 1.16 0.0082 
Glutamine 1.14 0.0339 1.14 0.0361 
 
Table 3.3.14 Significantly altered biochemicals in newly diagnosed type 1 diabetes specimens compared to healthy controls. Red boxes 
indicate biochemicals which are present at significantly higher levels in newly diagnosed type 1 diabetes serum specimens compared to 
control specimens. Green boxes indicate biochemicals which are present at lower levels in type 1 diabetes serum specimens compared to 
control specimens. 
 
 
 
.
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3.3.3.3 Validation of metabolomics targets 
 
Fibrinopeptide A – T1DM new Vs. Control new 
Fibrinopeptide A (FPA) levels were increased in T1DM new samples according to the 
metabolomics analysis by 2.67 and 5.01 fold in the groups and matched pairs analysis 
respectively. Levels of this peptide were assessed in the same T1DM new and control 
samples using an ELISA (Hyphen BioMed catalogue number RK016A) (protocol 
outlined in section 2.7.1). ELISA confirmed a significant increase (1.8 fold) in FPA 
levels in T1DM new samples (figure 3.3.35). 
 
Figure 3.3.36 shows ELISA quantification of FPA in individual matched pairs. Fold 
change for pair 2 and pair 3 was 10 and 14 fold respectively according to metabolomics 
analysis, however, according to ELISA quantification, fold changes for these pairs was 
1.37 and 1.49 respectively. 
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Figure 3.3.35 Average FPA concentration in T1DM new (n=8) and control (n=8) serum 
specimens. Error bars indicate standard deviation. 
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Figure 3.3.36 FPA concentration in each T1DM new and matched control specimen. 
 
 
*** p-value 0.0002  
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Fibrinopeptide A- Type 1 old versus control old 
 
To test whether increased FPA levels was specifically seen in newly diagnosed T1DM 
patients, or a more general diabetes related event, FPA levels were assessed in T1DM 
patients with established disease (T1DM old). No change in FPA levels was seen in 
T1DM old (n=30) compared to matched controls (n=30) (figure 3.3.37). 
 
Figure 3.3.38 shows FPA levels in individual T1DM old matched pairs. FPA was down-
regulated in T1DM old in 11 of 30 matched pairs, while it was up-regulated in 17 of 30 
matched pairs. 
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Figure 3.3.37 Average FPA concentration in T1DM old (n=30) compared to controls 
(n=30). Error bars indicate standard deviation. 
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Figure 3.3.38 FPA concentration in T1DM old (n=30) and matched control (n=30) pairs. 
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Fibrinopeptide A- Type 1 old versus control old 
FPA levels were assessed in T1DM new (n=8) compared to T1DM old (n=30) serum 
specimens, however, no significant change in expression levels was seen in these 
groups (figure 3.3.39).  
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Figure 3.3.39 Average FPA concentration in T1DM new (n=8) and T1DM old (n=30) 
serum specimens. Error bars indicate standard deviation. 
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FPA levels were decreased significantly in control new samples relative to T1DM new 
and control old samples (figure 3.3.40). Therefore differential expression seen in figure 
3.3.35 seems to be related to the control samples used rather than a disease specific 
change. 
 
 
 
Figure 3.3.40 Average FPA concentration in T1DM old (n=30), control old (n=30)  
T1DM new (n=8) and control new (n=8) serum specimens. Significance indicated by * 
≤ 0.05, ** ≤ 0.01, *** ≤ 0.005. Error bars indicate standard deviation. 
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3.3.3.4 Summary of metabolomic biomarker study 
 
• Metabolomic profiling of T1DM new and control new samples (n=8) 
• 23 differentially expressed metabolites 
o Mostly relating to carbohydrate, energy and lipid metabolism 
o Caffeine metabolites related the increase coffee consumption of 
controls 
• Fibrinogen cleavage peptide- fibrinopeptide A selected for validation 
o T1DM new and control new (n=8) 
o T1DM old and control old (n=30) 
o Fibrinopeptide A levels decreased in young control group, unrelated to 
disease phenotype. 
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4.0 Discussion 
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4.1 MicroRNAs with a role in glucose stimulated insulin secretion 
 
The aim of this study was to gain insight into molecular mechanisms governing 
regulated insulin secretion, in particular the role that miRNAs play in this process. To 
begin to identify miRNAs related to the pancreatic beta-cell phenotype, a study of 
miRNAs involved in regulated insulin secretion was performed, using the rodent 
insulinoma cell line MIN6. Two independent populations of MIN6 cells were analysed 
i.e. glucose responsive compared to glucose non-responsive cells. In order to identify 
miRNAs involved in GSIS, it was necessary to screen all possible miRNAs to check for 
differential expression between these two MIN6 variants. 
 
TLDA systems have been developed for this purpose; they enable relative quantification 
of expression of 365 different miRNAs using TaqMan real-time PCR chemistries. The 
TLDAs used here were designed for analysis of human miRNA expression; however, 
the GSIS cell line model used in this study was of murine origin (as there are no human 
GSIS cell lines available for analysis). In order to overcome this problem, human and 
murine homology comparisons were performed using the miRNA database, miRBase, 
to determine the quantity of miRNAs conserved between the two species. 67% of the 
365 miRNAs were found to be conserved between human and mouse. Due to this high 
level of conservation, the human TLDAs were deemed suitable for profiling murine 
miRNA expression. 
 
Of the remaining 33% of the human miRNAs represented on the TLDA card, which 
were thought not to have a murine homolog according to miRBase (release 18; as of 
November 2011), during the course of this study, 21 of these miRNAs were discovered 
to be reproducibly detected in all  murine RNA samples evaluated. Prior to this analysis, 
1283 miRNAs were known to be present in the murine species (miRBase, release 18; as 
of November 2011). The result from the study reported here potentially increases this to 
1304 murine miRNAs, indicating the high level of complexity of post-transcriptional 
regulation in this species. 
 
As indicated in figure 3.1.1, MIN6 cells secrete insulin in a glucose regulated manner; 
however, with increasing time in culture they lose this GSIS phenotype. Using TLDAs 
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to identify miRNAs involved in the GSIS mechanism, a panel of 12 miRNAs (i.e. mir-
376a, -369-5p, -130a, -27a, -410, -124a, -200a, -337, -532, -320, -192 and -379) were 
identified as down-regulated in glucose non-responsive cells compared to glucose 
responsive cells (table 3.1.2).  
 
Previous microarray and proteomic profiling studies in our laboratory identified 
mRNAs (Gammell 2002; O'Driscoll, Gammell et al. 2006; Rani 2008) and proteins 
(Dowling, O'Driscoll et al. 2006) differentially expressed in GSIS responsive compared 
to non-responsive MIN6 and MIN6 B1 cells. The miRanda algorithm was applied to 
determine if any of these mRNAs and proteins contained potential binding sites for 
regulation by the miRNAs identified in this study as potentially being involved in 
regulating GSIS (table 3.1.4). A number of mRNAs considered to be important for beta 
cell function such as neuroD1 and Isl1, contained potential binding sites for miRNA 
regulation. Thioredoxin-interacting protein (Txnip), identified as up-regulated in 
glucose non-responsive compared to GSIS responsive MIN6 B1 cells (Rani 2008), is an 
inhibitor of thioredoxin which plays a role in reducing oxidative stress.  It is thought 
that, through this mechanism, Txnip reduces the glucose responsiveness of MIN6 cells. 
Conversely, down-regulation of Txnip (and hence removal of the repressive effects on 
thioredoxin) led to improved glucose responsiveness of MIN6 cells (figure 4.1) (Rani 
2008).  
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Figure 4.1 shRNA-mediated knock-down of Txnip led to a significant increase in GSIS 
in sh-1 clone (Txnip shRNA-transfected cells clone #1). Changes in sh-3 and sh-9 
clones were not statistically significant. Performed by Dr. Sweta Rani (Rani 2008). 
 
 
Here we report that Txnip contains a potential binding site for mir-130a and mir-200a 
regulation. Furthermore, knockdown of mir-200a and mir-130a expression led to 
reduction of GSIS in MIN6 cells (figure 3.1.7 and figure 3.1.8), although it has yet to be 
established if the effects of mir-130a and mir-200a on GSIS are directly mediated 
through Txnip. A previous study has also identified mir-130a as being regulated by 
hyperglycaemia in a comparison of islets from the Goto-Katizaki rat model of type 2 
diabetes compared to control rats (Esguerra, Bolmeson et al. 2011). 
 
In this study, anti-mir transfections suggest that knockdown of mir-410 (figure 3.1.5), 
mir-200a (figure 3.1.7) and mir-130a (figure 3.1.8) may decrease the magnitude of 
GSIS in MIN6 cells, while pre-mir transfections suggest over-expression of mir-410 
(figure 3.1.6) may increase the GSIS response of MIN6 cells. However, the likely 
involvement of multiple miRNAs in GSIS and fluctuations in the GSIS assay makes it 
difficult to arrive at definitive functional assignments for individual miRNAs. Little is 
known of mir-410 in general, and its role in pancreatic beta cells has not been 
previously identified. This study suggests mir-410 may be involved in the regulation of 
insulin secretion, as manipulation of this miRNA in MIN6 cells led to changes in the 
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GSIS of these cells, although the mechanisms through which it functions still remain to 
be deciphered. 
 
Previous studies have reported mir-375, mir-9 and mir-96 to play a role in regulation of 
insulin secretion in rodent cell models (Poy, Eliasson et al. 2004; Plaisance, 
Abderrahmani et al. 2006; Lovis, Gattesco et al. 2008; Ramachandran, Roy et al. 2011). 
However, in this study, mir-375, mir-9 and mir-96 were not differentially expressed 
between the two populations, indicating that the loss of GSIS in these cells may 
potentially be via a myotrophin- and granuphilin- independent mechanism. In relation to 
mir-124a, over-expression in MIN6 B1 cells can contribute to increased insulin 
secretion at basal glucose levels and decreased insulin secretion in response to 
stimulatory glucose levels (Lovis, Gattesco et al. 2008). Conversely, in MIN6 and INS-
1E cells mir-124a was found to affect intracellular free calcium levels (via Foxa2 and its 
downstream targets i.e. potassium channel subunits SUR1 and Kir6.2), no effects on 
insulin secretion were observed (Baroukh, Ravier et al. 2007). In agreement with this 
latter study, we did not observe any effect on GSIS of MIN6 cells following over-
expression or knockdown of mir-124a (section 3.1.4.7), suggesting that this effect may 
be somewhat specific to the MIN6 B1 clonal population.  
 
While we identified potential functional relevance in GSIS for some of the 12 
differentially expressed miRNAs identified in this study, a number of those identified 
here did not exhibit any functional effect on GSIS when their levels were manipulated 
in MIN6 cells. These miRNAs may require combined action of more than one miRNA, 
as miRNAs were only tested individually. Alternatively, these miRNAs may be 
involved in other changes the cells are undergoing as they lose their GSIS. 
 
The GSIS response of MIN6 cells displays considerable day-to-day variation, while 
being the best cell-line model available for the study of regulated insulin secretion; it is 
not robust or routinely dependable. Pluripotent stem cells represent a potential route for 
the generation of a human pancreatic beta cell model for studying GSIS.  
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4.2 Generation and differentiation of iPS cells 
Generation of the first induced pluripotent stem (iPS) cells in 2006 (Takahashi and 
Yamanaka 2006) revolutionised the area of stem cell research. This discovery represents 
the most significant development in stem cell research since the isolation of the first 
human embryonic stem (ES) cell lines in 1998 (Thomson, Itskovitz-Eldor et al. 1998). 
iPS cells hold several advantages over ES cells. Human iPS cells can be used for 
autologous tissue repair or replacement, without the ethical and immunological issues 
associated with ES cells. An additional advantage of iPS cells lies in their potential for 
modelling human diseases, for analysis of disease mechanisms and for screening of 
potential drug candidates (Yamanaka and Blau 2010).   
 
4.2.1 Generation of iPS cells using retroviral transduction 
 
iPS cells were first generated by Yamanaka and colleagues in 2006. They used 
retroviral transduction to over-express four transcription factors- oct4, sox2, c-myc and 
klf4 (Takahashi and Yamanaka 2006; Takahashi, Tanabe et al. 2007). In this study we 
used lentivirus transduction for over-expression of these four factors. Lentiviruses are a 
subclass of the retrovirus family, but hold several transduction related advantages over 
retroviruses such as MMLV. Lentiviruses can infect and stably integrate into the host 
genome in both dividing and non-dividing cells, whereas retroviruses are limited to 
dividing cells (Naldini, Blomer et al. 1996), therefore increasing the range of cell types 
which can be used for iPS cell generation. Lentiviruses also elicit a lower immune 
response in target cells, relative to retroviruses (Naldini, Blomer et al. 1996). Generation 
of iPS cells using lentiviral transduction has previously been shown in human and 
mouse somatic cells, but with similarly low efficiency levels as retroviral generated iPS 
cells (Blelloch, Venere et al. 2007; Yu, Vodyanik et al. 2007). 
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4.2.1.1 Attempt to generate iPS cell from MiaPaCa2 cell line 
 
MiaPaCa2 pancreatic adenocarcinoma cells were treated with a virus cocktail of 3 (oct4, 
sox2 and klf4) or 4 (oct4, sox2, klf4 and c-myc) transcription factors. C-myc was 
excluded from the 3 transcription factor cocktail, as c-myc has been suggested to 
increase the incidence of false positive colonies (Eggan 2009). Changes in cell 
morphology were seen in virus treated MiaPaCa2 cultures. Untreated MiaPaCa2 cells 
grow in monolayer formation, even when cultured on MEF feeder layer (figure 3.2.5 B). 
However, 3 and 4 factor virus treated cells formed clusters, with densely packed cores 
of small rounded cells, while the periphery of clusters were cells with the standard 
MiaPaCa2 morphology (figure 3.2.6 and 3.2.7). Colonies were picked and levels of the 
four factors examined by RT-PCR. Untreated MiaPaCa2 cells already express three of 
the four factors, oct4, c-myc and klf4. Virus treated cells express similar levels of c-myc 
and klf4 to untreated MiaPaCa2 cells, while slight increase in expression of oct4 is seen 
in virus treated cells relative to control (figure 3.2.8). Very low levels of sox2 were seen 
in some of the virus treated clones; however, these bands were barely visible (figure 
3.2.8). RT-PCR of the pancreatic marker amylase (figure 3.2.9) showed that this very 
low expression of sox2 was not sufficient to induce full reprogramming. Clone 3 of 3-
transcription factor virus treated cells displayed altered expression of oct4 and amylase 
compared to other virus treated clones (figute 3.2.8 and figure 3.2.9), this may be 
caused by insertational mutagenesis at the oct4 and amylase locus, since lentiviruses 
insert into the host genome in a non-targeted manner. Virus treated MiaPaCa2 cells did 
not display the standard ES cell morphology (densely packed colonies with clearly 
defined borders), however, the morphology of these virus treated cells was distinctly 
different from untreated cells. These colonies may represent partially reprogrammed 
cells. 
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4.2.1.2 Attempt to generate iPS cells from keratinocytes 
 
Normal keratinocyte cultures were also treated with 3 factor and 4 factor virus cocktails. 
Following transfer of the lentivirus treated cells to MEF feeder layer cultures, cell 
clusters were observed (figure 3.2.10). However, similar clusters were observed in both 
untreated control and virus treated cultures. These clusters did not proliferate further 
and subsequently died off. Growth arrest and cell death were unexpected in these 
cultures, as growth of keratinocytes on feeder cells is known to enhance cell 
morphology and growth characteristics (Masson-Gadais, Fugere et al. 2006). MEF 
feeder layer cells used in this experiment were treated with mitomycin C to arrest 
growth. Any contaminating mitomycin C remaining could have caused the growth 
arrest and subsequent cell death observed with keratinocyte clusters. It could also have 
been the use of ES media which caused the growth arrest of keratinocyte cultures, as 
keratinocytes require a very specific culture medium with growth factors (bovine 
pituitary extract, epidermal growth factor, insulin, hydrocortisone, epinephrine and 
transferrin) to maintain viability of cells. Increased calcium concentrations in ES media 
may also have caused terminal differentiation and growth arrest of keratinocytes 
(Huang, Wang et al. 2006). 
 
 
4.2.1.3 Attempt to generate iPS cells from limbal epithelial cells using 4-factor 
virus cocktail 
 
Limbal epithelial cells were also used for the generation of iPS cells; these cells were 
treated with 3 factor and 4 factor virus cocktails. Morphology changes such as cell 
clusters and cell processes were seen in 3 factor and 4 factor treated cells after 72 hours 
(figure 3.2.12). However, similarly to keratinocyte cultures, once cells were transferred 
to MEF feeder layer cultures with ES media, no subsequent proliferation was observed. 
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4.2.1.4 Summary of attempts to generate iPS cells using lenti-viral over-expression 
of transcription factor cocktail 
 
While distinct cell morphology changes were seen in each of the different cell types 
transduced with lenti-virus containing 4 factors (oct4, sox2, klf4 and c-myc) or 3 factors 
(oct4, sox2 and klf4), no true iPS cells were generated. However, these morphology 
changes may indicate partially reprogrammed cells. iPS cell generation using 3 or 4 
factor virus cocktails remains a very inefficient procedure, with approximately 0.01% 
successful reprogramming rate reported from human dermal fibroblast and 0.8% for 
epidermal keratinocyte cultures (Aasen, Raya et al. 2008). Reprogramming depends on 
the transduction of each of the 3 or 4 individual viruses into each individual cell. 
However, even cells which have been successfully transduced with all four viruses and 
express all four transgenes are not guaranteed to become fully reprogrammed (Chan, 
Ratanasirintrawoot et al. 2009). In addition to expression of the four transgenes, it is 
also likely that the relative ratio of expression of these genes is also an important factor 
for true reprogramming. Even though cells are treated with equal MOI for each virus, 
this may not result in equal number of integration sites in the target cell genome, and 
hence varying expression levels for each factor. Reprogramming of somatic cells also 
requires heterochromatin reorganisation, with partially reprogrammed cells exhibiting 
densely packed chromatin fibres compared to the poorly defined chromcentre 
boundaries of fully reprogrammed iPS and ES cells (Fussner, Djuric et al. 2011).  
 
The lentivirus used in this study stably integrates into the host genome, although not in 
a targeted manner. Therefore, viral gene integration may occur in housekeeping gene 
sequences, or in genes necessary for reprogramming to occur, consequently adding to 
the low efficiency of iPS generation observed in this study and in the published 
literature (Yamanaka 2009). A recent study has shown that integration of the viral 
genome alone, without the use of exogenous factors is sufficient to transform somatic 
cells to a semi reprogrammed state, these cells were termed- lentivirus induced 
pluripotent-like (ViP) cells (Kane, Nowrouzi et al. 2010). In these cells a number of 
viral integration sites were observed in iPS signature genes. It is thought that the 
mutagenic effect of viral integration results from dysregulation of host genes in the 
vicinity of viral integration sites (Kane, Nowrouzi et al. 2010).  
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As induction of iPS cells is still a relatively new technology, the mechanisms of 
transcription factor-induced reprogramming of somatic cells have not been fully 
elucidated. The lack of truly reprogrammed iPS in this study could be a result of the 
reasons discussed above, or possibly from reasons not yet fully understood. Using 
currently available protocols, iPS cell generation is a very inefficient process, indicating 
that we still have a long way to go to fully understanding the mechanisms behind 
reprogramming, so these low efficiencies can be improved.  
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4.2.2 Attempt to generate iPS cells using ESD3 conditioned media 
 
Balasubramanian et al. 2009, have recently succeeded in the generation of iPS cells 
using conditioned media from rat corneal limbal epithelial cells (Balasubramanian, 
Babai et al. 2009). To our knowledge, this procedure has not yet been applied to human 
limbal epithelial cells. 
 
Limbal epithelial cells cultured in 6-well plate inserts with 3T3 feeder cells in the 
bottom layer led to improved yield of limbal progenitor cells, compared to standard 
culture protocols (Reddy et al., unpublished data). It was thought that using this newly 
established culture protocol with higher yield of limbal progenitor cells would lead to 
improved efficiency of iPS generation. 
 
Limbal epithelial cells were treated with enriched media containing B-27 supplement, 
noggin, bFGF and EGF for 7 days (figure 3.2.13). Noggin is thought to induce the 
generation of neural progenitors from limbal epithelial cells (Zhao, Das et al. 2008). 
After 7 days in enriched media Balasubramanian et al. 2009 observed the formation of 
neurospheres. In our own cultures we did not observe any neurosphere formation; 
however, a change in cell morphology was observed (figure 3.2.14). Untreated limbal 
epithelial cells (figure 3.2.14 A) displayed standard epithelial cuboidal morphology, 
while cultures treated with enriched media (figure 3.2.14 B and C) displayed long 
stretched cells with processes, reminiscent of neuronal cells. 
 
Cells were trypsinised and seeded onto plates coated with either gelatin alone, or gelatin 
and irradiated MEF (iMEF) feeder layer, and media was changed to 50% ESD3 
conditioned media (ESD3 CM) and 50% ES media. Control limbal epithelial cells were 
maintained in enriched media, to determine if iPS cells could be formed from enriched 
media treatment alone. After a total of 14 days in enriched media cells with the standard 
epithelial morphology became confluent and the long stretched cells with processes 
were no longer seen (figure 3.2.15 A and D). Cells which were switched to ESD3 CM 
and plated on an iMEF feeder layer displayed colony formation after 7 days (figure 
3.2.15 E and F). However, after a further 7 days, total 14 days ESD3 CM treatment, 
these colonies did not appear to be proliferating and no outgrowth was observed (figure 
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3.2.16). A single colony with a slightly different morphology, indicated by a red arrow 
in figure 3.2.16 D, was observed. This colony contained tightly packed cells and 
appeared more adherent to the culture dish, however the edges were less clearly defined 
compared to rat limbal iPS cells developed by Balasubramanian et al. 2009, (figure 4.2). 
 
 
 
 
Figure 4.2 Rat limbal iPS cells generated by Balasubramanian et al., (Balasubramanian, 
Babai et al. 2009). Colonies exhibit tightly packed cells with well defined colony edges. 
 
 
 
In cultures grown with iMEF feeder cells or on gelatin for 14 days ESD3 CM, a 
confluent monolayer of fibroblast/mesenchymal-like cells was observed (figure 3.2.16 
B, C, E and F). PCR analysis of marker expression was performed to investigate if the 
cells observed represented contamination or a semi-reprogrammed population. Stromal 
cell contamination of epithelial cultures is possible during dissection of the limbal ring 
and outgrowing from the explant. As stromal cells share similar morphology to the 
ESD3 CM treated limbal epithelial cells (figure 4.3), RNA from these cells was also 
included in the PCR analysis of marker expression, as a control (figure 3.2.17 and figure 
3.2.18).
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Figure 4.3 Comparison of stromal cells and ESD3 CM treated limbal epithelial cells. 
Image A represents stromal cells isolated from donor cornea-sclera ring. Image B 
represents limbal epithelial cells after 7 days of treatment with enriched media and 14 
days treatment with ESD3 conditioned media. Same scale bar used in both images. 
 
 
 
Oct-4, Klf-4 and c-myc expression was detected in control and ESD3 CM treated cells 
at similar levels to that of parental limbal epithelial cells. Sox2 however, was only 
expressed only in ESD3 CM treated cells on iMEFs, at a similar level to that of control 
iPS cells. iMEF cells could potentially contribute to marker expression, hence iMEF 
cells were also included in the PCR as a control for contamination. Sox2 primers, which 
also detected murine sox2, detected sox2 in the iMEF control cells. However, these 
were freshly thawed healthy iMEF cells, while iMEF feeder layer in ESD3 CM treated 
cultures was 15 days old at the time of harvesting cultures for RNA by which stage the 
iMEF cells would mostly have been apoptotic and unlikely to contribute to the positive 
sox2 expression seen in ESD3 CM treated cells. The same density of iMEF cells would 
also have been present in cultures of controls cells on iMEFs, but these cultures 
remained negative for sox2, indicating that the sox2 present in the ESD3 CM treated 
cells on iMEFs was due to the ESD3 CM treated cells, and not the iMEFs. This result 
indicates that an iMEF feeder layer is required to induce sox2 expression, as sox2 was 
not detected in ESD3 CM treated cells on gelatin. It is unknown if the induction is due 
to secreted factors or cell to cell contact with the iMEF feeder layer. Additionally, as 
sox2 expression is negative in stromal cells, this would indicate that ESD3 CM treated 
cells on iMEFs are different from stromal cells, and did not arise from stromal cell 
contamination. 
 
A B 
 278 
In various types of epithelia, cytokeratin expression can be linked to the differentiation 
status. In the stratified epithelia each stratified layer represents a more differentiated 
state. These differentiation states can be characterised by the expression of unique 
keratin pairs (Daly, Meleady et al. 1998). In the cornea the expression of keratin-3 
(CK3) and keratin-12 (CK12) are markers of terminal differentiation (Schermer, Galvin 
et al. 1986; Kasper, Moll et al. 1988). In our experiment, parental limbal epithelial cells 
do not express CK-12, due to high population of progenitor/trans-amplifying cells (Dua 
and Azuara-Blanco 2000) and the short time of in-vitro culture. The limbal epithelial 
control cells maintained in enriched media for 21 days express CK-12, representing the 
more differentiated or mature state of these cells (figure 3.2.18). This is possibly due to 
the longer in-vitro culture time relative to parental limbal epithelial cells. In confluent 
limbal epithelial cell cultures, stretched elongated cells can sometimes appear on top of 
the cuboidal cells (figure 3.2.16 D, indicated by the red arrow); however, the elongated 
fibroblast/mesenchymal-like cells shown in figure 3.2.16 B and E are not the result of 
confluent limbal epithelial cells, as verified by the lack of CK-12 expression. Lack of 
CK-12 expression in ESD3 CM treated cells indicates that these cells are less 
differentiated than control cells maintained in enriched media. This less-differentiated 
phenotype is due to the ESD3 conditioned media treatment, as ESD3 CM treated and 
control cells were cultured in vitro for the same period of time.  
 
CK-3 is also a marker for terminally differentiated epithelial cells (Schermer, Galvin et 
al. 1986). Control cells in enriched media were positive for CK-3 expression, as 
expected, due to their more differentiated state. However, parental limbal epithelial cells 
are also positive for CK-3, which could suggest a sub-population of differentiated cells 
in the limbal epithelium, or alternatively could indicate CK-3 to be less specific marker 
for terminal differentiation. Low levels of CK-3 expression was seen in stromal cells, 
ESD3 CM treated cells and iPS cells, representing a less differentiated phenotype. 
Analysis of marker expression using RT-PCR may not always give a true reflection of 
protein expression, as these mRNAs may potentially be regulated by post-translational 
control. Double bands are seen in some cases of CK-3 expression, this second band 
possibly represents a splice variant of CK-3. The second band is not a result of genomic 
DNA contamination as primer amplification of genomic DNA would result in a 924bp 
product, which is approximately the size of the highest band on the DNA gel (figure 
3.2.18), while the CK-3 mRNA amplification resulted in a band at 261 base pairs. 
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N-cadherin is a marker associated with adult stem cells, especially neuronal stem cells, 
it is also critical for the maintenance of the progenitor phenotype of limbal epithelial 
cells (Higa, Shimmura et al. 2009). Therefore, it was not surprising to find high levels 
of expression of this marker in iPS cells, parental limbal epithelial cells which have an 
abundant population of progenitor/trans-amplifying cells, and stromal cells which are 
thought to possess properties similar to mesenchymal stem cells (Reddy unpublished 
data). Reflecting the lack of neurosphere development following noggin treatment, N-
cadherin expression levels in enriched media treated cells were low relative to parental 
limbal epithelial cells (figure 3.2.18). This also indicates that these control cells 
represent a more differentiated corneal epithelial phenotype. ESD3 CM treated cells 
however, have maintained a high level of N-cadherin expression, indicating that these 
cells still possess some ‘stem-like’ properties. 
 
∆Np63 and ABCG2 are putative limbal stem cell markers (Parsa, Yang et al. 1999; Di 
Iorio, Barbaro et al. 2005; Kolli, Lako et al. 2008). In contrast to high CK-3/12 
expression and low N-cadherin expression indicating terminal differentiation in control 
cells, potential stem cell marker ∆Np63 is expressed at a level comparable to that of 
parental limbal epithelial cells (figure 3.2.18). ABCG2 expression is very low in 
parental limbal epithelial and stromal cells, and undetected in ESD3 CM treated cells, 
indicating that while ESD3 CM treated cells may lack expression of differentiation 
markers, the expression level of stem cell markers in these cells in still quite low 
relative to limbal epithelial cells and iPS cells. 
 
ESD3 CM treated limbal cells on iMEFs show increased expression of stem cell-
associated N-cadherin and reduced expression of terminal differentiation markers CK-
12 and CK-3. These cells also express the 4-factor cocktail thought to induce 
reprogramming of somatic cells to an iPS phenotype. However, these cells have not 
achieved full reprogramming, as they remain negative for pluripotency marker nanog 
(figure 3.2.18). It is possible that a partial reprogramming has occurred in these cells, as 
an altered cell morphology and mRNA expression pattern is observed in these cells. 
Partial reprogramming is frequently reported in the literature, however, it is not know 
what the distinguishes cells which will become fully reprogrammed from cells which 
remain partially reprogrammed, or if these partially reprogrammed cells have properties 
similar to lineage committed progenitors (Nagy and Nagy 2010). 
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This experiment was performed on limbal epithelial cells from a single donor cornea-
sclera ring; it is possible that subtle difference between donated tissues may impact the 
efficiency of iPS generation. Repeating this experiment with a number of donor cornea-
sclera rings should determine if it is possible to reprogram human limbal epithelial cells 
to iPS cells using non-cell autonomous techniques, or if this is a murine specific 
phenomena. 
 
In addition to retroviral and conditioned media induction of reprogramming attempted 
in this study, a number of other techniques for generation of iPS cells have recently 
been reported, including using mRNA transfection (Warren, Manos et al. 2010; 
Yakubov, Rechavi et al. 2010)  and recombinant protein transduction (Kim, Kim et al. 
2009) for over-expression of the four factor cocktail. A number of pluripotency 
associated miRNAs have also recently been identified, over-expression of which is 
sufficient to induce reprogramming (Anokye-Danso, Trivedi et al. 2011; Miyoshi, Ishii 
et al. 2011). As the molecular mechanisms of cellular reprogramming become more 
apparent, developments in iPS generation techniques have significantly increased 
reprogramming efficiencies since the first reprogramming papers in 2006 and 2007, 
which reported efficiencies of approximately 0.001% (Takahashi and Yamanaka 2006; 
Takahashi, Tanabe et al. 2007). Reprogramming kits available today from Stemgent 
using mRNA reprogramming technology quote efficiencies in the range of 5%, while (if 
verified) would make iPS technologies more amenable to labs less established in the 
reprogramming field. 
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4.2.3 Differentiation of iPS cells 
 
The iPS cell line hFib2-iPS4 generated from human fibroblasts in the George Daley lab, 
Children’s University Hospital, Boston, was used for differentiation studies presented in 
this thesis (Park, Zhao et al. 2008). A differentiation protocol by Jiang J. et al., designed 
to recapitulate the important in vivo signals that drive pluripotent stem cells towards 
pancreatic phenotypes was selected for differentiation of these iPS cells (Jiang, Au et al. 
2007). Using this protocol Jiang J. et al., have achieved 2-8% insulin positive cells from 
human ES cells, which secrete insulin in a glucose regulated manner, however, the 
glucose stimulated insulin secretion (GSIS) profile of these cells more closely resembles 
that of fetal islets, rather than mature adult islets (Jiang, Au et al. 2007). As of yet, no 
group has been able to fully differentiate pluripotent stem cells to mature adult islet 
cells in vitro. Differentiation studies with the murine cell line ESD3 in 3D culture have 
achieved up to 60% insulin positive cells, in comparison to fewer than 10% in standard 
2D cultures, using a slight different differentiation factor cocktail (Wang and Ye 2009). 
3D culture more closely reflects in vivo development and tissue organisation compared 
to 2D differentiation, the combination of 3D culture and growth factors present in the 
3D matrix led to a significant improvement in in vitro pancreatic differentiation 
protocols. A combination of the Jiang J. et al. 2007, directed differentiation protocol and 
3D culture was used to determine if the iPS cells used in this study could be 
differentiated towards pancreatic cells in vitro, and if an improvement in pancreatic 
differentiation was achieved with 3D culture compared to 2D culture. 
 
The effectiveness of differentiation was monitored by measuring expression levels of 
known markers for each stage of pancreatic differentiation. Definitive endoderm is the 
first stage of pancreatic development; definitive endoderm formation was assessed 
using markers- cxcr4, foxa2 and hnf4a. Cxcr4, foxa2 and hnf4a were up-regulated in 
both the 2D and 3D differentiation cultures compared to the original iPS cells (figure 
3.2.20). Improved definitive endoderm formation was seen in 3D cultures compared to 
2D cultures, based on increased expression of hnf4a (figure 3.2.21). Definitive 
endoderm differentiated 2D cultures were then transferred to suspension culture, 
however, cells did not respond well to suspension culture and entered growth arrest and 
eventually cell death (figure 3.2.22). 3D cultures were maintained in the same 3D 
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matrigel/collagen cultures for the complete duration of differentiation protocol (36 
days).  
 
3D cultures were further differentiated to pancreatic endoderm, the formation of which 
was assessed by pdx1, hlxb9, ngn3, nkx6.1 and ptf1a expression. Hlxb9, ngn3, nkx6.1 
and ptf1a levels were undetected, while very low levels of pdx1 were seen in 
differentiated cultures (figure 3.2.23). Differentiated cells also maintained similar levels 
of the pluripotency marker nanog as untreated iPS cells. In the replicate differentiation 
experiment, increased levels of pdx1 were seen in 3D control cells (figure 3.2.28), 
maintained in irradiated MEF conditioned ES media, indicating that growth factors 
present in the 3D matrigel matrix may have played a role in induction of pdx1 
expression in these control cells. 
 
A number of markers were also tested for presence of pancreatic exocrine and endocrine 
precursors – nkx6.1, nkx2.2, ngn3 and pax4; however, levels of these markers were 
undetected.  
 
Pancreatic hormone and mature pancreatic marker expression was examined in each 
differentiation stage (figure 3.2.26). β-actin endogenous control shows unequal 
expression levels in day 29 and day 36 cultures, in spite of equal RNA and cDNA 
concentrations being using for reverse transcription and PCR reactions. RNA quality 
and purity, as assessed by nanodrop 260/280nm absorbance readings, was also 
comparable between different time-points and treatments. As unequal β-actin 
endogenous control levels are seen, direct comparison cannot be taken from day 36 
control and differentiated cultures, however, equal β-actin levels are seen for day 36 
control cells and untreated iPS cells. Mature pancreatic markers- insulin, somatostatin 
and amylase were detected in day 36 control cells treated with iMEF conditioned ES 
media; however, these markers were also present in untreated iPS cells (figure 3.2.26). 
The expression of these markers in untreated iPS cells possibly indicates that these cells 
had undergone some spontaneous differentiation in culture before initiation of this 
differentiation experiment. Additional markers of mature pancreatic cells- insulin, 
ghrelin and glut2 were detected in day 36 control cells. Appearance of mature 
pancreatic markers- insulin, ghrelin and glut2 in day 36 3D control cultures and absence 
of these markers in untreated iPS cells indicated that the use of the 3D culture system 
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itself or the growth factors contained in the matrigel induced expression of these 
markers. 
 
Similar issues were seen in the repeat of the 36 day differentiation experiment. Levels 
on β-actin endogenous control were unequal between different time points and 
treatments (figure 3.2.29). Somatostatin and amylase were also detected in untreated 
iPS cells and 3D controls cells at day 29, however, unlike the previous experiment 
insulin and glut2 expression was not detected. Ghrelin levels were increased in day 29 
control cells compared to untreated iPS cells. By day 36 the pluripotency marker nanog 
has significantly decreased expression levels compared to untreated iPS cells. These 
results also suggest that untreated iPS cells may be partially differentiated prior to 
beginning the directed differentiation protocol. Also, the 3D culture system also seems 
to be having an effect on expression of differentiation markers in control cells. 
 
Matrigel is one of the most commonly used matrices for 3D culture systems 
(Kraehenbuehl, Langer et al. 2011); however, as matrigel is an animal product, batch to 
batch variations of growth factor concentrations occur. As different batches of matrigel 
were used for each replicate experiment, this may explain some of the difference 
between experiments. 
 
Due to the presence of the 3D matrix, it is technically difficult to remove the cells from 
this matrix for immunofluoresence or flow cytometry analysis. Therefore percentage 
efficiencies of pancreatic differentiation cannot be determined to allow direct 
comparison with efficiencies reported in the literature. However, assessment was 
possible using RT-PCR analysis for expression of differentiation markers. This 
assessment showed that the 3D differentiation system was superior to the 2D 
differentiation system used by Jiang J. et al. 
 
The expression of differentiation markers in untreated iPS cells potentially indicates that 
these cells may have undergone some spontaneous differentiation in culture, prior to 
initiation of the directed differentiation experiment; however cells did not display a 
differentiated morphology, but maintained colonies with ES-like characteristics. 
Alternatively, this may also indicate that these cells may not have been fully 
reprogrammed. The iPS cell line hFib2-iPS4 purchased from George Daley’s group 
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which was used for all experiments in this thesis did not have pluripotency tests such as 
teratoma formation and bisulphite sequencing of promoters of pluripotency genes oct4 
and nanog performed (Park, Zhao et al. 2008). Without pluripotency tests such as these, 
cell lines cannot be conclusively determined to be fully reprogrammed iPS cells (Daley, 
Lensch et al. 2009). In mouse iPS studies, germ line chimera formation is the definitive 
assay of choice for proving full reprogramming and true pluripotency. Currently, it is 
difficult to prove full reprogramming in human cells (Yamanaka 2009). Aberrant 
reprogramming may subsequently result in an impaired ability to differentiate using 
directed differentiation protocols (figure 4.3) (Yamanaka 2009). 
 
 
 
Figure 4.3 Types of reprogrammed cells. Reprogramming on somatic cells could 
result in fully reprogrammed iPS cells that are comparable to ES cells, partially 
reprogrammed iPS cells that can self-renew and differentiate into certain cell lineages, 
or aberrantly reprogrammed cells that self-renew but are refractory to differentiation 
(Yamanaka 2009). 
 
 
Viral transgenes are usually silenced in established iPS cell lines. Leaky expression of 
transgenes may also inhibit complete iPS cell differentiation and maturation (Okita, 
Ichisaka et al. 2007). Transgene expression was not monitored in iPS untreated cells in 
this study, however, on establishing this cell line, it was shown that viral c-myc 
expression was not completely silenced (Park, Zhao et al. 2008). 
 
Another issue which may be of importance for directed differentiation of iPS cells is the 
tissue of origin of the somatic cells. iPS cells generated from some cell types may have 
an inherent inability to re-differentiate to different lineages (Yamanaka 2009). A recent 
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study of pancreatic beta cell derived iPS cells (BiPS cells), showed that these BiPS cells 
retained epigenetic memory of their original cell type and maintained an open chromatin 
structure in key beta cell genes (Bar-Nur, Russ et al. 2011). BiPS cells were shown to 
have an increased propensity to differentiate towards pancreatic lineages in both 
spontaneous and directed differentiation experiments, compared to ES cells and iPS 
cells originating from non-beta cell types (Bar-Nur, Russ et al. 2011). The iPS cells 
used in this study were originally derived from adult dermal fibroblasts (Park, Zhao et 
al. 2008), therefore mature pancreatic genes may be epigenetically silenced in these 
cells, leading to reduced efficiencies of pancreatic differentiation. 
 
Similarly to ES cell lines, iPS cell lines also show considerable differences in 
differentiation potential (Tateishi, He et al. 2008). Directed differentiation protocols 
may need to be optimised for individual ES and iPS cell lines, a universal directed 
differentiation protocol is unlikely to achieve equal levels of pancreatic differentiation 
in a range of cell lines. D’Amour et al., a well established group in the pancreatic 
differentiation field, have reported promising results both in vitro and in vivo (D'Amour, 
Bang et al. 2006; Kroon, Martinson et al. 2008), however, this success is limited to a 
single ES cell line, attempts at replicating these results in iPS cell lines has also come up 
short. Ideally for differentiation experiments, a range of ES or iPS cell lines should be 
used as they will invariable differ in their differentiation potential. 
 
This study has shown that iPS cells generated from adult dermal fibroblasts can be 
differentiated to definitive endoderm-like cells through directed differentiation 
protocols. Further differentiation of these cells towards mature pancreatic cell types 
showed more varied results and is extremely inefficient. Ideally, for directed 
differentiation experiments, a range of iPS cell lines, generated from a number of 
different types of somatic cells should be used, specifically iPS cell lines from closely 
related cell lineages as the target tissue of interest. iPS cell lines should also be 
conclusively determined to be truly pluripotent, as variability in epigenetic remodelling, 
the extent of methylation, and the persistence of expression of integrated viral 
transgenes can alter the differentiation potential of iPS cell lines (Daley, Lensch et al. 
2009). 
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4.2.4 Differentiation of limbal stromal cells 
 
Limbal stromal cells have been shown to resemble bone marrow derived mesenchymal 
stem cells and possess differentiation potential into ectoderm, mesoderm and endoderm 
lineages (Dravida, Pal et al. 2005; Polisetty, Fatima et al. 2008). The differentiation 
potential of these cells was assessed in this study to determine if these cells could be 
differentiated towards pancreatic lineages. 
 
Stromal cells were treated with differentiation factors to induce formation of definitive 
endoderm in standard monolayer culture; however, no expression of definitive 
endoderm markers was detected using this technique. Previous studies with this cell 
type have shown that initial embryoid body formation of these cells can improve their 
differentiation potential in subsequent directed differentiation experiments (Reddy 
unpublished data). Following embryoid body formation, these cells were seeded into 
3D, 2D or monolayer cultures, and potential for definitive endoderm differentiation 
examined. Cxcr4 was the only definitive endoderm marker detected in these cells; cxcr4 
was detected in 2D and 3D cultures, with higher expression in control compared to 
differentiation cultures (figure 3.2.32). This result is reminiscent of iPS cell 
differentiation in 3D culture (figure 3.2.29). It would seem that the effect of matrigel 
and the growth factors contained within the matrigel improve the ability of limbal 
stromal cells to differentiate towards pancreatic endoderm compared to the directed 
differentiation media (containing activin A, sodium butyrate and B27). Further 
differentiation of these cells towards pancreatic endoderm did not achieve expression of 
pancreatic endoderm markers (figure 3.2.34). 
 
In light of the iPS differentiation experiments discussed above (section 4.2.3), which 
yielded superior differentiation marker expression in control cultures compared to 
directed differentiation cultures, the same 3D culture conditions with iMEF conditioned 
media, were applied to stromal cells for 36 days. After 36 days in 3D culture with either 
iMEF conditioned ES media or standard stromal media (DMEM, 10% FCS), mature 
exocrine marker- amylase expression was detected (figure 3.2.36). Amylase expression 
was also detected in the repeat experiment after 36 days; however, untreated and 
hanging drop cells were also positive for amylase expression (figure 3.2.37).  
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Limbal stromal cells have been suggested to possess a differentiation capacity similar to 
bone marrow-derived mesenchymal stem cells, with potential towards osteogenic, 
chrondrogenic and adipogenic lineages (Sosnova, Bradl et al. 2005; Polisetty, Fatima et 
al. 2008). Bone marrow-derived mesenchymal stem cells have previously shown 
differentiation potential towards pancreatic lineages (Zhang, Shen et al. 2010). 
However, the protocol used in this study did not achieve any substantial pancreatic 
differentiation. Since this study has been performed, an article has been published based 
on directed differentiation of limbal stromal cells towards functioning pancreatic beta 
cells (Criscimanna, Zito et al. 2011), however a different cocktails of growth factors 
was used in this study compared to the directed differentiation protocol used here. The 
lack of pancreatic endocrine differentiation in the limbal stromal cells used in this study 
may be a result of the specific directed differentiation protocol used, as this was 
designed for use with ES cells (Jiang, Au et al. 2007), and may be incompatible with 
adult stem cells, and may not support transdifferentiation of a more committed 
stem/progenitor cell type. Additionally, stromal cells isolated from the corneal-scleral 
ring may also exhibit subtle differences in differentiation potential between donors. In 
this thesis, all stromal experiments were performed with cells from a single donor. 
Using a range of stromal cell lines from different donors may give a more accurate view 
of the effectiveness of this directed differentiation protocol for stromal cell 
differentiation towards pancreatic cell types. 
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4.2.5 Summary of differentiation studies 
Two different approaches were used in this study to generate iPS cells; lentiviral 
transduction of the transcription factor cocktail and conditioned media induced 
reprogramming. However, cells have not progressed beyond the semi-reprogrammed 
state. Despite challenges with directed differentiation of iPS cells towards pancreatic 
phenotypes, our 3D culture system improved differentiation marker expression 
compared to 2D systems, using established directed differentiation protocols. 
 
Recent studies have identified miRNA families associated with regulation of 
pluripotency. Over-expression of these pluripotency related miRNAs induces 
reprogramming of somatic cells to iPS cells (Lin, Chang et al. 2008; Anokye-Danso, 
Trivedi et al. 2011; Miyoshi, Ishii et al. 2011). If miRNAs can be used to induce 
reprogramming, then maybe pancreatic beta cell related miRNAs could potentially 
direction differentiation of pluripotent stem cells towards pancreatic cell types.  
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4.3 Biomarker discovery in diabetes serum 
4.3.1 Serum miRNA biomarkers 
Serum miRNAs have been shown to be differentially expressed in a range of 
pathological conditions such as ovarian cancer (Resnick, Alder et al. 2009), lung cancer 
(Chen, Ba et al. 2008), large B-cell lymphoma (Lawrie, Gal et al. 2008), breast cancer 
(Zhu, Qin et al. 2009), colorectal cancer (Huang, Huang et al. 2009) and liver damage 
(Wang, Zhang et al. 2009), as well as physiological conditions such as pregnancy 
(Chim, Shing et al. 2008). Recent studies have also identified differential miRNA 
expression in serum from T2DM (Chen, Ba et al. 2008; Zampetaki, Kiechl et al. 2010; 
Kong, Zhu et al. 2011) and gestational diabetes (Zhao, Dong et al.) patients. Serum 
miRNAs are particularly resistant to digestion by serum RNases, in comparison to large 
mRNA fragments which are more sensitive to RNaseA action (Chen, Ba et al. 2008). 
This quality of serum miRNAs makes them particularly suitable for use as RNA 
biomarkers, and could represent a non-invasive method for diagnosis or monitoring of 
diseased state. 
 
As indicated in section 3.2.3.4, 12 miRNAs were identified as being differentially 
expressed in glucose responsive compared to glucose non-responsive MIN-6 cells. 
Expression levels of these miRNAs were subsequently tested in serum specimens from 
T1DM and T2DM patients in comparison to levels in serum from non-diabetic controls.  
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4.3.1.1 Serum miRNA analysis in T1DM serum specimens 
 
From the initial analysis of T1DM serum specimens, only mir-124a was found to be 
consistently differentially expressed in T1DM serum specimens tested (figure 3.3.2). 
Therefore, analysis of this miRNA was extended to examine a total of 15 T1DM serum 
specimens and BMI/age/gender matched controls. Of these 15 specimens, mir-124a was 
up-regulated in 11 of 15 T1DM specimens by approximately 1.9 fold; however, this 
increase was not statistically significant.   
 
As the majority of pancreatic beta cells in T1DM patients are dysfunctional or have 
been destroyed by autoimmune attack (Matveyenko and Butler 2008), it was 
hypothesised that reduced expression of these GSIS related miRNAs would be seen in 
T1DM sera. However, this was not the case, 11 of the 12 GSIS-related miRNAs tested 
showed no consistent change in expression levels in serum, while mir-124a was up-
regulated in 11 of 15 T1DM samples compared to the control specimens tested. The up-
regulation of mir-124a in T1DM serum specimens is unlikely to be related to its 
function in GSIS in pancreatic beta cells, as the majority of these cells have been 
destroyed. Mir-124 has previously been shown to be involved in neuronal 
differentiation, with increased expression leading to increased differentiation towards 
neuronal cell types, while knockdown of expression maintained cells in a stem cell state 
(Cheng, Pastrana et al. 2009). Increased levels of mir-124a in serum from T1DM 
patients could potentially reflect the body’s stem cell population attempting to 
differentiate towards beta cell types to compensate for the beta cells lost by autoimmune 
attack. 
 
Large scale miRNA profiling of T1DM serum specimens was performed in order to 
identify other potential miRNA biomarkers for this disease using TaqMan low density 
miRNA arrays (TLDAs). The endogenous controls incorporated in the TLDA cards 
were undetected in all serum specimens tested; therefore, the TLDA data was assessed 
to determine if any of the target miRNAs analysed could represent potential endogenous 
control miRNAs. Mir-28 and mir-326 levels were unchanged in T1DM samples 
compared to controls and also showed a low standard deviation across all samples 
analysed. Therefore, these two miRNAs were selected as endogenous controls for use in 
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this experiment. All TLDA data was normalised to these ‘endogenous control’ miRNAs 
individually to generate two lists of differentially expressed miRNAs. Only miRNAs 
common to both lists were chosen as targets for further investigation. Using this 
criterion a list of seven miRNAs (i.e. mir-140, -21, -24, -29a, 29c, -30d and -345) were 
identified as differentially expressed in T1DM sera relative to control sera, all of which 
were up-regulated in T1DM sera. 
 
Expression of these seven miRNA targets were examined in a total of 13 T1DM serum 
specimens and matched controls. Expression levels were not consistent among all 
samples analysed. However, the expression patterns of these miRNAs seemed to split 
the specimens into two distinct groups – T1DM specimens where all target miRNAs 
were over-expressed (n=6), and T1DM specimens where all target miRNAs showed 
reduced expression (n=5) (table 3.3.3). A further 2 T1DM specimens showed varying 
trends of miRNA expression and, hence, did not fit into either category (table 3.3.3). A 
comparison of the patient history and medical information was performed on the 
patients in these two categories, to determine any possible difference that may help 
explain why they grouped in separate categories and why patients with similar miRNA 
expression grouped together. Specimens with increased levels of the miRNA targets 
showed statistically significant higher alcohol and cigarette consumption (p-values 
0.036 and 0.044, respectively). These patients also showed increased exercise minutes 
per week; however, this increase was not significant (p-value 0.064).  
 
Control serum specimens used in this study were matched to patient sera based on age, 
gender and BMI; but not on smoking or alcohol intake. The trend of high expression of 
miRNA targets being associated with high smoking and alcohol intake is not mirrored 
in the control serum specimens. However, ignoring the normalisation of PCR data 
against these matched control serum specimens, the trends remain the same for T1DM 
specimens, i.e. T1DM specimens with higher smoking and alcohol consumption had 
higher expression of these miRNA targets, while the T1DM specimens, from low/non-
smoking and low alcohol consumption patients showed lower expression of these target 
miRNAs. 
 
In a study reported by Chen et al., (Chen, Ba et al. 2008), mir-140, mir-21, mir-24, mir-
29a and mir-30d were shown to be up-regulated in serum specimens from lung cancer 
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patients, while mir-29c was down-regulated in these specimens (Chen, Ba et al. 2008). 
These miRNAs showed dysregulation in our study of T1DM serum specimens 
compared to healthy control serum specimens. This overlap of miRNA targets in lung 
cancer and T1DM may reflect the body’s immune response or general inflammatory 
response to diseased state, rather than being disease-specific miRNAs. Alternatively, 
these miRNAs may reflect an effect of smoking, as these miRNAs were up-regulated in 
the T1DM serum specimens from our study with high cigarette consumption. There was 
no information on patient smoking habits or diabetes status published in the lung cancer 
serum study by Chen et al. However, as 90% of lung cancer cases can be attributed to 
smoking (Peto, Lopez et al. 1992), it is possible that the increased levels of these 
miRNAs in serum from lung cancer patients could also be related to smoking. 
 
As there is no available data on the direct effects of smoking or alcohol on miRNA 
levels in serum, we can only suggest that these changes in miRNA expression levels in 
T1DM serum specimens may be smoking-related. As the trend is not observed in 
smoking and non-smoking control serum specimens, it may be that this expression trend 
represents a ‘diabetic-smoking specific’ phenomenon. To further test this possibility, a 
large cohort of serum specimens would need to be examined, in smokers and non-
smokers, with and without lung cancer or type 1 diabetes, as well as non-diabetic and 
non-cancer controls.  
 
Mir-345 was the only miRNA identified from the TLDA experiment which did not 
overlap with the lung cancer study; therefore, this miRNA may more likely be diabetes-
related. However, much work on this target still needs to be carried out to determine its 
applicability as a biomarker of this disease, as this target also shows differential 
expression in T1DM serum specimens of high smoking and alcohol intake relative to 
low/non-smoking and low alcohol consumption T1DM patients. 
 
Mir-21, mir-24, mir-29a and mir-30d were identified in this study in the TLDA 
experiment with T1DM serum, however, expansion of the study to an additional ten 
T1DM and control samples did not show a consistent trend in expression levels. These 
miRNAs have since been shown to also be differentially expressed in serum from 
T2DM patients (Zampetaki, Kiechl et al. 2010; Kong, Zhu et al. 2011), indicating a 
potential commonality between serum markers in T1DM and T2DM. 
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4.3.1.2 Serum miRNA analysis in T2DM serum specimens 
 
Levels of GSIS related miRNAs (identified from section 3.2.3.2) were also analysed in 
serum from type 2 diabetic patients (T2DM). It was hypothesised that as these miRNAs 
were down-regulated in non-GSIS MIN6 cells, that this trend may be reflected in 
T2DM sera, as an indication of beta cell dysfunction associated with this disease. Mir-
369-5p was the only miRNA of the 12 analysed which showed a consistent change in all 
serum samples tested (6 T2DM specimens and 6 BMI/age/gender matched controls). 
Mir-369-5p was reduced approximately 2.1 fold in T2DM serum specimens; in two 
T2DM specimens mir-369-5p was reduced to the extent that it was undetectable by real-
time PCR, however, this change was not statistically significant. This consistent 
reduction of mir-369-5p in T2DM serum specimens could potentially represent beta cell 
dysfunction in these patients.  
 
In a study by Kong et al. 2011, mir-124a levels were significantly up-regulated in 
T2DM serum compared to patients with pre-diabetes or control patients with normal 
glucose tolerance (Kong, Zhu et al. 2011). However, in our study no significant change 
was seen in mir-124a levels in T2DM patients (figure 3.3.11). These conflicting results 
could be related to the ethnicity of patients used in the study, as the patients used in the 
Kong et al. 2011 study were from a Chinese population, while the samples used in our 
study were from Caucasian patients. 
 
This pilot study demonstrated the feasibility of using miRNAs as serum biomarkers for 
T1DM and T2DM patients. We have shown that the miRNA profile of T1DM serum is 
distinct from the miRNA profile in healthy control serum. We have also shown the 
differential expression of miRNAs in serum from T2DM specimens. This proof-of-
principle work has established that differences in miRNA expression profiles in diabetes 
versus healthy control sera could be potentially exploited for development of 
biomarkers for monitoring and diagnosis of T1DM and T2DM. 
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4.3.2 Serum protein biomarkers 
Serum specimens from diabetes patients were analysed using the latest proteomics 
technologies to identifiy biomarkers of potential use for diagnosis, prognosis and 
monitoring of disease progression. Label-free LC-MS techniques were employed for the 
analysis of these serum specimens.  
 
With the dawn of label-free LC-MS/MS technologies new software packages were 
developed to allow analysis of the resulting data from such experiments. Progenesis 
label-free LC-MS software (NonLinear Dynamics) is one such software package. 
Progenesis displays the MS/MS data as a 2D image, where one axis represents m/z and 
the other retention time. A reference sample which is most representative of the data is 
chosen. The 2D image of the reference sample is aligned against the 2D images of each 
of the other samples in the study to allow identification of matching peak clusters called 
features, which correspond to peptides. The software can identify all the common 
features or peptides between the reference sample and remaining samples. Identification 
of features and aligning of samples allows clean up of data, by the removal of signals 
resulting from white noise, background ions or chemical noise (Christin, Bischoff et al. 
2011). Data analysis was performed separately for each comparison to be analysed. 
Samples were designated into groups for comparison, while features/peptides were then 
filtered based on an ANOVA value of less than or equal to 0.2, to identify 
features/peptides which were present at different levels in the sample groups. The 
MS/MS data for each peptide which fulfilled the filter criteria was exported to an 
external database search engine called MASCOT. MASCOT software correlates the 
uninterpreted MS/MS data with sequences in a database to identify the proteins from 
which these peptides originated. Each identified peptide is then given a score based on 
the probability that the observed match between the experimental data and the database 
sequence is a random event. Resulting peptides are then filtered based on MASCOT 
score of greater than 40, and hits greater than 1. Subsequent identified proteins are then 
filtered based on the criteria of ANOVA value less than or equal to 0.05 and 
identification of at least two unique peptides. 
 
One of the issues associated with label-free LC-MS/MS and Progenesis analysis is the 
requirement for alignment of sample 2D images against a reference sample (Tuli and 
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Ressom 2009). Alignment allows correction of experimental variation in the LC 
dimension between LC-MS/MS runs, which subsequently allows the detection of 
corresponding peptides in each run (Sandin, Krogh et al. 2011). The reference sample 
should be chosen as the sample which is most representative of the data; choosing a 
reference sample which differs greatly from the rest of the data severely affects the 
quality of the alignment (Sandin, Krogh et al. 2011). In this study we found that 
choosing the sample with the highest number of detected features as the reference 
sample gave the most reproducible results. To identify the most robustly changed 
proteins each comparison was performed three times, using different reference samples 
with highest number of identified features, for each analysis. Three protein lists were 
generated for each comparison to be analysed. Only proteins which were present on all 
three lists were reported in the results section, individual lists are reported in appendix 
C. Performing the data analysis three times with different reference samples allowed us 
to identify proteins with increased confidence that these protein changes were the result 
of a real differential expression rather than a false positive result. 
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4.3.2.1 All groups analysis 
 
Control sample DS-171 could not be aligned to any reference sample selected; therefore 
this sample was not included in the analysis. A number of issues could have contributed 
this problem, such as variability in sample preparation process or variability due to 
analytical equipment performance (Tuli and Ressom 2009). 
 
Principal component analysis (PCA) plots are a statistical technique commonly used for 
the identification of patterns in data of high dimensions. PCA plots can be useful when 
interpreting relationships between different experimental groups. Outliers can also be 
easily identified from PCA plots. A PCA plot was generated using all sample groups 
(figure 3.3.16). While distinct cloud clusters were not seen for each individual sample 
group, the diabetes samples T1DM new (pink spots), T1DM old (blue spots), and 
control samples (orange and purple spots), were loosely localised in separate quadrants 
of the cloud cluster. While the autoimmune/inflammatory samples clustered in a similar 
pattern to the T1DM new samples, indicating that these samples have a similar protein 
expression pattern. Type 1 diabetes patients have previously been reported to have T 
cells responsive to a number of islet proteins for up to 1 year post-diagnosis (Brooks-
Worrell, Starkebaum et al. 1996; Brooks-Worrell, Greenbaum et al. 2004), therefore the 
T1DM new samples used in this study which are approximately 3.14 months post 
diagnosis are likely to still express autoimmune related proteins. 
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4.3.2.2 Selection of target proteins 
 
Each comparison to be analysed was performed in triplicate using a different reference 
sample for each replicate. Long lists of proteins were identified as being significantly 
differentially expressed for each comparison performed. However, only proteins which 
were consistently changed in each replicate analysis using a different reference sample 
were reported in the results section, leaving a long list of proteins which were not 
consistently changed. Therefore, we believe it is a good idea to do repeat analysis of 
sample data using different reference samples to get a reliable list of differentially 
expressed proteins. 
 
Proteins for follow-up were selected based on their potential interest in both T1DM 
newly diagnosed (T1DM new) and established disease (T1DM old) studies. Comparison 
of control groups used for T1DM new and T1DM old stuies (i.e. control new and 
control old samples) was also performed to ensure that the proteins of interest were not 
related to the control samples used, but were indeed patient related. Additionally, 
comparison of autoimmune versus control samples was performed, to ensure that target 
proteins, while patient related, were not due to general autoimmune or inflammatory 
related causes, but rather a diabetes specific effect. Vitronectin, clusterin, vitamin K-
dependent protein S and apolipoprotein L1 satisfied the selection criteria and were 
chosen for further analysis. 
 
Levels of these proteins were quantified using ELISA technology in the same 8 T1DM 
new, T1DM old and control samples as well as an additional 22 T1DM old samples and 
matched controls.  
 
4.3.2.3 Vitronectin 
 
Vitronectin belongs to a family of adhesive glycoproteins which play a role in 
attachment of cells to their surrounding matrix and may be involved in regulation of cell 
differentiation, proliferation, migration and morphogenesis (Preissner and Jenne 1991; 
Tomasini and Mosher 1991). Vitronectin is also involved in regulation of complement 
activation and blood coagulation (Preissner and Jenne 1991). In conjunction with 
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plasminogen activator inhibitor-1 (PAI-1) levels, vitronectin has been shown to be a 
marker of metabolic syndrome incidence (Alessi, Nicaud et al. 2011), possibly through 
its regulatory role in insulin signalling (Lebrun, Baron et al. 2000). Vitronectin 
depositions have been suggested to be a marker of tissue injury and necrosis, playing a 
possible role as a protective factor against tissue destruction (Preissner and Seiffert 
1998). In our study, increased levels of vitronectin were seen in T1DM new samples 
(n=8) according to the label-free proteomics analysis; however this finding was not 
supported by the ELISA data. Higher levels of vitronectin in T1DM new samples could 
potentially be indicative of recent β-cell destruction in these samples. Conversely, in the 
T1DM old samples, vitronectin levels were significantly down-regulated (1.14 fold) 
compared to old controls (n=30).  
 
4.3.2.4 Clusterin 
 
Clusterin, also know as apolipoprotein J, has been proposed to be involved in a number 
of biological functions including complement activity, lipid transport and apoptosis 
(Aronis, Kim et al. 2011). A number of studies have evaluated clusterin levels in 
diabetes patients. Clusterin levels can be measured as circulating clusterin or lipoprotein 
associated clusterin. In T2DM patients, high circulating clusterin (Trougakos, Poulakou 
et al. 2002; Kujiraoka, Hattori et al. 2006) and LDL-associated clusterin (Pettersson, 
Karlsson et al. 2011) have been detected, while low levels of HDL-associated clusterin 
is seen in patients with metabolic syndrome (Hoofnagle, Wu et al. 2010). 
Polymorphisms of the clusterin gene have also been associated with prevalence of 
T2DM (Daimon, Oizumi et al. 2011). Oxidation of lipoproptein lipids is raised in 
T2DM patients (Dimitriadis, Griffin et al. 1996), therefore altered levels of circulating 
clusterin and lipoprotein associated clusterin may be related to altered lipid metabolism 
in these patients (Kujiraoka, Hattori et al. 2006).  
 
Clusterin levels in T1DM are less well studied, as lipid metabolism dysfunction is less 
extreme in these patients. One previous study identified decreased circulating clusterin 
levels in T1DM samples compared to controls (Metz, Qian et al. 2008). In our initial 
biomarker discovery experiment, increased clusterin levels were detected in T1DM new 
samples compared to controls; however, follow up validation of this target using ELISA 
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technology did not show any significant change in clusterin levels in these patients. The 
increased clusterin expression detected in the label-free experiment may have been 
skewed by the outlier T1DM new sample in pair 1 (figure 3.2.26), which shows almost 
double the level of clusterin compared to the other T1DM new samples. As the label-
free proteomics approach analyses sample groups rather than individual samples, 
therefore outlier samples could potentially skew the results. Increased clusterin levels in 
the label-free proteomics could also be as a result of increased LDL- or HDL- 
associated clusterin. Proteins associated with complexes in serum may be quantified 
using label-free LC-MS, as long as a protein on the surface of the complex associates 
with the ProteoMinerTM beads, so the complex is retained. Subsequent sample 
preparation and digestion steps release all proteins from complexes allowing them to be 
quantified. However, in an ELISA setup, if the protein is not at the surface of the 
complex, with the specific epitope exposed for capture antibody recognition, then this 
protein will not be bound and quantified. Therefore, conflicting results in the label-free 
proteomics and ELISA data may indicate the involvement of protein complexes, 
hindering quantification by ELISA. 
 
Increased total clusterin levels in T1DM new samples (according to label-free 
proteomic analysis) negatively correlated with HDL levels, as T1DM new group had the 
lowest HDL measurement of the sample groups (table 3.3.4). As with the T2DM and 
metabolic syndrome studies mentioned previously (Trougakos, Poulakou et al. 2002; 
Kujiraoka, Hattori et al. 2006; Hoofnagle, Wu et al. 2010; Pettersson, Karlsson et al. 
2011), it may be interesting to determine clusterin levels in isolated HDL and LDL 
complexes in T1DM samples. 
4.3.2.5 Vitamin K-dependent protein S 
 
Vitamin K-dependent protein S functions as an anticoagulant, it may also be involved in 
regulation of complement activation through binding of C4b-binding protein (Dahlback 
2007). Protein S can also bind cells undergoing apoptosis and stimulate phagocytosis of 
these cells (Anderson, Maylock et al. 2003). Label-free proteomic analysis found this 
protein to be increased in T1DM new samples and decreased in T1DM old samples 
(n=8). Higher levels of vitamin K-dependent protein S in T1DM new samples may be 
indicative of increased β-cell apoptosis in these samples, as β-cell apoptosis has been 
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suggested to be the initiating factor in T-cell mediated autoimmunity associated with 
type 1 diabetes (Mathis, Vence et al. 2001). Conversely, ELISA validation of this target 
in the same T1DM new samples showed that Vitamin K-dependent protein S was 
significantly down-regulated in these patients. As diabetes patients have increased 
incidence of coagulation abnormalities (Ceriello 1993), a reduced level of the 
anticoagulant vitamin K-dependent protein S may be a contributory factor to this effect. 
However, as vitamin K-dependent protein S levels in T1DM new patients are 
conflicting according to proteomic profiling and ELISA results, the potential of this 
protein as a biomarker in T1DM patients needs to be further studied. 
 
4.3.2.6 Apolipoprotein L1 
 
Apolipoprotein L1 is a HDL-associated protein (Duchateau, Pullinger et al. 1997). 
Levels of apolipoprotein L1 were decreased in T1DM old samples compared to 
controls. Apolipoprotein L1 levels were also shown to be increased in the T1DM new 
versus T1DM old comparison. However, as no change is seen in T1DM new versus 
control comparison, therefore the increased level in T1DM new is most likely due to the 
reduced levels in T1DM old samples rather than an increase in T1DM new 
apolipoprotein L1 levels. A negative correlation with HDL measurements is also seen 
with apolipoprotein L1, T1DM old samples with decreased levels of apolipoprotein L1 
display the highest HDL measurement of each of the sample groups (table 3.3.5). A 
number of studies have linked apolipoprotein L1 with non-diabetic renal disease (Tzur, 
Rosset et al. 2010; Freedman, Langefeld et al. 2011), but in the context of diabetes, this 
protein is relatively unstudied. The ELISA kit employed in this study was unable to 
measure apolipoprotein L1 levels in our serum samples; therefore an alternative method 
for measurement of this protein is required to validate apolipoprotein L1 as a potential 
biomarker of T1DM. 
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4.3.2.7 Summary of proteomics target validation 
A number of proteomic profiling studies have previously been performed in the attempt 
to identify biomarkers for early diagnosis, treatment and management of diabetes 
(Matsumura, Suzuki et al. 2006; Kruger, Yang et al. 2010; Zhang, Sun et al. 2010), as 
well as biomarkers to detect the onset of secondary complications in these patients (Otu, 
Can et al. 2007; Madan, Gupt et al. 2010). Of the potential biomarker proteins identified 
in this study, only clusterin has been previously linked to T1DM (Metz, Qian et al. 
2008). 
 
In this study, differentially expressed proteins of interest initially detected by proteomic 
profiling studies, were further validated by an additional technique, ELISA, to ensure 
protein changes observed were consistent. In the T1DM new study, the same eight 
samples used in the profiling experiment were used in the ELISA validation. However, 
no change was seen in vitronectin and clusterin levels, but decreased levels of vitamin 
K-dependent protein S were detected, directly opposing the initial result of the 
proteomic profiling experiment. Four and five unique peptides of vitamin K-dependent 
protein S were identified for protein ID confirmation; therefore, the opposing results 
from label-free LC-MS and ELISA technologies on the same samples may potentially 
indicate the presence of multiple isoforms/variants of vitamin K-dependent protein S in 
serum. If the capture antibody used in the ELISA is specific for one isoform, this may 
explain the discrepancies seen between the label-free proteomics and ELISA analysis. 
As sample numbers are quite small, additional samples would be required to assess the 
validity of vitamin K-dependent protein S as a potential T1DM new biomarker. In the 
T1DM old versus control study, additional samples were available for validation of 
target proteins. Protein levels were assessed in 22 T1DM old samples and controls, in 
addition to the 8 T1DM old and control samples that were also used for the profiling 
experiment. In this larger cohort of patients, clusterin and vitamin K-dependent protein 
S levels were not significantly different. However, vitronectin was significantly 
decreased in the larger sample group, in agreement with the profiling data. While, in the 
T1DM new versus T1DM old comparison, no significant change was detected in levels 
of vitronectin, clusterin and vitamin K-dependent protein S. Lack of correlation between 
label-free LC-MS and ELISA findings could also be attributed to the sample pre-
treatment – ProteoMinerTM if target proteins are associated with high abundance 
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proteins. As high abundance proteins quickly saturate their ligands, therefore 
quantitative information on these high abundance proteins and interacting proteins may 
be effected. 
 
Pancreatic beta-cell specific markers would make ideal biomarkers for T1DM, with 
decreasing levels leading up to diagnosis of diabetes reflecting the gradual beta-cell 
destruction seen in these patients in the months prior to diagnosis. However, as serum is 
such a complex mixture, containing factors secreted from all tissues in the body, it is 
difficult to detect changes in beta-cell specific proteins, as beta-cells make up a very 
small percentage of the total cell mass in humans. Biomarkers identified in this study, 
although seemingly not directly related to pathogenesis of diabetes could potentially be 
reflective of the effect of beta cell destruction on other cells and tissues in the body, as 
insulin has many target tissues in the body, a lack of insulin signalling may affect a 
number of different organs and signalling mechanisms. 
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4.3.3 Serum metabolite biomarkers 
 
In this study 8 newly diagnosed type 1 diabetes (T1N) serum samples were analysed in 
comparison to 8 non-diabetic healthy controls. Samples were matched according to age, 
BMI and gender. Table 3.3.11 shows mean values for general characteristics of control 
and T1N groups. Fasting plasma glucose and HbA1c tests are used routinely for 
monitoring glycemic control in diabetes patients. T1N samples show increased fasting 
glucose and HbA1c values compared to control samples. T1N fasting plasma glucose 
levels fall within the impaired/pre-diabetes glucose range (table 4.3.1) (Genuth, Alberti 
et al. 2003). Mean HbA1c level of T1N group is also above the American Diabetes 
Associations (ADA) recommended level of 7% . T1N serum samples used in this study 
were taken approximately 3 months following diagnosis, although these patients are 
receiving insulin therapy, their fasting glucose and HbA1c levels signify the need for 
optimisation of insulin therapy and glucose monitoring for maintenance of glycemic 
control.  
 
Condition Fasting Plasma Glucose 
Normal < 5.6 mmol/L (< 100 mg/dL) 
Impaired (Pre-diabetes) 5.6 – 6.9 mmol/L (100 – 125 mg/dL) 
Diabetes > 7.0 mmol/L (> 126 mg/dL) 
Table 4.3.1 Diagnostic threshold for diabetes and impaired fasting glucose (Genuth, 
Alberti et al. 2003). 
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4.3.3.1 Carbohydrate Metabolism 
 
This study identified 23 metabolites which were present at significantly different levels 
in our T1N population relative to control. The metabolite with the greatest fold change 
was 1,5-anhydroglucitol (1,5-AG). 1,5-AG is a naturally occurring unmetabolisable 
dietary monosaccharide (Yamanouchi, Tachibana et al. 1992). After filtering of the 
blood by the kidney, 1,5-AG competes with glucose for re-absorption (Akanuma, 
Morita et al. 1988). When glucose levels rise above the renal threshold for glucose, 
increased glucose levels prevent re-absorption of 1,5-AG in the kidney, therefore as a 
direct result of hyperglycaemia, 1,5-AG levels in blood are reduced, while levels in 
urine are increased (figure 4.3.2) (Yamanouchi, Moromizato et al. 1992; Yamanouchi, 
Ogata et al. 1996). In this study 1,5-AG levels were decreased by 2.8 fold in T1N 
patients, in agreement with published effects of glucose on 1,5-AG (Yamanouchi, 
Moromizato et al. 1992; Yamanouchi, Ogata et al. 1996), these T1N patients also 
exhibit higher fasting glucose levels of approximately 1.5 fold, as measured by 
metabolic profiling by Metabolon, as well as part of routine blood work performed at 
Connolly Hospital, Blanchardstown following sample collection. 1,5-AG has also been 
identified in recent metabolomic profiling studies of type 2 diabetes in humans (Suhre, 
Meisinger et al. 2010) and a rodent model of hepatic insulin resistance (Li, Hu et al. 
2010). In agreement with our observations and previously published data (Yamanouchi, 
Moromizato et al. 1992; Yamanouchi, Ogata et al. 1996), decreased 1,5-AG levels in 
type 2 diabetes serum was accompanied by higher levels of glucose relative to control 
non-diabetes serum (Suhre, Meisinger et al. 2010). While in the rodent model of hepatic 
insulin resistance, 1,5-AG levels were shown to be decreased in both liver and plasma 
samples (Li, Hu et al. 2010). 
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Figure 4.3.2 1,5-anhydroglucitol in normoglycemic and hyperglycaemic conditions. 
During normoglycemia 1,5-AG is filtered in the kidneys and reabsorbed into the blood 
stream, maintaining constant levels in the blood. Under hyperglycaemic conditions 
glucose competes with 1,5-AG for reabsorption in the kidneys, thereby causing reduced 
levels of 1,5-AG in blood and increased levels in urine.  
 
 
Routinely used markers for glycemic control such as HbA1c and fructosamine give an 
average value for glycemic control; this average value may mask glycemic instability as 
hyperglycaemic events may be balanced by hypoglycaemic events (Dungan, Buse et al. 
2006). Patients with seemingly well controlled diabetes, HbA1c values between 6.5 – 
8%, may experience significant postprandial hyperglycaemia (Erlinger and Brancati 
2001). 1,5-AG levels correlate more robustly with post-prandial glucose compared to 
HbA1c (Yamanouchi, Inoue et al. 2001; Dungan, Buse et al. 2006). 1,5-AG levels also 
respond more rapidly to fluctuations in glucose levels (Yamanouchi, Moromizato et al. 
1992; Yamanouchi, Ogata et al. 1996). Therefore 1,5-AG may be of use as a marker of 
short-term post-prandial glucose control in patients at or near target HbA1c levels 
(Kishimoto, Yamasaki et al. 1995; McGill, Cole et al. 2004; Dungan, Buse et al. 2006). 
A reduction of 1,5-AG levels in serum from patients with pre-diabetes conditions- 
impaired glucose tolerance and impaired fasting glucose, indicates the possible use of 
1,5-AG screening for determining patients at risk of developing diabetes (Tsukui, 
Fukumura et al. 1996; Won, Park et al. 2009).  
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Other metabolites involved in glucose metabolism such as pyruvate and lactate also 
showed slightly decreased levels in T1N patients (1.6 and 1.2 fold respectively), 
however, this reduction was not statistically significant (figure 4.3.3). Low levels of 
lactate have previously been observed in studies of Type 1 diabetes, Type 2 diabetes 
and hepatic insulin resistance (Bao, Zhao et al. 2009; Lanza, Zhang et al. 2010; Li, Hu 
et al. 2010). High serum levels of glucose, in conjunction with low levels of 1,5-AG and 
glycolysis end products- pyruvate and lactate could possibly indicate a reduction of 
glucose utilisation, or glucose  transportation into cells in T1N patients. Transport of 
glucose across the cell membrane is the rate limiting step in glucose utilisation 
pathways in mammals (Pickup and Williams 1997), inefficient insulin levels may 
hinder transport of glucose into target cells, leading to lower levels of glycolysis 
intermediates. 
 
Other glycolysis intermediates were not detected in this serum study, as all nine 
glycolysis intermediates are phosphorylated, which prevents these high energy sugar 
molecules from leaving the cell as cell membranes generally lack transporter molecules 
for phosphorylated sugars (Nelson and Cox 2005). 
 
Pyruvate, the end-product of glycolysis, is the starting material in the TCA cycle. 
Possibly due to the reduced pyruvate, lower levels of some TCA cycle intermediates 
and by-products- malate and succinylcarnitine were seen in T1N samples (1.72 and 1.37 
fold respectively) (figure 4.3.3). Succinylcarnitine is likely formed from TCA cycle 
component succinyl CoA (Carrozzo, Dionisi-Vici et al. 2007). High glucose levels in 
addition to low levels of TCA cycle intermediates have also been reported in studies of 
type 2 diabetes and impaired glucose regulation (Zhang, Wang et al. 2009). 
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Figure 4.3.3 Glycolysis and Citric Acid Cycle. Molecules marked with red arrow were 
present at higher levels and molecules marked with green arrow were present at lower 
levels in serum from newly diagnosed Type 1 diabetes patients. 
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Lactate levels generated in muscle tissue through anaerobic glycolysis are transported to 
the liver to undergo gluconeogenesis. This transport of lactate from muscle to liver is 
known as the Cori cycle (figure 4.3.4). Reduced levels of lactate may indicate reduced 
Cori cycle activity in T1N patients.  
 
 
 
 
Figure 4.3.4 Cori Cycle. Lactate produced in muscle under anaerobic glycolysis is 
transported to the liver to undergo gluconeogenesis where glucose supplies are 
replenished and then transported back to the muscle for energy. 
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4.3.3.2 Fat Metabolism 
The lipid profile of serum samples was measured along with the routine blood work at 
Connolly Hospital, Blanchardtown. Total triglycerides, cholesterol, HDL-cholesterol 
and LDL-cholesterol were lower in T1N serum compared to control serum. 
Metabolomic analysis also showed that cholesterol was slightly lower in T1N patients 
(1.09 fold), but not significantly so. Poorly controlled type 1 diabetes patients can 
exhibit raised cholesterol, triglyceride and LDL-cholesterol levels, in addition to low 
HDL-cholesterol levels (Pickup and Williams 1997), however, the within-normal range 
lipid profile (table 4.3.2) of T1N patients used in this study indicates that they are 
relatively well controlled. Total cholesterol and LDL-cholesterol values for control 
samples were beyond the Irish Heart Foundations (http://www.irishheart.ie/iopen24/) 
recommended healthy values (table 4.3.2). Lower cholesterol and triglyceride levels in 
T1N serum specimens could be indicative of a healthier diet and lifestyle. High 
cholesterol levels in control serum could also be indicative of genetic predisposition to 
high cholesterol; however, none of the control specimens included in this study has 
reported familial hypercholesterolemia.  
 
Lipid Profile Recommended Level 
(mmol/L) 
Total cholesterol < 5 
LDL cholesterol < 3 
HDL cholesterol > 1 
Triglycerides < 2 
Table 4.3.2 Healthy cholesterol and triglyceride levels, as recommended by the Irish 
Heart Foundation. 
 
 
Fatty acid dicarboxylates- sebacate and 3-carboxy-4-methyl-5-propy-2-furanpropanoate 
(CMPF) were present at significantly lower levels in serum from T1N patients 
compared to control serum, at 1.47 and 1.72 fold respectively. Serum fatty acids may 
originate from 3 different sources, 1- fatty acids consumed in the diet, 2- stored in 
adipocytes as triglycerides, or 3- be biosynthesized in the body from excess glucose 
(Nelson and Cox 2005).  
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Decreased levels of fatty acid dicarboxylates seen in T1N patients could potentially be 
indicative of decreased levels of lipolysis in the adipose tissue, or reduction of fatty acid 
biosynthesis. Fatty acid biosynthesis requires acetyl-CoA, most of which is obtained 
from pyruvate oxidation (Nelson and Cox 2005), as pyruvate levels are decreased in 
T1N samples (1.6 fold), this may lead to reduced fatty acid biosynthesis. 
 
Reduced lipolysis could also be the cause of decreased serum fatty acid dicarboxylate 
levels in T1N serum. High levels of lipolysis are characteristically seen in untreated or 
poorly controlled type 1 diabetes patients, therefore lower levels of fatty acid 
dicarboxylates and reduced lipolysis indicates that these patients are well-controlled. 
 
Lipolysis involves the hydrolyzation of adipose tissue stored triglycerides into free fatty 
acids when hormones signal the need for metabolic energy. FFAs can then pass into the 
blood stream and travel to sites of energy requirements. β-oxidation is the breakdown of 
FFAs to acetyl coenzyme-A (CoA), which can enter the TCA cycle to generate energy. 
β-oxidation of FFAs occurs in the mitochondrial matrix and in order for FFAs to access 
the mitochondrial matrix they must be transported via a carnitine shuttle (figure 4.3.5). 
Firstly FFAs undergo conjugation to CoA generating fatty acyl-CoA. Fatty acyl-CoA is 
then transiently attached to carnitine via a transesterification reaction to form fatty acyl-
carnitine, which can then be translocated into the mitochondrial matrix via the acyl-
carnitine transporter.  Once inside the mitochondrial matrix the fatty acyl-CoA is 
regenerated while the carnitine molecule is released and transported back into the 
intermembrane space ready to transport the next fatty acyl-CoA molecule (Nelson and 
Cox 2005). In this study, a number of these fatty acyl-carnitine compounds were present 
at lower levels in the T1N group compared to controls.  
 
Propionylcarnitine and hexanoylcarnitine levels were significantly lower in T1N versus 
control group by 1.39 and 1.47 fold respectively. While butyrylcarnitine (1.72 fold), 
deoxycarnitine (1.15 fold), carnitine (1.15 fold), acetylcarnitine (1.18 fold), 
octanoylcarnitine (1.54 fold) and decanoylcarnitine (1.32 fold) were also present at 
slightly lower levels in diabetes patients, but these changes were not significant. A 
number of acyl-carnitines including propionylcarnitine and hexanoylcarnitine have 
previously been reported to correlate with insulin resistance (Gall, Beebe et al. 2010; Li, 
Hu et al. 2010). 
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Decreased levels of fatty acyl-carnitine compounds in T1N group could indicate a 
reduced level of β-oxidation in these patients. Lower levels of carnitine were also seen 
in diabetes serum relative to control. As carnitine-shuttle mediated transportation of 
fatty acyl-CoA molecules into the mitochondrial matrix is the rate limiting step of fatty 
acid β-oxidation, therefore lower levels of free carnitine would lead to lower levels of 
fatty acid β-oxidation, and subsequently lower levels of fatty acid dicarboxylates. 
 
 
 
 
Figure 4.3.5 Transport of fatty acyl-CoA into mitochondria by the carnitine shuttle. 
Image taken from Mountain West Digital Library, Utah Academic Library Consortium 
(http://mwdl.org/index.php/home). 
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During low glucose conditions such as fasting, the brain cannot utilise fatty acids for 
energy, therefore acetyl-CoA from fatty acid β-oxidation is converted to ketone bodies. 
The ketone body- 3-hydroxybutyrate, is the main energy source for the brain under 
fasting conditions (Owen, Morgan et al. 1967). Raised levels of 3-hydroxybutyrate were 
seen in serum from T1N patients relative to controls. Raised levels of 3-
hydroxybutyrate have also been seen in serum from type 2 diabetes patients (Suhre, 
Meisinger et al. 2010). Ketone bodies are known to be raised in the insulin deficient 
state (Balasse and Fery 1989). Insulin inhibits ketogenesis, while insulin deficiency 
stimulates it (Johnston and Alberti 1982; McGarry, Woeltje et al. 1989). Ketogenesis is 
necessary in small amounts; however, excess ketogenesis as a result of insulin 
deficiency can lead to diabetic ketoacidosis. 
 
The lysolipid- 1-pentadecanoylglyerophosphocholine was also present at significantly 
lower levels (1.82 fold) in diabetes serum relative to control serum. Lysolipids are 
involved in the formation of lipid bilayers of cell membranes. Of the 16 lysolipids 
detected in this study 1-pentadecanoylglycerophosphocholine is the only lysolipid 
which is significantly changed in diabetes serum. No obvious trend was seen in the 
other lysolipids analysed.  
 
Previous studies have shown altered levels of free fatty acids (Li, Xu et al. 2009; Gall, 
Beebe et al. 2010; Lucio, Fekete et al. 2010), long chain fatty acids (Bao, Zhao et al. 
2009), essential fatty acids (Li, Xu et al. 2009; Lucio, Fekete et al. 2010), acyl-
carnitines (Gall, Beebe et al. 2010) and ketone bodies (Huo, Cai et al. 2009; Gall, Beebe 
et al. 2010; Suhre, Meisinger et al. 2010) in type 2 diabetes and insulin resistant 
patients. Although lipid abnormities occur more frequently in type 2 diabetes patients 
(Pickup and Williams 1997), we have identified changes in lipid metabolites in serum 
from type 1 diabetes patients compared to control samples. Altered lipid metabolism is 
also seen in children who later develop type 1 diabetes, these lipid changes are evident 
before the patients exhibit autoantibody positivity (Oresic, Simell et al. 2008), therefore 
lipid metabolites may represent a good target for screening patients at risk of developing 
type 1 diabetes. 
 
Lipid metabolite changes identified in this study cannot be conclusively determined to 
be related to the T1DM disease state. As control samples used in this study displayed 
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high cholesterol, this may have a knock on effect on lipid metabolism; therefore 
metabolite changes may be more characteristic of high cholesterol rather than the 
presence of diabetes. 
 
4.3.3.3 Amino Acid Metabolism 
A number of amino acid metabolites were also significantly changed in diabetes 
patients relative to control. Of the 247 amino acid metabolites detected in these serum 
samples, 7 were significantly different in T1N versus control, indicating that no vast 
differences were present in amino acid metabolism of diabetes and control patients. 
Altered amino acid metabolism has also previously been reported in metabolomic 
profiling studies of type 1 diabetes (Oresic, Simell et al. 2008; Zhang, Nagana Gowda et 
al. 2008; Lanza, Zhang et al. 2010; Godzien, Ciborowski et al. 2011), type 2 diabetes 
(van Doorn, Vogels et al. 2007; Bao, Zhao et al. 2009; Cai, Huo et al. 2009; Huo, Cai et 
al. 2009; Zhang, Yan et al. 2009; Connor, Hansen et al. 2010; Suhre, Meisinger et al. 
2010) and impaired glucose tolerance / insulin resistance (Atherton, Bailey et al. 2006; 
Zhang, Wang et al. 2009; Gall, Beebe et al. 2010; Lankinen, Schwab et al. 2010; Li, Hu 
et al. 2010; Tsutsui, Maeda et al. 2010; Zhao, Fritsche et al. 2010) studies. 
 
The amino acids arginine and glutamine were present at significantly increased levels in 
T1N samples relative to control, 1.56 and 1.14 fold respectively (table 3.3.14). 
Increased levels of amino acids could be an indication of increased proteolysis or 
increased amino acid synthesis. However, increased levels of protein metabolites in 
overnight fasting serum samples generally indicate increased proteolysis in the fasting 
state, to allow the release of amino acids for oxidation and energy production (Pickup 
and Williams 1997). Arginine and glutamine are glucogenic amino acids, therefore, on 
amino acid degradation the carbon skeleton of these amino acids are diverted to 
gluconeognesis (figure 4.3.6) (Nelson and Cox 2005). Arginine is also a urea cycle 
intermediate (figure 4.3.6), further indicating an increase in proteolysis, as the urea 
cycle functions to convert ammonia from amino acid oxidation to urea for excretion. 
Glutamine is also a major component of amino acid oxidation (figure 4.3.6). Ammonia 
generated from amino acid oxidation is toxic to tissues, therefore, it is combined with 
glutamate to yield glutamine, which can then be transported safely to the liver or 
kidneys for excretion (Nelson and Cox 2005). Therefore, increased levels of glutamine 
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also suggest increased activity of the amino acid degradation pathway. Increased levels 
of glutamine were also identified in a study of type 2 diabetes serum (van Doorn, 
Vogels et al. 2007). Newly presenting patients with type 1 diabetes and patients with 
poorly controlled established diabetes typically exhibit increased protein catabolism and 
muscle wasting (Pickup and Williams 1997). However, as arginine and glutamine were 
the only amino acids to show increased levels in T1N patients and the fold change of 
these metabolites was relatively small, below 1.6 fold, this may indicate that these 
patients were in relatively good metabolic control at the time the samples were taken, as 
also indicated by HbA1c levels of approximately 7.69. Enhanced urea cycle activity has 
previously been suggested to be a feature of hepatic insulin resistance (Li, Hu et al. 
2010), therefore this could indicate that these patients are beginning to display effects of 
insulin resistance. 
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Figure 4.3.6 Overview of amino acid catabolism. Glutamine and arginine shown with 
red arrows were increased in serum from T1N patients relative to control serum. 
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Other proteolysis and amino acid oxidation related metabolites which were significantly 
different include isovalerylcarnitine, 2-methylbutyroylcarnitine and propionylcarnitine 
involved in valine, leucine and isoleucine metabolism were down regulated by 1.92, 
1.64 and 1.39 fold respectively, in T1N serum compared to control. Isovalerylcarnitine, 
2-methylbutyroylcarnitine and propionylcarnitine have also been shown to correlate 
with impaired glucose tolerance and impaired fasting glucose (Gall, Beebe et al. 2010). 
As valine, leucine and isoleucine are essential amino acids, and cannot by synthesized 
in the body, therefore metabolites of these amino acids are an indication of amino acid 
oxidation rather than amino acid synthesis. Valine, leucine and isoleucine amino acids 
contain aliphatic side chains and are therefore known as the branched chain amino acids 
(BCAA). BCAAs have previously been reported to be of significance in diabetes, with 
raised BCAA levels presenting prior to autoantibody positivity in children which later 
develop type 1 diabetes (Oresic, Simell et al. 2008). Increased levels of BCAAs are also 
seen in poorly controlled type 1 and type 2 diabetes patients (Vannini, Marchesini et al. 
1982; Tessari, Biolo et al. 1990; Lanza, Zhang et al. 2010). As BCAA metabolites in 
this study were decreased this may indicate that the patients used in this study were 
under good metabolic control. BCAAs and BCAA metabolites may be useful for 
detection of people who will develop type 1 diabetes later in life, and also for 
monitoring of metabolic control in patients with established diabetes. 
 
N-acetyl threonine involved in threonine metabolism, another essential amino acid, was 
also down regulated by 1.54 fold in T1N samples. 5-oxyproline, involved in glutathione 
metabolism was also down regulated 1.16 fold in T1N patient serum. 
 
Essential amino acid metabolites were seen to be present at lower levels in T1N patients 
compared to control. These amino acids cannot be synthesized in the body and need to 
be taken up in the diet, therefore lower levels of essential amino acid metabolites could 
indicate a lower level of essential amino acid intake in the diet or reduced essential 
amino acid oxidation in the body. Conversely, non-essential or conditionally essential 
amino acid metabolites are present at higher levels, indicating increased levels of non-
essential amino acid oxidation. If low levels of essential amino acids are taken up in the 
diet these amino acids are required for protein synthesis, while surplus non-essential 
amino acids may be oxidised for energy production. 
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4.3.3.4 Nucleotide Metabolism 
 
Urate levels were significantly decreased in T1N samples relative to control, by 1.23 
fold. Urate is formed from the degradation of purine containing nucleotides (adenine 
and guanine), and is excreted in the urine. Altered urate levels have previously been 
linked to development of insulin resistance (Gall, Beebe et al. 2010), type 2 diabetes 
(Lin, Tsai et al. 2004; Bao, Zhao et al. 2009; Gall, Beebe et al. 2010), and kidney 
dysfunction in diabetes (Fukui, Tanaka et al. 2008; Xia, Liang et al. 2009). Low levels 
of urate could indicate reduced activity of nucleotide catabolism, due to either reduced 
purine intake in the diet, or reduced proteolysis, or could indicate altered excretion of 
urate by the kidneys. Altered urate levels may also be indicative of kidney dysfunction, 
however, kidney function markers creatinine and 3-indoxyl sulphate were unchanged in 
the T1N serum samples used in this study, relative to control serum. 
 
11 nucleotide related metabolites were detected in the samples used in this study. 
However, as urate was the only significantly altered nucleotide-related metabolite in 
T1N versus control samples, and the fold change was quite low, therefore the alterations 
in nucleotide metabolism in T1N serum were relatively minor.  
 
4.3.3.5 Benzoate Metabolism 
 
Benzoates are frequently used as preservatives for acidic foods such as fruit juices and 
soft drinks (Warth 1991). Increased levels of catechol sulphate, a benzoate metabolite 
could indicate that T1N patients consume more benzoate containing food items than the 
control group. 
 
4.3.3.6 Caffeine Metabolism 
 
Caffeine metabolism was the most obviously altered pathway in T1N compared to 
control samples. Of the 7 caffeine related metabolites detected in these samples, all 7 
metabolites were down-regulated in T1N samples. Caffeine (2.5 fold), paraxanthine 
(1.78 fold), theophylline (1.89 fold), 1,3-dimethylurate (1.37 fold) and 1,7-
dimethylurate (1.67 fold) were all significantly down-regulated. While theobromine and 
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1,3,7-trimethylurate were not significantly down-regulated they still followed the same 
trend. 
 
An obvious explanation for this trend would be that the T1N patients consumed lower 
levels of caffeine containing products. The control samples used in this study were 
taken from healthy medical interns. The intern year of medical training is well known to 
be very demanding and stressful. It is generally accepted that people in high stress jobs 
tend to drink more coffee than those in less stressful jobs (Conway, Vickers et al. 1981), 
therefore it is likely that the reduced levels of caffeine and caffeine related metabolites 
in T1N samples are due to the higher than normal caffeine consumption of the control 
group. 
 
Caffeine is also known to have a negative effect on insulin sensitivity (Keijzers, De 
Galan et al. 2002). While patients in this study were not specifically advised against 
caffeine consumption, some may have become aware of the effect of caffeine on their 
disease through their own research, and are limiting caffeine intake accordingly. 
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4.3.3.7 Peptides 
 
A number of peptides were also detected by the metabolon platform. The fibrinogen 
cleavage peptide – fibrinopeptide A (FPA) was significantly increased in T1N samples. 
FPA is produced during the clotting process, when thrombin cleaves fibrinogen to 
produce fibrin and fibrinopeptide. Up-regulation of FPA has previously been reported in 
type 1 (Gianazza, Mainini et al. 2010) and type 2 diabetes (Meigs, D'Agostino et al. 
1997), and may be associated with diabetic nephropathy (Gianazza, Mainini et al. 
2010). 
 
FPA levels were validated in the same 8 T1N and control samples used in the 
metabolomic profiling study using an ELISA. The ELISA showed a significant up-
regulation of FPA levels in T1N samples compared to controls (figure 3.3.36). 
Additionally, FPA levels were quantified in 30 T1DM old and control samples, to 
determine if this change in FPA levels was specifically related to newly diagnosed 
diabetes, or a more general diabetes marker. When looking at the additional T1DM old 
and control old sample groups, it appears than FPA levels are reduced in control new 
samples, rather than increased in the T1N samples, as originally thought (figure 3.3.41). 
Altered levels of FPA have previously been linked with alcohol consumption (Nomura, 
Tomonaga et al. 2004). T1N patients in this study, on average consume 5.8 units of 
alcohol per week, while this number is raised to 14.3 for the control new subjects. 
While this difference in alcohol consumption is not statistically significant, it may play 
a role in the altered levels of FPA in these samples. These results may also indicate 
potential dysregulation of FPA in the control old samples, possibly due to clotting 
related issue in these patients, however, no clotting or coagulation related conditions 
had been diagnosed in these patients at the time of sample collection. 
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4.3.3.8 Metabolites as biomarkers 
 
Twenty-three metabolites were significantly different between T1N and control serum, 
incorporating metabolites from varying pathways of carbohydrate, lipid and amino acid 
metabolism. Untreated diabetes is characterised by increased carbohydrate anabolism 
via gluconeogenesis, in addition to increased lipid and amino acid catabolism. Diabetes 
patients used in this study have been on insulin treatment for approximately 3 months, 
the metabolomic profiling of these patients shows that while some differences in these 
metabolic pathways still remain, these patients are in relatively good metabolic control. 
 
The usefulness of multiple markers for diagnosis, prognosis and for predicting the risk 
of developing diseases or their complications is now widely recognised (Landers, 
Burger et al. 2005; Zethelius, Berglund et al. 2008). Metabolite biomarkers have been 
used extensively over the years for monitoring disease, e.g. glucose for diabetes, 
cholesterol for heart disease. Individual metabolites can also be very easily and rapidly 
quantified using biochemical assays or ELISAs, once a select panel has been identified 
for a particular disease. Biomarkers for early diagnosis of type 1 diabetes, could 
potentially allow treatment of the autoimmune disease before extensive beta cell death 
has occurred, thereby potentially avoiding the need for insulin therapy and the long term 
secondary complications of diabetes, such as diabetic nephropathy, retinopathy and 
microvascular disease. 
 
However, to conclusively determine if the metabolites identified in this study are of use 
as biomarkers for early diagnosis, these metabolites would need to be analysed in a 
larger cohort of patients at various stages of development of the disease. 
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5.0 Summary and Conclusions 
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5.1 MIN6 as a model for studying GSIS 
 
• MIN6 cells exhibit glucose stimulated insulin secretion (GSIS) when exposed to 
3.3mM to 16.7mM glucose concentrations. With increasing time in culture the 
GSIS response of these cells diminishes. 
• Some assays performed during the course of this study needed to be repeated a 
large number of times to determine if the treatment effects on GSIS were 
significant, as we observed considerable interplate variations in GSIS and basal 
insulin secretion. Also, the same pre/anti-mirs and controls sometimes 
stimulated or decreased insulin secretion. 
• However, in spite of these problems, as there is no human pancreatic beta cell 
line available, in order to study the mechanisms of GSIS we had no alternative 
but to continue this study with MIN6 cells; being mindful of its limitations. 
 
5.2 MicroRNAs involved in glucose stimulated insulin secretion 
 
• MIN6 cells at passage 37 showed a glucose concentration-dependent increase in 
insulin secretion producing a 3.3 fold increased insulin secretion when glucose 
stimulation was increased from 3.3 mmol/L to 16.7 mmol/L for 1 hr and so these 
cells were subsequently termed glucose-responsive MIN6 cells. In contrast, the 
same increase in glucose concentration when added to MIN6 cells at passage 40 
resulted in 1.3-fold increase in insulin secretion only i.e. non-glucose responsive 
MIN6 cells (figure 3.1.1). 
• Gradual loss of GSIS was observed in continuously cultured MIN6 cells from 
passage 37 to 40 (figure 3.1.1). 
• TaqMan low density miRNA arrays were performed on passage 37 glucose 
responsive and passage 40 glucose non-responsive MIN6 cells. 12 miRNAs 
were identified as differentially expressed in these two cell populations (table 
3.1.2). All 12 were down-regulated in glucose non-responsive cells. This data 
was presented at RNAi 2008, Oxford, UK (see poster appendix E). 
 323 
• 21 novel murine miRNAs were also detected in MIN6 cells in this study, these 
21 miRNAs have not been previously reported to be present in mouse cells 
(table 3.1.1). 
• Validation of the TLDA miRNA targets showed that 5 of the 12 targets were not 
significantly differentially expressed using single-plex PCR (table 3.1.3). 
• Bioinformatic analysis using MiRanda software identified putative targets of 
differentially expressed miRNAs from microarray and proteomics profiling data 
on glucose responsive and glucose non-responsive MIN6 cells (table 3.1.4). 
Among these miRNA targets were a number of genes considered important for 
beta cell function, such as neuroD1, Isl1 and txnip. Txnip knockdown has 
previously been shown to increase GSIS responsiveness in MIN6 cells. Mir-
200a and mir-130a may potentially mediate their effect on GSIS by regulation of 
Txnip. 
• Functional validation of miRNA targets was performed using pre-mirs and anti-
mirs for over- and under-expression of miRNAs. All miRNA targets were 
under-expressed in non-glucose responsive cells in TLDA analysis; therefore, 
over-expression using pre-mirs would be expected to improve GSIS in MIN6 
cells, while under-expression using anti-mirs would be expected to reduce GSIS 
in MIN6 cells. 
• Due to large variations in GSIS response of control cells, pre-mir and anti-mir 
transfections were performed a number of times to achieve consistent GSIS 
response in the control untreated and negative control (am-neg and pm-neg) 
cells, to allow effect of over-expression and knockdown of target miRNA on 
GSIS response to be assessed. 
• Knockdown of mir-410 in GSIS-competent cells using anti-mir-410 led to a 
significantly reduced GSIS response in these cells compared to untreated and 
negative control cells (figure 3.1.5). Over-expression of mir-410 in GSIS-
competent cells using pre-mir-410 led to a significant increase in GSIS 
responsiveness (figure 3.1.6). 
• Knockdown of mir-200a in GSIS-competent cells using anti-mir-200a led to a 
significant decrease in GSIS response (figure 3.1.7). No consistent effect was 
seen on GSIS for over-expression of mir-200a. 
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• Knockdown of mir-130a in GSIS-competent cells using anti-mir-130a led to a 
significant decrease in GSIS (figure 3.1.8). No significant difference was seen in 
GSIS-competent cells treated with pm-130a for over-expression of mir-130a. 
• No significant changes were seen in GSIS response in cells treated with pre-mirs 
and anti-mirs for mir-376a, mir-369-5p, mir-27a, mir-124a, mir-337, mir-532, 
mir-320, mir-192 and mir-379.  
• MiRNAs identified in this study as exhibiting functional effects on GSIS could 
potentially represent therapeutic targets for manipulation to maintain/restore 
GSIS in insulin-producing cells. However, the mechanism by which these 
miRNAs are involved in insulin secretion still remains to be elucidated. 
• Study of miRNAs involved in GSIS in MIN6 cells was published as: Hennessy 
E., Clynes M., Jeppesen P.B. and O’Driscoll L. 2010 Identification of 
microRNAs with a role in glucose stimulated insulin secretion by expression 
profiling of MIN6 cells. BBRC 396(2):457-62 (appendix E). 
• The MIN6 cell line as a model for studying GSIS can be undependable due to 
considerable day to day variations in GSIS response between control cells. This 
varying GSIS response of control cells makes it difficult to decipher effect of 
treatment on GSIS i.e. the assay, while being the best available is not robust or 
routinely dependable. 
• During the course of this study, somatic cell reprogramming and induced 
pluripotent stem cell generation was beginning to be widely reported in the 
literature, following the landmark paper by Yamanaka et al in 2006 (Takahashi 
and Yamanaka 2006; Takahashi, Tanabe et al. 2007). This new technology 
represented a route to developing human pancreatic beta cells in vitro from iPS 
cells for the study of GSIS. 
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MicroRNA 
Anti-Mir knockdown 
of miRNA 
Pre-Mir over-expression 
of miRNA 
mir-376a No effect No effect 
mir-369-5p Reduced GSIS minimally No effect 
mir-130a Reduced GSIS *  Reduced GSIS minimally 
mir-27a No effect No effect 
mir-410 Reduced GSIS *  Improved GSIS *  
mir-124a No effect No effect 
mir-200a Reduced GSIS *  No effect 
mir-337 No effect No effect 
mir-532 No effect No effect 
mir-320 No effect Reduced GSIS minimally 
mir-192 No effect Reduced GSIS minimally 
mir-379 No effect Reduced GSIS minimally 
Table 5.1 Functional validation of miRNA targets in MIN6 cells. (* denotes statistical 
significance). 
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5.3 Attempt to generate iPS cells and differentiation of an established iPS cell line 
towards pancreatic phenotypes 
 
5.3.1 Attempt to generate iPS cells 
 
• Four retro-viruses were generated to over-express oct4, sox2, c-myc and klf4 in 
transduced target cells. Optimised transduction conditions were identified to 
achieve up to 80% transduction efficiency after 72 hours, measured using GFP 
(figure 3.2.3)  
• Attempts were made to generate iPS cells from a number of different cell types 
o MiaPaCa2 pancreatic adenocarcinoma cell line 
o Normal human epidermal keratinocytes 
o Limbal epithelial cells 
• Virus-treated MiaPaCa2 cells displayed morphological changes, cell colonies 
with a tightly packed dense core but uneven colony edges were seen (figure 
3.2.7). PCR analysis of these colonies indicated that they expressed oct4, c-myc 
and klf4, but at similar levels to parental untreated MiaPaCa2 cells. Very low 
sox2 expression was seen in one virus treated clone, however, this low sox2 
expression was evidently not sufficient to drive full reprogramming (figure 
3.2.8). 
• Virus-treated keratinocytes also displayed morphological changes, but similar 
morphology changes were also seen for control keratinocytes not treated with 
virus; therefore, the morphology changes observed were probably a result of 
growth on MEF feeder layer rather than viral transduction (figure 3.2.10). Virus 
treated and control keratinocytes did not proliferate once transferred to MEF 
feeder layer culture, therefore, PCR analysis could not be performed to check if 
they expressed the four factors (oct4, sox2, c-myc and klf4). 
• Morphological changes were also seen in virus-treated limbal epithelial cells. 
Virus-treated cultures displayed cell processes and cell clusters, while untreated 
cultures displayed typical cuboidal morphology (figure 3.2.12). Unfortunately, 
virus-treated cells did not proliferate further, therefore oct4, sox2, c-myc and 
klf4 expression could not be examined. 
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5.3.2 Attempts to generate iPS cells using conditioned media 
 
• Attempts were also made to reprogram limbal epithelial cells using conditioned 
media from the murine embryonic stem cell line ESD3 (Balasubramanian, Babai 
et al. 2009). Cells were firstly treated with enriched media for 7 days (stage 1), 
followed by treatment with ESD3 conditioned media (ESD3 CM) for 14 days 
(stage 2). 
• Cell morphology changes were seen in ESD3 conditioned media treated cells; 
cell clusters formed initially, but did not proliferate much further, while a 
fibroblast-like cell type proliferated rapidly until confluence (figure 3.2.16). 
Control cells maintained in enriched media (extended stage 1) displayed similar 
morphology to untreated limbal epithelial cells (figure 3.2.16).  
• PCR analysis showed that parental cells expressed c-myc, oct4 and klf4, 
expression of these factors was maintained in control and ESD3 CM treated 
cells, however, treatment did not induce expression of the stem cell marker sox2 
(figure 3.2.17). 
• ESD3 CM treated cells lack expression of the differentiation markers CK-3 and 
CK-12 and have high expression of the stem cell associated marker N-cadherin. 
These cells lack expression of stem cell markers ABCG2 and nanog, indicating 
that these cells are not fully reprogrammed (figure 3.2.18). These cells may 
represent a semi-reprogrammed state. 
. 
5.3.3 Differentiation of an established iPS cell line towards pancreatic phenotypes 
 
• During the course of this study iPS cell lines became commercially available 
from the George Daley lab, Children’s Hospital, Boston. The hFib-iPS2 cell line 
was purchased for pancreatic differentiation experiments, as we had not 
achieved fully reprogrammed iPS cells from our own attempts. 
• Directed differentiation was performed in 2D and 3D cultures. 2D cultures 
consisted of cells grown on top of a thin matrigel layer, while in 3D culture cell 
clusters were suspended within a thick matrigel/collagen layer. Differentiation 
growth factor cocktail was used as described by Jiang J. et al., (Jiang, Au et al. 
2007). 
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• iPS cells differentiated in 3D culture showed improved efficiency for definitive 
endoderm formation compared to 2D culture, based on expression of definitive 
endoderm markers cxcr4, foxa2 and hnf4α (figure 3.2.21). This work was 
presented at ‘Stem Cells in Development and Disease 2011’ in Berlin, Germany 
(see poster appendix E). 
• Further differentiation of 2D cultures towards pancreatic endoderm and 
pancreatic endocrine cells failed, as cell died off after the definitive endoderm 
stage. 
• Untreated iPS cells expressed mature pancreatic markers- somatostatin and 
amylase, indicating that iPS cells may have undergone some spontaneous 
differentiation before initiation of differentiation experiment. 
• 3D control cells maintained in iMEF conditioned media at 36 days displayed 
induced expression of insulin, ghrelin and glut2 (figure 3.2.26). Therefore the 
use of 3D culture, or growth factors present in the matrigel may be responsible 
for induction of mature pancreatic markers in these control cells. Similar results 
were observed in the repeat experiment (figure 3.2.29), while somatostatin and 
amylase were present in untreated iPS cells, ghrelin expression was induced in 
3D control cultures in iMEF conditioned media. 
• The differentiation protocol used in this study from Jiang J. et al. (Jiang, Au et 
al. 2007), is a 36 day procedure, the long duration of this procedure allows for 
increased variability between replicate experiments. Different batches of 
matrigel used for replicate experiments may also lead to subtle differences 
between repeat experiments.  
 
 
 329 
5.3.4 Transdifferentiation of limbal stromal cells to pancreatic phenotypes 
 
• Limbal stromal cells isolated from donor cornea-sclera ring possess 
differentiation properties similar to mesenchymal stem cells (Dravida, Pal et al. 
2005; Polisetty, Fatima et al. 2008). 
• Embryoid bodies were initially formed with these limbal stromal cells followed 
by subsequent differentiation to definitive endoderm in 3D, 2D and monolayer 
cultures. 3D cultures involved embedding stromal embryoid bodies in a thick 
matrigel/collagen gel, for 2D cultures embryoid bodies were cultured on top of a 
thin matrigel layer, while in monolayer cultures embryoid bodies were 
disaggregated using trypsin and single cell suspension was cultured on standard 
tissue culture plastic. 
• Stromal embryoid body cells in 2D culture showed an increased propensity to 
differentiate towards definitive endoderm compared to 3D and monolayer 
cultures, based on expression of definitive endoderm marker- cxcr4 (figure 
3.2.32). Further differentiation towards pancreatic endoderm did not induce 
expression of pancreatic endoderm markers. 
• High cxcr4 expression was also observed in 3D control cells in iMEF CM. 
Cultures were maintained in these conditions for 36 days and levels of mature 
pancreatic markers assessed. Mature pancreatic exocrine marker – amylase was 
detected in 3D cultures maintained in iMEF CM or standard stromal media 
(DMEM, 10% FCS), indicating that it was the use of the 3D culture system 
rather than CM which induced expression of this marker. However, repeats of 
this experiment showed slightly different results, amylase expression was 
present in untreated stromal cells as well as 3D cultures, but increased amylase 
was observed in hanging drop generated embryoid bodies. 
• All limbal stromal cell experiments conducted in this study were performed 
using limbal stromal cells from a single donor. Differences may exist between 
tissue from different donors. Using tissue from a range of donors may give a 
more accurate determination of pancreatic differentiation efficiency using this 
directed differentiation protocol. 
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5.4 Biomarker discovery in diabetes serum specimens 
 
All in all the results were disappointing in that leads from profiling of small numbers of 
patients did not, in general, validate using specific assays for the candidate markers in 
larger patient numbers. 
 
5.4.1 Analysis of serum for miRNA biomarkers 
 
• Levels of GSIS-related miRNAs (table 3.1.2) were examined in T1DM old and 
control old serum specimens 
o Mir-124a, mir-130a, mir-9, mir-532, mir-192 and mir-379 were 
differentially expressed (n=3) 
o The study was expanded to n=5 (n=15 for mir-124a), however miRNA 
expression trends were not consistent  
• TLDA miRNA profiling of T1DM old and control old (n=3) identified 7 
differentially expressed miRNAs 
o mir-140, mir-21, mir-24, mir-29a, mir-29c, mir-30d and mir-345 
o TLDA miRNA targets validated in 6 T1DM and control samples 
o miRNA expression trends were not consistent  
• Levels of GSIS related miRNAs were examined in T2DM and control samples  
o No statistically significant changes were seen in these miRNA levels in 
T2DM and control samples (n=6) 
o Although mir-369-5p levels did not reach statistical significant (p≤ 0.05), 
it did show a consistent trend in expression levels in T2DM and control 
serum. 
o Mir-369-5p was down-regulated approximately 2.1 fold in 6 T2DM 
serum specimens relative to matched controls; in two specimens mir-
369-5p was down-regulated to the extent that it was undetectable by real-
time PCR. This down-regulation of mir-369-5p in T2DM serum 
specimens could potentially reflect beta cell dysfunction in these 
patients. 
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5.4.2 Analysis of serum for proteomic biomarkers 
 
• Proteomic profiling was performed on newly diagnosed type 1 diabetes (T1DM 
new) and established type 1 diabetes (T1DM old). Age/BMI/gender matched 
controls were also included in the analysis control new samples matched to the 
T1DM new group and control old samples matched to the T1DM old group. 
• Principal component analysis (PCA) plots showed clear distinctions between 
control and disease groups (figure 3.3.17, 3.3.18 and 3.3.19). 
• Data analysis was performed in triplicate using a different reference sample for 
each repeat. Only proteins which were common to all three lists were reported in 
the results section (table 3.3.6, 3.3.7 and 3.3.8), to improve confidence in 
identification of differentially expressed proteins in the respective studies. 
• Targets for follow-up validation were chosen based on their potential interest in 
multiple comparisons, i.e. T1DM new versus control new, T1DM old versus 
control old, or T1DM new versus T1DM old. 
• Vitronectin, clusterin, vitamin K-dependent protein S and apolipoprotein L1 
were selected for follow-up validation using ELISAs to measure levels of these 
proteins in serum samples. 
• Follow-up validation was performed on the same 8 T1DM new and control new 
samples, while in addition to the 8 T1DM old and control old samples used in 
the initial profiling experiment, a further 22 T1DM old and control old samples 
were analysed. 
• Vitronectin levels were up-regulated in T1DM new versus control new, T1DM 
old versus control old, and T1DM new versus T1DM old comparisons according 
to label-free LC-MS experiment. However, ELISA validation showed a 
significant down-regulation of vitronectin in T1DM old versus control old 
comparison, but no significant change in expression levels was seen in the other 
comparisons (table 3.3.10). 
• Clusterin levels were up-regulated in T1DM new versus control new and T1DM 
new versus T1DM old comparisons, according to label-free LC-MS experiment. 
However, ELISA showed no significant change in clusterin levels in any 
comparison analysed (table 3.3.10). 
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• Vitamin K-dependent protein S levels were up-regulated in T1DM new versus 
control new and T1DM new versus T1DM old comparison, and down-regulated 
in the T1DM old versus control old comparison according to label-free LC-MS 
experiment. However, according to the ELISA data, vitamin K-dependent 
protein S levels were significantly down-regulated in T1DM new versus control 
new comparison, while no significant change was seen in other comparisons 
analysed. In this instance, ELISA shows directly opposite result to label-free 
LC-MS data. 
• Apolipoprotein L1 was down-regulated in T1DM old versus control old 
comparison and up-regulated in T1DM new versus T1DM old. Expression levels 
of this protein could not be validated using ELISA, due to technical issues with 
the assay. 
 
5.4.3 Analysis of serum for metabolite biomarkers 
 
• Metabolomic analysis was performed on 8 T1DM new and control new serum 
specimens by Metabolon, a commercial metabolomic profiling company. 
• 23 metabolites were differentially expressed between the T1DM new and control 
new serum specimens (table 3.3.14). 18 of which were down-regulated in T1DM 
new serum relative to controls. The remaining 5 metabolites were up-regulated 
in T1DM new serum. 
• The most consistently altered metabolic pathway in these samples was the 
caffeine metabolism, with 5 caffeine metabolites being significantly down-
regulated in T1DM new serum. 
• Control new samples used in this study were from medical interns. Therefore 
reduced levels of caffeine metabolites in the T1DM new versus control new 
comparison most likely reflects a higher intake of caffeine by the medical intern 
controls. 
• Other pathways significantly altered in T1DM new and control new samples 
were carbohydrate and lipid metabolism. 1,5-AG a known marker of glycemic 
control was significantly down-regulated in T1DM new samples, in conjunction 
with significantly raised glucose levels in these patients. 
• Lipid metabolites were reduced in T1DM new versus control new samples. 
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• Control new samples used in this study displayed high cholesterol and LDL-
cholesterol (table 3.3.11), above the Irish Heart Foundation recommended 
healthy guidelines (table 4.3.2). Therefore it is unknown if changes in lipid 
metabolites are reflective of T1DM or due to the high cholesterol in control 
samples. 
• Fibrinopeptide A (FPA) was identified as 2.7 fold increased in T1DM new 
samples compared to control.  
• Follow-up validation of FPA was performed on the 8 T1DM new and control 
samples used for the profiling experiment, in addition to 30 T1DM old and 
control samples. 
• Similar levels of FPA were detected in T1DM new, T1DM old and control old 
samples. While FPA levels were significantly decreased in control new samples 
(figure 3.3.40).  
• This study highlighted the importance of using adequately matched control 
samples for biomarker discovery experiments. Suitable controls allow the 
identification of biomarkers related to disease phenotype, rather than an effect of 
the control samples. 
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6.0 Future Work 
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6.1 MicroRNAs involved in glucose stimulated insulin secretion 
 
• If a more consistent GSIS responsive pancreatic beta cell line became available, 
stable knockdown and over-expression of mir-410 expression could be 
performed using shRNA technology, to investigate if effect of mir-410 on GSIS 
could be maintained in long term culture. Followed by proteomic analysis of 
shRNA-treated cells to identify proteins which are responsible for the effector 
functions of mir-410.  
• Over-expression of mir-410 in mouse models with impaired insulin secretion. 
Conditional over-expression of mir-410 by inserting mir-410 sequence under the 
control of beta cell specific promoter, thereby allowing over-expression 
specifically in pancreatic beta cells. Effects of mir-410 on insulin secretion could 
be monitored by testing blood insulin and glucose levels. 
• Expression patterns of mir-410, mir-200a and mir-130a could be examined in 
isolated human islets to determine if these miRNAs can also play a role in 
human beta cells. Purified beta cells could be isolated using laser-capture micro 
dissection and miRNA levels could be manipulated using pre/anti-mir 
technology, to check if these miRNAs play a functional role in GSIS in humans. 
If miRNAs were found to enhance GSIS of human beta cells, they could be 
manipulated in islet cultures and transplanted into mice to determine if these 
miRNA manipulations led to improved control of blood glucose levels, achieved 
longer period of insulin independence and extended graft survival following 
transplantation. 
• Determine if mir-200a and mir-130a effect on GSIS is mediated by Txnip. 
Functional validation of mir-200a and mir-130a regulation of Txnip by cloning 
3’UTR of Txnip into a mammalian expression vector containing the luciferase 
reporter gene. If Txnip is regulated by mir-200a and mir-130a, manipulation of 
these miRNAs will lead to altered levels of luciferase, measured with a 
luminometer. 
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6.2 Attempt to generate iPS cells and differentiation of an established iPS cell line 
towards pancreatic phenotypes 
 
• Generation of iPS cells using new mRNA transient transfection technique, 
which promises improved reprogramming efficiency and in a shorter duration 
(Warren, Manos et al. 2010).  
• Initial cell types for reprogramming could be selected from tissues of 
endodermal lineage, as recent evidence shows that reprogramming cells retain 
epigenetic memory, and differentiate more efficiently towards cell types of a 
related lineage to the starting cell population (Bar-Nur, Russ et al. 2011). 
• Screening of a number of different iPS cells line for pancreatic differentiation 
potential, as iPS and ES cell lines are known for the variability of differentiation 
potential between cell lines. 
• iPS cell differentiation shows successful definitive endoderm formation in 3D 
culture, if definitive endoderm marker expressing cells (cxcr4, foxa2, hnf4α) 
were sorted using FACS, this sub-population may differentiate further towards 
pancreatic endoderm and pancreatic endocrine cells, more efficiently than when 
in a mixed population with undifferentiated cells.  
• MicroRNAs have recently been show to have the potential to reprogram somatic 
cells to iPS cells (Lin, Chang et al. 2008; Anokye-Danso, Trivedi et al. 2011; 
Miyoshi, Ishii et al. 2011), therefore miRNAs involved in functions of mature 
pancreatic beta cells, such as those identified in table 3.1.2 may have the 
potential to direct re-differentiation towards pancreatic phenotypes. 
• ES cell conditioned media has the ability to reprogram cells to an iPS phenotype 
(Balasubramanian, Babai et al. 2009), therefore, conditioned media from islet 
cell preparations may have potential to direct differentiation towards islet cell 
phenotypes. 
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6.3 Biomarker discovery in diabetes serum specimens 
6.3.1 miRNA biomarkers 
 
• Mir-369-5p showed a consistent trend in this study in T2DM serum. Larger 
cohorts of patients should be examined to determine if the expression trend 
remains consistent.  
• To determine if mir-369-5p plays a role in the pathogenesis of T2DM, levels of 
this miRNA could be determined in muscle, liver and adipose tissue of T2DM 
and control patients to assess if this miRNA plays a role in insulin resistance. If 
mir-369-5p was suspected of being directly involved in insulin resistance, mouse 
models of insulin resistance could also be used for manipulation of mir-369-5p 
for elucidation of biological function. 
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6.3.2 Proteomic biomarkers 
 
• Vitronectin levels in T1DM old versus control comparison, and vitamin K-
dependent protein S in T1DM new versus control new comparison were the only 
targets which achieved statistical significance when validated using ELISA. 
Levels of these proteins should be assessed in a larger cohort of patients to 
determine if the expression trend of these proteins in maintained. 
• Additionally, a large number of proteins identified from the label-free LC-MS 
remain to be validated in larger cohorts of patients, to evaluate their potential use 
as biomarkers. 
• Serum samples could be collected periodically, from patients with T1DM and 
T2DM from date of diagnosis. Once secondary complications of diabetes occur, 
large scale profiling of miRNA, mRNA and protein expression could be 
performed to identify miRNA, mRNA and proteins differentially expressed in 
association with the secondary complications. Such targets could then be tested 
in pre-secondary complications serum specimens to determine if these targets 
could be used as early biomarkers for prediction of development of secondary 
complications. 
 
6.3.3 Metabolite biomarkers 
 
• 23 metabolites were identified as differentially expressed in T1DM new 
compared to control new serum samples. Considering that caffeine and lipid 
metabolite changes are likely to be related to control samples used. Therefore 
there are 10 remaining metabolites which could represent potential biomarkers 
for T1DM. 
• Validation of these 10 metabolites could be performed in a larger cohort of 
patient, with adequately matched control samples. 
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Appendix A 
MiRNA functional analysis – Raw Data 
 
 
 
 II 
1.1 Functional Validation Mir-410 
Functional validation of TLDA targets (table 3.2.2) was performed to investigate if 
manipulation of expression of these miRNAs in MIN6 cells led to a phenotypic effect 
on GSIS on the cells. 
 
(a) Knockdown of mir-410 
Figure 1 shows the GSIS assay following knockdown of mir-410 levels in MIN6 cells. 
This experiment shows instability of the 3.3mM glucose baseline in control samples, 
therefore no conclusions can be drawn from this experiment. 
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Figure 1. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
Mir-410 knockdown, figure 2 was not taken as a representative of the effect of mir-410 
on GSIS. Although am-410 showed knockdown of GSIS compared to controls, the 
3.3mM baseline was very low compared to controls. Pm-410 showed slightly improved 
GSIS compared to pm-negative, however untreated cells showed very high GSIS 
compared to pm-negative control. 
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Figure 2. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
Following analysis of bulk assays (figure 1 and figure 2) it was observed that 
performing assays in bulk led to a decrease in GSIS of all sample transfected cells as 
well as control cells, compared to the GSIS of cells at the previous passage where a 
single GSIS assay was performed. Therefore lipofectamine only and kinesin siRNA 
controls were not used in subsequent experiments in an attempt to reduce to length of 
assay setup and maintain high GSIS levels of MIN6 cells during transfection assays. 
 
Knockdown of mir-410 (figure 3) shows a reduction of GSIS compared to untreated and 
am-negative treated cells. 
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Figure 3. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 IV 
 
Knockdown of mir-410 (figure 4) shows slightly increased GSIS compared to control 
cells. This is the opposite effect as expected, as mir-410 expression was reduced in 
glucose non-responsive cells therefore knockdown of mir-410 levels would be expected 
to reduce GSIS. 
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Figure 4. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-410 (figure 5) shows stable large decrease in GSIS of am-neg 
control transfected cells, however, in relation to untreated and gapdh siRNA treated 
cells, am-410 treated cells show a slight knockdown of GSIS.  
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Figure 5. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 V 
Knockdown of mir-410 (figure 6) shows a reduction of GSIS compared to untreated and 
am-negative treated cells. 
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Figure 6. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
Knockdown of mir-410 (figure 7) shows a reduction of GSIS compared to untreated and 
am-negative treated cells. 
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Figure 7. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 VI 
Knockdown of mir-410 assay (figure 8) shows large decrease in GSIS of am-neg 
control and am-410 treated cells compared to untreated cells. 
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Figure 8. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-410 (figure 9) assay also shows a big difference in GSIS fold 
change between control samples. 
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Figure 9. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 VII 
Knockdown of mir-410 (figure 10) shows a reduction of GSIS for am-410 transfected 
cells compared to untreated and am-neg treated cells. 
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Figure 10. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-410 (figure 11) shows a reduction of GSIS for am-410 transfected 
cells compared to untreated and am-neg treated cells. 
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Figure 11. Knockdown of mir-410 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 
 
 VIII 
(b) Over-expression of mir-410 
 
Over-expression of mir-410 assay (figure 12) showed large differences in GSIS of 
control cells. 
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Figure 12. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
Over-expression of mir-410 (figure 13) showed increased GSIS compared to untreated 
and pm-neg treated cells. 
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Figure 13. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 IX 
Over-expression of mir-410 (figure 14) showed no change in GSIS compared to 
untreated and control transfected cells. 
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Figure 14. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 
Over-expression of mir-410 (figure 15) showed no change in GSIS compared to 
untreated and control transfected cells. 
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Figure 15. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 X 
Over-expression of mir-410 (figure 16) showed increased GSIS compared to untreated 
and pm-neg transfected cells. 
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Figure 16. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 
Over-expression of mir-410 (figure 17) showed  increased GSIS compared to untreated 
and pm-neg transfected cells. 
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Figure 17. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 XI 
Over-expression of mir-410 assay (figure 18) showed large differences in the GSIS fold 
change of control cells.  
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Figure 18. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 
Over-expression of mir-410 (figure 19) showed increased GSIS compared to untreated 
and pm-neg transfected cells. 
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Figure 19. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 
 
 
 XII 
Over-expression of mir-410 (figure 20) showed no change in GSIS compared to 
untreated and pm-neg transfected cells. 
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Figure 20. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
Over-expression of mir-410 (figure 21) showed increased GSIS compared to untreated 
and pm-neg transfected cells. 
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Figure 21. Over-expression of mir-410 levels in MIN6 cells (error bars indicate 
standard error of technical replicates). 
 
 XIII 
1.2 Functional Validation of mir-200a 
 
Mir-200a expression was reduced in non-GSIS MIN6 cells (table 3.2.2), therefore 
knockdown of this target with mir-410 inhibitors was expected to reduce GSIS function 
of MIN6 cells, while mir-410 over-expression was expected to improve GSIS function. 
 
(a) Knockdown of mir-200a 
 
Knockdown of mir-200a (figure 22) shows reduced GSIS relative to control cells. 
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Figure 22. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
Knockdown of mir-200a (figure 23) shows reduced GSIS compared to untreated and 
am-neg transfected cells. 
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Figure 23. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XIV 
Mir-200a knockdown assay (figure 24) shows large difference in GSIS response of 
control cells. 
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Figure 24. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Mir-200a knockdown (figure 25) shows reduced GSIS relative to untreated and am-neg 
transfected cells. 
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Figure 25. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XV 
Mir-200a knockdown (figure 26) shows reduced GSIS relative at untreated and am-neg 
transfected cells. 
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Figure 26. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-200a (figure 27) shows reduced GSIS relative to untreated and am-
neg transfected cells. 
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Figure 27. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 XVI 
Knockdown of mir-200a assay (figure 28) large differences in GSIS of controls are 
observed, making it difficult to draw any conclusion regarding an effect of mir-200a 
knockdown. 
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Figure 28. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-200a assay (figure 29), GSIS lies within the large GSIS range of 
controls therefore cannot draw any conclusions from this experiment. 
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Figure 29. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XVII 
Knockdown of mir-200a (figure 30) shows reduced GSIS relative to untreated and am-
neg transfected cells. 
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Figure 30. Knockdown of mir-200a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XVIII 
(b) Over-expression of mir-200a 
 
 
GAPDH siRNA treated cells show a high GSIS fold change in figure 31. However, 
relative to untreated and pm-neg transfected cells, over-expression of mir-200a showed 
no change in GSIS.  
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Figure 31. Over-expression of mir-200a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-200a (figure 32) showed reduced GSIS relative to control cells. 
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Figure 32. Over-expression of mir-200a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 XIX 
Over-expression of mir-200a (figure 33) showed increased GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 33. Over-expression of mir-200a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XX 
1.3 Functional Validation of mir-130a 
Mir-130a expression was manipulated using pre- and anti-mir miRNA mimics and 
inhibitors to increase and decrease mir-130a expression respectively. GSIS of 
transfected cells was examined to determine if manipulation of mir-130a effected GSIS 
phenotype. 
 
(a) Knockdown of mir-130a 
 
Knockdown of mir-130a (figure 34) reduced GSIS relative to control cells. 
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Figure 34. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-130a (figure 35) reduced GSIS relative to control cells. 
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Figure 35. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XXI 
Knockdown of mir-130a (figure 36) reduced GSIS relative to untreated and am-neg 
tranfected cells. 
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Figure 36. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-130a (figure 37) reduced GSIS relative to control cells. 
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Figure 37. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 
 XXII 
Large differences are observed between GSIS of control cells (figure 38) making it 
difficult to draw conclusions regarding the effect of mir-130a knockdown.   
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Figure 38. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Large differences are observed between the GSIS of control cells (figure 39) making it 
difficult to draw conclusions regarding the effect of mir-130a knockdown. 
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Figure 39. Knockdown of mir-130a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XXIII 
(b) Over-expression of mir-130a 
 
 
Over-expression of mir-130a (figure 40) showed no effect on GSIS relative to controls. 
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Figure 40. Over-expression of mir-130a in MIN6 cells (error bars indicated standard 
error of technical replicates). 
 
 
Over-expression of mir-130a (figure 41) showed reduced GSIS relative to controls. 
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Figure 41. Over-expression of mir-130a in MIN6 cells (error bars indicated standard 
error of technical replicates). 
 
 
 
 
 
 XXIV 
Over-expression of mir-130a (figure 42) showed reduced GSIS relative to untreated and 
pm-neg transfected cells. 
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Figure 42. Over-expression of mir-130a in MIN6 cells (error bars indicated standard 
error of technical replicates). 
 
 
Over-expression of mir-130a (figure 43) showed no effect on GSIS relative to controls. 
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Figure 43. Over-expression of mir-130a in MIN6 cells (error bars indicated standard 
error of technical replicates). 
 
 
 
 
 
 XXV 
Over-expression of mir-130a (figure 44) showed reduced GSIS relative to untreated and 
pm-neg transfected cells. 
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Figure 44. Over-expression of mir-130a in MIN6 cells (error bars indicated standard 
error of technical replicates). 
 XXVI 
1.4 Functional Validation of mir-376a 
Functional validation of mir-376a was carried out in MIN6 cells to determine if 
manipulation of this miRNA led to changes in the GSIS phenotype of these cells.  
 
(a) Knockdown of mir-376a 
 
Knockdown of mir-376a (figure 45) showed reduced GSIS relative to control cells. 
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Figure 45. Knockdown of mir-376a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-376a (figure 46) showed reduced GSIS relative to control cells. 
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Figure 46. Knockdown of mir-376a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XXVII 
Large differences in GSIS of control cells was observed (figure 47), making it difficult 
to draw conclusions on the effect of mir-376a knockdown. 
0
500
1000
1500
2000
2500
untreated gapdh am-neg am-376a
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
1.1 fold 0.9 fold 1.5 fold 0.8 fold
 
Figure 47. Knockdown of mir-376a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effects on GSIS were observed for mir-376a knockdown (figure 48). 
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Figure 48. Knockdown of mir-376a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 
 
 
 XXVIII 
No effects on GSIS were observed for mir-376a knockdown (figure 49). 
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Figure 49. Knockdown of mir-376a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XXIX 
(b) Over-expression of mir-376a 
 
 
Over-expression of mir-376a (figure 50) showed reduced GSIS relative to control cells. 
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Figure 50. Over-expression of mir-376a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Large differences in GSIS were observed between untreated and am-neg transfected 
cells (figure 51), therefore no conclusions could be drawn from this experiment. 
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Figure 51. Over-expression of mir-376a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 
 
 XXX 
Over-expression of mir-376a (figure 52) showed improved GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 52. Over-expression of mir-376a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-376a (figure 53) showed increased GSIS relative to control 
cells). 
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Figure 53. Over-expression of mir-376a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 
 
 
 XXXI 
Over-expression of mir-376a (figure 54) showed decreased GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 54. Over-expression of mir-376a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XXXII 
1.5 Functional Validation of mir-369-5p 
Mir-369-5p expression was manipulated to determine if this miRNA could affect the 
GSIS function of MIN6 cells. 
 
(a) Large-scale assays for over-expression and knockdown of mir-369-5p 
expression 
 
Large fluctuations were observed in baseline insulin secretion in response to 3.3mM 
glucose of control cells (figure 55), therefore no conclusions could be drawn on the 
effects of mir-369-5p over-expression and knockdown. 
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Figure 55. Over-expression and knockdown of mir-369-5p levels in MIN6 cells (error 
bars indicate standard error of technical replicates).  
 
 XXXIII 
No effect on GSIS is observed for knockdown or over-expression of mir-369-5p relative 
to control cells (figure 56). 
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Figure 56. Over-expression and knockdown of mir-369-5p levels in MIN6 cells (error 
bars indicate standard error of technical replicates).  
 
 
(b) Knockdown of mir-369-5p 
 
 
Large differences observed in baseline insulin secretion in response to 3.3mM glucose 
on control cells (figure 57), therefore cannot draw any conclusions on effects of mir-
369-5p knockdown. 
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Figure 57. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 XXXIV 
No change in GSIS observed for knockdown of mir-369-5p levels (figure 58) relative to 
control cells. 
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Figure 58. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 
Large differences in baseline insulin secretion in response to 3.3mM glucose observed 
for control cells (figure 59) therefore cannot draw any conclusions on effects on mir-
369-5p knockdown. 
0
500
1000
1500
2000
2500
untreated gapdh am-neg am-369-5p
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
1.1 fold 0.9 fold 1.5 fold 1.3 fold
 
Figure 59. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 XXXV 
Knockdown of mir-369-5p (figure 60) shows decreased GSIS and a large increase in 
basal insulin secretion relative to untreated and am-neg transfected cells 
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Figure 60. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 
Knockdown of mir-369-5p (figure 61) shows decreased GSIS relative to untreated and 
am-neg transfected cells. 
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Figure 61. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 XXXVI 
Knockdown of mir-369-5p (figure 62) shows decreased GSIS relative to untreated and 
am-neg transfected cells. 
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Figure 62. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 
Knockdown of mir-369-5p (figure 63) shows no effect on GSIS relative to control cells. 
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Figure 63. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 XXXVII 
Knockdown of mir-369-5p (figure 64) shows decreased GSIS relative to control cells. 
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Figure 64. Knockdown of mir-369-5p levels in MIN6 cells (error bars indicated 
standard error of technical replicates). 
 
 
(c) Over-expression of mir-369-5p 
 
 
Over-expression of mir-369-5p (figure 65) showed no effect on GSIS relative to control 
cells. 
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Figure 65. Over-expression of mir-369-5p in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
Large differences in baseline insulin secretion in response to 3.3mM glucose were 
observed for control cells (figure 66) therefore cannot draw any conclusions on effects 
on mir-369-5p over-expression. 
 
 XXXVIII 
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Figure 66. Over-expression of mir-369-5p in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-369-5p (figure 67) shows increased GSIS relative to untreated 
and pm-neg transfected cells). 
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Figure 67. Over-expression of mir-369-5p in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XXXIX 
Over-expression of mir-369-5p (figure 68) shows no effect on GSIS relative to control 
cells. 
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Figure 68. Over-expression of mir-369-5p in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-369-5p (figure 69) shows no effect on GSIS fold change, 
however a large is observed in basal insulin secretion at 3.3mM glucose, relative to 
untreated and pm-neg transfected cells. 
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Figure 69. Over-expression of mir-369-5p in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 XL 
1.6 Functional Validation of mir-27a 
Over-expression and knockdown experiments were performed on MIN6 cells with 
miRNA targets identified from TLDA analysis (table 3.1.2), to determine if 
manipulation of these miRNAs led to changes in GSIS phenotype of the cells. 
 
(a) Large-scale assays for over-expression and knockdown of mir-27a  
 
Large fluctuations were observed in baseline insulin secretion in response to 3.3mM 
glucose of control cells (figure 70) therefore no conclusions could be drawn on the 
effects of mir-27a over-expression and knockdown. 
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Figure 70. Knockdown of mir-27a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XLI 
No effect on GSIS was observed for mir-27a over-expression or knockdown relative to 
control cells (figure 71). 
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Figure 71. Knockdown of mir-27a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
(b) Knockdown of mir-27a 
 
No effect on GSIS was observed for knockdown of mir-27a relative to control cells 
(figure 72) 
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Figure 72. Knockdown of mir-27a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 XLII 
Knockdown of mir-27a (figure 73) showed a reduction in GSIS relative to control cells. 
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Figure 73. Knockdown of mir-27a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS is observed for mir-27a knockdown relative to untreated and am-neg 
transfected cells (figure 74). 
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Figure 74. Knockdown of mir-27a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 XLIII 
(c) Over-expression of mir-27a 
 
 
No effect on GSIS was observed for mir-27a over-expression relative to control cells 
(figure 75). 
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Figure 75. Over-expression of mir-27a in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 
 
No effect on GSIS was observed for mir-27a over-expression relative to control cells 
(figure 76). 
0
500
1000
1500
2000
2500
3000
untreated pm-neg gapdh pm-27a
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
1.5 fold 1.1 fold 2.1 fold 1.1 fold
 
Figure 76. Over-expression of mir-27a in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 
 
 
 XLIV 
Over-expression of mir-27a (figure 77) showed a decrease in GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 77. Over-expression of mir-27a in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 
 
Over-expression of mir-27a (figure 78) showed a decrease in GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 78. Over-expression of mir-27a in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 XLV 
1.7 Functional Validation of mir-124a 
 
Mir-124a expression was increased and decreased using miRNA inhibitors and mimics 
to determine if manipulation of this miRNA could affect the GSIS phenotype of MIN6 
cells. 
 
(a) Knockdown of mir-124a 
 
Knockdown of mir-124a (figure 79) showed a decrease in GSIS relative to control cells. 
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Figure 79. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XLVI 
Knockdown of mir-124a (figure 80) showed an increase in GSIS relative to control 
cells. 
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Figure 80. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
No effect on GSIS of am-124a transfected cells was observed relative to control cells 
(figure 81).  
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Figure 81. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XLVII 
No effect on GSIS of am-124a transfected cells was observed relative to control cells 
(figure 82). 
 
0
100
200
300
400
500
600
700
untreated gapdh am-neg am-124a
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
1.5 fold 1.0 fold 1.7 fold 1.7 fold
 
Figure 82. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Large differences in baseline insulin secretion in response to 3.3mM glucose were 
observed for control cells (figure 83) therefore cannot draw any conclusions on effects 
on mir-124a knockdown. 
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Figure 83. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 XLVIII 
No effect on GSIS of am-124a transfected cells was observed relative to control cells 
(figure 84). 
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Figure 84. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-124a (figure 85) showed a decrease in GSIS relative to untreated 
and am-neg transfected cells. 
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Figure 85. Knockdown of mir-124a levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 XLIX 
(b) Over-expression of mir-124a 
 
 
Over-expression of mir-124a (figure 86) shows a decrease in GSIS relative to control 
cells. 
 
0
200
400
600
800
1000
1200
1400
untreated gapdh pm-neg pm-124a
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
1.9 fold 2.0 fold 2.4 fold 1.4 fold
 
Figure 86. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-124a (figure 87) shows an increase in GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 87. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 L 
Over-expression of mir-124a (figure 88) shows a slight increase in GSIS relative to 
control cells. 
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Figure 88. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-124a (figure 89) shows a decrease in GSIS relative to control 
cells. 
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Figure 89. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 LI 
Large differences in baseline insulin secretion in response to 3.3mM glucose were 
observed for control cells (figure 90) therefore cannot draw any conclusions on effects 
on mir-124a over-expression. 
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Figure 90. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS is observed for over-expression of mir-124a relative to control cells 
(figure 91). 
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Figure 91. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 LII 
No effect on GSIS is observed for mir-124a over-expression relative to control cells 
(figure 92). 
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Figure 92. Over-expression of mir-124a in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LIII 
1.8 Functional Validation of mir-337 
 
Mir-337 expression was reduced in non-GSIS MIN6 cells, therefore it was expected that 
manipulation to increase and decrease expression levels of this miRNA in MIN6 cells 
could lead to increased and decreased GSIS response in these cells. 
 
(a) Knockdown of mir-337 
 
 
No effect on GSIS was observed for knockdown of mir-337 compared to control cells 
(figure 93). 
 
 
0
200
400
600
800
1000
1200
1400
untreated gapdh am-neg am337
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
3.0 fold 2.7 fold 3.0 fold 2.8 fold
 
Figure 93. Knockdown of mir-337 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LIV 
No effect on GSIS was observed for knockdown of mir-337 relative to control cells 
(figure 94). 
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Figure 94. Knockdown of mir-337 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Knockdown of mir-337 (figure 95) showed an increase in GSIS relative to untreated and 
am-neg transfected cells. 
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Figure 95. Knockdown of mir-337 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 LV 
No effect on GSIS was observed for knockdown of mir-337 levels relative to untreated 
and am-neg transfected cells (figure 96). 
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Figure 96. Knockdown of mir-337 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
A slight decrease in GSIS was observed for knockdown of mir-337 relative to untreated 
and am-neg transfected cells (figure 97). 
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Figure 97. Knockdown of mir-337 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LVI 
(b) Over-expression of mir-337 
 
 
No effect on GSIS is observed for over-expression of mir-337 relative to control cells 
(figure 98). 
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Figure 98. Over-expression of mir-337 in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 
 
Over-expression of mir-337 (figure 99) shows an increase in GSIS relative to control 
cells. 
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Figure 99. Over-expression of mir-337 in MIN6 cells (error bars indicate standard error 
of technical replicates). 
 
 
 LVII 
Large differences in baseline insulin secretion in response to 3.3mM glucose were 
observed for control cells (figure 100) therefore cannot draw any conclusions on effects 
on mir-337 over-expression. 
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Figure 100. Over-expression of mir-337 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LVIII 
1.9 Functional Validation of mir-532 
 
Expression levels of mir-532 were manipulated using miRNA inhibitors and mimics to 
determine if differential expression of this miRNA could affect GSIS phenotype of 
MIN6 cells. 
 
 
(a) Knockdown of mir-532 
 
 
No effect on GSIS is observed for knockdown of mir-532 relative to control cells 
(figure 101). 
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Figure 101. Knockdown of mir-532 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LIX 
No effect on GSIS is observed for knockdown of mir-532 levels relative to control cells 
(figure 102). 
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Figure 102. Knockdown of mir-532 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
(b) Over-expression of mir-532 
 
 
No effect on GSIS was observed for over-expression of mir-532 relative to control cells 
(figure 103). 
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Figure 103. Over-expression of mir-532 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LX 
A slight decrease in GSIS was observed for cells treated with pm-532 relative to 
untreated and pm-neg transfected cells (figure 104). 
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Figure 104. Over-expression of mir-532 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS was observed for pm-532 treated cells relative to untreated and pm-
neg transfected cells (figure 105). 
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Figure 105. Over-expression of mir-532 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXI 
1.10 Functional Validation of mir-320 
 
Mir-320 expression was manipulated using anti- and pre-mirs as miRNA inhibitors and 
mimics for altering miRNA levels in vitro. 
 
(a) Knockdown of mir-320 
 
No effect on GSIS is observed for knockdown of mir-320 relative to control cells 
(figure 106). 
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Figure 106. Knockdown of mir-320 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
No effect on GSIS is observed for mir-320 knockdown relative to control cells (figure 
107). 
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Figure 107. Knockdown of mir-320 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXII 
No effect on GSIS is observed for knockdown of mir-320 relative to control cells 
(figure 108). 
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Figure 108. Knockdown of mir-320 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS is observed for knockdown of mir-320 relative to control cells 
(figure 109). 
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Figure 109. Knockdown of mir-320 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
 
 LXIII 
Knockdown of mir-320 (figure 110) shows a decrease in GSIS relative to untreated and 
am-neg transfected cells. 
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Figure 110. Knockdown of mir-320 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
(b) Over-expression of mir-320 
 
 
Over-expression of mir-320 (figure 111) shows a decrease in GSIS relative to control 
cells. 
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Figure 111. Over-expression of mir-320 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LXIV 
Large differences in baseline insulin secretion in response to 3.3mM glucose were 
observed for control cells (figure 112) therefore cannot draw any conclusions on effects 
on mir-320 over-expression. 
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Figure 112. Over-expression of mir-320 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXV 
1.11 Functional Validation of mir-192 
Expression levels of mir-192 were manipulated in MIN6 cells to determine if this 
miRNA plays a role in GSIS in these cells. 
 
(a) Knockdown of mir-192 
No effect on GSIS is observed for knockdown of mir-192 relative to control cells 
(figure 113). 
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Figure 113. Knockdown of mir-192 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
No effect on GSIS is observed for knockdown of mir-192 relative to untreated and am-
neg transfected cells (figure 114). 
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Figure 114. Knockdown of mir-192 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXVI 
Knockdown of mir-192 (figure 115) shows a decrease in GSIS relative to untreated and 
am-neg transfected cells. 
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Figure 115. Knockdown of mir-192 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS is observed for knockdown of mir-192 relative to control cells 
(figure 116). 
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Figure 116. Knockdown of mir-192 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXVII 
(b) Over-expression of mir-192 
 
 
Over-expression of mir-192 (figure 117) shows a decrease in GSIS relative to untreated 
and pm-neg transfected cells. 
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Figure 117. Over-expression of mir-192 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
Over-expression of mir-192 (figure 118) shows a decrease in GSIS relative to untreated 
and pm-neg transfected cells. 
 
0
500
1000
1500
2000
2500
3000
untreated pmneg pm192
Treatments
In
su
lin
 
Se
cr
et
io
n
 
(pm
o
l/L
/m
g 
pr
o
te
in
)
3.3mM glucose 16.7mM glucose
5.5 fold 2.1 fold 2.0 fold
 
 
Figure 118. Over-expression of mir-192 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 LXVIII 
Over-expression of mir-192 (figure 119) shows no effect on GSIS fold change, however 
a large increase in basal insulin secretion and stimulated insulin secretion is observed. 
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Figure 119. Over-expression of mir-192 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 LXIX 
1.12 Functional Validation of mir-379 
Mir-379 expression levels were reduced in non-GSIS MIN6 cells, therefore increasing 
and decreasing levels of this miRNA would be expected to increase and decrease the 
GSIS responsiveness to these cells, respectively. 
 
(a) Knockdown of mir-379 
No effect on GSIS is observed for knockdown of mir-379 relative to control cells 
(figure 120). 
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Figure 120. Knockdown of mir-379 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
No effect on GSIS is observed for knockdown of mir-379 relative to control cells 
(figure 121). 
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Figure 121. Knockdown of mir-379 levels in MIN6 cells (error bars indicate standard 
error of technical replicates). 
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(b) Over-expression of mir-379 
 
 
Over-expression of mir-379 (figure 122) showed a decrease in GSIS relative to 
untreated and pm-neg transfected cells. 
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Figure 122. Over-expression of mir-379 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
 
 
No effect on GSIS was observed for over-expression of mir-379 relative to control cells 
(figure 123). 
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Figure 123. Over-expression of mir-379 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
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Over-expression of mir-379 (figure 124) showed a decrease in GSIS relative to 
untreated and pm-neg transfected cells. 
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Figure 124. Over-expression of mir-379 in MIN6 cells (error bars indicate standard 
error of technical replicates). 
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Appendix B 
miRNA biomarker study – raw data 
 LXXIII 
Evaluation of target miRNA levels in serum from type 1 diabetes patients and 
control serum : 
 
 
Target Ct ∆Ct Fold Change 
  Control T1DM     
mir-9* 33.914 33.271 -0.643 1.56 
mir-376a 35.046 35.348 0.302 -1.23 
mir-192 32.496 31.945 -0.551 1.46 
mir-375* 32.588 32.173 -0.415 1.33 
mir-532 31.735 31.175 -0.56 1.47 
mir-320 28.073 28.442 0.369 -1.29 
mir-130a 28.944 29.846 0.902 -1.86 
mir-369-5p 34.185 34.461 0.276 -1.21 
mir-27a 28.11 28.477 0.367 -1.28 
mir-124a 34.152 32.424 1.728 3.31 
mir-379 33.506 32.979 0.527 1.44 
         
mir-337 Not detected 
mir-200a Not detected 
mir-410 Not detected 
Table 2.1 Fold changes of miRNA levels in T1DM sera compared to non-diabetic sera 
controls. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous 
control identified for this work) (* miRNAs identified from the literature). 
 
 LXXIV 
Mir-124a 
T1DM Ct Control Ct ∆Ct Fold change 
DS-29 33.615 DS-39 34.85 1.235 2.35 
DS-35 30.847 DS-33 34.147 3.3 9.85 
DS-11 32.144 DS-49 34.467 2.323 5 
DS-13 32.159 DS-18 33.271 1.112 2.16 
DS-25 31.253 DS-19 34.119 2.866 7.29 
       
average 
fold change 5.33 
Stdev +/-3.29 
       P-value 0.004 
Table 2.2 Fold changes in mir-124a levels in T1DM sera compared to non-diabetic 
sera. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
 
 
Mir-130a 
T1DM Ct Control Ct ∆Ct Fold Change 
DS-11 34.055 DS-49 32.414 -1.641 -3.11 
DS-13 30.856 DS-18 30.251 -0.605 -1.52 
DS-25 30.966 DS-72 33.947 2.981 7.89 
DS-29 31.095 DS-37 31.258 0.163 1.11 
DS-35 29.1899 DS-33 33.091 3.901 14.94 
Table 2.3 Fold changes in mir-9 levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Mir-9 
T1DM Ct Control Ct ∆Ct Fold change 
DS-11 undet DS-49 undet     
DS-13 31.828 DS-18 33.8995 -2.07 4.2 
DS-25 33.861 DS-72 undet     
DS-29 undet DS-37 undet     
DS-35 34.7 DS-33 undet     
Table 2.4 Fold changes in mir-9 levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
 
Mir-532 
T1DM Ct Control Ct ∆Ct Fold Change 
DS-11 35.732 DS-49 33.963 1.769 -3.41 
DS-13 32.944 DS-18 32.115 0.829 -1.78 
DS-25 32.725 DS-72 35.545 -2.82 7.06 
DS-29 33.328 DS-37 33.765 -0.44 1.35 
DS-35 31.235 DS-33 34.432 -3.19 9.17 
Table 2.5 Fold changes in mir-9 levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
 
Mir-192 
T1DM Ct Control Ct ∆Ct Fold Change 
DS-11 36.087 DS-49 36.255 -0.168 1.12 
DS-13 34.252 DS-18 34.261 -0.009 1.006 
DS-25 33.26 DS-72 36.749 -3.489 11.23 
DS-29 33.664 DS-37 34.827 -1.163 2.23 
DS-35 32.01 DS-33 undet     
Table 2.6 Fold changes in mir-9 levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Mir-379 
T1DM Ct Control Ct ∆Ct Fold change 
DS-29 33.061 DS-39 34.9 1.839 3.58 
DS-35 31.01 DS-33 33.23 2.22 4.66 
DS-11 32.387 DS-49 33.457 1.07 2.1 
DS-13 32.103 DS-18 30.881 -1.222 -2.33 
DS-25 32.043 DS-19 34.7 2.657 6.31 
      
average 
fold change 4.16 
Stdev 1.77 
      P-value 0.017 
Table 2.7 Fold changes in mir-379 levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). DS-13 / DS-18 pair were removed from average fold change 
calculations as they were outliers. 
 
 
 
 
Mir-124a expanded study : 
 
 
Mir-124a 
T1DMs Ct Controls Ct  ∆Ct RQ Fold 
DS-68 33.286 DS-56 33.834 -0.548 1.46206 1.46 
DS-74 33.993 DS-36 34.898 -0.905 1.87254 1.87 
DS-82 35.938 DS-7 34.032 1.906 0.26683 -3.75 
DS-84 36.061 DS-27 35.588 0.473 0.72047 -1.39 
DS-88 33.459 DS-39 35.044 -1.585 3.00008 3.00 
DS-90 35.02 DS-53 34.175 0.845 0.55671 -1.80 
DS-93 34.389 DS-33 35.629 -1.24 2.36199 2.36 
DS-98 34.543 DS-50 35.431 -0.888 1.85061 1.85 
DS-95 36.427 DS-51 36.449 -0.022 1.01537 1.02 
DS-99 35.717 DS-53 34.175 1.542 0.34341 -2.91 
Table 2.8 Fold change of mir-124a levels in T1DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Evaluation of GSIS related miRNAs in serum from type 2 diabetes patients 
relative to control serum : 
 
Mir-369-5p 
T2DM Ct Control Ct ∆Ct Fold Change 
DS-9 35.884 DS-52 35.494 0.39 -1.31 
DS-10 undet DS-3 35.516     
DS-14 undet DS-2 36.162     
DS-15 35.7335 DS-54 34.517 1.2165 -2.33 
DS-21 35.108 DS-16 33.828 1.28002 -2.43 
DS-23 34.8782 DS-18 33.699 1.17921 -2.26 
        
Average 
Fold -2.08 
Table 2.9 Fold change of mir-369-5p levels in T2DM sera compared to non-diabetic 
sera. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
Mir-130a 
T2DM Ct Control Ct ∆Ct Fold Change 
DS-9 31.499 DS-52 32.018 -0.519 1.433 
DS-10 35.012 DS-3 36.321 -1.309 2.478 
DS-14 32.825 DS-2 33.345 -0.52 1.434 
DS-15 32.826 DS-54 32.147 0.679 -1.601 
DS-21 32.061 DS-16 30.876 1.185 -2.27 
DS-23 32.531 DS-18 31.967 0.564 -1.478 
Table 2.10 Fold change of mir-130a levels in T2DM sera compared to non-diabetic 
sera. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Mir-27a 
T2DM Ct Control Ct ∆Ct Fold Change 
DS-9 31.192 DS-52 30.975 0.217 -1.62 
DS-10 34.07 DS-3 33.776 0.294 -1.22 
DS-14 31.559 DS-2 32.853 -1.294 2.45 
DS-15 31.291 DS-54 30.853 0.438 -1.35 
DS-21 30.947 DS-16 29.986 0.961 -1.95 
DS-23 31.611 DS-18 30.715 0.896 -1.86 
Table 2.11 Fold change of mir-27a levels in T2DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
 
Mir-124a 
T2DM Ct Control Ct ∆Ct Fold Change 
DS-9 33.899 DS-52 34.828 -0.929 1.9 
DS-10 34.879 DS-3 35.573 -0.694 1.62 
DS-14 36.598 DS-2 35.403 1.195 -2.29 
DS-15 35.969 DS-54 36.085 -0.116 1.08 
DS-21 35.912 DS-16 35.062 0.85 -1.8 
DS-23 35.396 DS-18 33.854 1.542 -2.91 
Table 2.12 Fold change of mir-124a levels in T2DM sera compared to non-diabetic 
sera. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Mir-410 
T2DM Ct Control Ct ∆Ct Fold Change 
DS-9 35.344 DS-52 35.135 0.209 -1.16 
DS-10 35.65 DS-3 35.523 0.127 -1.09 
DS-14 34.711 DS-2 34.795 -0.084 1.06 
DS-15 35.172 DS-54 34.012 1.16 -2.23 
DS-21 34.026 DS-16 33.482 0.544 -1.46 
DS-23 33.772 DS-18 32.799 0.973 -1.96 
Table 2.13 Fold change of mir-410 levels in T2DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
Mir-200a 
T2DM Ct Control Ct ∆Ct Fold change 
DS-9 33.634 DS-52 36.617 -2.983 7.91 
DS-10 undeter DS-3 undeter    
DS-14 36.03 DS-2 undeter    
DS-15 34.867 DS-54 35.687 -0.82 1.76 
DS-21 35.859 DS-16 35.28 0.579 -1.49 
DS-23 34.615 DS-18 33.649 0.966 -1.95 
Table 2.14 Fold change of mir-200a levels in T2DM sera compared to non-diabetic 
sera. Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
 
 
Mir-532 
T2DM Ct Control Ct ∆Ct Fold change 
DS-9 32.535 DS-52 34.605 -2.07 4.2 
DS-10 35.5208 DS-3 36.103 -0.5822 1.5 
DS-14 34.463 DS-2 34.29 0.173 -1.13 
DS-15 34.3358 DS-54 34.195 0.1408 -1.1 
DS-21 34.0148 DS-16 33.314 0.7008 -1.62 
DS-23 35.6051 DS-18 33.876 1.7291 -3.31 
Table 2.15 Fold change of mir-532 levels in T2DM sera compared to non-diabetic sera. 
Fold changes calculated from 2-(ct(T1DM)-ct(Control) (as no suitable endogenous control 
identified for this work). 
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Appendix C 
Label-free LC-MS serum study raw data 
 
 
 
 
 
 LXXXI 
T1DM new versus control new- Analysis 1 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new Control new 
P0C0L4 43 4138 0.02 1.58 Complement C4-A  1.56E+008 9.88E+007 
P01024 35 3123 0.05 1.55 Complement C3  4.95E+007 3.19E+007 
P01031 20 1427 0.03 1.65 Complement C5  1.88E+006 1.14E+006 
P02647 16 1126 0.03 1.53 Apolipoprotein A-I  7.57E+007 4.94E+007 
P10909 13 988 0.04 1.72 Clusterin  1.78E+007 1.03E+007 
P02748 10 950 0.008 1.79 Complement component C9  4.28E+006 2.39E+006 
P04004 8 689 0.05 1.43 Vitronectin  4.72E+007 3.30E+007 
P06727 9 652 0.01 1.58 Apolipoprotein A-IV  9.07E+006 5.74E+006 
P23142 7 640 0.03 1.61 Fibulin-1  5.67E+006 3.53E+006 
P02768 8 628 0.04 1.64 Serum albumin  9.07E+006 5.54E+006 
Q08380 8 581 0.05 1.58 Galectin-3-binding protein  1.77E+006 1.12E+006 
Q14624 6 520 0.04 7.81 Inter-alpha-trypsin inhibitor heavy chain H4  1.23E+006 1.58E+005 
P01009 6 490 0.02 1.78 Alpha-1-antitrypsin  8.31E+005 4.66E+005 
P18428 4 392 0.02 2.29 Lipopolysaccharide-binding protein  5.66E+005 2.47E+005 
P07996 6 368 0.008 1.65 Thrombospondin-1  3.03E+005 5.00E+005 
P02741 6 334 0.02 6.09 C-reactive protein  1.22E+006 2.00E+005 
P02746 3 279 0.03 1.59 Complement C1q subcomponent subunit B  2.60E+006 1.63E+006 
P10643 4 272 0.003 2.24 Complement component C7  4.26E+005 1.90E+005 
P04003 3 270 0.03 1.51 C4b-binding protein alpha chain  3.63E+006 2.40E+006 
 LXXXII 
P00450 4 258 0.01 2.41 Ceruloplasmin  2.70E+005 1.12E+005 
P68032 4 232 0.02 1.95 Actin, alpha cardiac muscle 1  9.88E+004 1.93E+005 
P07225 4 218 0.03 1.51 Vitamin K-dependent protein S  3.45E+005 2.29E+005 
P02788 3 205 0.04 1.74 Lactotransferrin  3.86E+004 6.70E+004 
Q06033 3 180 0.01 2.43 Inter-alpha-trypsin inhibitor heavy chain H3 9.40E+004 3.88E+004 
Q6S8J3 3 178 0.02 1.97 POTE ankyrin domain family member E  5.39E+004 1.06E+005 
P07358 3 171 0.05 1.86 Complement component C8 beta chain  5.52E+005 2.97E+005 
P04070 2 164 0.03 1.81 Vitamin K-dependent protein C  2.12E+005 1.17E+005 
Q9UK55 2 153 0.02 2.69 Protein Z-dependent protease inhibitor  1.97E+005 7.33E+004 
Q12805 2 136 0.05 1.94 EGF-containing fibulin-like extracellular matrix 
protein 1  
1.78E+005 9.16E+004 
P09871 3 135 0.03 1.5 Complement C1s subcomponent  4.01E+004 2.67E+004 
Q562R1 2 117 0.02 1.91 Beta-actin-like protein 2  5.31E+004 1.02E+005 
Q9BYX7 2 113 0.02 1.98 Beta-actin-like protein 3  4.86E+004 9.63E+004 
Table 1. Differentially expressed proteins in T1DM new verus control new comparison.T1DM new sample DS-169 was used as reference 
run. 
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T1DM new versus control new- Analysis 2 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new Control new 
P0C0L5 40 3836 0.005 1.65 Complement C4-B  1.95E+008 1.18E+008 
P01024 42 3693 0.03 1.56 Complement C3  6.88E+007 4.41E+007 
P01031 20 1420 0.004 1.74 Complement C5  2.24E+006 1.28E+006 
P02647 17 1233 0.02 1.57 Apolipoprotein A-I  8.52E+007 5.43E+007 
P10909 12 1010 0.01 1.68 Clusterin  2.68E+007 1.59E+007 
P02748 11 1000 0.003 1.86 Complement component C9  4.93E+006 2.66E+006 
P06727 14 972 0.005 1.64 Apolipoprotein A-IV  1.15E+007 7.06E+006 
P02768 10 777 0.03 1.58 Serum albumin  1.29E+007 8.20E+006 
P04004 7 644 0.04 1.46 Vitronectin  5.38E+007 3.70E+007 
P23142 7 631 0.02 1.64 Fibulin-1  6.42E+006 3.93E+006 
P18428 5 541 0.02 2.29 Lipopolysaccharide-binding protein  1.30E+006 5.68E+005 
P02743 7 530 0.04 1.48 Serum amyloid P-component  7.41E+006 5.02E+006 
P08603 8 521 0.02 1.41 Complement factor H  2.70E+006 1.92E+006 
P01008 9 512 0.05 1.47 Antithrombin-III  2.75E+007 1.87E+007 
P01871 7 500 0.05 1.42 Ig mu chain C region  1.44E+007 1.02E+007 
P07996 7 425 0.01 1.53 Thrombospondin-1  5.18E+005 7.94E+005 
P01009 5 412 0.004 2.19 Alpha-1-antitrypsin  9.02E+005 4.11E+005 
P04003 3 346 0.01 1.61 C4b-binding protein alpha chain  4.45E+006 2.77E+006 
P07225 5 297 0.02 1.33 Vitamin K-dependent protein S  1.22E+006 9.16E+005 
Q06033 5 278 0.007 2.7 Inter-alpha-trypsin inhibitor heavy chain H3  1.53E+005 5.66E+004 
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P10643 3 267 0.001 2.35 Complement component C7  5.43E+005 2.31E+005 
P68133 5 246 0.01 2.19 Actin, alpha skeletal muscle  1.11E+005 2.43E+005 
P02745 2 241 0.02 1.47 Complement C1q subcomponent subunit A  2.71E+006 1.84E+006 
P02741 4 236 0.01 6.22 C-reactive protein  1.24E+006 1.99E+005 
Q9UK55 3 228 0.03 2.51 Protein Z-dependent protease inhibitor  3.81E+005 1.52E+005 
P02788 3 218 0.02 2.26 Lactotransferrin  4.63E+004 1.05E+005 
P01834 2 210 0.05 1.5 Ig kappa chain C region  1.23E+007 8.18E+006 
P12259 3 200 0.04 1.63 Coagulation factor V  2.57E+005 1.57E+005 
P02746 2 195 0.02 1.55 Complement C1q subcomponent subunit B  1.68E+006 1.09E+006 
P13671 3 185 0.04 1.58 Complement component C6  4.21E+005 2.66E+005 
P09871 2 124 0.03 1.7 Complement C1s subcomponent  2.47E+005 1.46E+005 
Q9BYX7 2 113 0.03 1.92 Beta-actin-like protein 3  6.34E+004 1.22E+005 
Q6S8J3 2 113 0.03 1.92 POTE ankyrin domain family member E  6.34E+004 1.22E+005 
A5A3E0 2 113 0.03 1.92 POTE ankyrin domain family member F  6.34E+004 1.22E+005 
P04196 2 95 0.05 2.61 Histidine-rich glycoprotein  1.13E+004 2.94E+004 
Table 2. Differentially expressed proteins in T1DM new versus control new comparison. Control sample DS-175 was used as reference 
run. 
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T1DM new versus control new- Analysis 3 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new Control new 
P0C0L5 26 2000 0.05 3.01 Complement C4-B  4.46e+007 1.48e+007 
P01031 9 586 0.04 1.63 Complement C5  4.70e+005 2.88e+005 
P00734 7 555 0.04 35.59 Prothrombin  1.05e+007 2.96e+005 
P60709 8 446 0.04 1.66 Actin, cytoplasmic 1  3.25e+005 5.40e+005 
P68032 7 357 0.009 2.30 Actin, alpha cardiac muscle 1  1.24e+005 2.84e+005 
P63267 6 314 0.009 2.23 Actin, gamma-enteric smooth muscle  1.16e+005 2.60e+005 
P10909 4 246 0.02 1.57 Clusterin  8.49e+005 5.41e+005 
P02741 4 196 0.02 8.05 C-reactive protein  4.21e+005 5.23e+004 
A5A3E0 3 178 0.03 2.02 POTE ankyrin domain family member F  6.91e+004 1.40e+005 
Q6S8J3 3 178 0.03 2.02 POTE ankyrin domain family member E  6.91e+004 1.40e+005 
P05154 3 167 0.02 2.08 Plasma serine protease inhibitor  2.81e+004 5.83e+004 
Q08380 2 121 0.04 1.54 Galectin-3-binding protein  4.31e+005 2.79e+005 
Q06033 2 117 0.02 2.50 Inter-alpha-trypsin inhibitor heavy chain H3  8.37e+004 3.34e+004 
Q562R1 2 117 0.03 1.87 Beta-actin-like protein 2  6.40e+004 1.20e+005 
Q9BYX7 2 113 0.03 2.03 Beta-actin-like protein 3  6.31e+004 1.28e+005 
P08697 2 111 0.03 1.58 Alpha-2-antiplasmin  7.70e+004 1.22e+005 
Table 3. Differentially expressed proteins in T1DM new and control new comparison. Control samples DS-178 was used as reference run. 
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T1DM old versus control old- Analysis 1 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM old Control old 
P04114 56 4308 0.05 2.5 Apolipoprotein B-100  7.65E+006 1.91E+007 
P01008 18 1712 0.05 2.55 Antithrombin-III  6.43E+007 1.64E+008 
P02649 12 1248 0.02 2.19 Apolipoprotein E  1.46E+007 3.20E+007 
P07225 7 545 0.05 2.47 Vitamin K-dependent protein S  1.52E+006 3.75E+006 
P04004 5 491 0.03 1.72 Vitronectin  2.55E+007 4.39E+007 
P02655 4 456 0.01 2.41 Apolipoprotein C-II  4.06E+006 9.79E+006 
P02647 5 429 0.05 1.9 Apolipoprotein A-I  2.66E+007 5.06E+007 
P00450 6 412 0.03 1.7 Ceruloplasmin  5.53E+005 3.25E+005 
Q15485 5 406 0.02 3 Ficolin-2  5.81E+005 1.75E+006 
P02766 4 377 0.04 2.69 Transthyretin  2.14E+006 5.74E+006 
P35542 2 245 0.02 2.34 Serum amyloid A-4 protein  8.40E+005 1.97E+006 
P48740 4 243 0.005 1.97 Mannan-binding lectin serine protease 1  4.04E+005 7.95E+005 
P04003 3 243 0.04 2.62 C4b-binding protein alpha chain  5.67E+006 1.49E+007 
Q03591 3 227 0.006 1.88 Complement factor H-related protein 1  2.30E+006 4.34E+006 
P01776 1 211 0.04 2.78 Ig heavy chain V-III region WAS  4.24E+005 1.18E+006 
P01774 1 211 0.04 2.78 Ig heavy chain V-III region POM  4.24E+005 1.18E+006 
P02776 2 211 0.05 2.1 Platelet factor 4  7.12E+005 1.49E+006 
P63261 4 201 0.03 3.42 Actin, cytoplasmic 2  1.28E+005 4.38E+005 
P05546 3 189 0.04 1.98 Heparin cofactor 2  2.49E+004 4.94E+004 
O14791 2 189 3.71E-003 4.07 Apolipoprotein L1  7.27E+004 2.96E+005 
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P36980 2 168 0.02 1.88 Complement factor H-related protein 2  7.12E+005 1.34E+006 
P07358 3 158 0.01 1.46 Complement component C8 beta chain  8.24E+004 5.64E+004 
Q9BYX7 3 154 0.01 3.99 Beta-actin-like protein 3  6.77E+004 2.70E+005 
Q6S8J3 3 154 0.01 3.99 POTE ankyrin domain family member E  6.77E+004 2.70E+005 
P55056 2 135 0.02 2.9 Apolipoprotein C-IV  5.04E+004 1.46E+005 
P04275 2 117 0.02 4.42 von Willebrand factor  1.76E+004 7.80E+004 
P07357 2 98 0.03 1.73 Complement component C8 alpha chain  5.12E+004 2.96E+004 
P01023 2 96 0.02 2.27 Alpha-2-macroglobulin  8.06E+004 3.55E+004 
Table 4. Differentially expressed proteins in T1DM old and control old comparison. T1DM old sample DS-84 was used as reference run. 
 LXXXVIII 
T1DM old versus control old- Analysis 2 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM old Control old 
P01008 17 1510 0.03 2.31 Antithrombin-III  3.15E+007 7.27E+007 
P02649 15 1226 0.02 2.05 Apolipoprotein E  1.07E+007 2.19E+007 
Q15485 7 544 0.02 2.81 Ficolin-2  4.37E+005 1.23E+006 
P02655 5 518 0.01 2.25 Apolipoprotein C-II  3.13E+006 7.05E+006 
P04004 5 446 0.03 1.62 Vitronectin  1.71E+007 2.77E+007 
P00450 8 445 0.04 1.44 Ceruloplasmin  4.51E+005 3.13E+005 
P02647 4 347 0.04 1.76 Apolipoprotein A-I  1.99E+007 3.50E+007 
P07225 4 337 0.006 2.13 Vitamin K-dependent protein S  4.03E+005 8.59E+005 
P02766 3 335 0.03 2.39 Transthyretin  1.63E+006 3.91E+006 
P19827 4 298 0.01 2.14 Inter-alpha-trypsin inhibitor heavy chain H1  2.66E+005 5.69E+005 
P48740 4 243 0.002 1.95 Mannan-binding lectin serine protease 1  2.82E+005 5.49E+005 
P04003 3 243 0.03 2.39 C4b-binding protein alpha chain  4.23E+006 1.01E+007 
P01765 1 211 0.05 2.5 Ig heavy chain V-III region TIL  3.20E+005 8.00E+005 
P02776 2 211 0.05 1.98 Platelet factor 4  5.30E+005 1.05E+006 
P35542 2 202 0.02 2.25 Serum amyloid A-4 protein  5.16E+005 1.16E+006 
P63261 4 201 0.02 3.14 Actin, cytoplasmic 2  1.45E+005 4.56E+005 
O14791 3 186 0.03 2.44 Apolipoprotein L1  7.75E+004 1.89E+005 
P05154 2 184 0.05 2.01 Plasma serine protease inhibitor  5.14E+004 1.03E+005 
Q03591 3 160 0.02 1.74 Complement factor H-related protein 1  1.42E+006 2.47E+006 
P08697 3 159 0.03 3.54 Alpha-2-antiplasmin  2.47E+004 8.74E+004 
 LXXXIX 
Q6S8J3 3 154 0.009 3.72 POTE ankyrin domain family member E  4.79E+004 1.78E+005 
A5A3E0 3 154 0.009 3.72 POTE ankyrin domain family member F  4.79E+004 1.78E+005 
Q9BYX7 3 154 0.009 3.72 Beta-actin-like protein 3  4.79E+004 1.78E+005 
P07357 3 139 0.02 1.67 Complement component C8 alpha chain  4.30E+004 2.58E+004 
P55056 2 135 0.003 3.53 Apolipoprotein C-IV  2.86E+004 1.01E+005 
P01023 2 133 0.03 2.08 Alpha-2-macroglobulin  8.89E+004 4.28E+004 
P02654 2 117 0.02 2.32 Apolipoprotein C-I  1.37E+006 3.18E+006 
P04275 2 117 0.01 3.51 von Willebrand factor  1.67E+004 5.87E+004 
P68032 2 108 0.01 3.64 Actin, alpha cardiac muscle 1  4.64E+004 1.69E+005 
P68133 2 108 0.01 3.64 Actin, alpha skeletal muscle  4.64E+004 1.69E+005 
P02774 2 106 0.05 3.04 Vitamin D-binding protein  2.71E+004 8.23E+004 
P36980 2 101 0.02 1.71 Complement factor H-related protein 2  2.27E+005 3.89E+005 
P07358 2 92 0.001 1.86 Complement component C8 beta chain  6.35E+004 3.41E+004 
Table 5. Differentially expressed proteins in T1DM old and control old comparison. Control old sample DS-162 was used as reference run. 
 XC 
T1DM old versus control old- Analysis 3 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM old Control old 
P01008 16 1381 0.03 2.37 Antithrombin-III  2.79E+007 6.63E+007 
P02649 15 1269 0.02 2.05 Apolipoprotein E  1.05E+007 2.16E+007 
P02655 5 518 0.007 2.5 Apolipoprotein C-II  2.76E+006 6.88E+006 
P04004 6 501 0.03 1.57 Vitronectin  1.76E+007 2.77E+007 
Q15485 6 494 0.02 2.88 Ficolin-2  4.10E+005 1.18E+006 
P00450 7 477 0.03 1.6 Ceruloplasmin  5.17E+005 3.23E+005 
P07225 6 446 0.005 2.24 Vitamin K-dependent protein S  4.03E+005 9.04E+005 
P02647 5 429 0.05 1.75 Apolipoprotein A-I  1.96E+007 3.44E+007 
P02766 3 335 0.04 2.46 Transthyretin  1.51E+006 3.71E+006 
P04003 4 316 0.03 2.4 C4b-binding protein alpha chain  4.16E+006 9.97E+006 
P35542 3 287 0.01 2.37 Serum amyloid A-4 protein  5.00E+005 1.19E+006 
P05154 3 245 0.05 2.13 Plasma serine protease inhibitor  5.80E+004 1.24E+005 
P48740 4 243 0.002 1.91 Mannan-binding lectin serine protease 1  2.79E+005 5.35E+005 
O14791 3 233 0.02 2 Apolipoprotein L1  1.25E+005 2.49E+005 
P19827 3 224 0.007 2.26 Inter-alpha-trypsin inhibitor heavy chain H1  2.13E+005 4.81E+005 
P01774 1 211 0.05 2.51 Ig heavy chain V-III region POM  3.13E+005 7.87E+005 
P01776 1 211 0.05 2.51 Ig heavy chain V-III region WAS  3.13E+005 7.87E+005 
P02776 2 211 0.05 1.97 Platelet factor 4  5.22E+005 1.03E+006 
P63261 4 201 0.03 3.09 Actin, cytoplasmic 2  1.52E+005 4.71E+005 
A5A3E0 3 154 0.02 3.63 POTE ankyrin domain family member F  5.17E+004 1.88E+005 
Q9BYX7 3 154 0.02 3.63 Beta-actin-like protein 3  5.17E+004 1.88E+005 
Q6S8J3 3 154 0.02 3.63 POTE ankyrin domain family member E  5.17E+004 1.88E+005 
P55056 2 135 0.004 3.03 Apolipoprotein C-IV  3.58E+004 1.08E+005 
P05546 2 125 0.02 2.81 Heparin cofactor 2  1.05E+004 2.95E+004 
 XCI 
P04275 2 117 0.01 3.9 von Willebrand factor  1.41E+004 5.50E+004 
Q9UK55 2 112 0.02 1.98 Protein Z-dependent protease inhibitor  3.47E+004 1.75E+004 
P00742 2 111 0.04 2.96 Coagulation factor X  3.78E+004 1.12E+005 
P68032 2 108 0.02 3.59 Actin, alpha cardiac muscle 1  4.97E+004 1.79E+005 
Q03591 2 106 0.03 1.74 Complement factor H-related protein 1  1.34E+006 2.33E+006 
P02774 2 106 0.05 3.2 Vitamin D-binding protein  2.52E+004 8.07E+004 
P07358 2 92 5.89E-004 1.91 Complement component C8 beta chain  6.34E+004 3.31E+004 
Table 6. Differentially expressed proteins in T1DM old and control old comparison. Control old sample DS-39 was used as reference run. 
 
 
 
 
 
 
 
 XCII 
T1DM new versus T1DM old- Analysis 1 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new T1DM old 
P0C0L5 47 4330 0.02 1.35 Complement C4-B  1.11E+08 8.23E+07 
P00734 19 1580 0.05 1.39 Prothrombin  3.08E+07 2.22E+07 
P00450 12 841 0.03 1.55 Ceruloplasmin  8.18E+05 1.27E+06 
P10909 7 766 0.005 1.43 Clusterin  2.10E+07 1.47E+07 
P01871 4 763 0.04 1.57 Ig mu chain C region  6.61E+06 4.21E+06 
P01031 13 749 0.03 1.59 Complement C5  6.09E+05 3.83E+05 
P01008 10 724 0.006 1.44 Antithrombin-III  2.35E+07 1.63E+07 
P19823 9 697 0.02 1.47 Inter-alpha-trypsin inhibitor heavy chain H2  2.58E+06 1.76E+06 
P01009 8 586 0.05 1.49 Alpha-1-antitrypsin  5.32E+05 3.57E+05 
P01834 4 483 0.03 1.54 Ig kappa chain C region  6.15E+06 4.00E+06 
P04004 4 375 0.03 1.45 Vitronectin  1.72E+07 1.18E+07 
P07225 4 316 0.007 1.71 Vitamin K-dependent protein S  6.27E+05 3.67E+05 
P02768 4 255 0.007 1.69 Serum albumin  4.50E+05 2.66E+05 
P00747 3 255 0.05 1.29 Plasminogen  3.79E+05 4.91E+05 
P02654 4 213 0.004 1.55 Apolipoprotein C-I  2.59E+06 1.67E+06 
Q06033 4 213 0.05 1.81 Inter-alpha-trypsin inhibitor heavy chain H3  1.03E+05 5.70E+04 
P04180 3 183 0.05 1.24 Phosphatidylcholine-sterol acyltransferase  5.96E+05 4.80E+05 
P07996 3 171 0.05 1.48 Thrombospondin-1  1.52E+05 2.24E+05 
Q03591 2 153 0.02 1.77 Complement factor H-related protein 1  6.05E+04 3.42E+04 
P01617 2 121 0.05 1.48 Ig kappa chain V-II region TEW  2.07E+05 1.40E+05 
P04264 2 96 0.04 4.01 Keratin, type II cytoskeletal 1  1.49E+04 3.72E+03 
Table 7. Differentially expressed proteins in T1DM new and T1DM old comparison. T1DM new sample DS-169 was used as reference 
run. 
 XCIII 
T1DM new versus T1DM old- Analysis 2 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new T1DM old 
P0C0L5 46 4003 0.01 1.45 Complement C4-B  1.56E+08 1.08E+08 
P00734 15 1402 0.05 1.4 Prothrombin  4.57E+07 3.27E+07 
P01871 5 1006 0.04 1.57 Ig mu chain C region  1.26E+07 8.04E+06 
P10909 9 889 0.003 1.42 Clusterin  3.31E+07 2.34E+07 
P01008 13 886 0.01 1.43 Antithrombin-III  3.12E+07 2.18E+07 
P19827 9 781 0.04 1.46 Inter-alpha-trypsin inhibitor heavy chain H1  2.25E+06 1.55E+06 
P01834 5 524 0.02 1.55 Ig kappa chain C region  9.42E+06 6.07E+06 
P04004 5 437 0.03 1.46 Vitronectin  2.57E+07 1.76E+07 
P02748 5 355 0.05 1.53 Complement component C9  2.39E+06 1.56E+06 
P08603 4 287 0.04 1.57 Complement factor H  7.80E+05 4.96E+05 
P07225 5 259 9.13E-04 1.49 Vitamin K-dependent protein S  6.24E+05 4.18E+05 
P02654 2 123 0.002 1.56 Apolipoprotein C-I  3.78E+06 2.42E+06 
Table 8. Differentially expressed proteins in T1DM new and T1DM old comparison. T1DM old samples DS-74 was used as reference run. 
 
 
 
 
 
 
 XCIV 
T1DM new versus T1DM old- Analysis 3 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
T1DM new T1DM old 
P0C0L5 44 3766 0.01 1.48 Complement C4-B  1.62E+08 1.09E+08 
P00734 17 1532 0.03 1.42 Prothrombin  4.69E+07 3.31E+07 
P01871 6 963 0.02 1.55 Ig mu chain C region  1.43E+07 9.25E+06 
P10909 10 962 0.003 1.45 Clusterin  3.35E+07 2.31E+07 
P19827 10 959 0.04 1.48 Inter-alpha-trypsin inhibitor heavy chain H1  2.56E+06 1.73E+06 
P01008 13 912 0.007 1.46 Antithrombin-III  4.18E+07 2.87E+07 
P19823 10 766 0.009 1.46 Inter-alpha-trypsin inhibitor heavy chain H2  4.43E+06 3.04E+06 
P04004 4 447 0.03 1.42 Vitronectin  3.39E+07 2.38E+07 
P01834 4 418 0.02 1.58 Ig kappa chain C region  9.56E+06 6.06E+06 
P07225 2 190 0.003 2.2 Vitamin K-dependent protein S  6.16E+05 2.80E+05 
P04180 3 183 0.03 1.26 Phosphatidylcholine-sterol acyltransferase  8.95E+05 7.09E+05 
P02654 3 171 0.002 1.59 Apolipoprotein C-I  3.88E+06 2.45E+06 
O14791 3 147 0.02 1.88 Apolipoprotein L1  1.43E+05 7.61E+04 
Table 9. Differentially expressed proteins in T1DM new and T1DM old comparison. T1DM old sample DS-90 was used as reference run. 
 
 
 XCV 
Comparison of control groups for newly diagnosed and controls for established diabetes 
 
  
 
Figure 1. PCA plot for control new and control old samples. Sample DS-178 as reference run. Blue spots indicate the control old, while 
pink spots indicate control new samples. Old control sample DS-7 is a slight outlier relative to the rest of the control old group.  
 
 
 
 
 
 
 
DS-7 
 XCVI 
Control new versus control old- Analysis 1 
Average Normalised Abundances Accession  Peptides  Score   Anova (p)*   Fold   Description  
control new control old 
P02649 9 844 0.02 2.35 Apolipoprotein E  8.81E+06 2.07E+07 
Q08380 8 786 0.02 2.55 Galectin-3-binding protein  1.65E+06 4.22E+06 
P01871 8 557 0.04 1.6 Ig mu chain C region  5.71E+06 3.57E+06 
P10909 6 516 0.05 2.33 Clusterin  7.93E+06 1.85E+07 
P07225 6 429 0.05 2.69 Vitamin K-dependent protein S 8.16E+05 2.19E+06 
P02655 3 422 0.004 2.61 Apolipoprotein C-II  2.76E+06 7.18E+06 
P02741 5 353 0.01 10.84 C-reactive protein  2.18E+05 2.36E+06 
P04003 3 251 0.03 2.61 C4b-binding protein alpha chain  4.22E+06 1.10E+07 
Q12805 2 212 0.04 2.35 EGF-containing fibulin-like extracellular matrix protein 1  1.62E+05 3.82E+05 
P18428 2 210 0.04 2.01 Lipopolysaccharide-binding protein  2.92E+05 5.88E+05 
P48740 3 191 0.02 1.77 Mannan-binding lectin serine protease 1  2.71E+05 4.79E+05 
Q06033 3 178 0.01 2.21 Inter-alpha-trypsin inhibitor heavy chain H3 4.41E+04 9.75E+04 
P08603 2 176 0.003 1.52 Complement factor H  1.12E+06 7.35E+05 
P35542 2 173 0.03 2.34 Serum amyloid A-4 protein  5.48E+05 1.28E+06 
Table 10. Differentially expressed proteins in control old versus control new comparison. DS-162 control old sample was used as reference 
run.
 XCVII 
Control new versus control old- Analysis 2  
Average Normalised Abundances Accession  Peptides  Score   Anova (p)*   Fold   Description  
control new control old 
P00734 12 1100 0.05 2.31 Prothrombin  2.30E+07 5.31E+07 
P02649 9 844 0.02 2.33 Apolipoprotein E  8.78E+06 2.05E+07 
Q08380 6 676 0.005 2.94 Galectin-3-binding protein  1.40E+06 4.10E+06 
P01871 9 612 0.04 1.57 Ig mu chain C region  7.37E+06 4.68E+06 
P10909 6 516 0.05 2.25 Clusterin  8.14E+06 1.83E+07 
P19823 7 512 0.04 1.39 Inter-alpha-trypsin inhibitor heavy chain H2  8.33E+05 5.98E+05 
P02671 6 507 0.01 2.34 Fibrinogen alpha chain  4.72E+05 1.10E+06 
P02655 3 422 0.008 2.83 Apolipoprotein C-II  2.52E+06 7.13E+06 
P08603 6 357 0.005 1.5 Complement factor H  1.54E+06 1.02E+06 
P02741 5 353 0.01 10.73 C-reactive protein  2.20E+05 2.37E+06 
P12259 3 263 0.02 2.58 Coagulation factor V  1.80E+05 4.64E+05 
P35542 3 260 0.01 2.21 Serum amyloid A-4 protein  6.65E+05 1.47E+06 
Q06033 4 259 0.01 2.32 Inter-alpha-trypsin inhibitor heavy chain H3  4.72E+04 1.09E+05 
P04003 3 251 0.03 2.51 C4b-binding protein alpha chain  4.33E+06 1.09E+07 
P04070 3 240 0.05 2.24 Vitamin K-dependent protein C  1.66E+05 3.72E+05 
P48740 3 191 0.02 1.72 Mannan-binding lectin serine protease 1  2.80E+05 4.81E+05 
P02765 2 112 0.03 1.4 Alpha-2-HS-glycoprotein  3.06E+05 2.19E+05 
P01834 2 106 0.03 1.79 Ig kappa chain C region  4.31E+05 2.40E+05 
P07996 2 105 0.05 1.72 Thrombospondin-1  7.02E+04 4.07E+04 
P02788 2 100 0.02 3.19 Lactotransferrin  1.88E+04 5.89E+03 
Table 11. Differentially expressed proteins in control old versus control new comparison. DS-178 control new sample was used as 
reference run. 
 
 
 XCVIII 
Control new versus control old- Analysis 3  
 Average Normalised Abundances Accession  Peptides  Score   Anova (p)*   Fold   Description  
control new control old 
P0C0L5 53 4906 0.05 1.53 Complement C4-B  1.21E+08 1.85E+08 
P02649 15 1315 0.02 1.71 Apolipoprotein E  1.13E+07 1.92E+07 
P00734 16 1221 0.05 1.34 Prothrombin  2.48E+07 3.33E+07 
Q08380 12 964 0.02 1.73 Galectin-3-binding protein  1.78E+06 3.08E+06 
P10909 12 927 0.01 1.64 Clusterin  1.47E+07 2.41E+07 
P07225 8 566 0.05 1.55 Vitamin K-dependent protein S  9.76E+05 1.52E+06 
P04003 7 503 0.005 1.55 C4b-binding protein alpha chain  5.05E+06 7.83E+06 
P02655 4 469 0.003 1.99 Apolipoprotein C-II  2.91E+06 5.80E+06 
P08603 5 446 0.001 1.6 Complement factor H  1.90E+06 1.19E+06 
P00450 5 441 0.05 1.5 Ceruloplasmin  1.99E+05 3.00E+05 
P02741 5 353 0.03 10.3 C-reactive protein  2.19E+05 2.25E+06 
P02671 4 308 0.03 2.24 Fibrinogen alpha chain  1.26E+05 2.81E+05 
P35542 4 295 0.008 1.66 Serum amyloid A-4 protein  7.99E+05 1.32E+06 
P01620 3 226 0.04 1.5 Ig kappa chain V-III region SIE  6.89E+05 4.60E+05 
P48740 3 191 0.03 1.38 Mannan-binding lectin serine protease 1  2.80E+05 3.85E+05 
Q06033 3 178 0.03 1.93 Inter-alpha-trypsin inhibitor heavy chain H3  4.42E+04 8.54E+04 
P04070 2 169 0.05 1.58 Vitamin K-dependent protein C  1.36E+05 2.15E+05 
P02656 2 168 0.008 1.58 Apolipoprotein C-III  4.03E+06 6.38E+06 
P04180 3 161 0.04 1.41 Phosphatidylcholine-sterol acyltransferase  1.72E+05 2.43E+05 
P55056 2 120 7.18E-06 3.07 Apolipoprotein C-IV  2.65E+04 8.13E+04 
P03950 2 118 0.01 1.69 Angiogenin  6.20E+04 1.05E+05 
Table 12. Differentially expressed proteins in control old versus control new comparison. DS-39 control old sample was used as reference 
run. DS-7 was excluded from this analysis as protein expression pattern for this sample differed from other samples in the same group. 
 XCIX 
Autoimmune versus control- Analysis 1 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
Autoimmune All controls 
P02751 32 2998 0.02 1.52 Fibronectin 3.23E+07 4.91E+07 
P02768 24 2101 0.009 1.86 Serum albumin  2.72E+07 1.46E+07 
P20742 17 1420 0.01 5.03 Pregnancy zone protein 2.40E+06 4.78E+05 
P06727 10 990 0.02 1.53 Apolipoprotein A-IV  2.12E+07 1.39E+07 
P02748 10 968 0.02 1.6 Complement component C9  5.83E+06 3.64E+06 
P00450 6 736 0.05 1.42 Ceruloplasmin  1.20E+06 8.48E+05 
P01009 10 626 0.02 1.53 Alpha-1-antitrypsin  1.07E+06 7.00E+05 
P04264 5 546 0.05 2.95 Keratin, type II cytoskeletal 1  3.49E+05 1.18E+05 
P13645 7 509 0.04 3.27 Keratin, type I cytoskeletal 10  2.57E+05 7.84E+04 
P18428 6 457 0.05 1.77 Lipopolysaccharide-binding protein 1.60E+06 9.04E+05 
P00734 5 404 0.03 1.79 Prothrombin  2.71E+06 1.51E+06 
P10643 5 396 0.02 2 Complement component C7 1.07E+06 5.38E+05 
P01008 5 396 0.05 1.94 Antithrombin-III  3.50E+06 1.80E+06 
P51884 6 395 0.03 1.9 Lumican  4.56E+05 2.40E+05 
Q06033 6 364 0.01 1.77 Inter-alpha-trypsin inhibitor heavy chain H3  2.21E+05 1.25E+05 
P35527 2 177 0.04 2.37 Keratin, type I cytoskeletal 9  4.22E+04 1.78E+04 
Q15848 2 174 0.02 1.83 Adiponectin 1.98E+06 1.08E+06 
P07357 3 170 0.003 1.44 Complement component C8 alpha chain  9.45E+04 6.56E+04 
P00488 2 146 0.03 2.47 Coagulation factor XIII A chain  1.45E+04 3.58E+04 
P55056 2 121 0.04 2.12 Apolipoprotein C-IV  3.88E+04 8.23E+04 
P07360 2 108 0.05 1.47 Complement component C8 gamma chain 7.82E+04 5.31E+04 
P02746 2 96 0.02 1.48 Complement C1q subcomponent subunit B 8.02E+04 5.43E+04 
Table 13. Differentially expressed proteins in autoimmune versus control samples. Control sample DS-175 was used as reference run. 
 C 
Autoimmune versus control- Analysis 2 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
Autoimmune All controls 
P02751 36 2983.27 0.005 1.53 Fibronectin  2.59E+07 3.97E+07 
P04114 36 2388.22 0.03 1.52 Apolipoprotein B-100  1.72E+06 2.60E+06 
P02768 24 1979.44 0.01 1.93 Serum albumin 2.41E+07 1.25E+07 
P20742 18 1452.68 0.009 5.19 Pregnancy zone protein 2.43E+06 4.69E+05 
P06727 12 1049.54 0.02 1.53 Apolipoprotein A-IV  1.87E+07 1.22E+07 
P02748 12 973.92 0.02 1.65 Complement component C9 4.92E+06 2.97E+06 
P00450 7 787.88 0.05 1.44 Ceruloplasmin 1.16E+06 8.06E+05 
P13645 9 661.8 0.04 3.78 Keratin, type I cytoskeletal 10  2.87E+05 7.58E+04 
P01009 10 625.66 0.03 1.55 Alpha-1-antitrypsin 9.69E+05 6.24E+05 
P10643 4 347.48 0.01 2.5 Complement component C7  6.79E+05 2.71E+05 
P18428 5 312.49 0.03 1.7 Lipopolysaccharide-binding protein 9.40E+05 5.53E+05 
P51884 5 307.51 0.04 1.88 Lumican 4.02E+05 2.14E+05 
Q06033 5 305.6 0.02 1.65 Inter-alpha-trypsin inhibitor heavy chain H3 1.94E+05 1.17E+05 
P13671 4 286.31 0.03 1.53 Complement component C6 4.13E+05 2.69E+05 
Q15848 3 251.12 0.02 1.86 Adiponectin 2.00E+06 1.08E+06 
P00734 3 219.48 0.03 1.78 Prothrombin  2.39E+06 1.34E+06 
O14791 3 185.39 0.03 1.35 Apolipoprotein L1 1.13E+05 1.53E+05 
P07360 3 162.9 0.05 1.44 Complement component C8 gamma chain 9.52E+04 6.63E+04 
P07357 2 121.76 0.03 1.38 Complement component C8 alpha chain 5.57E+04 4.03E+04 
P01700 2 113.45 0.02 1.6 Ig lambda chain V-I region HA  7.18E+04 4.47E+04 
Table 14. Differentially expressed proteins in autoimmune versus control samples. Control sample DS-178 was used as reference run. 
 CI 
Autoimmune versus control- Analysis 3 
Average Normalised Abundances Accession Peptides Score Anova (p)* Fold Description 
Autoimmune All Controls 
P02751 35 3096.62 0.03 1.53 Fibronectin 3.14E+07 4.80E+07 
P0C0L4 27 2157.02 0.05 1.39 Complement C4-A  5.43E+07 3.92E+07 
P02768 25 2054.78 0.02 1.86 Serum albumin  2.53E+07 1.36E+07 
P20742 22 1472.88 0.009 4.39 Pregnancy zone protein 3.21E+06 7.32E+05 
P06727 13 1084.59 0.02 1.52 Apolipoprotein A-IV  1.98E+07 1.31E+07 
P02748 13 997.78 0.03 1.59 Complement component C9  5.33E+06 3.35E+06 
P04264 10 906.06 0.05 2.67 Keratin, type II cytoskeletal 1  4.86E+05 1.82E+05 
P13645 10 685.93 0.04 3.24 Keratin, type I cytoskeletal 10  3.06E+05 9.45E+04 
P35908 5 606.39 0.03 4.21 Keratin, type II cytoskeletal 2 epidermal  7.93E+04 1.88E+04 
P01009 8 479.04 0.04 1.48 Alpha-1-antitrypsin  9.45E+05 6.40E+05 
Q06033 7 407.35 0.01 1.75 Inter-alpha-trypsin inhibitor heavy chain H3 2.23E+05 1.27E+05 
P51884 5 335.57 0.01 2.06 Lumican 2.87E+05 1.39E+05 
P10643 4 283.97 0.02 2.26 Complement component C7  8.63E+05 3.81E+05 
Q15848 3 265.93 0.02 1.81 Adiponectin  2.57E+06 1.42E+06 
P07357 3 170.49 0.006 1.39 Complement component C8 alpha chain  9.01E+04 6.50E+04 
P02671 2 165.21 0.03 1.63 Fibrinogen alpha chain 9.25E+04 1.51E+05 
P04220 2 134.48 0.02 16.64 Ig mu heavy chain disease protein  2.01E+03 3.35E+04 
Table 15. Differentially expressed proteins in autoimmune versus control samples. Control sample DS-39 was used as reference run. 
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Appendix D 
Metabolomics serum study raw data  
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Figure 1. Box and whisker plots of all significantly different biochemicals in disease- newly diagnosed type 1 diabetes, compared to 
control- healthy specimens. Box and whisker plots show the distribution of the dataset. The median indicates the middle of the data, with 
50% of the data being above and 50% below this value. Upper quartile indicates 25% of the data is above this value, while the lower 
quartile indicates that 25% of the data is below this value.  
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